{"40d702b6cd7b874d6e9907fdc262c8eb35e622f0": [["Infection Prevention and ControlInfection prevention and control is a series of practices, processes, and programs within healthcare to reduce the spread of infection among patients and staff.", [["Infection", "DISEASE", 0, 9], ["infection", "DISEASE", 157, 166], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["Infection Prevention", "TREATMENT", 0, 20], ["ControlInfection prevention", "TREATMENT", 25, 52], ["infection", "PROBLEM", 157, 166], ["infection", "OBSERVATION", 157, 166]]], ["Infection prevention and control (IPC) programs within hospitals and healthcare facilities typically consist of infection preventionists (IPs) who are commonly nurses, epidemiologists, and microbiologists.", [["infection preventionists", "DISEASE", 112, 136], ["Infection prevention", "TREATMENT", 0, 20], ["control (IPC) programs", "TREATMENT", 25, 47]]], ["The duties of the IP and IPC program includes a variety of responsibilities; disease surveillance, case investigation for hospitalassociated infections, education, training of staff, policy review, risk assessments for construction in patient care areas, emergency preparedness, reporting of communicable diseases to local health departments, reporting of healthcare-associated infections for reimbursement and federal requirements, etc. Traditionally, the role of the infection prevention program is to focus on reducing healthcare-associated infections (HAIs) however, communicable diseases play a large role in their duties.", [["infections", "DISEASE", 141, 151], ["infections", "DISEASE", 378, 388], ["infection", "DISEASE", 469, 478], ["infections", "DISEASE", 544, 554], ["HAIs", "DISEASE", 556, 560], ["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242], ["the IP and IPC program", "TREATMENT", 14, 36], ["disease surveillance", "TEST", 77, 97], ["hospitalassociated infections", "PROBLEM", 122, 151], ["risk assessments", "TEST", 198, 214], ["construction in patient care", "TREATMENT", 219, 247], ["communicable diseases", "PROBLEM", 292, 313], ["healthcare-associated infections", "PROBLEM", 356, 388], ["the infection prevention program", "TREATMENT", 465, 497], ["infections", "OBSERVATION", 378, 388], ["infection", "OBSERVATION", 469, 478], ["infections", "OBSERVATION", 544, 554], ["large", "OBSERVATION_MODIFIER", 600, 605]]], ["Properly training and educating staff on the correct use of personal protective equipment (PPE) and ensuring isolation precautions are correctly maintained is a daily responsibility for the IPC department.", [["personal protective equipment (PPE)", "TREATMENT", 60, 95], ["ensuring isolation precautions", "TREATMENT", 100, 130]]], ["Aside from ensuring staff compliance to PPE and isolation precautions, IPC works to educate and facilitate compliance among visitors, as they can be a source for disease spread within a healthcare facility.", [["PPE", "TREATMENT", 40, 43], ["isolation precautions", "TREATMENT", 48, 69], ["IPC", "TREATMENT", 71, 74], ["disease", "PROBLEM", 162, 169]]], ["The role of the IPC program and infection preventionists is also as the connective tissue within healthcare facilities to ensure that infectious diseases have the proper response across the healthcare sector, which includes departments like environmental services, security, emergency medicine, facilities, administration, interventional radiology, sterile processing departments, etc. Infection and control programs are the sentinels for underlying issues within the health of the community and healthcare facility.PractitionersInfection prevention and control departments are comprised of infection preventionists, who have a variety of backgrounds.", [["connective tissue", "ANATOMY", 72, 89], ["infection", "DISEASE", 32, 41], ["infectious diseases", "DISEASE", 134, 153], ["infection", "DISEASE", 591, 600], ["connective tissue", "TISSUE", 72, 89], ["the IPC program", "TREATMENT", 12, 27], ["infection preventionists", "TREATMENT", 32, 56], ["infectious diseases", "PROBLEM", 134, 153], ["Infection", "PROBLEM", 386, 395], ["control programs", "TREATMENT", 400, 416], ["underlying issues", "PROBLEM", 439, 456], ["infection", "OBSERVATION", 32, 41], ["infectious", "OBSERVATION", 134, 144], ["infection", "OBSERVATION", 591, 600]]], ["The IP, even at the most novice level, must have a rudimentary understanding of microbiology, disease transmission, and public health interventions.", [["The IP", "TREATMENT", 0, 6], ["disease transmission", "PROBLEM", 94, 114], ["public health interventions", "TREATMENT", 120, 147]]], ["IP competencies are built up according the Association for Professionals in Infection Prevention and Epidemiology (APIC) model, which is considered the gold standard.", [["Infection", "DISEASE", 76, 85], ["Infection Prevention", "TREATMENT", 76, 96], ["Infection", "OBSERVATION", 76, 85]]], ["The APIC competency model is based upon a text that includes topics that highlight the range of IP duties-occupational health, sterilization and disinfection, bioterrorism, emergency preparedness, outbreak response, infection prevention in a variety of settings (e.g., behavioral health, correctional facilities, dental services), aseptic technique, infection prevention for specialty care populations (e.g., burns, pediatrics, organ transplants), as well as the environmental components to infection prevention work (e.g., waste management, heating and ventilation, healthcare textiles).", [["organ", "ANATOMY", 428, 433], ["infection", "DISEASE", 216, 225], ["infection", "DISEASE", 350, 359], ["burns", "DISEASE", 409, 414], ["infection", "DISEASE", 491, 500], ["organ", "ORGAN", 428, 433], ["sterilization", "TREATMENT", 127, 140], ["disinfection", "TREATMENT", 145, 157], ["bioterrorism", "PROBLEM", 159, 171], ["infection prevention", "TREATMENT", 216, 236], ["dental services", "TREATMENT", 313, 328], ["aseptic technique", "TREATMENT", 331, 348], ["infection prevention", "TREATMENT", 350, 370], ["specialty care populations", "TREATMENT", 375, 401], ["organ transplants", "TREATMENT", 428, 445], ["infection prevention work", "TREATMENT", 491, 516], ["waste management", "TREATMENT", 524, 540], ["heating and ventilation, healthcare textiles", "TREATMENT", 542, 586], ["infection", "OBSERVATION", 216, 225]]], ["The duties and capabilities of the IP are required to be extensive and diverse.", [["the IP", "TREATMENT", 31, 37]]], ["Infection preventionists are expected to sit for the Certification in Infection Control (CIC) after 2 years.", [["Infection", "DISEASE", 70, 79], ["Infection", "PROBLEM", 0, 9], ["Infection", "OBSERVATION", 70, 79]]], ["The CIC is a complex certification which aims to ensure the IP is well-versed in the variety of issues that plague healthcare systems.", [["versed", "TREATMENT", 71, 77], ["CIC", "OBSERVATION", 4, 7]]], ["Since the 2002 severe acute respiratory syndrome (SARS) coronavirus and 2013-2016 Ebola virus disease outbreaks, infection preventionists' duties have increasingly involved high-consequence pathogens and emergency preparedness.", [["acute respiratory syndrome", "DISEASE", 22, 48], ["SARS", "DISEASE", 50, 54], ["coronavirus", "DISEASE", 56, 67], ["Ebola virus disease", "DISEASE", 82, 101], ["infection", "DISEASE", 113, 122], ["Ebola virus", "ORGANISM", 82, 93], ["coronavirus", "SPECIES", 56, 67], ["Ebola virus", "SPECIES", 82, 93], ["2002 severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 10, 67], ["Ebola virus", "SPECIES", 82, 93], ["severe acute respiratory syndrome", "PROBLEM", 15, 48], ["coronavirus", "PROBLEM", 56, 67], ["Ebola virus disease outbreaks", "PROBLEM", 82, 111], ["infection", "PROBLEM", 113, 122], ["high-consequence pathogens", "PROBLEM", 173, 199], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["respiratory syndrome", "OBSERVATION", 28, 48]]], ["Overall, infection preventionists are responsible for all manner of infectious disease threats within a healthcare facility, regardless of origin.Surveillance and Coordination with Health DepartmentsPerhaps one of the most crucial responsibilities of the infection prevention and control program is to perform surveillance and report communicable diseases to local health departments.", [["infection", "DISEASE", 9, 18], ["infection", "DISEASE", 255, 264], ["infection preventionists", "PROBLEM", 9, 33], ["the infection prevention", "TREATMENT", 251, 275], ["surveillance", "TEST", 310, 322], ["infection", "OBSERVATION", 9, 18], ["infectious", "OBSERVATION", 68, 78], ["infection", "OBSERVATION", 255, 264]]], ["While IPC programs are frequently responsible for reporting hospital-associated infections within their facility, it is the responsibility for reporting communicable diseases that is relevant to defense against biological attacks.", [["infections", "DISEASE", 80, 90], ["IPC programs", "TREATMENT", 6, 18], ["communicable diseases", "PROBLEM", 153, 174], ["biological attacks", "PROBLEM", 211, 229], ["infections", "OBSERVATION", 80, 90]]], ["Communicable disease reporting requirements (also known as Infectious Disease Reporting) vary within each state and even county, but overall, there are state laws requiring medical providers to report notifiable disease to local public health departments [1] .", [["Communicable disease reporting requirements", "PROBLEM", 0, 43]]], ["While there is variation in the lists of notifiable diseases that states require healthcare providers to report, there is a general consistency of common and concerning microorganisms that includes all Category A agents and a majority of those listed within the Center for Disease Control and Prevention's (CDC) bioterrorism agents page [2] [3] [4] [5] .", [["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 337, 352], ["a general consistency of common and concerning microorganisms", "PROBLEM", 122, 183], ["Disease Control", "TREATMENT", 273, 288], ["Prevention's (CDC) bioterrorism agents", "TREATMENT", 293, 331], ["variation", "OBSERVATION_MODIFIER", 15, 24]]], ["Within hospitals and healthcare facilities, it is generally the IPC program that is responsible for reporting communicable diseases to local public health authorities.", [["communicable diseases", "PROBLEM", 110, 131]]], ["While laboratory reporting can and does happen, it is mostly incomplete information and commonly limited to the positive laboratory result and the name of the patient.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166]]], ["The legal responsibility of reporting the communicable diseases ultimately tends to fall upon the infection prevention and control program, which must not only report such diseases with complete patient and laboratory information, but also within the required time frame.", [["communicable diseases", "DISEASE", 42, 63], ["infection", "DISEASE", 98, 107], ["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202], ["the communicable diseases", "PROBLEM", 38, 63], ["the infection prevention", "TREATMENT", 94, 118], ["such diseases", "PROBLEM", 167, 180], ["infection", "OBSERVATION", 98, 107]]], ["State reporting laws dictate the list of notifiable diseases and their required reporting time frame.", [["notifiable diseases", "PROBLEM", 41, 60]]], ["For example, in California, the California Code of Regulations requires a report for West Nile virus infection be submitted by electronic transmission, telephone, or mail within one working day of identification, while a human or animal case of plague requires immediate reporting by phone [6] .", [["West Nile virus infection", "DISEASE", 85, 110], ["West Nile virus", "ORGANISM", 85, 100], ["human", "ORGANISM", 221, 226], ["Nile virus", "SPECIES", 90, 100], ["human", "SPECIES", 221, 226], ["West Nile virus", "SPECIES", 85, 100], ["human", "SPECIES", 221, 226], ["West Nile virus infection", "PROBLEM", 85, 110], ["California", "OBSERVATION_MODIFIER", 16, 26]]], ["These lists mirror that of the CDC's National Notifiable Diseases Surveillance System (NNDSS).", [["Notifiable Diseases", "DISEASE", 46, 65]]], ["In essence, the reporting structure commonly begins with the IP performing surveillance based off laboratory reports and daily reports of admitting diagnoses for newly admitted patients.", [["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185]]], ["In short, national diseases surveillance and reporting frequently starts with hospital IPC programs.", [["hospital IPC programs", "TREATMENT", 78, 99]]], ["IPC programs have a critical role in communicable disease reporting, which aids in public health response.", [["IPC programs", "TREATMENT", 0, 12], ["communicable disease", "PROBLEM", 37, 57]]], ["The strength of the infection prevention and control program will be seen in their ability to perform more specific surveillance and real-time disease reporting.", [["infection", "DISEASE", 20, 29], ["the infection prevention", "TREATMENT", 16, 40], ["control program", "TREATMENT", 45, 60], ["specific surveillance", "TEST", 107, 128], ["strength", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 20, 29]]], ["Poorly supported or minimally staffed IPC programs will likely rely solely on microbiology reports and might be delayed in their surveillance and reporting efforts.", [["minimally staffed IPC programs", "TREATMENT", 20, 50]]], ["Some diseases, like Kawasaki syndrome, cannot be confirmed by laboratory tests, which can be challenging, but is overcome through daily chart review and a strong relationship with physicians and other clinical staff.", [["Kawasaki syndrome", "DISEASE", 20, 37], ["Some diseases", "PROBLEM", 0, 13], ["Kawasaki syndrome", "PROBLEM", 20, 37], ["laboratory tests", "TEST", 62, 78], ["diseases", "OBSERVATION", 5, 13], ["Kawasaki syndrome", "OBSERVATION", 20, 37]]], ["Moreover, once a case is identified as a communicable disease that must be reported, the skilled IP will not only report the required information (e.g., laboratory results, demographics, contact info) but also relevant medical record information for the condition, which will include a timeline of illness, travel history, physician notes, etc. Such attention to detail facilitates a more rapid and efficient response from public health authorities.", [["illness", "DISEASE", 298, 305], ["a communicable disease", "PROBLEM", 39, 61]]], ["Overall, the infection prevention and control program within healthcare facilities is frequently the primary source of communicable disease reporting, which is a vital part of public health response during biological events.Coordination Among Internal DepartmentsIPC programs are a connective tissue within the healthcare setting, working across professions and job roles to ensure the response to infectious disease threats is appropriate.", [["connective tissue", "ANATOMY", 282, 299], ["infection", "DISEASE", 13, 22], ["connective tissue", "TISSUE", 282, 299], ["the infection prevention", "TREATMENT", 9, 33], ["communicable disease", "PROBLEM", 119, 139], ["infectious disease threats", "PROBLEM", 398, 424], ["infection", "OBSERVATION", 13, 22]]], ["It is the responsibility of the IPC program to ensure that clinical staff follow infection control guidelines, but also ancillary staff, which includes but is not limited to environmental services, facilities, sterile processing and disinfection, laboratory, security, or food services.", [["infection", "DISEASE", 81, 90], ["the IPC program", "TREATMENT", 28, 43], ["infection control guidelines", "TREATMENT", 81, 109], ["sterile processing", "TREATMENT", 210, 228]]], ["IPC coordinates with these departments to ensure the proper education and compliance is ongoing as interaction with patients is not solely limited to healthcare providers.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124]]], ["Aside from ensuring infection control practices are followed, the IPC program must also coordinate with different departments within the healthcare facility/system to ensure the proper expertise are being utilized.", [["infection", "DISEASE", 20, 29], ["ensuring infection control practices", "PROBLEM", 11, 47], ["the IPC program", "TREATMENT", 62, 77], ["infection", "OBSERVATION", 20, 29]]], ["A relatively simple task, like installing cabling or renovating a new space can bring with it substantial patient safety concerns due to dust, mold, etc. IPC must consider the full spectrum of affected people and departments during biological incidents, for example; during a public health emergency or treatment of a patient in enhanced precautions, IPC must coordinate with environmental services to ensure proper waste disposal is being performed.", [["patient", "ORGANISM", 106, 113], ["people", "ORGANISM", 202, 208], ["patient", "ORGANISM", 318, 325], ["patient", "SPECIES", 106, 113], ["people", "SPECIES", 202, 208], ["patient", "SPECIES", 318, 325], ["dust", "PROBLEM", 137, 141], ["IPC", "TREATMENT", 154, 157], ["treatment", "TREATMENT", 303, 312], ["a patient in enhanced precautions", "TREATMENT", 316, 349], ["IPC", "TREATMENT", 351, 354], ["environmental services", "TREATMENT", 376, 398]]], ["In the event of a pediatric patient with Ebola virus disease, IPC must ensure that Child Life Services are able to provide recommendations and guidance in regards to the unique needs of pediatric patients.", [["Ebola virus disease", "DISEASE", 41, 60], ["patient", "ORGANISM", 28, 35], ["Ebola virus", "ORGANISM", 41, 52], ["patients", "ORGANISM", 196, 204], ["patient", "SPECIES", 28, 35], ["Ebola virus", "SPECIES", 41, 52], ["patients", "SPECIES", 196, 204], ["Ebola virus", "SPECIES", 41, 52], ["Ebola virus disease", "PROBLEM", 41, 60], ["IPC", "TREATMENT", 62, 65]]], ["Such unique situations require IPC response and coordination of expert opinions to ensure the most appropriate actions are taken.", [["IPC response", "TREATMENT", 31, 43]]], ["During an influx of patients with an infectious disease or in the wake of an attack, IPC will be an integral component to hospital response and coordination of efforts.", [["infectious disease", "DISEASE", 37, 55], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["an infectious disease", "PROBLEM", 34, 55], ["IPC", "TREATMENT", 85, 88], ["infectious", "OBSERVATION", 37, 47]]], ["In emergent situations, the Hospital Incident Command System (HICS) may be initiated, of which IPC plays a vital role in providing instructions and expert recommendations.Isolation Precautions and Personal Protective EquipmentIsolation precautions are singularly one of the most critical components to preventing the spread of infectious diseases during patient care.", [["infectious diseases", "DISEASE", 327, 346], ["patient", "ORGANISM", 354, 361], ["patient", "SPECIES", 354, 361], ["Isolation Precautions", "TREATMENT", 171, 192], ["Personal Protective EquipmentIsolation precautions", "TREATMENT", 197, 247], ["infectious diseases", "PROBLEM", 327, 346], ["infectious", "OBSERVATION", 327, 337]]], ["The rapid isolation and adherence to personal protective equipment guidelines are imperative in daily patient care, but will become even more pertinent during infectious disease crises.", [["infectious disease crises", "DISEASE", 159, 184], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["The rapid isolation", "TREATMENT", 0, 19], ["personal protective equipment guidelines", "TREATMENT", 37, 77], ["infectious disease crises", "PROBLEM", 159, 184], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["isolation", "OBSERVATION", 10, 19]]], ["Adherence to standard precautions and hand hygiene is fundamental for all patient interactions.", [["hand", "ANATOMY", 38, 42], ["hand", "ORGANISM_SUBDIVISION", 38, 42], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["standard precautions", "TREATMENT", 13, 33], ["hand hygiene", "TREATMENT", 38, 50]]], ["However, additional transmission-based precautions may be needed during the medical care of patients with infectious diseases.", [["infectious diseases", "DISEASE", 106, 125], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["based precautions", "TREATMENT", 33, 50], ["infectious diseases", "PROBLEM", 106, 125], ["infectious", "OBSERVATION", 106, 116]]], ["Transmission-based precautions (isolation precautions) are often required in addition to standard precautions.", [["Transmission", "TEST", 0, 12], ["based precautions (isolation precautions", "TREATMENT", 13, 53], ["standard precautions", "TREATMENT", 89, 109]]], ["Full information on microorganism-specific isolation precautions and detailed PPE directions can be found within several CDC and World Health Organization (WHO) publications.", [["microorganism", "TEST", 20, 33], ["specific isolation precautions", "TREATMENT", 34, 64], ["detailed PPE directions", "TREATMENT", 69, 92]]], ["IPC recommendations follow CDC guidelines for isolation precautions and corresponding PPE based upon the identified microorganism (e.g., bacterial, viral, fungal).", [["isolation precautions", "TREATMENT", 46, 67], ["corresponding PPE", "PROBLEM", 72, 89], ["the identified microorganism", "PROBLEM", 101, 129], ["bacterial, viral, fungal)", "PROBLEM", 137, 162]]], ["Reference is made to the patient room, but isolation precautions should be applied to the area in which the patient is present (e.g., treatment room, post-procedural recovery bay).Personal Protective EquipmentPersonal protective equipment (PPE) in the healthcare setting includes gloves, gowns, masks, shoe covers, and eye-protection.", [["patient", "ORGANISM", 25, 32], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 25, 32], ["patient", "SPECIES", 108, 115], ["isolation precautions", "TREATMENT", 43, 64], ["Personal Protective EquipmentPersonal protective equipment", "TREATMENT", 180, 238], ["gloves", "TREATMENT", 280, 286], ["masks", "TREATMENT", 295, 300], ["shoe covers", "TREATMENT", 302, 313], ["eye-protection", "TREATMENT", 319, 333]]], ["These items are the most common and frequently used PPE during patient care, but additional PPE may be recommended in emergent situations.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["patient care", "TREATMENT", 63, 75], ["additional PPE", "TREATMENT", 81, 95]]], ["PPE provides a mutual benefit to both patient and healthcare worker as it reduces the spread of diseases between the two parties.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["PPE", "TREATMENT", 0, 3], ["diseases", "PROBLEM", 96, 104], ["diseases", "OBSERVATION", 96, 104]]], ["Correct utilization of PPE decreases the microbial burden in the environment as well, preventing the spread of disease through cross-contamination.", [["PPE", "CHEMICAL", 23, 26], ["PPE", "PROBLEM", 23, 26], ["disease through cross-contamination", "PROBLEM", 111, 146], ["PPE", "OBSERVATION_MODIFIER", 23, 26], ["decreases", "OBSERVATION_MODIFIER", 27, 36], ["microbial", "OBSERVATION_MODIFIER", 41, 50], ["burden", "OBSERVATION_MODIFIER", 51, 57], ["disease", "OBSERVATION", 111, 118]]], ["Improper use of PPE is common among healthcare workers, as the time to properly don can be taxing or because it is thought to be easier to continue wearing PPE if only leaving a patient's room momentarily (e.g., keeping a facemask on while running to the medication room).", [["PPE", "CHEMICAL", 16, 19], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["PPE", "TREATMENT", 156, 159], ["a facemask", "TREATMENT", 220, 230]]], ["For PPE to be effective, it must be donned prior to entering the patient room and doffed prior to leaving or upon exiting (depending upon the layout of the care area) to avoid contamination of the hospital unit.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["PPE", "PROBLEM", 4, 7]]], ["PPE should always be changed between patients and should never leave the patient's room, regardless of how short a simple task may appear.", [["patients", "ORGANISM", 37, 45], ["patient", "ORGANISM", 73, 80], ["patients", "SPECIES", 37, 45], ["patient", "SPECIES", 73, 80], ["PPE", "TREATMENT", 0, 3]]], ["If a patient is in isolation, anyone entering the room should don PPE, regardless of whether the planned task does not involve patient interaction or expected contact with the environment.", [["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 127, 134]]], ["Once in the patient's room, one cannot predict what will be needed or if an emergency will occur, meaning that PPE should be worn at all times while caring for a patient in isolation.Personal Protective EquipmentIsolation precautions and the required PPE range from standard precautions to airborne isolation, all of which have different and distinct requirements.", [["patient", "ORGANISM", 12, 19], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 12, 19], ["patient", "SPECIES", 162, 169], ["PPE", "TREATMENT", 111, 114], ["Personal Protective EquipmentIsolation precautions", "TREATMENT", 183, 233], ["PPE range", "TREATMENT", 251, 260], ["standard precautions", "TREATMENT", 266, 286], ["airborne isolation", "TREATMENT", 290, 308], ["distinct", "OBSERVATION_MODIFIER", 342, 350], ["requirements", "OBSERVATION_MODIFIER", 351, 363]]], ["Adherence to CDC isolation precaution guidelines and manufacturer recommendations for the PPE are imperative for the treatment of patients with infectious diseases.", [["infectious diseases", "DISEASE", 144, 163], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["CDC isolation precaution guidelines", "TREATMENT", 13, 48], ["the PPE", "TREATMENT", 86, 93], ["the treatment", "TREATMENT", 113, 126], ["infectious diseases", "PROBLEM", 144, 163], ["infectious", "OBSERVATION", 144, 154]]], ["Regardless of origin, vigilant adherence to proper isolation and PPE guidelines will aid in infection prevention and control efforts, which can halt an outbreak in its tracks.", [["infection", "DISEASE", 92, 101], ["proper isolation", "TREATMENT", 44, 60], ["PPE guidelines", "TREATMENT", 65, 79], ["infection prevention", "TREATMENT", 92, 112], ["infection", "OBSERVATION", 92, 101]]], ["PPE can and should be worn by visitors of the patient however, this is limited to PPE that does not require fit-testing (i.e., respiratory protection for patients with airborne microorganisms, like N-95 masks, should not be worn by visitors or patients as they require special fit-testing to ensure proper sizing).", [["patient", "ORGANISM", 46, 53], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 244, 252], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 244, 252], ["PPE", "PROBLEM", 82, 85], ["fit-testing", "TEST", 108, 119], ["respiratory protection", "TREATMENT", 127, 149], ["airborne microorganisms", "PROBLEM", 168, 191], ["special fit-testing", "TEST", 269, 288]]], ["During hospitalization, the room of an contagious patient should have the proper signage on the door indicating which transmission-based precautions are being used so that all staff or visitors entering may wear the necessary PPE.Standard PrecautionsStandard precautions (also referred to Universal Precautions) are basic precautions that should be utilized on all patients as a means of reducing the transmission risk of, for instance, bloodborne pathogens [37] .", [["patient", "ORGANISM", 50, 57], ["patients", "ORGANISM", 365, 373], ["patient", "SPECIES", 50, 57], ["patients", "SPECIES", 365, 373], ["based precautions", "TREATMENT", 131, 148], ["the necessary PPE", "TREATMENT", 212, 229], ["Standard precautions", "TREATMENT", 250, 270], ["Universal Precautions", "TREATMENT", 289, 310], ["basic precautions", "TREATMENT", 316, 333], ["bloodborne pathogens", "PROBLEM", 437, 457]]], ["The most basic premise is to use hand hygiene and assess the risk of a potential exposure to blood or other potentially contaminated material (e.g., urine, feces, breast milk) and use the corresponding PPE.", [["hand", "ANATOMY", 33, 37], ["blood", "ANATOMY", 93, 98], ["urine", "ANATOMY", 149, 154], ["feces", "ANATOMY", 156, 161], ["breast milk", "ANATOMY", 163, 174], ["hand", "ORGANISM_SUBDIVISION", 33, 37], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["material", "TISSUE", 133, 141], ["urine", "ORGANISM_SUBSTANCE", 149, 154], ["feces", "ORGANISM_SUBDIVISION", 156, 161], ["breast", "ORGANISM_SUBDIVISION", 163, 169], ["milk", "ORGANISM_SUBSTANCE", 170, 174], ["hand hygiene", "TREATMENT", 33, 45], ["blood or other potentially contaminated material (e.g., urine, feces, breast milk", "PROBLEM", 93, 174], ["the corresponding PPE", "TREATMENT", 184, 205], ["breast", "ANATOMY", 163, 169]]], ["Standard precautions encourage the healthcare worker to consider the tasks being performed and apply critical thinking to the risk of potential exposure and then select PPE based upon this assessment.", [["Standard precautions", "TREATMENT", 0, 20], ["the tasks", "TEST", 65, 74], ["this assessment", "TEST", 184, 199]]], ["For example, drawing blood typically only calls for gloves, but if the patient is thrashing or aggressive, the healthcare worker should consider eye protection.", [["blood", "ANATOMY", 21, 26], ["eye", "ANATOMY", 145, 148], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["patient", "ORGANISM", 71, 78], ["eye", "ORGAN", 145, 148], ["patient", "SPECIES", 71, 78], ["drawing blood", "TEST", 13, 26], ["gloves", "TREATMENT", 52, 58], ["thrashing", "PROBLEM", 82, 91], ["eye protection", "TREATMENT", 145, 159]]], ["Another component to standard precautions is respiratory hygiene and cough etiquette.", [["respiratory", "ANATOMY", 45, 56], ["cough", "DISEASE", 69, 74], ["standard precautions", "TREATMENT", 21, 41], ["respiratory hygiene", "TREATMENT", 45, 64], ["cough etiquette", "PROBLEM", 69, 84]]], ["This lesson was developed and became essential during the SARS outbreak and has now become a staple within universal precautions.", [["SARS", "DISEASE", 58, 62], ["the SARS outbreak", "PROBLEM", 54, 71], ["a staple within universal precautions", "TREATMENT", 91, 128], ["staple", "OBSERVATION", 93, 99]]], ["Respiratory hygiene and cough etiquette highlights the importance of education for healthcare workers, patients, and visitors, to ensure they cover their mouth and nose when coughing or sneezing, perform hand hygiene following exposure to respiratory secretions, and practice spatial separation of febrile persons with respiratory symptoms.", [["Respiratory", "ANATOMY", 0, 11], ["mouth", "ANATOMY", 154, 159], ["hand", "ANATOMY", 204, 208], ["respiratory secretions", "ANATOMY", 239, 261], ["respiratory", "ANATOMY", 319, 330], ["cough", "DISEASE", 24, 29], ["sneezing", "DISEASE", 186, 194], ["febrile", "DISEASE", 298, 305], ["respiratory symptoms", "DISEASE", 319, 339], ["patients", "ORGANISM", 103, 111], ["mouth", "ORGANISM_SUBDIVISION", 154, 159], ["nose", "ORGANISM_SUBDIVISION", 164, 168], ["hand", "ORGANISM_SUBDIVISION", 204, 208], ["persons", "ORGANISM", 306, 313], ["patients", "SPECIES", 103, 111], ["persons", "SPECIES", 306, 313], ["Respiratory hygiene", "TREATMENT", 0, 19], ["coughing", "PROBLEM", 174, 182], ["sneezing", "PROBLEM", 186, 194], ["hand hygiene", "TREATMENT", 204, 216], ["respiratory secretions", "PROBLEM", 239, 261], ["febrile persons", "PROBLEM", 298, 313], ["respiratory symptoms", "PROBLEM", 319, 339], ["mouth", "ANATOMY", 154, 159], ["nose", "ANATOMY", 164, 168], ["respiratory", "ANATOMY", 239, 250], ["secretions", "OBSERVATION", 251, 261]]], ["The goal of standard precautions is to ensure that, at the most basic level, healthcare workers are protected against blood and other potentially contaminated material through hand hygiene and risk-based PPE utilization.", [["blood", "ANATOMY", 118, 123], ["hand", "ANATOMY", 176, 180], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["hand", "ORGANISM_SUBDIVISION", 176, 180], ["standard precautions", "TREATMENT", 12, 32], ["blood", "PROBLEM", 118, 123], ["hand hygiene", "TREATMENT", 176, 188]]], ["Additional transmission-based precautions, such as contact isolation precautions, build upon standard precautions, meaning that standard precautions will always be used.Hand HygieneThe most basic and effective tool in the infection prevention arsenal is hand hygiene.", [["hand", "ANATOMY", 254, 258], ["infection", "DISEASE", 222, 231], ["hand", "ORGANISM_SUBDIVISION", 254, 258], ["based precautions", "TREATMENT", 24, 41], ["contact isolation precautions", "TREATMENT", 51, 80], ["standard precautions", "TREATMENT", 93, 113], ["standard precautions", "TREATMENT", 128, 148], ["Hygiene", "OBSERVATION", 174, 181], ["most basic", "OBSERVATION_MODIFIER", 185, 195], ["effective", "OBSERVATION_MODIFIER", 200, 209], ["infection", "OBSERVATION", 222, 231]]], ["Competent hand hygiene practices can prevent the transmission of diseases, making it the foundation for infection prevention [32] .", [["hand", "ANATOMY", 10, 14], ["infection", "DISEASE", 104, 113], ["hand", "ORGANISM_SUBDIVISION", 10, 14], ["diseases", "PROBLEM", 65, 73], ["infection prevention", "TREATMENT", 104, 124]]], ["Efforts to maintain compliance can be challenging as healthcare workers are expected to perform hand hygiene before and after patient interaction [30, 31] .", [["hand", "ANATOMY", 96, 100], ["hand", "ORGANISM_SUBDIVISION", 96, 100], ["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133]]], ["The new WHO model for hand hygiene goes beyond the \"before and after patient care\" practice and emphasizes moments during the patient care process.", [["hand", "ANATOMY", 22, 26], ["hand", "ORGANISM_SUBDIVISION", 22, 26], ["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 126, 133], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["The Five Moments of Hand Hygiene (frequently called \"5 moments\") model emphasizes a broader approach to hand hygiene that encompasses the intricacies of patient care.", [["hand", "ANATOMY", 104, 108], ["hand", "ORGANISM_SUBDIVISION", 104, 108], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["hand hygiene", "TREATMENT", 104, 116]]], ["The WHO's 5 Moments model is increasingly becoming the standard practice and includes five moments in which hand hygiene should be performed: before patient contact, before aseptic tasks, after body fluid exposure risk, after patient contact, and after contact with patient surroundings [7] .", [["hand", "ANATOMY", 108, 112], ["body fluid", "ANATOMY", 194, 204], ["hand", "ORGANISM_SUBDIVISION", 108, 112], ["patient", "ORGANISM", 149, 156], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["patient", "ORGANISM", 226, 233], ["patient", "ORGANISM", 266, 273], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 226, 233], ["patient", "SPECIES", 266, 273], ["aseptic tasks", "TEST", 173, 186], ["body fluid exposure risk", "PROBLEM", 194, 218]]], ["Hand hygiene should also be performed after removing gloves.", [["Hand hygiene", "TREATMENT", 0, 12], ["gloves", "TREATMENT", 53, 59]]], ["Gloves can easily be seen as a cure-all protective barrier however, hand hygiene should be performed following their removal as leakage during care and cross-contamination during removal is possible [8] .Hand HygieneHand hygiene is performed with either soap and water or alcohol-based hand sanitizer.", [["hand", "ANATOMY", 68, 72], ["hand", "ANATOMY", 286, 290], ["alcohol", "CHEMICAL", 272, 279], ["alcohol", "CHEMICAL", 272, 279], ["hand", "ORGANISM_SUBDIVISION", 68, 72], ["alcohol", "SIMPLE_CHEMICAL", 272, 279], ["hand", "ORGANISM_SUBDIVISION", 286, 290], ["Gloves", "TREATMENT", 0, 6], ["a cure", "TREATMENT", 29, 35], ["all protective barrier", "TREATMENT", 36, 58], ["hand hygiene", "TREATMENT", 68, 80], ["their removal", "TREATMENT", 111, 124], ["leakage during care", "TREATMENT", 128, 147], ["cross-contamination", "TREATMENT", 152, 171], ["removal", "TREATMENT", 179, 186], ["Hand HygieneHand hygiene", "TREATMENT", 204, 228]]], ["According to the CDC, washing with soap and water for 15-20 seconds should be performed when hands are visibly soiled, after known exposures to Clostridium difficile, after known or suspected exposures to patients with diarrhea during a norovirus outbreak, when exposure to Bacillus anthracis is suspected or proven, before eating, and after using the restroom.", [["Clostridium difficile", "DISEASE", 144, 165], ["diarrhea", "DISEASE", 219, 227], ["norovirus", "DISEASE", 237, 246], ["Bacillus anthracis", "DISEASE", 274, 292], ["hands", "ORGANISM_SUBDIVISION", 93, 98], ["Clostridium difficile", "ORGANISM", 144, 165], ["patients", "ORGANISM", 205, 213], ["Bacillus anthracis", "ORGANISM", 274, 292], ["Clostridium difficile", "SPECIES", 144, 165], ["patients", "SPECIES", 205, 213], ["Bacillus anthracis", "SPECIES", 274, 292], ["Clostridium difficile", "SPECIES", 144, 165], ["Bacillus anthracis", "SPECIES", 274, 292], ["soap and water", "TREATMENT", 35, 49], ["Clostridium difficile", "PROBLEM", 144, 165], ["diarrhea", "PROBLEM", 219, 227], ["a norovirus outbreak", "PROBLEM", 235, 255], ["Bacillus anthracis", "PROBLEM", 274, 292]]], ["If none of those situations are applicable, alcohol-based hand sanitizer is recommended and considered the most effective product.", [["hand", "ANATOMY", 58, 62], ["alcohol", "CHEMICAL", 44, 51], ["alcohol", "CHEMICAL", 44, 51], ["alcohol", "SIMPLE_CHEMICAL", 44, 51], ["hand", "ORGANISM_SUBDIVISION", 58, 62], ["alcohol-based hand sanitizer", "TREATMENT", 44, 72]]], ["Alcohol-based hand sanitizer (composed of 60-95% alcohol to maintain efficacy) is an easy and effective manner for hand hygiene that takes roughly 20 seconds to dry.", [["hand", "ANATOMY", 14, 18], ["hand", "ANATOMY", 115, 119], ["Alcohol", "CHEMICAL", 0, 7], ["alcohol", "CHEMICAL", 49, 56], ["alcohol", "CHEMICAL", 49, 56], ["hand", "ORGANISM_SUBDIVISION", 14, 18], ["alcohol", "SIMPLE_CHEMICAL", 49, 56], ["hand", "ORGANISM_SUBDIVISION", 115, 119], ["hand sanitizer", "TREATMENT", 14, 28], ["hand hygiene", "TREATMENT", 115, 127]]], ["Depending upon the situation, alcohol-based hand sanitizer can easily provide staff with an effective and timely method for cleaning their hands, which significantly improves compliance.Contact PrecautionsContact isolation precautions are used for microorganisms that are transmissible through touch or contact with the patient or a contaminated item (fomite).", [["hand", "ANATOMY", 44, 48], ["alcohol", "CHEMICAL", 30, 37], ["alcohol", "CHEMICAL", 30, 37], ["alcohol", "SIMPLE_CHEMICAL", 30, 37], ["hand", "ORGANISM_SUBDIVISION", 44, 48], ["patient", "ORGANISM", 320, 327], ["patient", "SPECIES", 320, 327], ["hand sanitizer", "TREATMENT", 44, 58], ["Contact isolation precautions", "TREATMENT", 205, 234], ["microorganisms", "PROBLEM", 248, 262]]], ["Contact precautions include wearing a gown and gloves during interaction with the patient or their environment.", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["Contact precautions", "TREATMENT", 0, 19], ["a gown", "TREATMENT", 36, 42], ["gloves", "TREATMENT", 47, 53]]], ["The most common examples of infections in which contact isolation is used include diarrheal illnesses, methicillin-resistant Staphylococcus aureus (MRSA), and draining abscesses.", [["draining abscesses", "ANATOMY", 159, 177], ["infections", "DISEASE", 28, 38], ["diarrheal illnesses", "DISEASE", 82, 101], ["methicillin", "CHEMICAL", 103, 114], ["Staphylococcus aureus", "DISEASE", 125, 146], ["MRSA", "DISEASE", 148, 152], ["abscesses", "DISEASE", 168, 177], ["methicillin", "CHEMICAL", 103, 114], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 103, 146], ["MRSA", "CANCER", 148, 152], ["abscesses", "PATHOLOGICAL_FORMATION", 168, 177], ["Staphylococcus aureus", "SPECIES", 125, 146], ["MRSA", "SPECIES", 148, 152], ["Staphylococcus aureus", "SPECIES", 125, 146], ["MRSA", "SPECIES", 148, 152], ["infections", "PROBLEM", 28, 38], ["diarrheal illnesses", "PROBLEM", 82, 101], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 103, 146], ["MRSA", "PROBLEM", 148, 152], ["draining abscesses", "PROBLEM", 159, 177], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infections", "OBSERVATION", 28, 38], ["Staphylococcus aureus", "OBSERVATION", 125, 146], ["draining", "OBSERVATION_MODIFIER", 159, 167], ["abscesses", "OBSERVATION", 168, 177]]], ["Contact precautions should also be taken during the care for patients infected with known or suspected multi-drug resistant microorganisms, Human Parainfluenza virus (HPIV) infection in pediatric patients, poliovirus, vaccinia virus (adverse events following vaccination, like generalized vaccinia or conjunctivitis), etc. Broadly speaking, contact precautions, should be used for patients with diarrhea or draining wounds, and should be considered for children who have respiratory illnesses.", [["wounds", "ANATOMY", 416, 422], ["respiratory", "ANATOMY", 471, 482], ["Human Parainfluenza virus (HPIV) infection", "DISEASE", 140, 182], ["vaccinia virus", "DISEASE", 218, 232], ["vaccinia", "DISEASE", 289, 297], ["conjunctivitis", "DISEASE", 301, 315], ["diarrhea", "DISEASE", 395, 403], ["respiratory illnesses", "DISEASE", 471, 492], ["patients", "ORGANISM", 61, 69], ["Human", "ORGANISM", 140, 145], ["Parainfluenza virus", "ORGANISM", 146, 165], ["patients", "ORGANISM", 196, 204], ["poliovirus", "ORGANISM", 206, 216], ["vaccinia virus", "ORGANISM", 218, 232], ["vaccinia", "ORGANISM", 289, 297], ["patients", "ORGANISM", 381, 389], ["wounds", "PATHOLOGICAL_FORMATION", 416, 422], ["children", "ORGANISM", 453, 461], ["patients", "SPECIES", 61, 69], ["Human", "SPECIES", 140, 145], ["Parainfluenza virus", "SPECIES", 146, 165], ["patients", "SPECIES", 196, 204], ["vaccinia virus", "SPECIES", 218, 232], ["patients", "SPECIES", 381, 389], ["children", "SPECIES", 453, 461], ["Human Parainfluenza virus", "SPECIES", 140, 165], ["HPIV", "SPECIES", 167, 171], ["vaccinia virus", "SPECIES", 218, 232], ["Contact precautions", "TREATMENT", 0, 19], ["multi-drug resistant microorganisms", "PROBLEM", 103, 138], ["Human Parainfluenza virus (HPIV) infection in pediatric patients", "PROBLEM", 140, 204], ["poliovirus", "PROBLEM", 206, 216], ["vaccinia virus", "PROBLEM", 218, 232], ["adverse events", "PROBLEM", 234, 248], ["vaccination", "TREATMENT", 259, 270], ["generalized vaccinia", "PROBLEM", 277, 297], ["conjunctivitis", "PROBLEM", 301, 315], ["contact precautions", "TREATMENT", 341, 360], ["diarrhea", "PROBLEM", 395, 403], ["draining wounds", "PROBLEM", 407, 422], ["respiratory illnesses", "PROBLEM", 471, 492], ["multi-drug resistant microorganisms", "OBSERVATION", 103, 138], ["Parainfluenza virus", "OBSERVATION", 146, 165], ["conjunctivitis", "OBSERVATION", 301, 315]]], ["The necessary PPE for contact precautions, gown and gloves, should be donned appropriately before entering the room, and removed at the threshold, prior to exiting.", [["The necessary PPE", "TREATMENT", 0, 17], ["contact precautions", "TREATMENT", 22, 41], ["gown and gloves", "TREATMENT", 43, 58]]], ["Depending on the make of the gown, it is important to follow manufacturers' recommendations for removal (like pulling away from the body to break any ties in the back.) and wear (i.e., wearing the gown over the shoulders, not hanging down around the elbows).", [["body", "ANATOMY", 132, 136], ["shoulders", "ANATOMY", 211, 220], ["elbows", "ANATOMY", 250, 256], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["shoulders", "ORGANISM_SUBDIVISION", 211, 220], ["elbows", "ORGANISM_SUBDIVISION", 250, 256], ["removal", "TREATMENT", 96, 103], ["back", "ANATOMY", 162, 166], ["shoulders", "ANATOMY", 211, 220], ["elbows", "ANATOMY", 250, 256]]], ["Contact precautions are an effective practice for protecting the healthcare worker against infectious diseases that are spread through touch and fomites.Droplet PrecautionsDroplet isolation precautions are used to help stop the spread of microorganisms that are spread through tiny droplets that are disseminated through sneezing and coughing.", [["infectious diseases", "DISEASE", 91, 110], ["sneezing", "DISEASE", 321, 329], ["coughing", "DISEASE", 334, 342], ["Contact precautions", "TREATMENT", 0, 19], ["infectious diseases", "PROBLEM", 91, 110], ["Droplet Precautions", "TREATMENT", 153, 172], ["Droplet isolation precautions", "TREATMENT", 172, 201], ["microorganisms", "PROBLEM", 238, 252], ["tiny droplets", "PROBLEM", 277, 290], ["sneezing", "PROBLEM", 321, 329], ["coughing", "PROBLEM", 334, 342], ["tiny", "OBSERVATION_MODIFIER", 277, 281], ["droplets", "OBSERVATION", 282, 290], ["disseminated", "OBSERVATION_MODIFIER", 300, 312]]], ["The most common causes of droplet precautions are pneumonia, seasonal influenza, pertussis, and bacterial meningitis.", [["pneumonia", "DISEASE", 50, 59], ["seasonal influenza, pertussis", "DISEASE", 61, 90], ["bacterial meningitis", "DISEASE", 96, 116], ["droplet precautions", "TREATMENT", 26, 45], ["pneumonia", "PROBLEM", 50, 59], ["seasonal influenza", "PROBLEM", 61, 79], ["pertussis", "PROBLEM", 81, 90], ["bacterial meningitis", "PROBLEM", 96, 116], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["droplet precautions", "OBSERVATION", 26, 45], ["pneumonia", "OBSERVATION", 50, 59], ["seasonal influenza", "OBSERVATION", 61, 79], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["meningitis", "OBSERVATION", 106, 116]]], ["Droplet precautions can frequently be confused with airborne precautions, but these precautions focus on those microorganisms that are transmitted via droplets during close proximity interactions [9] .", [["Droplet precautions", "TREATMENT", 0, 19], ["confused", "PROBLEM", 38, 46], ["airborne precautions", "TREATMENT", 52, 72], ["these precautions", "TREATMENT", 78, 95]]], ["To protect against droplet-spread microorganisms, a surgical mask should be worn while in the patient's room.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["droplet-spread microorganisms", "PROBLEM", 19, 48], ["a surgical mask", "TREATMENT", 50, 65]]], ["The mask should be put on prior to entering the room and removed upon exiting the room.", [["The mask", "TREATMENT", 0, 8]]], ["While most PPE should not be worn outside of the room, a surgical mask should be discarded in the trash after leaving the room [10] .", [["a surgical mask", "TREATMENT", 55, 70]]], ["Hand hygiene should be performed after the mask is removed upon exiting of the room.", [["Hand hygiene", "TREATMENT", 0, 12], ["the mask", "TREATMENT", 39, 47]]], ["Masks should always be disposed of after leaving the room and should not be re-used for multiple patients as the mask is considered contamination after being touched.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["the mask", "TREATMENT", 109, 117]]], ["The Association of Perioperative Registered Nurses (AORN), Food and Drug Administration (FDA), WHO, and CDC all recommend disposal of FDA-approved medical masks after single use and that healthcare workers should don a new mask for each contact with a new patient [11] .", [["patient", "ORGANISM", 256, 263], ["patient", "SPECIES", 256, 263], ["Perioperative Registered Nurses (AORN)", "TREATMENT", 19, 57], ["a new mask", "TREATMENT", 217, 227]]], ["AORN highlights the hazards of reusing surgical masks by saving them or hanging them around the neck.", [["neck", "ANATOMY", 96, 100], ["AORN", "DISEASE", 0, 4], ["neck", "ORGANISM_SUBDIVISION", 96, 100], ["surgical masks", "TREATMENT", 39, 53], ["surgical masks", "OBSERVATION", 39, 53], ["neck", "ANATOMY", 96, 100]]], ["Droplet precautions are an effective infection control strategy for preventing the spread of infectious diseases that are spread via droplets and close contact.Airborne PrecautionsAirborne isolation precautions are required during the care of patients who have or are suspected of having diseases like tuberculosis, measles, or chickenpox, which are caused by small organisms (<5 \u03bcm in diameter) that easily flow on air currents.", [["infection", "DISEASE", 37, 46], ["infectious diseases", "DISEASE", 93, 112], ["tuberculosis", "DISEASE", 302, 314], ["measles", "DISEASE", 316, 323], ["chickenpox", "DISEASE", 328, 338], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["Droplet precautions", "TREATMENT", 0, 19], ["an effective infection control strategy", "TREATMENT", 24, 63], ["infectious diseases", "PROBLEM", 93, 112], ["Airborne Precautions", "TREATMENT", 160, 180], ["Airborne isolation precautions", "TREATMENT", 180, 210], ["diseases", "PROBLEM", 288, 296], ["tuberculosis", "PROBLEM", 302, 314], ["measles", "PROBLEM", 316, 323], ["chickenpox", "PROBLEM", 328, 338], ["small organisms", "PROBLEM", 360, 375], ["effective", "OBSERVATION_MODIFIER", 27, 36], ["infection", "OBSERVATION", 37, 46], ["infectious", "OBSERVATION", 93, 103], ["tuberculosis", "OBSERVATION", 302, 314], ["small", "OBSERVATION_MODIFIER", 360, 365], ["air currents", "OBSERVATION", 416, 428]]], ["Patients infected with such pathogens are capable of transmitting disease through respiratory secretions that are aerosolized during coughing, sneezing, suctioning procedures, etc. Airborne precautions are perhaps the most challenging as they require healthcare workers to wear appropriate respirators that have been fit-tested.", [["respiratory secretions", "ANATOMY", 82, 104], ["sneezing", "DISEASE", 143, 151], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["such pathogens", "PROBLEM", 23, 37], ["transmitting disease through respiratory secretions", "PROBLEM", 53, 104], ["coughing", "PROBLEM", 133, 141], ["sneezing", "PROBLEM", 143, 151], ["suctioning procedures", "TREATMENT", 153, 174], ["Airborne precautions", "TREATMENT", 181, 201], ["appropriate respirators", "TREATMENT", 278, 301], ["infected", "OBSERVATION", 9, 17], ["respiratory", "ANATOMY", 82, 93], ["secretions", "OBSERVATION", 94, 104], ["aerosolized", "OBSERVATION_MODIFIER", 114, 125]]], ["Adherence to airborne isolation requires healthcare workers to be fit-tested to ensure the National Institute for Occupational Safety and Health (NIOSH)-approved N-95 or higher level respirators maintain a proper seal around the face.", [["N-95", "CHEMICAL", 162, 166], ["airborne isolation", "TREATMENT", 13, 31], ["airborne isolation", "OBSERVATION", 13, 31], ["proper seal", "OBSERVATION", 206, 217], ["face", "ANATOMY", 229, 233]]], ["These masks should be donned prior to entering the room, removed after exiting the room, and then disposed of.Airborne PrecautionsOne of the most crucial aspects of airborne precautions is that the patient must be in an appropriate negative air pressure room.", [["patient", "ORGANISM", 198, 205], ["patient", "SPECIES", 198, 205], ["These masks", "TREATMENT", 0, 11], ["airborne precautions", "TREATMENT", 165, 185], ["airborne precautions", "OBSERVATION", 165, 185], ["air pressure", "OBSERVATION", 241, 253]]], ["Negative pressure rooms (also called airborne isolation rooms or AIIR) are designated rooms with the proper engineering controls to ensure that aerosol particles containing microorganisms <5 \u03bcm in diameter are kept inside the room.", [["aerosol particles containing microorganisms", "PROBLEM", 144, 187], ["pressure rooms", "OBSERVATION", 9, 23]]], ["It is vital to maintain negative air pressure, as it ensures that the air flow is from outside into the room, which prevents such microorganisms from being carried into the hallway and adjacent spaces (more information on negative air pressure rooms can be found in the section on environmental infection control).", [["infection", "DISEASE", 295, 304], ["the air flow", "PROBLEM", 66, 78], ["such microorganisms", "PROBLEM", 125, 144], ["negative air pressure rooms", "TREATMENT", 222, 249], ["environmental infection control", "TREATMENT", 281, 312], ["air pressure", "OBSERVATION", 33, 45], ["air flow", "OBSERVATION", 70, 78]]], ["If a patient is suspected of having a disease that requires airborne isolation, it is critical to have them wear a surgical mask until a negative pressure room is available.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["a disease", "PROBLEM", 36, 45], ["airborne isolation", "TREATMENT", 60, 78], ["a surgical mask", "TREATMENT", 113, 128], ["disease", "OBSERVATION", 38, 45], ["airborne isolation", "OBSERVATION", 60, 78]]], ["One of the most common sources for exposures is delay in placing the patient into airborne isolation.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["airborne isolation", "TREATMENT", 82, 100]]], ["Healthcare workers should don N-95 respirators while in the patient's room and the patient should wear a regular surgical mask during transportation or in an area that is not negative pressure.", [["patient", "ORGANISM", 60, 67], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 60, 67], ["patient", "SPECIES", 83, 90], ["a regular surgical mask", "TREATMENT", 103, 126], ["not", "UNCERTAINTY", 171, 174], ["negative", "OBSERVATION", 175, 183]]], ["The use of a surgical mask for patients acts as a protection for those in the rest of the healthcare space.Airborne PrecautionsAirborne isolation is perhaps the most prudent during bioweapons-related or high-consequence biological events.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["a surgical mask", "TREATMENT", 11, 26], ["a protection", "TREATMENT", 48, 60], ["Airborne Precautions", "TREATMENT", 107, 127], ["Airborne isolation", "TREATMENT", 127, 145], ["high-consequence biological events", "PROBLEM", 203, 237]]], ["Patients with high-consequence pathogens, such as monkeypox, SARS, smallpox, viral hemorrhagic fevers, MERS, and influenza, require airborne isolation with some additional isolation precautions.", [["high-consequence pathogens", "DISEASE", 14, 40], ["monkeypox", "DISEASE", 50, 59], ["SARS", "DISEASE", 61, 65], ["smallpox", "DISEASE", 67, 75], ["viral hemorrhagic fevers", "DISEASE", 77, 101], ["MERS", "DISEASE", 103, 107], ["influenza", "DISEASE", 113, 122], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["high-consequence pathogens", "PROBLEM", 14, 40], ["monkeypox", "PROBLEM", 50, 59], ["SARS", "PROBLEM", 61, 65], ["smallpox", "TREATMENT", 67, 75], ["viral hemorrhagic fevers", "PROBLEM", 77, 101], ["MERS", "PROBLEM", 103, 107], ["influenza", "PROBLEM", 113, 122], ["airborne isolation", "TREATMENT", 132, 150], ["some additional isolation precautions", "TREATMENT", 156, 193], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["hemorrhagic", "OBSERVATION_MODIFIER", 83, 94], ["fevers", "OBSERVATION", 95, 101]]], ["Airborne isolation is the most challenging aspect of dealing with such biological threats as it requires the unique environmental controls that can pose challenging during an influx of patients with infectious diseases or in resource poor areas.", [["infectious diseases", "DISEASE", 199, 218], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["Airborne isolation", "TREATMENT", 0, 18], ["infectious diseases", "PROBLEM", 199, 218], ["most challenging", "OBSERVATION_MODIFIER", 26, 42]]], ["A recent WHO report highlighted the role of healthcare facilities and infection control failures in MERS outbreaks, which underscores the consequences of PPE and infection control failures [12, 13] .", [["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 162, 171], ["infection control failures in MERS outbreaks", "PROBLEM", 70, 114], ["PPE", "PROBLEM", 154, 157], ["infection control failures", "PROBLEM", 162, 188], ["infection", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 162, 171]]], ["It is a common practice in healthcare that a patient with a cough/fever has to wear a mask until infectious etiologies can be ruled out.", [["cough", "DISEASE", 60, 65], ["fever", "DISEASE", 66, 71], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["a cough", "PROBLEM", 58, 65], ["fever", "PROBLEM", 66, 71], ["a mask", "TREATMENT", 84, 90], ["infectious etiologies", "PROBLEM", 97, 118]]], ["By simply having a potentially sick patient wear a surgical mask during the triage process, healthcare workers and other patients can be protected, regardless whether the patient has an infectious disease that is spread by droplet or airborne mechanisms.", [["patient", "ORGANISM", 36, 43], ["patients", "ORGANISM", 121, 129], ["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 36, 43], ["patients", "SPECIES", 121, 129], ["patient", "SPECIES", 171, 178], ["a surgical mask", "TREATMENT", 49, 64], ["an infectious disease", "PROBLEM", 183, 204], ["infectious", "OBSERVATION", 186, 196]]], ["Although airborne isolation can be the most taxing in terms of ensuring properly fitted masks are used and negative pressure rooms are available, these are vital components to infection control for high-consequence and highly transmissible diseases.Combination or Enhanced PrecautionsIn many cases, combining isolation precautions is most beneficial.", [["infection", "DISEASE", 176, 185], ["airborne isolation", "TREATMENT", 9, 27], ["pressure rooms", "TREATMENT", 116, 130], ["infection control", "TREATMENT", 176, 193], ["highly transmissible diseases", "PROBLEM", 219, 248], ["Enhanced Precautions", "TREATMENT", 264, 284], ["combining isolation precautions", "TREATMENT", 299, 330], ["airborne isolation", "OBSERVATION", 9, 27]]], ["As medical care grow is in complexity and more people are involved in patient care, there is a higher risk for spreading microorganisms via aerosol-generating procedures or contaminated surfaces/objects.", [["people", "ORGANISM", 47, 53], ["patient", "ORGANISM", 70, 77], ["people", "SPECIES", 47, 53], ["patient", "SPECIES", 70, 77], ["spreading microorganisms", "PROBLEM", 111, 135], ["aerosol-generating procedures", "TREATMENT", 140, 169]]], ["Additional PPE, like boot/shoe covers, caps, etc., may be utilized in such isolation practices.", [["Additional PPE", "TREATMENT", 0, 14], ["boot/shoe covers", "TREATMENT", 21, 37], ["caps", "TREATMENT", 39, 43], ["such isolation practices", "TREATMENT", 70, 94], ["PPE", "OBSERVATION", 11, 14]]], ["However, proper PPE donning and doffing practices should always be followed [33] .", [["doffing practices", "TREATMENT", 32, 49]]], ["Some microorganisms, like Human herpesvirus 3 (HHV-3, varicella-zoster virus), require a combination of airborne and contact isolation due to the nature of the illness they cause and transmission mechanisms.", [["varicella-zoster virus", "DISEASE", 54, 76], ["Human herpesvirus 3", "ORGANISM", 26, 45], ["HHV-3", "ORGANISM", 47, 52], ["varicella-zoster virus", "ORGANISM", 54, 76], ["Human herpesvirus", "SPECIES", 26, 43], ["HHV-3", "SPECIES", 47, 52], ["varicella-zoster virus", "SPECIES", 54, 76], ["Human herpesvirus 3", "SPECIES", 26, 45], ["HHV-3", "SPECIES", 47, 52], ["varicella-zoster virus", "SPECIES", 54, 76], ["Some microorganisms", "PROBLEM", 0, 19], ["Human herpesvirus", "TEST", 26, 43], ["HHV", "TEST", 47, 50], ["varicella-zoster virus", "PROBLEM", 54, 76], ["airborne", "TREATMENT", 104, 112], ["contact isolation", "TREATMENT", 117, 134], ["the illness", "PROBLEM", 156, 167], ["microorganisms", "OBSERVATION", 5, 19], ["zoster virus", "OBSERVATION", 64, 76]]], ["It is also common in pediatric care to combine contact and droplet isolation during the care of patients with respiratory viruses (e.g., human metapneumonvirus, respiratory syncytial virus, rhinovirus) as children frequently spread such microorganisms through touch.", [["respiratory viruses", "DISEASE", 110, 129], ["respiratory syncytial virus", "DISEASE", 161, 188], ["rhinovirus", "DISEASE", 190, 200], ["patients", "ORGANISM", 96, 104], ["human", "ORGANISM", 137, 142], ["metapneumonvirus", "ORGANISM", 143, 159], ["respiratory syncytial virus", "ORGANISM", 161, 188], ["rhinovirus", "ORGANISM", 190, 200], ["children", "ORGANISM", 205, 213], ["patients", "SPECIES", 96, 104], ["human", "SPECIES", 137, 142], ["respiratory syncytial virus", "SPECIES", 161, 188], ["children", "SPECIES", 205, 213], ["human metapneumonvirus, respiratory syncytial virus", "SPECIES", 137, 188], ["droplet isolation", "TREATMENT", 59, 76], ["respiratory viruses", "PROBLEM", 110, 129], ["human metapneumonvirus", "PROBLEM", 137, 159], ["respiratory syncytial virus", "PROBLEM", 161, 188], ["rhinovirus", "PROBLEM", 190, 200], ["respiratory viruses", "OBSERVATION", 110, 129], ["respiratory syncytial", "ANATOMY", 161, 182]]], ["For example, according to CDC guidelines, respiratory infectious diseases (except for influenza, pertussis, etc.) only require standard precautions in adults.", [["respiratory infectious diseases", "DISEASE", 42, 73], ["influenza", "DISEASE", 86, 95], ["pertussis", "DISEASE", 97, 106], ["respiratory infectious diseases", "PROBLEM", 42, 73], ["influenza", "PROBLEM", 86, 95], ["pertussis", "PROBLEM", 97, 106], ["standard precautions", "TREATMENT", 127, 147], ["respiratory", "ANATOMY", 42, 53], ["infectious", "OBSERVATION", 54, 64]]], ["However, in infants and young children, standard plus contact isolation is encouraged, which emphasizes the need to assess the patient population when considering isolation precautions during care.", [["infants", "ORGANISM", 12, 19], ["children", "ORGANISM", 30, 38], ["patient", "ORGANISM", 127, 134], ["infants", "SPECIES", 12, 19], ["children", "SPECIES", 30, 38], ["patient", "SPECIES", 127, 134], ["isolation precautions", "TREATMENT", 163, 184]]], ["Combination precautions are especially beneficial if microorganisms are isolated from multiple sources, such as a patient with Carbapenem-resistant Enterobacteriaceae isolated from both a draining wound and an endotracheal secretion.", [["wound", "ANATOMY", 197, 202], ["endotracheal", "ANATOMY", 210, 222], ["Carbapenem", "CHEMICAL", 127, 137], ["patient", "ORGANISM", 114, 121], ["wound", "PATHOLOGICAL_FORMATION", 197, 202], ["patient", "SPECIES", 114, 121], ["Combination precautions", "TREATMENT", 0, 23], ["microorganisms", "PROBLEM", 53, 67], ["Carbapenem", "TREATMENT", 127, 137], ["resistant Enterobacteriaceae", "PROBLEM", 138, 166], ["a draining wound", "PROBLEM", 186, 202], ["an endotracheal secretion", "PROBLEM", 207, 232], ["draining wound", "OBSERVATION", 188, 202], ["endotracheal secretion", "OBSERVATION", 210, 232]]], ["Typically, contact precautions are sufficient.", [["contact precautions", "TREATMENT", 11, 30]]], ["However, if the microorganism is isolated in respiratory secretions, it is suggested that droplet precautions also be used.Combination or Enhanced PrecautionsThere is an increasing practice of combining and enhancing isolation precautions for severe, high-consequence, or novel infections as research is ongoing regarding their transmission mechanisms.", [["respiratory secretions", "ANATOMY", 45, 67], ["infections", "DISEASE", 278, 288], ["the microorganism", "PROBLEM", 12, 29], ["respiratory secretions", "PROBLEM", 45, 67], ["droplet precautions", "TREATMENT", 90, 109], ["Enhanced Precautions", "TREATMENT", 138, 158], ["enhancing isolation precautions", "TREATMENT", 207, 238], ["severe, high-consequence", "PROBLEM", 243, 267], ["novel infections", "PROBLEM", 272, 288], ["respiratory secretions", "OBSERVATION", 45, 67], ["increasing", "OBSERVATION_MODIFIER", 170, 180], ["infections", "OBSERVATION", 278, 288]]], ["Enhanced isolation goes beyond just combining transmission based precautions, but adding additional measures and processes [33, 34] .", [["Enhanced isolation", "TREATMENT", 0, 18]]], ["Ebola virus disease, SARS, MERS, and many other diseases require a combination of isolation precautions that include airborne and contact prevention measures, but also enhanced isolation practices that include additional PPE and precautions.", [["Ebola virus disease", "DISEASE", 0, 19], ["SARS", "DISEASE", 21, 25], ["MERS", "DISEASE", 27, 31], ["Ebola virus", "ORGANISM", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus disease", "PROBLEM", 0, 19], ["SARS", "PROBLEM", 21, 25], ["MERS", "PROBLEM", 27, 31], ["many other diseases", "PROBLEM", 37, 56], ["isolation precautions", "TREATMENT", 82, 103], ["airborne", "TREATMENT", 117, 125], ["contact prevention measures", "TREATMENT", 130, 157], ["enhanced isolation practices", "TREATMENT", 168, 196], ["additional PPE", "TREATMENT", 210, 224], ["precautions", "TREATMENT", 229, 240], ["diseases", "OBSERVATION", 48, 56]]], ["Novel or emerging infectious diseases may require an amalgamation of isolation precautions, especially in advanced medical settings.", [["infectious diseases", "DISEASE", 18, 37], ["emerging infectious diseases", "PROBLEM", 9, 37], ["isolation precautions", "TREATMENT", 69, 90]]], ["The 2013-2016 Ebola virus disease outbreak highlighted the challenges of managing patients in American hospitals and required substantial revisions to existing PPE and isolation guidelines.", [["Ebola virus disease", "DISEASE", 14, 33], ["Ebola virus", "ORGANISM", 14, 25], ["patients", "ORGANISM", 82, 90], ["Ebola virus", "SPECIES", 14, 25], ["patients", "SPECIES", 82, 90], ["Ebola virus", "SPECIES", 14, 25], ["Ebola virus disease outbreak", "PROBLEM", 14, 42], ["substantial revisions", "TREATMENT", 126, 147], ["existing PPE", "TREATMENT", 151, 163], ["isolation guidelines", "TREATMENT", 168, 188]]], ["At the most rudimentary level, isolation precautions should be designed around the transmission mechanisms of the infectious disease.", [["infectious disease", "DISEASE", 114, 132], ["isolation precautions", "TREATMENT", 31, 52], ["the infectious disease", "PROBLEM", 110, 132], ["infectious", "OBSERVATION", 114, 124]]], ["SARS and MERS coronaviruses are primarily spread through respiratory droplets, which caused significant issues in the early stages of outbreaks due to delayed airborne isolation.", [["respiratory droplets", "ANATOMY", 57, 77], ["SARS", "DISEASE", 0, 4], ["MERS coronaviruses", "ORGANISM", 9, 27], ["MERS coronaviruses", "SPECIES", 9, 27], ["SARS", "PROBLEM", 0, 4], ["MERS coronaviruses", "PROBLEM", 9, 27], ["respiratory droplets", "PROBLEM", 57, 77], ["significant issues", "PROBLEM", 92, 110], ["delayed airborne isolation", "PROBLEM", 151, 177], ["respiratory droplets", "OBSERVATION", 57, 77], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["early stages", "OBSERVATION_MODIFIER", 118, 130], ["airborne isolation", "OBSERVATION", 159, 177]]], ["On the other hand, Ebola virus disease cases within the United States revealed gaps in isolation guidance and preparedness when responding to patients with emerging infectious diseases.", [["Ebola virus disease", "DISEASE", 19, 38], ["infectious diseases", "DISEASE", 165, 184], ["Ebola virus", "ORGANISM", 19, 30], ["patients", "ORGANISM", 142, 150], ["Ebola virus", "SPECIES", 19, 30], ["patients", "SPECIES", 142, 150], ["Ebola virus", "SPECIES", 19, 30], ["Ebola virus disease cases", "PROBLEM", 19, 44], ["isolation guidance", "TREATMENT", 87, 105], ["emerging infectious diseases", "PROBLEM", 156, 184], ["gaps", "OBSERVATION_MODIFIER", 79, 83], ["infectious", "OBSERVATION", 165, 175]]], ["Although aerosol-generating procedures were a topic of concern for SARS and MERS, respiratory precautions were already considered for isolation precautions.", [["respiratory", "ANATOMY", 82, 93], ["SARS", "DISEASE", 67, 71], ["aerosol-generating procedures", "TREATMENT", 9, 38], ["SARS", "PROBLEM", 67, 71], ["MERS", "PROBLEM", 76, 80], ["respiratory precautions", "TREATMENT", 82, 105], ["isolation precautions", "TREATMENT", 134, 155]]], ["The limited experience and knowledge among healthcare workers surrounding Ebola virus disease also posed unique challenges for training on enhanced isolation precautions and PPE during the 2013-2016 outbreak.", [["Ebola virus disease", "DISEASE", 74, 93], ["Ebola virus", "ORGANISM", 74, 85], ["Ebola virus", "SPECIES", 74, 85], ["Ebola virus", "SPECIES", 74, 85], ["Ebola virus disease", "PROBLEM", 74, 93], ["enhanced isolation precautions", "TREATMENT", 139, 169], ["PPE", "TREATMENT", 174, 177], ["Ebola virus", "OBSERVATION", 74, 85]]], ["Overall, enhancing isolation precautions is a helpful strategy for handling a novel or emerging infectious disease, especially if newer or more invasive medical procedures or pediatric patients are involved.", [["infectious disease", "DISEASE", 96, 114], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["enhancing isolation precautions", "TREATMENT", 9, 40], ["enhancing", "OBSERVATION_MODIFIER", 9, 18], ["isolation", "OBSERVATION", 19, 28], ["infectious", "OBSERVATION", 96, 106]]], ["One of the most common lessons infection preventionists highlight for clinical staff is that it is always better to quickly initiate isolation precautions and remove them later than find out hours or days into a patient's care that they were contagious.", [["infection", "DISEASE", 31, 40], ["patient", "ORGANISM", 212, 219], ["patient", "SPECIES", 212, 219], ["isolation precautions", "TREATMENT", 133, 154], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["infection", "OBSERVATION", 31, 40]]], ["Patients may voice frustration with being placed in isolation, but delay in isolating a patient who potentially has an infectious disease, runs the risk of furthering disease transmission.Isolation and PPE Compliance in VisitorsVisitors play a significant role in the well-being of hospitalized patients however, they also can facilitate the transmission of infectious diseases.", [["infectious diseases", "DISEASE", 358, 377], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 88, 95], ["patients", "ORGANISM", 295, 303], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 88, 95], ["patients", "SPECIES", 295, 303], ["voice frustration", "PROBLEM", 13, 30], ["an infectious disease", "PROBLEM", 116, 137], ["furthering disease transmission", "PROBLEM", 156, 187], ["Isolation", "TREATMENT", 188, 197], ["infectious diseases", "PROBLEM", 358, 377], ["infectious", "OBSERVATION", 119, 129], ["disease", "OBSERVATION", 167, 174], ["PPE Compliance", "OBSERVATION", 202, 216], ["infectious", "OBSERVATION", 358, 368]]], ["Healthcare facilities will ultimately need to grapple with balancing patient satisfaction and the potential for visitors to act as amplifiers of disease, especially during outbreaks.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["disease", "PROBLEM", 145, 152]]], ["Adherence to isolation precautions and hand hygiene is vital among healthcare workers, but the role of visitors has also become a topic of concern.", [["hand", "ANATOMY", 39, 43], ["hand", "ORGANISM_SUBDIVISION", 39, 43], ["isolation precautions", "TREATMENT", 13, 34]]], ["There is substantial evidence for the horizontal transmission of even multi-drug resistant microorganisms involving the hands and attire of healthcare workers.", [["hands", "ORGANISM_SUBDIVISION", 120, 125], ["multi-drug resistant microorganisms", "PROBLEM", 70, 105], ["substantial evidence for", "UNCERTAINTY", 9, 33], ["drug resistant microorganisms", "OBSERVATION", 76, 105], ["hands", "ANATOMY", 120, 125]]], ["However, consideration must also be given regarding the role of visitors in infection prevention and control [14] .", [["infection", "DISEASE", 76, 85], ["infection prevention", "TREATMENT", 76, 96], ["infection", "OBSERVATION", 76, 85]]], ["While there is no universal recommendation for handling visitor compliance to standard or more advanced precautions, it is encouraged that those visiting a contagious patient should use PPE for their own safety.", [["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["more advanced precautions", "TREATMENT", 90, 115], ["PPE", "TREATMENT", 186, 189], ["no", "UNCERTAINTY", 15, 17]]], ["The Society for Healthcare Epidemiology of America (SHEA) has provided recommendations that highlight the challenges in enforcing visitor compliance, but also notes that it is crucial to consider the infectious microorganism when dealing with visitors who are unwilling to follow precautions.", [["the infectious microorganism", "PROBLEM", 196, 224]]], ["However, hand hygiene is perhaps the most important and likely practice to be followed.", [["hand", "ANATOMY", 9, 13], ["hand", "ORGANISM_SUBDIVISION", 9, 13], ["hand", "ANATOMY", 9, 13], ["hygiene", "OBSERVATION", 14, 21]]], ["SHEA notes that \"hospital visitors may play a significant role in the ecology of healthcare-associated infections\" but few visit more than one patient, which makes the transmission between visitors and multiple patients less likely [14] .", [["infections", "DISEASE", 103, 113], ["patient", "ORGANISM", 143, 150], ["patients", "ORGANISM", 211, 219], ["patient", "SPECIES", 143, 150], ["patients", "SPECIES", 211, 219]]], ["There is a consistent challenge in enforcing compliance with visitors and little research that has focused solely on their compliance and role within healthcareassociated disease transmission.", [["consistent", "OBSERVATION_MODIFIER", 11, 21], ["challenge", "OBSERVATION", 22, 31]]], ["Several things should be considered to address visitors of patients in isolation for an infection.", [["infection", "DISEASE", 88, 97], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["an infection", "PROBLEM", 85, 97], ["infection", "OBSERVATION", 88, 97]]], ["If the visitor is a breast-feeding mother who is involved in the care of the patient, it is unlikely isolation precautions can be enforced.", [["breast", "ANATOMY", 20, 26], ["breast", "ORGANISM_SUBDIVISION", 20, 26], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["isolation precautions", "TREATMENT", 101, 122], ["breast", "ANATOMY", 20, 26]]], ["Many hospitals within the U.S. also make it a practice to screen visitors during respiratory virus season to prevent symptomatic visitors from exposing patients or staff [35] .", [["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160]]], ["This practice should be considered for visitors of such patients, especially if they are house-hold or close contacts and may be a source for further transmission.Isolation and PPE Compliance in VisitorsPatients with high-consequence diseases, like Ebola virus disease or SARS, may pose a unique challenge for healthcare workers in terms of visitors and isolation precautions and should addressed on a case by case basis.", [["high-consequence diseases", "DISEASE", 217, 242], ["Ebola virus disease", "DISEASE", 249, 268], ["SARS", "DISEASE", 272, 276], ["patients", "ORGANISM", 56, 64], ["Patients", "ORGANISM", 203, 211], ["Ebola virus", "ORGANISM", 249, 260], ["patients", "SPECIES", 56, 64], ["Patients", "SPECIES", 203, 211], ["Ebola virus", "SPECIES", 249, 260], ["Ebola virus", "SPECIES", 249, 260], ["Isolation", "TREATMENT", 163, 172], ["high-consequence diseases", "PROBLEM", 217, 242], ["Ebola virus disease", "PROBLEM", 249, 268], ["SARS", "PROBLEM", 272, 276], ["isolation precautions", "TREATMENT", 354, 375], ["PPE Compliance", "OBSERVATION", 177, 191], ["Ebola virus", "OBSERVATION", 249, 260]]], ["CDC recommendations for visitors of Ebola virus disease patients include that healthcare workers should \"avoid entry of visitors into the patient's room\" and that visits should be scheduled and controlled [15] .", [["Ebola virus disease", "DISEASE", 36, 55], ["Ebola virus", "ORGANISM", 36, 47], ["patients", "ORGANISM", 56, 64], ["patient", "ORGANISM", 138, 145], ["Ebola virus", "SPECIES", 36, 47], ["patients", "SPECIES", 56, 64], ["patient", "SPECIES", 138, 145], ["Ebola virus", "SPECIES", 36, 47], ["Ebola virus disease", "PROBLEM", 36, 55]]], ["Visitors played a significant role in furthering the spread of SARS and MERS during outbreaks and consideration should be given to restricting the number of visitors during such events.", [["SARS", "DISEASE", 63, 67], ["MERS", "DISEASE", 72, 76], ["SARS", "PROBLEM", 63, 67]]], ["A recent WHO report on MERS found that of the cases between December 2016 and July 2017, 31% were associated with transmission in a healthcare facility, including healthcare workers, patients sharing rooms/wards with MERS patients, and visitors [12, 13] .", [["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 222, 230]]], ["CDC guidance for infection control during treatment of patients with SARS also encourages limiting visits to those who are necessary for the patient's emotional well being.", [["infection", "DISEASE", 17, 26], ["SARS", "DISEASE", 69, 73], ["patients", "ORGANISM", 55, 63], ["patient", "ORGANISM", 141, 148], ["patients", "SPECIES", 55, 63], ["patient", "SPECIES", 141, 148], ["infection control", "TREATMENT", 17, 34], ["treatment", "TREATMENT", 42, 51], ["SARS", "PROBLEM", 69, 73], ["infection", "OBSERVATION", 17, 26]]], ["Visitors should be educated and encouraged to wear the necessary PPE when visiting an isolated patient.", [["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102]]], ["At the bare minimum, it is prudent to educate and encourage visitors to practice hand hygiene upon entering and exiting the patient's room.Isolation and PPE Compliance in VisitorsAirborne isolations pose a challenge for visitor compliance.", [["hand", "ANATOMY", 81, 85], ["hand", "ORGANISM_SUBDIVISION", 81, 85], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["Isolation", "TREATMENT", 139, 148], ["PPE Compliance", "OBSERVATION", 153, 167]]], ["Since hospitals can not support fit-testing visitors for N-95 masks or other respirators, each situation should be evaluated on an individual basis.", [["N-95 masks", "TREATMENT", 57, 67]]], ["Surgical masks can provide some protection but will not provide a true seal.", [["Surgical masks", "TREATMENT", 0, 14], ["a true seal", "TREATMENT", 64, 75]]], ["It is a common practice for many healthcare institutions to allow house-hold contacts to visit a patient in airborne isolation without a mask (or wearing a surgical mask) since exposure has likely already occurred.", [["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["a mask", "TREATMENT", 135, 141], ["a surgical mask", "TREATMENT", 154, 169]]], ["It may be prudent to have visitors in such situations wear a surgical mask upon exiting the patient's room and wear it until they exit the hospital.Isolation and PPE Compliance in VisitorsVisitor adherence to isolation precautions is challenging for even the most common hospitalizations.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["a surgical mask", "TREATMENT", 59, 74], ["Isolation", "TREATMENT", 148, 157], ["isolation precautions", "TREATMENT", 209, 230], ["PPE Compliance", "OBSERVATION", 162, 176]]], ["Staff compliance and vigilance can be a strong rolemodel and reminder for visitors, especially in regards to hand hygiene.", [["hand", "ANATOMY", 109, 113], ["hand", "ORGANISM_SUBDIVISION", 109, 113]]], ["In the event of a bioweapons-related attack or outbreak of a highly infectious disease (i.e., Ebola virus disease), visitor protocols should be established.", [["infectious disease", "DISEASE", 68, 86], ["Ebola virus disease", "DISEASE", 94, 113], ["Ebola virus", "ORGANISM", 94, 105], ["Ebola virus", "SPECIES", 94, 105], ["Ebola virus", "SPECIES", 94, 105], ["a highly infectious disease", "PROBLEM", 59, 86], ["Ebola virus disease", "PROBLEM", 94, 113], ["visitor protocols", "TREATMENT", 116, 133], ["highly", "OBSERVATION_MODIFIER", 61, 67], ["infectious", "OBSERVATION", 68, 78]]], ["Unique events and microorganisms can pose a challenge for isolation precaution compliance and recommendations may need to be modified for novel or specific situations (i.e., caring for a pediatric patient and maintaining parent/guardian visitor isolations).", [["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 197, 204], ["Unique events", "PROBLEM", 0, 13], ["microorganisms", "PROBLEM", 18, 32], ["isolation precaution compliance", "TREATMENT", 58, 89]]], ["Changes to IPC guidelines for such unique situations should be done in conjunction with CDC (and other expert) guidance and discussed in a multidisciplinary setting to ensure support is facility-wide.", [["IPC guidelines", "TREATMENT", 11, 25], ["such unique situations", "PROBLEM", 30, 52]]], ["Visitors do play a significant role in infection prevention and control within the healthcare environment, which makes their adherence to standard precautions and isolation precautions important and challenging.Discontinuation of Isolation PrecautionsTransmission-based precautions should be maintained until the patient is no longer considered capable of transmitting the disease.", [["infection", "DISEASE", 39, 48], ["patient", "ORGANISM", 313, 320], ["patient", "SPECIES", 313, 320], ["infection prevention", "TREATMENT", 39, 59], ["standard precautions", "TREATMENT", 138, 158], ["isolation precautions", "TREATMENT", 163, 184], ["Isolation Precautions", "TREATMENT", 230, 251], ["Transmission-based precautions", "TREATMENT", 251, 281], ["the disease", "PROBLEM", 369, 380], ["infection", "OBSERVATION", 39, 48], ["no longer", "UNCERTAINTY", 324, 333], ["disease", "OBSERVATION", 373, 380]]], ["The CDC's Guidelines for Isolation Precautions is an excellent resource for duration of isolation.", [["The CDC", "TEST", 0, 7], ["Isolation Precautions", "TREATMENT", 25, 46], ["duration of isolation", "TREATMENT", 76, 97]]], ["Consideration should be given for immune status of the patient as immunocompromised patients may need to be isolated for longer periods of time due to lengthier microorganism shedding.Patient Placement and CohortingPatient placement is a vital component to infection control measures, especially during an influx of ill patients.", [["infection", "DISEASE", 257, 266], ["patient", "ORGANISM", 55, 62], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 320, 328], ["patient", "SPECIES", 55, 62], ["patients", "SPECIES", 84, 92], ["Patient", "SPECIES", 184, 191], ["patients", "SPECIES", 320, 328], ["immunocompromised", "PROBLEM", 66, 83], ["lengthier microorganism shedding", "PROBLEM", 151, 183], ["Patient Placement and CohortingPatient placement", "TREATMENT", 184, 232], ["a vital component", "TREATMENT", 236, 253], ["infection control measures", "TREATMENT", 257, 283], ["infection", "OBSERVATION", 257, 266]]], ["Isolation practices and cohorting (grouping like patients in a shared hospital room or designated unit) plays a significant role in reducing the microbial burden within the healthcare environment.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Isolation practices", "TREATMENT", 0, 19]]], ["Patient cohorting is a common practice during outbreaks or limited availability of negative pressure rooms however, it is important to consider transmission-based precautions during the assignment of patient rooms and establishing cohorted units.Placement of PatientsIsolating patients with the appropriate transmission-based precautions is often done during admission.", [["patient", "ORGANISM", 200, 207], ["Patients", "ORGANISM", 259, 267], ["patients", "ORGANISM", 277, 285], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 200, 207], ["Patients", "SPECIES", 259, 267], ["patients", "SPECIES", 277, 285], ["transmission-based precautions", "TREATMENT", 144, 174], ["establishing cohorted units", "TREATMENT", 218, 245], ["PatientsIsolating patients", "TREATMENT", 259, 285], ["the appropriate transmission", "TREATMENT", 291, 319], ["based precautions", "TREATMENT", 320, 337]]], ["However, if patients are transferred to the healthcare facility and there is already suspicion of an infectious disease, this may also determine where the patient is placed.", [["patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 155, 162], ["patients", "SPECIES", 12, 20], ["patient", "SPECIES", 155, 162], ["an infectious disease", "PROBLEM", 98, 119], ["infectious", "OBSERVATION", 101, 111]]], ["There is a myriad of components that impact patient placement and such efforts should be performed with IPC in mind.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["patient placement", "TREATMENT", 44, 61], ["such efforts", "TREATMENT", 66, 78], ["IPC", "TREATMENT", 104, 107], ["myriad", "OBSERVATION_MODIFIER", 11, 17]]], ["Although many healthcare facilities have private rooms, there is always the possibility that patients may have to share rooms.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["Efforts should be made to place patients with infectious diseases that are transmitted via the contact, droplet, or airborne route, in private rooms.", [["infectious diseases", "DISEASE", 46, 65], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["infectious diseases", "PROBLEM", 46, 65], ["infectious", "OBSERVATION", 46, 56]]], ["Consideration for route of transmission should always be made during patient admission, which would determine both isolation status and patient placement.", [["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 136, 143], ["patient placement", "TREATMENT", 136, 153]]], ["Patients needing airborne isolation require rooms that maintain negative pressure, which are typically only a handful of rooms per care area.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["airborne isolation", "TREATMENT", 17, 35], ["negative pressure", "OBSERVATION", 64, 81]]], ["These patients should be place within private negative pressure rooms.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["There is an increasingly common practice of requiring private rooms for patients infected with highly resistant microorganisms, such as carbapenem-resistant Enterobacteriaceae (CRE) or multidrug-resistant TB (MDR-TB).", [["carbapenem", "CHEMICAL", 136, 146], ["Enterobacteriaceae", "CHEMICAL", 157, 175], ["multidrug-resistant TB", "DISEASE", 185, 207], ["MDR-TB", "DISEASE", 209, 215], ["carbapenem", "CHEMICAL", 136, 146], ["patients", "ORGANISM", 72, 80], ["carbapenem-resistant Enterobacteriaceae", "SIMPLE_CHEMICAL", 136, 175], ["patients", "SPECIES", 72, 80], ["highly resistant microorganisms", "PROBLEM", 95, 126], ["carbapenem", "PROBLEM", 136, 146], ["resistant Enterobacteriaceae (CRE", "PROBLEM", 147, 180], ["multidrug-resistant TB", "PROBLEM", 185, 207], ["increasingly", "OBSERVATION_MODIFIER", 12, 24], ["common", "OBSERVATION_MODIFIER", 25, 31]]], ["Patient placement should be determined with transmission-based precautions in mind and efforts should be made to ensure patients with highly contagious or high consequence pathogens (e.g., Ebola virus, SARS and MERS coronaviruses) are in private isolation rooms per CDC guidelines.Cohorting of Patients and Staff AssignmentsDespite our best efforts, during peak respiratory virus season or an influx of patients, private room availability may be constrained.", [["Ebola virus", "DISEASE", 189, 200], ["SARS", "DISEASE", 202, 206], ["patients", "ORGANISM", 120, 128], ["Ebola virus", "ORGANISM", 189, 200], ["MERS coronaviruses", "ORGANISM", 211, 229], ["Patients", "ORGANISM", 294, 302], ["patients", "ORGANISM", 403, 411], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 120, 128], ["Ebola virus", "SPECIES", 189, 200], ["Patients", "SPECIES", 294, 302], ["patients", "SPECIES", 403, 411], ["Ebola virus", "SPECIES", 189, 200], ["transmission-based precautions", "TREATMENT", 44, 74], ["highly contagious or high consequence pathogens", "PROBLEM", 134, 181], ["Ebola virus", "PROBLEM", 189, 200], ["SARS", "PROBLEM", 202, 206], ["MERS coronaviruses", "PROBLEM", 211, 229]]], ["There are two kinds of cohorting; sharing of private rooms or grouping patients within a defined entire hospital unit.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["If private rooms are not available, patients infected or colonized with the same microorganism (e.g., influenza A virus, MRSA) can be cohorted together to share a room.", [["influenza A virus", "DISEASE", 102, 119], ["MRSA", "DISEASE", 121, 125], ["patients", "ORGANISM", 36, 44], ["influenza A virus", "ORGANISM", 102, 119], ["patients", "SPECIES", 36, 44], ["influenza A virus", "SPECIES", 102, 119], ["MRSA", "SPECIES", 121, 125], ["influenza A virus", "SPECIES", 102, 119], ["MRSA", "SPECIES", 121, 125], ["the same microorganism", "PROBLEM", 72, 94], ["influenza A virus", "PROBLEM", 102, 119], ["MRSA", "PROBLEM", 121, 125]]], ["During respiratory virus season, cohorting based off clinical symptoms is often utilized.", [["clinical symptoms", "PROBLEM", 53, 70]]], ["While it was necessary to cohort Ebola virus disease patients during the Western African 2013-2016 Ebola virus disease outbreak, CDC guidelines for U.S. hospitals is that patients should be placed in a private room.", [["Ebola virus disease", "DISEASE", 33, 52], ["Ebola virus disease", "DISEASE", 99, 118], ["Ebola virus", "ORGANISM", 33, 44], ["patients", "ORGANISM", 53, 61], ["Ebola virus", "ORGANISM", 99, 110], ["patients", "ORGANISM", 171, 179], ["Ebola virus", "SPECIES", 33, 44], ["patients", "SPECIES", 53, 61], ["Ebola virus", "SPECIES", 99, 110], ["patients", "SPECIES", 171, 179], ["Ebola virus", "SPECIES", 33, 44], ["African 2013-2016 Ebola virus", "SPECIES", 81, 110], ["cohort Ebola virus disease", "PROBLEM", 26, 52], ["Ebola virus disease outbreak", "PROBLEM", 99, 127]]], ["If there should be an influx of patients with a high consequence pathogen, consideration for cohorting within the same room should be made on a case-by-case basis with infection prevention and control coordinating with the appropriate public health authorities.Cohorting of Patients and Staff AssignmentsDuring an outbreak or influx of patients in which hospital bed capacity is strained, cohorting can be utilized for an entire hospital unit or well-defined space.", [["infection", "DISEASE", 168, 177], ["patients", "ORGANISM", 32, 40], ["Patients", "ORGANISM", 274, 282], ["patients", "ORGANISM", 336, 344], ["patients", "SPECIES", 32, 40], ["Patients", "SPECIES", 274, 282], ["patients", "SPECIES", 336, 344], ["a high consequence pathogen", "PROBLEM", 46, 73], ["infection prevention", "TREATMENT", 168, 188], ["infection", "OBSERVATION", 168, 177]]], ["Designated hospital units can be cohorted for infected patients.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63]]], ["These units should either be dedicated to patients affected by an outbreak (and the same microorganism) or of all patients in isolation who are cohorted within their rooms based off the previously mentioned criteria.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 114, 122], ["an outbreak", "PROBLEM", 63, 74]]], ["This is an effective practice for segregating the patients and their visitors from healthy/non-infected patients.", [["non-infected", "DISEASE", 91, 103], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 104, 112]]], ["The CDC notes that \"cohorting healthcare personnel to care only for patients infected or colonized with a single target pathogen limits further transmission to uninfected patients but is difficult to achieve in the face of staff shortages in hospitals and residential healthcare sites.", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 171, 179], ["a single target pathogen", "PROBLEM", 104, 128]]], ["However, if continued transmission is occurring after implementing routine infection control measures and creating patient cohorts, cohorting of healthcare personnel may be beneficial.\" [17] .", [["infection", "DISEASE", 75, 84], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["routine infection control measures", "TREATMENT", 67, 101]]], ["Designated staff can be assigned to cohorted patients or units.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["It is highly encouraged that healthcare workers (especially nurses) caring for cohorted patients, should not also be assigned to patients who are immunocompromised.", [["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 129, 137], ["immunocompromised", "PROBLEM", 146, 163], ["immunocompromised", "OBSERVATION", 146, 163]]], ["Cohorting in single rooms or in well-defined units can be an effective mechanism for reducing the spread of infectious diseases during patient care.Designated Staff For Specific MicroorganismsThe Ebola virus disease outbreak in 2013-2016 highlighted the role of healthcare worker transmission, not only between themselves, but also among patients.", [["infectious diseases", "DISEASE", 108, 127], ["Ebola virus disease", "DISEASE", 196, 215], ["patient", "ORGANISM", 135, 142], ["Ebola virus", "ORGANISM", 196, 207], ["patients", "ORGANISM", 338, 346], ["patient", "SPECIES", 135, 142], ["Ebola virus", "SPECIES", 196, 207], ["patients", "SPECIES", 338, 346], ["Ebola virus", "SPECIES", 196, 207], ["infectious diseases", "PROBLEM", 108, 127], ["Specific Microorganisms", "PROBLEM", 169, 192], ["The Ebola virus disease outbreak", "PROBLEM", 192, 224], ["infectious", "OBSERVATION", 108, 118], ["Ebola virus disease", "OBSERVATION", 196, 215]]], ["CDC guidelines encouraged healthcare facilities to minimize staff with direct patient care.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["direct patient care", "TREATMENT", 71, 90]]], ["It was encouraged that those staff caring for a person under investigation (PUI) or infected with Ebola virus, be dedicated to that patient as to minimize the potential for additional exposure.", [["Ebola virus", "DISEASE", 98, 109], ["Ebola virus", "ORGANISM", 98, 109], ["patient", "ORGANISM", 132, 139], ["person", "SPECIES", 48, 54], ["Ebola virus", "SPECIES", 98, 109], ["patient", "SPECIES", 132, 139], ["Ebola virus", "SPECIES", 98, 109], ["Ebola virus", "PROBLEM", 98, 109]]], ["During the 2011 outbreak of carbapenem-resistant Klebsiella pneumonia at the National Institute of Health's Clinical Center, IPC staff adopted a series of control measures that included cohorting, limiting activities of hospital staff exposed to infected patients, and hiring monitors to ensure healthcare providers were wearing appropriate PPE and using hand hygiene [18] .", [["hand", "ANATOMY", 355, 359], ["carbapenem", "CHEMICAL", 28, 38], ["Klebsiella pneumonia", "DISEASE", 49, 69], ["carbapenem", "CHEMICAL", 28, 38], ["carbapenem", "SIMPLE_CHEMICAL", 28, 38], ["patients", "ORGANISM", 255, 263], ["hand", "ORGANISM_SUBDIVISION", 355, 359], ["patients", "SPECIES", 255, 263], ["carbapenem", "PROBLEM", 28, 38], ["resistant Klebsiella pneumonia", "PROBLEM", 39, 69], ["IPC staff", "TREATMENT", 125, 134], ["a series of control measures", "TREATMENT", 143, 171], ["resistant", "OBSERVATION_MODIFIER", 39, 48], ["Klebsiella", "OBSERVATION_MODIFIER", 49, 59], ["pneumonia", "OBSERVATION", 60, 69]]], ["Incidents involving bioweapons, novel or emerging infectious diseases, or high consequence pathogens, will surely require unique guidelines that could test the capacity for hospitals.", [["infectious diseases", "DISEASE", 50, 69], ["emerging infectious diseases", "PROBLEM", 41, 69], ["high consequence pathogens", "PROBLEM", 74, 100], ["unique guidelines", "TREATMENT", 122, 139]]], ["It behooves healthcare facilities and preparedness efforts to consider staffing and cohorting needs during such challenging situations.Patient Screening and MovementThe flow of patients from triage to discharge also poses vulnerabilities for infectious disease transmission.", [["infectious disease transmission", "DISEASE", 242, 273], ["patients", "ORGANISM", 177, 185], ["Patient", "SPECIES", 135, 142], ["patients", "SPECIES", 177, 185], ["Patient Screening", "TEST", 135, 152], ["infectious disease transmission", "PROBLEM", 242, 273], ["flow", "OBSERVATION_MODIFIER", 169, 173], ["infectious", "OBSERVATION", 242, 252]]], ["The initial screening of patients can be an effective infection control measure for rapid isolation and PPE utilization.", [["infection", "DISEASE", 54, 63], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["The initial screening", "TEST", 0, 21], ["an effective infection control", "TREATMENT", 41, 71], ["rapid isolation", "TREATMENT", 84, 99], ["PPE utilization", "TREATMENT", 104, 119], ["infection", "OBSERVATION", 54, 63]]], ["Proper communication and triage questions can aid in the rapid identification of patients with increased risk for infectious diseases.", [["infectious diseases", "DISEASE", 114, 133], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["infectious diseases", "PROBLEM", 114, 133], ["infectious", "OBSERVATION", 114, 124]]], ["Hasty identification of a patient with a potential infection within their first moments within the healthcare facility can substantially decrease the risk for additional exposure.", [["infection", "DISEASE", 51, 60], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["a potential infection", "PROBLEM", 39, 60], ["infection", "OBSERVATION", 51, 60]]], ["Once admitted to a healthcare facility, patients are frequently transported for diagnostic tests and care.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["diagnostic tests", "TEST", 80, 96]]], ["The transportation of a patient can also act as a facilitator for disease transmission if infection control practices are not maintained.Emergency Department Screening and TriageThe initial interaction a patient within a healthcare facility or urgent care unit is the first opportunity to identify risk for infection.", [["infection", "DISEASE", 90, 99], ["infection", "DISEASE", 307, 316], ["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 204, 211], ["disease transmission", "TREATMENT", 66, 86], ["infection control practices", "TREATMENT", 90, 117], ["Triage", "TEST", 172, 178], ["infection", "PROBLEM", 307, 316], ["infection", "OBSERVATION", 307, 316]]], ["The triage process determines the degree of urgency of the patient's condition, which then decides the order they are seen.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["urgency of the patient's condition", "PROBLEM", 44, 78], ["urgency", "OBSERVATION", 44, 51]]], ["During this process, there are many opportunities to not only identify patients with potentially contagions infections, but also rapidly isolate them to prevent further exposure to staff and other patients.", [["infections", "DISEASE", 108, 118], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 197, 205], ["contagions infections", "PROBLEM", 97, 118], ["infections", "OBSERVATION", 108, 118]]], ["It is encouraged for triage staff to provide patients presenting with a cough, (i.e., a potential respiratory infection) a mask to wear during their time in a waiting room.", [["respiratory", "ANATOMY", 98, 109], ["cough", "DISEASE", 72, 77], ["respiratory infection", "DISEASE", 98, 119], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["a cough", "PROBLEM", 70, 77], ["a potential respiratory infection", "PROBLEM", 86, 119], ["a mask", "TREATMENT", 121, 127], ["infection", "OBSERVATION", 110, 119]]], ["This simple act can be hugely preventative, whether the patient has influenza, MERS, or TB.", [["influenza", "DISEASE", 68, 77], ["MERS", "DISEASE", 79, 83], ["TB", "DISEASE", 88, 90], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["influenza", "PROBLEM", 68, 77], ["MERS", "PROBLEM", 79, 83], ["TB", "PROBLEM", 88, 90], ["influenza", "OBSERVATION", 68, 77]]], ["While the triage process primarily focuses on medical questions, this is also an opportunity for questions regarding international travel and fever.", [["fever", "DISEASE", 142, 147], ["fever", "PROBLEM", 142, 147]]], ["Since the SARS outbreak in 2002, it has become a relatively common practice to incorporate a question within the patient screening/triage process regarding international travel and fever.", [["SARS", "DISEASE", 10, 14], ["fever", "DISEASE", 181, 186], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["the patient screening", "TEST", 109, 130], ["fever", "PROBLEM", 181, 186]]], ["Travel history is always an important component to the patient's medical history but we should not forget its significance during triage and patient screening.", [["patient", "ORGANISM", 55, 62], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 55, 62], ["patient", "SPECIES", 141, 148], ["patient screening", "TEST", 141, 158]]], ["Presence of fever is a standard part of the medical triage and intake during initial screening and if the patient is febrile, questions regarding travel history become that much more important.", [["fever", "DISEASE", 12, 17], ["febrile", "DISEASE", 117, 124], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["fever", "PROBLEM", 12, 17], ["initial screening", "TEST", 77, 94], ["febrile", "PROBLEM", 117, 124], ["fever", "OBSERVATION", 12, 17]]], ["There are a mixture of recommendations regarding processes, but it is consistently thought that if a patient with an acute illness (e.g., fever within 2 weeks, diarrhea) has traveled outside the U.S. within the last 21 days, the patient should be isolated.", [["fever", "DISEASE", 138, 143], ["diarrhea", "DISEASE", 160, 168], ["patient", "ORGANISM", 101, 108], ["patient", "ORGANISM", 229, 236], ["patient", "SPECIES", 101, 108], ["patient", "SPECIES", 229, 236], ["an acute illness", "PROBLEM", 114, 130], ["fever", "PROBLEM", 138, 143], ["diarrhea", "PROBLEM", 160, 168], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["illness", "OBSERVATION", 123, 130]]], ["Isolation should be based upon the presenting signs and symptoms but providers should also consider the area of travel and if there are ongoing epidemiologically-significant outbreaks.", [["Isolation", "TREATMENT", 0, 9], ["the presenting signs and symptoms", "PROBLEM", 31, 64], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["outbreaks", "OBSERVATION", 174, 183]]], ["During outbreaks, like those of SARS and MERS, screening and triage can include questions regarding not just travel, but also exposure or close contact with a sick person who recently traveled to those areas or was infected.", [["SARS", "DISEASE", 32, 36], ["person", "SPECIES", 164, 170], ["SARS", "PROBLEM", 32, 36], ["screening", "TEST", 47, 56], ["infected", "PROBLEM", 215, 223], ["infected", "OBSERVATION", 215, 223]]], ["The screening and triage process is especially beneficial for early detection and isolation of potentially infectious patients because it can easily be modified.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["The screening", "TEST", 0, 13], ["potentially infectious patients", "PROBLEM", 95, 126], ["infectious", "OBSERVATION", 107, 117]]], ["Questions related to travel history should be maintained during all times though and it is encouraged that patients with an acute illness and international travel within 21 days, be placed in a private room until further evaluation by a healthcare provider.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["an acute illness", "PROBLEM", 121, 137], ["further evaluation", "TEST", 213, 231]]], ["Measles and TB are frequent suspected in patients with respiratory symptoms and a recent international travel history.", [["respiratory", "ANATOMY", 55, 66], ["Measles", "DISEASE", 0, 7], ["TB", "DISEASE", 12, 14], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Measles", "PROBLEM", 0, 7], ["TB", "PROBLEM", 12, 14], ["respiratory symptoms", "PROBLEM", 55, 75], ["TB", "OBSERVATION", 12, 14]]], ["However, the inclusion of travel history in medical triage and screening can also potentially capture cases of avian influenza, MERS, viral hemorrhagic fever, etc.Transportation of Patient Within HospitalPatients are frequently transported throughout the hospital during their care, which can make maintaining isolation precautions challenging.", [["avian influenza", "DISEASE", 111, 126], ["viral hemorrhagic fever", "DISEASE", 134, 157], ["avian", "ORGANISM", 111, 116], ["avian", "SPECIES", 111, 116], ["Patient", "SPECIES", 181, 188], ["medical triage", "TEST", 44, 58], ["screening", "TEST", 63, 72], ["influenza", "PROBLEM", 117, 126], ["MERS", "PROBLEM", 128, 132], ["viral hemorrhagic fever", "PROBLEM", 134, 157], ["isolation precautions", "TREATMENT", 310, 331], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["hemorrhagic", "OBSERVATION_MODIFIER", 140, 151], ["fever", "OBSERVATION", 152, 157]]], ["It is encouraged for patient transportation to be limited, but there are several recommendations to further reduce the spread of disease during patient movement.", [["patient", "ORGANISM", 21, 28], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 21, 28], ["patient", "SPECIES", 144, 151], ["disease", "PROBLEM", 129, 136], ["disease", "OBSERVATION", 129, 136]]], ["Using appropriate barriers is crucial during the transportation of an infectious patient.Transportation of Patient Within HospitalPatients in contact isolation are encouraged to change into a new hospital gown or attire and should be transported on a wheelchair or bed covered with a clean sheet (or other barrier).", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["Patient", "SPECIES", 107, 114], ["a clean sheet", "TREATMENT", 282, 295], ["infectious", "OBSERVATION", 70, 80]]], ["Infectious skin lesions should be covered.", [["skin lesions", "ANATOMY", 11, 23], ["Infectious skin lesions", "DISEASE", 0, 23], ["skin lesions", "PATHOLOGICAL_FORMATION", 11, 23], ["Infectious skin lesions", "PROBLEM", 0, 23], ["skin", "ANATOMY", 11, 15], ["lesions", "OBSERVATION", 16, 23]]], ["The transporter should wear the appropriate PPE while assisting the patient into or out of the covered wheelchair or bed, which should then be removed upon exiting the room (gown and gloves are not required during the transport of patients in contact precautions).", [["patient", "ORGANISM", 68, 75], ["patients", "ORGANISM", 231, 239], ["patient", "SPECIES", 68, 75], ["patients", "SPECIES", 231, 239], ["the appropriate PPE", "TREATMENT", 28, 47], ["gloves", "TREATMENT", 183, 189], ["contact precautions", "TREATMENT", 243, 262]]], ["The CDC notes that \"when transport or movement in any healthcare setting is necessary, ensure that infected or colonized areas of the patient's body are contained and covered.\" [17] .", [["body", "ANATOMY", 144, 148], ["patient", "ORGANISM", 134, 141], ["body", "ORGANISM_SUBDIVISION", 144, 148], ["patient", "SPECIES", 134, 141], ["infected", "PROBLEM", 99, 107], ["infected", "OBSERVATION", 99, 107]]], ["Those patients in droplet or airborne isolation should wear a mask during the transportation process.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["airborne isolation", "TREATMENT", 29, 47], ["a mask", "TREATMENT", 60, 66], ["the transportation process", "TREATMENT", 74, 100]]], ["It is important that notification of the patient's isolation status be done to the receiving department or healthcare personnel to facilitate the continuation of isolation precautions.Exposure ResponseDespite best efforts, patients are not always isolated or transported appropriately.", [["patient", "ORGANISM", 41, 48], ["patients", "ORGANISM", 223, 231], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 223, 231], ["isolation precautions", "TREATMENT", 162, 183]]], ["If a patient with an infectious disease has potentially exposed a considerable number of staff and other patients, infection prevention and control programs may be used to the contain further spread.", [["infectious disease", "DISEASE", 21, 39], ["infection", "DISEASE", 115, 124], ["patient", "ORGANISM", 5, 12], ["patients", "ORGANISM", 105, 113], ["patient", "SPECIES", 5, 12], ["patients", "SPECIES", 105, 113], ["an infectious disease", "PROBLEM", 18, 39], ["infection prevention", "TREATMENT", 115, 135], ["control programs", "TREATMENT", 140, 156], ["infectious", "OBSERVATION", 21, 31], ["infection", "OBSERVATION", 115, 124]]], ["All exposures are not equal, meaning that MRSA is a common microorganism within the community and an exposure response is often not warranted, whereas exposure to mycobacteria or a more severe illness may require follow-up.", [["MRSA", "DISEASE", 42, 46], ["illness", "DISEASE", 193, 200], ["MRSA", "SPECIES", 42, 46], ["MRSA", "SPECIES", 42, 46], ["MRSA", "PROBLEM", 42, 46], ["a common microorganism", "PROBLEM", 50, 72], ["mycobacteria", "PROBLEM", 163, 175], ["a more severe illness", "PROBLEM", 179, 200], ["not", "UNCERTAINTY", 18, 21], ["equal", "OBSERVATION_MODIFIER", 22, 27], ["MRSA", "OBSERVATION", 42, 46], ["mycobacteria", "OBSERVATION", 163, 175]]], ["Post-exposure prophylaxis may be necessary for staff and patients, but medication distribution should be determined by the appropriate hospital experts.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Post-exposure prophylaxis", "TREATMENT", 0, 25]]], ["Hospitals and IPC programs should have a functioning process for determining patients with exposure to specific staff or in other patients (i.e., those in the waiting lobby of an emergency department).", [["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 130, 138], ["IPC programs", "TREATMENT", 14, 26]]], ["Commonly, exposure monitoring and notifications are used for patients, visitors, and staff exposed to measles, pertussis, etc., as post-exposure prophylaxis is recommended.", [["measles", "DISEASE", 102, 109], ["pertussis", "DISEASE", 111, 120], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["exposure monitoring", "TEST", 10, 29], ["measles", "PROBLEM", 102, 109], ["pertussis", "PROBLEM", 111, 120], ["post-exposure prophylaxis", "TREATMENT", 131, 156]]], ["IPC programs might monitor admitted patients who were exposed or potentially isolate them during the incubation period.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["IPC programs", "TREATMENT", 0, 12]]], ["Exposures may also be the result of infectious healthcare staff, which may require patient notification.", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["infectious", "OBSERVATION", 36, 46]]], ["Overall, these events should be addressed on an individual basis and adequate response measures should be applied to reduce the time between exposure and follow-up.Environmental Infection ControlAlthough isolation and PPE utilization are a significant portion of preventing the spread of disease during hospitalization or medical treatment, the role of environmental transmission should not be forgotten.", [["adequate response measures", "TREATMENT", 69, 95], ["Environmental Infection ControlAlthough isolation", "TREATMENT", 164, 213], ["PPE utilization", "TREATMENT", 218, 233], ["disease", "PROBLEM", 288, 295], ["medical treatment", "TREATMENT", 322, 339], ["environmental transmission", "TREATMENT", 353, 379], ["Infection", "OBSERVATION", 178, 187], ["spread", "OBSERVATION_MODIFIER", 278, 284]]], ["Many diseases can be spread through fomites and poor consideration for the environmental aspects of infection control only fuel transmission.", [["infection", "DISEASE", 100, 109], ["Many diseases", "PROBLEM", 0, 13], ["infection control", "TREATMENT", 100, 117], ["diseases", "OBSERVATION", 5, 13], ["infection", "OBSERVATION", 100, 109]]], ["There is considerable literature on the recommendations and guidelines for environmental infection control, specifically by the CDC, OSHA, WHO, and APIC.", [["infection", "DISEASE", 89, 98], ["environmental infection control", "TREATMENT", 75, 106], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["literature", "OBSERVATION", 22, 32], ["infection", "OBSERVATION", 89, 98]]], ["This section will provide a very high-level overview of these publications.", [["This section", "TREATMENT", 0, 12]]], ["The goal of this section is to raise awareness for environmental mechanisms of transmission and encourage consideration during the development of preparedness and response plans.", [["this section", "TREATMENT", 12, 24]]], ["Healthcare environmental components, such as building design, waste management, disinfection and sterilization, and air monitoring, are critical to reducing the spread of microorganisms, but the ability to make changes may be hindered by high costs and other restraints.Cleaning, Disinfection, and SterilizationCleaning and disinfection of non-critical surfaces is a basic premise of infection control practices, especially standard precautions [17] .", [["infection", "DISEASE", 384, 393], ["waste management", "TREATMENT", 62, 78], ["disinfection", "TREATMENT", 80, 92], ["sterilization", "TREATMENT", 97, 110], ["air monitoring", "TEST", 116, 130], ["microorganisms", "PROBLEM", 171, 185], ["other restraints", "TREATMENT", 253, 269], ["Cleaning", "TREATMENT", 270, 278], ["Disinfection", "TREATMENT", 280, 292], ["SterilizationCleaning", "TREATMENT", 298, 319], ["disinfection", "TREATMENT", 324, 336], ["non-critical surfaces", "PROBLEM", 340, 361], ["infection control practices", "TREATMENT", 384, 411], ["Disinfection", "OBSERVATION", 280, 292], ["non-critical surfaces", "OBSERVATION_MODIFIER", 340, 361], ["infection", "OBSERVATION", 384, 393]]], ["These practices become even more significant when caring for patients with infectious diseases.", [["infectious diseases", "DISEASE", 75, 94], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["infectious diseases", "PROBLEM", 75, 94]]], ["Cleaning is the process of removing pathogens, whereas disinfecting kills germs on the surface, and sanitizing lowers the number of pathogens on an object to a safe level.", [["germs", "ANATOMY", 74, 79], ["surface", "ANATOMY", 87, 94], ["surface", "CELLULAR_COMPONENT", 87, 94], ["removing pathogens", "PROBLEM", 27, 45], ["sanitizing", "TREATMENT", 100, 110], ["pathogens", "OBSERVATION", 36, 45], ["surface", "OBSERVATION_MODIFIER", 87, 94]]], ["Rutala and Weber provide an extensive outline of such methods for cleaning, which include:Cleaning, Disinfection, and Sterilization\u2022 Sterilization: destroys all microorganisms, including bacterial spores \u2022 High-level disinfection: destroys all microorganisms except high numbers of bacterial spores \u2022 Intermediate level disinfection: destroys vegetative bacterial, mycobacteria, most viruses, most fungi, but not bacterial spores \u2022 Low-level disinfection: destroys vegetative bacteria, some fungi and viruses, but not mycobacteria or spores.Cleaning, Disinfection, and SterilizationSuch practices should be closely followed, especially in the event of novel or severe illnesses requiring enhanced precautions.", [["spores", "ANATOMY", 197, 203], ["spores", "ANATOMY", 292, 298], ["spores", "ANATOMY", 423, 429], ["spores", "ANATOMY", 534, 540], ["such methods", "TREATMENT", 49, 61], ["cleaning", "TREATMENT", 66, 74], ["Disinfection", "TREATMENT", 100, 112], ["Sterilization\u2022 Sterilization", "TREATMENT", 118, 146], ["all microorganisms", "PROBLEM", 157, 175], ["bacterial spores", "PROBLEM", 187, 203], ["High-level disinfection", "PROBLEM", 206, 229], ["all microorganisms", "PROBLEM", 240, 258], ["bacterial spores", "PROBLEM", 282, 298], ["Intermediate level disinfection", "PROBLEM", 301, 332], ["destroys vegetative bacterial", "PROBLEM", 334, 363], ["mycobacteria", "PROBLEM", 365, 377], ["most viruses", "PROBLEM", 379, 391], ["most fungi", "PROBLEM", 393, 403], ["bacterial spores", "PROBLEM", 413, 429], ["Low-level disinfection", "PROBLEM", 432, 454], ["destroys vegetative bacteria", "PROBLEM", 456, 484], ["some fungi", "PROBLEM", 486, 496], ["viruses", "PROBLEM", 501, 508], ["mycobacteria", "PROBLEM", 518, 530], ["spores", "PROBLEM", 534, 540], ["Disinfection", "TREATMENT", 551, 563], ["SterilizationSuch practices", "TREATMENT", 569, 596], ["severe illnesses", "PROBLEM", 661, 677], ["enhanced precautions", "TREATMENT", 688, 708], ["bacterial spores", "OBSERVATION", 282, 298], ["mycobacteria", "OBSERVATION", 365, 377], ["vegetative bacteria", "OBSERVATION", 465, 484], ["viruses", "OBSERVATION", 501, 508], ["not", "UNCERTAINTY", 514, 517], ["mycobacteria", "OBSERVATION", 518, 530], ["Disinfection", "OBSERVATION", 551, 563], ["severe", "OBSERVATION_MODIFIER", 661, 667], ["illnesses", "OBSERVATION", 668, 677]]], ["Disinfection recommendations may be revised based upon recommendations from OSHA and the CDC, as was seen during treatment of patients with Ebola virus disease in U.S. hospitals.", [["Ebola virus disease", "DISEASE", 140, 159], ["patients", "ORGANISM", 126, 134], ["Ebola virus", "ORGANISM", 140, 151], ["patients", "SPECIES", 126, 134], ["Ebola virus", "SPECIES", 140, 151], ["Ebola virus", "SPECIES", 140, 151], ["Ebola virus disease", "PROBLEM", 140, 159], ["Ebola virus", "OBSERVATION", 140, 151]]], ["Environmental contamination can be a significant mechanism for disease transmission during patient care and invasive procedures can increase this substantially.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["Environmental contamination", "PROBLEM", 0, 27], ["disease transmission", "PROBLEM", 63, 83], ["patient care", "TREATMENT", 91, 103], ["invasive procedures", "TREATMENT", 108, 127]]], ["Poorly disinfected or sterilized equipment has been the culprit of many healthcareassociated infections and outbreaks.", [["infections", "DISEASE", 93, 103], ["sterilized equipment", "TREATMENT", 22, 42], ["many healthcareassociated infections", "PROBLEM", 67, 103], ["disinfected", "OBSERVATION", 7, 18], ["many", "OBSERVATION_MODIFIER", 67, 71], ["healthcareassociated", "OBSERVATION_MODIFIER", 72, 92], ["infections", "OBSERVATION", 93, 103]]], ["High-touch surfaces or objects, like sinks and bedrails, require frequent cleaning and disinfection.", [["frequent cleaning", "TREATMENT", 65, 82], ["disinfection", "TREATMENT", 87, 99], ["touch surfaces", "OBSERVATION_MODIFIER", 5, 19]]], ["Frequency and intensity of cleaning and disinfection may also need to be increased depending up on the \"degree of environmental contamination\" [17] .", [["cleaning", "TREATMENT", 27, 35], ["disinfection", "TREATMENT", 40, 52]]], ["Environmental Protection Agency (EPA)registered disinfectant should be used to combat the environmental contamination that occurs during patient care.", [["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["Environmental Protection Agency (EPA)registered disinfectant", "TREATMENT", 0, 60], ["the environmental contamination", "PROBLEM", 86, 117]]], ["It is important to note that certain pathogens may be resistant to routine disinfectants (e.g., rotaviruses, noroviruses, Clostridium difficile, Bacillus anthracis), meaning that healthcare workers should ensure the cleaning product they are using is effective against the specific microorganism.", [["noroviruses", "DISEASE", 109, 120], ["Clostridium difficile", "DISEASE", 122, 143], ["Clostridium difficile", "ORGANISM", 122, 143], ["Bacillus anthracis", "ORGANISM", 145, 163], ["Clostridium difficile", "SPECIES", 122, 143], ["Bacillus anthracis", "SPECIES", 145, 163], ["Clostridium difficile", "SPECIES", 122, 143], ["Bacillus anthracis", "SPECIES", 145, 163], ["certain pathogens", "PROBLEM", 29, 46], ["routine disinfectants", "TREATMENT", 67, 88], ["rotaviruses", "PROBLEM", 96, 107], ["noroviruses", "PROBLEM", 109, 120], ["Clostridium difficile, Bacillus anthracis", "PROBLEM", 122, 163], ["the cleaning product", "TREATMENT", 212, 232], ["the specific microorganism", "PROBLEM", 269, 295]]], ["Disinfection and sterilization of medical equipment should always follow manufacturer recommendations and be handled with care.Cleaning, Disinfection, and SterilizationThere are frequently forgotten objects and surfaces that are common culprits for contamination and should be highlighted during routine cleaning.", [["Disinfection", "TREATMENT", 0, 12], ["sterilization of medical equipment", "TREATMENT", 17, 51], ["Disinfection", "TREATMENT", 137, 149], ["Sterilization", "TREATMENT", 155, 168], ["contamination", "PROBLEM", 249, 262], ["routine cleaning", "TREATMENT", 296, 312], ["Disinfection", "OBSERVATION", 137, 149], ["Sterilization", "OBSERVATION", 155, 168], ["frequently", "OBSERVATION_MODIFIER", 178, 188], ["forgotten objects", "OBSERVATION", 189, 206]]], ["Computer keyboards, stethoscopes, and clinical work stations are all areas that routinely have a high microbial burden and are frequently neglected during cleaning.", [["stethoscopes", "TREATMENT", 20, 32], ["a high microbial burden", "PROBLEM", 95, 118], ["high microbial", "OBSERVATION_MODIFIER", 97, 111], ["burden", "OBSERVATION", 112, 118]]], ["There is extensive literature on practices for disinfection and sterilization, but at the most basic level, preparedness and response efforts should work to ensure routine cleaning and disinfection is done appropriately and correctly [36] .", [["disinfection", "TREATMENT", 47, 59], ["sterilization", "TREATMENT", 64, 77], ["routine cleaning", "TREATMENT", 164, 180], ["disinfection", "TREATMENT", 185, 197], ["extensive", "OBSERVATION_MODIFIER", 9, 18], ["literature", "OBSERVATION", 19, 29]]], ["Environmental contamination is a continued source for disease transmission in healthcare.", [["Environmental contamination", "PROBLEM", 0, 27]]], ["These practices should be strengthened during routine care and also refined to meet special needs during public health emergencies and care of patients in enhanced precautions.Ventilation SystemsHospital ventilation systems are a critical component to patient safety.", [["patients", "ORGANISM", 143, 151], ["patient", "ORGANISM", 252, 259], ["patients", "SPECIES", 143, 151], ["patient", "SPECIES", 252, 259], ["enhanced precautions", "TREATMENT", 155, 175], ["Ventilation SystemsHospital ventilation systems", "TREATMENT", 176, 223]]], ["These systems maintain negative pressure within airborne isolation rooms and positive pressure in operating/procedure rooms, as well as protective precaution rooms (for severely immunocompromised patients).", [["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["operating/procedure rooms", "TREATMENT", 98, 123], ["protective precaution rooms", "TREATMENT", 136, 163], ["negative", "OBSERVATION", 23, 31], ["pressure", "OBSERVATION_MODIFIER", 32, 40], ["pressure", "OBSERVATION_MODIFIER", 86, 94]]], ["Negative pressure rooms will become a critical need in outbreaks of microorganisms that require airborne isolation.", [["microorganisms", "PROBLEM", 68, 82], ["airborne isolation", "TREATMENT", 96, 114], ["pressure rooms", "OBSERVATION", 9, 23], ["airborne isolation", "OBSERVATION", 96, 114]]], ["These rooms should have high-efficiency particulate air (HEPA) and should also follow CDC guidelines for environmental infection control regarding air exchanges per hour (ACH) (i.e. 12 ACH for new construction as of 2001; 6 ACH for construction before 2001) and be monitored in accordance with engineers' and manufacturers' recommendations [19] .", [["infection", "DISEASE", 119, 128], ["environmental infection control", "TREATMENT", 105, 136]]], ["The negative pressure rooms should maintain air pressure by being properly sealed and are encouraged to have self-sealing doors and ante-rooms.", [["air pressure", "TEST", 44, 56], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["pressure", "OBSERVATION_MODIFIER", 13, 21], ["air pressure", "OBSERVATION", 44, 56]]], ["The heating, ventilation, air conditioning (HVAC) systems should also have humidity monitors to ensure the moisture levels are adequate as to discourage microbial growth.", [["The heating", "TREATMENT", 0, 11], ["ventilation", "TREATMENT", 13, 24], ["air conditioning (HVAC) systems", "TREATMENT", 26, 57], ["humidity monitors", "TEST", 75, 92], ["the moisture levels", "TEST", 103, 122], ["microbial growth", "PROBLEM", 153, 169], ["air conditioning", "OBSERVATION", 26, 42]]], ["The CDC has specific recommendations for air-handling systems in healthcare facilities, which are vital to patient safety and reduction of disease transmission.", [["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["disease transmission", "PROBLEM", 139, 159], ["disease", "OBSERVATION", 139, 146]]], ["In the event of a biological attack or outbreak, ensuring that these systems are operational and can maintain proper negative pressure in designated rooms will be of the utmost importance.", [["a biological attack", "PROBLEM", 16, 35], ["outbreak", "PROBLEM", 39, 47]]], ["Although negative pressure rooms are limited on each hospital unit, there is potential to convert entire units to negative pressure through adjustments to the ventilation system and sealing of the unit [20] .Environmental ServicesEnvironmental cleaning, waste management, and handling of textiles are all components of environmental service work in healthcare.", [["negative pressure through adjustments", "TREATMENT", 114, 151], ["the ventilation system", "TREATMENT", 155, 177], ["waste management", "TREATMENT", 254, 270], ["pressure", "OBSERVATION_MODIFIER", 18, 26], ["pressure", "OBSERVATION_MODIFIER", 123, 131]]], ["These duties are especially important upon discharge of the patient when a deep clean of the room is required (commonly called \"terminal cleaning\").", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67]]], ["Within a single day of admission, the composition of a hospital room's microbes begin to change and mirror that of the patient [21] .", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["a hospital room's microbes", "TREATMENT", 53, 79]]], ["Environmental services staff frequently manage these tasks and should be aware of the patient's isolation status so that staff utilizes proper PPE and ensures use of proper Environmental Protection Agency (EPA)-registered disinfectants (example: Clostridium difficile requires the use of bleach products to kill spores).", [["spores", "ANATOMY", 312, 318], ["Clostridium difficile", "DISEASE", 246, 267], ["patient", "ORGANISM", 86, 93], ["Clostridium difficile", "ORGANISM", 246, 267], ["patient", "SPECIES", 86, 93], ["Clostridium difficile", "SPECIES", 246, 267], ["Clostridium difficile", "SPECIES", 246, 267], ["Clostridium difficile", "PROBLEM", 246, 267], ["bleach products", "TREATMENT", 288, 303]]], ["Typically, hospitals have contracts with linen services and waste management companies (for both regular and medical waste).", [["linen services", "TREATMENT", 41, 55], ["waste management", "TREATMENT", 60, 76]]], ["However, practices may change during the care of patients with high consequence pathogens that require enhanced isolation.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["high consequence pathogens", "PROBLEM", 63, 89], ["enhanced isolation", "TREATMENT", 103, 121]]], ["CDC guidelines regarding medical waste, dishes and eating utensils and textiles all note that these objects have not been implicated in SARS coronavirus transmission and that routine procedures should be utilized [22] .", [["SARS coronavirus transmission", "DISEASE", 136, 165], ["SARS coronavirus", "ORGANISM", 136, 152], ["SARS coronavirus", "SPECIES", 136, 152], ["routine procedures", "TREATMENT", 175, 193]]], ["In the case of Ebola virus, recommendations were significantly different.", [["Ebola virus", "DISEASE", 15, 26], ["Ebola virus", "ORGANISM", 15, 26], ["Ebola virus", "SPECIES", 15, 26], ["Ebola virus", "SPECIES", 15, 26], ["Ebola virus", "PROBLEM", 15, 26], ["Ebola virus", "OBSERVATION", 15, 26]]], ["For example, despite Ebola virus forming enveloped virions (which are susceptible to a wide range of hospital disinfectants), no EPA-registered disinfectants had labels that specifically cited efficacy against the virus.", [["EPA", "CHEMICAL", 129, 132], ["EPA", "CHEMICAL", 129, 132], ["Ebola virus", "ORGANISM", 21, 32], ["EPA", "SIMPLE_CHEMICAL", 129, 132], ["Ebola virus", "SPECIES", 21, 32], ["Ebola virus", "SPECIES", 21, 32], ["Ebola virus", "PROBLEM", 21, 32], ["enveloped virions", "PROBLEM", 41, 58], ["hospital disinfectants", "TREATMENT", 101, 123], ["the virus", "PROBLEM", 210, 219], ["Ebola virus", "OBSERVATION", 21, 32]]], ["Consequently, CDC recommendations were changed to encourage use of EPA-registered disinfectants that were effective against viruses that form non-enveloped virions, which are more resistant to hospital germicidal disinfectant cleaning products.", [["virions", "ANATOMY", 156, 163], ["EPA", "CHEMICAL", 67, 70], ["EPA", "CHEMICAL", 67, 70], ["EPA", "SIMPLE_CHEMICAL", 67, 70], ["EPA-registered disinfectants", "TREATMENT", 67, 95], ["viruses", "PROBLEM", 124, 131], ["non-enveloped virions", "PROBLEM", 142, 163], ["hospital germicidal disinfectant cleaning products", "TREATMENT", 193, 243]]], ["CDC recommendations also included discarding of all textiles to avoid staff exposure during the laundering process [15] .", [["all textiles", "TREATMENT", 48, 60]]], ["Many hospitals developed Ebola virus preparedness plans that placed environmental service duties more on the clinical staff caring for a PUI instead of potential exposing additional staff.", [["Ebola", "DISEASE", 25, 30], ["Ebola", "ORGANISM", 25, 30], ["Ebola virus", "SPECIES", 25, 36], ["Ebola virus preparedness", "TREATMENT", 25, 49], ["Ebola virus", "OBSERVATION", 25, 36]]], ["Environmental services practices should be closely followed during routine patient care but may require modification during the care of patients in enhanced precautions or during outbreaks.Environmental ServicesIn the pursuit of more effective and efficient cleaning and disinfecting processes, newer technologies have been utilized, like that of ultraviolet disinfection technology and copper-infused linen.", [["patient", "ORGANISM", 75, 82], ["patients", "ORGANISM", 136, 144], ["patient", "SPECIES", 75, 82], ["patients", "SPECIES", 136, 144], ["routine patient care", "TREATMENT", 67, 87], ["modification", "TREATMENT", 104, 116], ["enhanced precautions", "TREATMENT", 148, 168], ["ultraviolet disinfection technology", "TREATMENT", 347, 382], ["copper-infused linen", "TREATMENT", 387, 407]]], ["Environmental monitoring to check room cleaning quality is also a frequently used measure to test true cleaning of the space.", [["Environmental monitoring", "TEST", 0, 24]]], ["Overall, environmental infection control by means of environmental services staff, textile care, and waste management are critical components to breaking the chain of infection.", [["infection", "DISEASE", 23, 32], ["infection", "DISEASE", 167, 176], ["environmental infection control", "TREATMENT", 9, 40], ["textile care", "TREATMENT", 83, 95], ["waste management", "TREATMENT", 101, 117], ["critical components", "PROBLEM", 122, 141], ["infection", "PROBLEM", 167, 176], ["environmental", "OBSERVATION_MODIFIER", 9, 22], ["infection", "OBSERVATION", 23, 32], ["infection", "OBSERVATION", 167, 176]]], ["The efficacy of these duties and the adherence to transmission-based precautions when working throughout a healthcare facility is a monumental task and becomes even more critical during outbreaks.WaterThere is a considerable amount of literature and regulatory guidance on environmental infection control as it relates to water however, this section will focus on only a handful.", [["infection", "DISEASE", 287, 296], ["transmission-based precautions", "TREATMENT", 50, 80], ["regulatory guidance", "TREATMENT", 250, 269], ["environmental infection control", "TREATMENT", 273, 304], ["this section", "TREATMENT", 337, 349], ["considerable", "OBSERVATION_MODIFIER", 212, 224], ["amount", "OBSERVATION_MODIFIER", 225, 231], ["infection", "OBSERVATION", 287, 296]]], ["Firstly, facilities should consider the mechanisms for preventing the spread of waterborne microorganisms through proper hand hygiene, cleaning of sinks, avoidance of decorative fountains and fish tanks in patient-care areas, and maintaining proper temperatures for hot and cold water [19] .", [["hand", "ANATOMY", 121, 125], ["hand", "ORGANISM_SUBDIVISION", 121, 125], ["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213], ["waterborne microorganisms", "PROBLEM", 80, 105], ["decorative fountains", "TREATMENT", 167, 187], ["fish tanks", "TREATMENT", 192, 202]]], ["Should water disruptions occur, corrective decontamination of the hot water system may be necessary, which can include flushing the water lines and outlets with chlorine and/or superheated water.", [["chlorine", "CHEMICAL", 161, 169], ["chlorine", "CHEMICAL", 161, 169], ["chlorine", "SIMPLE_CHEMICAL", 161, 169], ["water disruptions", "PROBLEM", 7, 24], ["corrective decontamination", "TREATMENT", 32, 58], ["the hot water system", "TREATMENT", 62, 82], ["the water lines", "TREATMENT", 128, 143], ["chlorine", "TREATMENT", 161, 169], ["water lines", "OBSERVATION", 132, 143]]], ["Hospitals should have contingency plans for water in the event that water disruptions are prolonged due to intrusions or contamination.Construction and RenovationConstruction, renovation, remediation, repair, and demolition within a healthcare environment can be sources for infection.", [["infection", "DISEASE", 275, 284], ["water", "TREATMENT", 44, 49], ["water disruptions", "PROBLEM", 68, 85], ["intrusions", "PROBLEM", 107, 117], ["contamination", "PROBLEM", 121, 134], ["RenovationConstruction", "TREATMENT", 152, 174], ["renovation", "TREATMENT", 176, 186], ["remediation", "TREATMENT", 188, 199], ["repair", "TREATMENT", 201, 207], ["demolition", "TREATMENT", 213, 223], ["infection", "PROBLEM", 275, 284], ["repair", "OBSERVATION", 201, 207], ["infection", "OBSERVATION", 275, 284]]], ["All work must be reviewed by infection prevention and control to coordinate prevention methods that include containment barriers and post-construction cleaning.", [["infection", "DISEASE", 29, 38], ["infection prevention", "TREATMENT", 29, 49], ["coordinate prevention methods", "TREATMENT", 65, 94], ["containment barriers", "TREATMENT", 108, 128], ["post-construction cleaning", "TREATMENT", 133, 159], ["infection", "OBSERVATION", 29, 38]]], ["Such efforts are necessary as demolition can lead to airborne infections associated with fungal spores in immunocompromised patients.", [["spores", "ANATOMY", 96, 102], ["infections", "DISEASE", 62, 72], ["fungal spores", "DISEASE", 89, 102], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["airborne infections", "PROBLEM", 53, 72], ["fungal spores in immunocompromised patients", "PROBLEM", 89, 132], ["fungal spores", "OBSERVATION", 89, 102]]], ["Moreover, if the proper planning is not done, engineering outages can impact negative pressure rooms, which decreases their efficacy.", [["negative pressure rooms", "TREATMENT", 77, 100]]], ["Conversion of spaces to negative pressure wards or specialty isolation units should be planned and tested ahead of time to ensure proper ventilation is possible.Poor Utilization and SupportIn the day-to-day world of medical care, infection prevention and control practices, like hand hygiene, frequently have poor compliance [23] .", [["hand", "ANATOMY", 279, 283], ["infection", "DISEASE", 230, 239], ["hand", "ORGANISM_SUBDIVISION", 279, 283], ["negative pressure wards", "TREATMENT", 24, 47], ["specialty isolation units", "TREATMENT", 51, 76], ["proper ventilation", "TREATMENT", 130, 148], ["medical care", "TREATMENT", 216, 228], ["infection prevention", "TREATMENT", 230, 250], ["control practices", "TREATMENT", 255, 272], ["negative", "OBSERVATION_MODIFIER", 24, 32], ["pressure", "OBSERVATION_MODIFIER", 33, 41], ["ventilation", "OBSERVATION", 137, 148], ["infection", "OBSERVATION", 230, 239]]], ["While there are a multitude of issues that IPC programs face, perhaps the most damning one is internally.", [["IPC programs face", "TREATMENT", 43, 60], ["multitude", "OBSERVATION_MODIFIER", 18, 27]]], ["Typically, IPC programs are seen as cost centers and not revenue generators, which frequently translates to lackluster support and prioritization [24] .", [["IPC programs", "TREATMENT", 11, 23]]], ["While there have been studies evaluating the cost of healthcare-associated infections in relation to that of an IPC program, there is a considerable gap within the research regarding IPC programs and response during outbreaks or cases of high-consequence pathogens.", [["infections", "DISEASE", 75, 85], ["studies", "TEST", 22, 29], ["associated infections", "PROBLEM", 64, 85], ["an IPC program", "TREATMENT", 109, 123], ["a considerable gap", "PROBLEM", 134, 152], ["IPC programs", "TREATMENT", 183, 195], ["high-consequence pathogens", "PROBLEM", 238, 264], ["infections", "OBSERVATION", 75, 85]]], ["Given that a single healthcareassociated infection (HAI), like a surgical-site infection, can cost upwards of $50,000 and preventing just a handful of these infections can pay for the entire budget of an IPC program, it is not unreasonable to think that such cost-saving could be applied to biothreat response within hospitals [25] .", [["healthcareassociated infection", "DISEASE", 20, 50], ["HAI", "DISEASE", 52, 55], ["infection", "DISEASE", 79, 88], ["infections", "DISEASE", 157, 167], ["a single healthcareassociated infection (HAI)", "PROBLEM", 11, 56], ["a surgical-site infection", "PROBLEM", 63, 88], ["these infections", "PROBLEM", 151, 167], ["an IPC program", "TREATMENT", 201, 215], ["cost-saving", "TREATMENT", 259, 270], ["infection", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 79, 88], ["infections", "OBSERVATION", 157, 167]]], ["The cases of Ebola virus disease in Dallas, Texas, in 2014 exposed the lack of preparedness within U.S. hospitals, poor compliance with infection control, and the cost of treating such a severe illness with enhanced precautions.", [["Ebola virus disease", "DISEASE", 13, 32], ["infection", "DISEASE", 136, 145], ["Ebola virus", "ORGANISM", 13, 24], ["Ebola virus", "SPECIES", 13, 24], ["Ebola virus", "SPECIES", 13, 24], ["Ebola virus disease", "PROBLEM", 13, 32], ["infection control", "TREATMENT", 136, 153], ["a severe illness", "PROBLEM", 185, 201], ["enhanced precautions", "TREATMENT", 207, 227], ["Ebola virus", "OBSERVATION", 13, 24], ["infection", "OBSERVATION", 136, 145], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["illness", "OBSERVATION", 194, 201]]], ["It was estimated that the cost of treating a hospitalized patient with Ebola virus disease in the United States is $30,000 per day [26] .", [["Ebola virus disease", "DISEASE", 71, 90], ["patient", "ORGANISM", 58, 65], ["Ebola virus", "ORGANISM", 71, 82], ["patient", "SPECIES", 58, 65], ["Ebola virus", "SPECIES", 71, 82], ["Ebola virus", "SPECIES", 71, 82], ["Ebola virus disease", "PROBLEM", 71, 90]]], ["Despite spending $60 billion on biodefense since 2001 to prepare for biothreats, a single imported case of Ebola virus disease revealed deep breaks within U.S. preparedness efforts [27] .", [["Ebola virus disease", "DISEASE", 107, 126], ["Ebola virus", "ORGANISM", 107, 118], ["Ebola virus", "SPECIES", 107, 118], ["Ebola virus", "SPECIES", 107, 118], ["Ebola virus disease", "PROBLEM", 107, 126], ["deep breaks", "PROBLEM", 136, 147], ["Ebola virus", "OBSERVATION", 107, 118], ["deep breaks", "OBSERVATION", 136, 147]]], ["During the 2013-2016 Ebola virus disease outbreak, it frequently fell on the IPC programs to coordinate hospital-wide preparedness and response efforts to ensure facilities were prepared to identify, isolate, and potentially treat a patient.", [["Ebola virus disease", "DISEASE", 21, 40], ["Ebola virus", "ORGANISM", 21, 32], ["patient", "ORGANISM", 233, 240], ["Ebola virus", "SPECIES", 21, 32], ["patient", "SPECIES", 233, 240], ["Ebola virus", "SPECIES", 21, 32], ["Ebola virus disease outbreak", "PROBLEM", 21, 49], ["the IPC programs", "TREATMENT", 73, 89]]], ["While such events highlight the importance of IPC programs and the diversity of their responsibilities, for many in healthcare the looming threat of Ebola has passed and so has the support.", [["Ebola", "DISEASE", 149, 154], ["Ebola", "ORGANISM", 149, 154], ["IPC programs", "TREATMENT", 46, 58], ["Ebola", "OBSERVATION", 149, 154]]], ["The focus for many IPC programs has gone back to preventing HAIs and Ebola virus disease response plans have been neglected.", [["HAIs", "DISEASE", 60, 64], ["Ebola virus disease", "DISEASE", 69, 88], ["Ebola virus", "ORGANISM", 69, 80], ["Ebola virus", "SPECIES", 69, 80], ["Ebola virus", "SPECIES", 69, 80], ["many IPC programs", "TREATMENT", 14, 31], ["HAIs", "PROBLEM", 60, 64], ["Ebola virus disease response", "PROBLEM", 69, 97]]], ["A 2015 APIC survey found that 92% of IPC program leaders believe they were more prepared than the previously year to receive a patient with a highly infectious disease [28] .", [["infectious disease", "DISEASE", 149, 167], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["A 2015 APIC survey", "TEST", 0, 18], ["IPC program", "TREATMENT", 37, 48], ["a highly infectious disease", "PROBLEM", 140, 167], ["infectious", "OBSERVATION", 149, 159]]], ["While this is encouraging, would hospitals and IPC programs feel the same today, several years after the 2013-2016 Ebola virus disease outbreak?", [["Ebola virus disease", "DISEASE", 115, 134], ["Ebola virus", "ORGANISM", 115, 126], ["Ebola virus", "SPECIES", 115, 126], ["Ebola virus", "SPECIES", 115, 126], ["Ebola virus disease outbreak", "PROBLEM", 115, 143]]], ["There is a substantial need within healthcare to truly support IPC programs for not only day-to-day HAI prevention, but also as a means of establishing an all-hazards approach.", [["IPC programs", "TREATMENT", 63, 75], ["HAI prevention", "TREATMENT", 100, 114], ["an all-hazards approach", "TREATMENT", 152, 175], ["substantial", "OBSERVATION_MODIFIER", 11, 22]]], ["Infection prevention and control, as shown within this chapter, involves collaboration with many internal and external partners to ensure patient safety.", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["Infection prevention", "TREATMENT", 0, 20]]], ["IPC programs are sentinels within hospitals, alerting internal and external partners of issues, so that they may form a collective response effort.", [["IPC programs", "TREATMENT", 0, 12]]], ["It behooves bio-preparedness efforts to utilize IPC programs and consider IPC practices as a vital resource for disease control, medical countermeasures, and surveillance.Invasive Medical InterventionsWhile advances in medicine have given us the capabilities to increasingly counter disease, the invasiveness of certain medical procedures and treatments can pose substantial infection control risks.", [["infection", "DISEASE", 375, 384], ["IPC programs", "TREATMENT", 48, 60], ["IPC practices", "TREATMENT", 74, 87], ["disease control", "TREATMENT", 112, 127], ["medical countermeasures", "TREATMENT", 129, 152], ["surveillance", "TEST", 158, 170], ["Invasive Medical Interventions", "TREATMENT", 171, 201], ["increasingly counter disease", "PROBLEM", 262, 290], ["certain medical procedures", "TREATMENT", 312, 338], ["treatments", "TREATMENT", 343, 353], ["substantial infection control risks", "PROBLEM", 363, 398], ["substantial", "OBSERVATION_MODIFIER", 363, 374], ["infection", "OBSERVATION", 375, 384]]], ["The treatment of Thomas Duncan, the first Ebola virus-diagnosed patient in the United States, in a seemingly \"regular\" hospital without specialized training or facilities to handle a patient under enhanced precautions, points to this very dilemma.", [["Ebola virus", "DISEASE", 42, 53], ["Ebola virus", "ORGANISM", 42, 53], ["patient", "ORGANISM", 64, 71], ["patient", "ORGANISM", 183, 190], ["Ebola virus", "SPECIES", 42, 53], ["patient", "SPECIES", 64, 71], ["patient", "SPECIES", 183, 190], ["Ebola virus", "SPECIES", 42, 53], ["enhanced precautions", "TREATMENT", 197, 217], ["this very dilemma", "PROBLEM", 229, 246]]], ["In the weeks following his hospitalization, there were conversations in hospital around the U.S. as to the safety and ethical considerations for more invasive and riskier medical interventions during the treatment of a patient with such an infectious disease.", [["infectious disease", "DISEASE", 240, 258], ["patient", "ORGANISM", 219, 226], ["patient", "SPECIES", 219, 226], ["riskier medical interventions", "TREATMENT", 163, 192], ["the treatment", "TREATMENT", 200, 213], ["an infectious disease", "PROBLEM", 237, 258], ["infectious", "OBSERVATION", 240, 250]]], ["Medical interventions like invasive surgery, dialysis, insertion of central lines, ventilation, extracorporeal membrane oxygenation (ECMO), or even labor and delivery, all carry inherent risks for the staff performing them.", [["central lines", "ANATOMY", 68, 81], ["extracorporeal membrane", "ANATOMY", 96, 119], ["Medical interventions", "TREATMENT", 0, 21], ["invasive surgery", "TREATMENT", 27, 43], ["dialysis", "TREATMENT", 45, 53], ["insertion of central lines", "TREATMENT", 55, 81], ["ventilation", "TREATMENT", 83, 94], ["extracorporeal membrane oxygenation", "TREATMENT", 96, 131], ["ECMO", "TREATMENT", 133, 137], ["delivery", "TREATMENT", 158, 166], ["invasive", "OBSERVATION_MODIFIER", 27, 35], ["central lines", "OBSERVATION", 68, 81]]], ["The outbreaks of SARS and MERS coronaviruses, and Ebola virus disease all challenged PPE and isolation recommendations, requiring changes to protect healthcare workers and visitors during treatment, especially those interventions that generate aerosols.", [["SARS", "DISEASE", 17, 21], ["MERS coronaviruses", "DISEASE", 26, 44], ["Ebola virus disease", "DISEASE", 50, 69], ["MERS coronaviruses", "ORGANISM", 26, 44], ["Ebola virus", "ORGANISM", 50, 61], ["Ebola virus", "SPECIES", 50, 61], ["MERS coronaviruses", "SPECIES", 26, 44], ["Ebola virus", "SPECIES", 50, 61], ["SARS", "PROBLEM", 17, 21], ["MERS coronaviruses", "PROBLEM", 26, 44], ["Ebola virus disease", "PROBLEM", 50, 69], ["treatment", "TREATMENT", 188, 197], ["those interventions", "TREATMENT", 210, 229]]], ["These outbreaks have taught vital lessons regarding the life-saving capabilities of modern medicine and technology, but also reveal a lack of preparedness consideration for medical interventions in patients with such severe and uncommon diseases.", [["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["modern medicine", "TREATMENT", 84, 99], ["medical interventions", "TREATMENT", 173, 194], ["such severe and uncommon diseases", "PROBLEM", 212, 245], ["uncommon diseases", "OBSERVATION", 228, 245]]], ["Future efforts should establish treatment and procedure plans with these diseases in mind, drawing on lessons learned and creating new protocols so that afflicted patients may receive the full range of medical care and healthcare workers can perform such work with minimal risk.Conflicting GuidelinesPerhaps one of the most challenging aspects of infection prevention during the Ebola virus disease response in American hospitals was the continuous evolution of guidelines for isolation, PPE, disinfection, handling of medical waste, etc. The Blue Ribbon Study Panel on Biodefense highlighted this very issue in its recommendations, pointing to the \"need for a standardized process to develop and issue clinical infection control guidance for biological events.\" [29] .", [["infection", "DISEASE", 347, 356], ["Ebola virus disease", "DISEASE", 379, 398], ["infection", "DISEASE", 712, 721], ["patients", "ORGANISM", 163, 171], ["Ebola virus", "ORGANISM", 379, 390], ["patients", "SPECIES", 163, 171], ["Ebola virus", "SPECIES", 379, 390], ["Ebola virus", "SPECIES", 379, 390], ["treatment", "TREATMENT", 32, 41], ["procedure", "TREATMENT", 46, 55], ["these diseases", "PROBLEM", 67, 81], ["medical care", "TREATMENT", 202, 214], ["infection prevention", "TREATMENT", 347, 367], ["the Ebola virus disease response", "PROBLEM", 375, 407], ["isolation", "TREATMENT", 477, 486], ["PPE", "PROBLEM", 488, 491], ["disinfection", "TREATMENT", 493, 505], ["medical waste", "TREATMENT", 519, 532], ["The Blue Ribbon Study Panel", "TEST", 539, 566], ["a standardized process", "TREATMENT", 659, 681], ["clinical infection control guidance", "TREATMENT", 703, 738], ["infection", "OBSERVATION", 347, 356]]], ["The recommendations from the CDC regarding isolation precautions, specifically the use of negative pressure rooms/airborne isolation and the necessary PPE, were an evolving process in the days following Thomas Duncan's hospitalization.", [["isolation precautions", "TREATMENT", 43, 64], ["negative pressure rooms", "TREATMENT", 90, 113], ["airborne isolation", "TREATMENT", 114, 132]]], ["As an infection preventionist, these days were taxing due to the constant scramble to not only train staff on the appropriate donning and doffing procedures, but even acquire the correct PPE.", [["infection", "DISEASE", 6, 15], ["doffing procedures", "TREATMENT", 138, 156], ["infection", "OBSERVATION", 6, 15]]], ["Novel diseases like SARS and MERS also tax the public health and healthcare response systems in terms of providing adequate recommendations for isolation.", [["SARS", "DISEASE", 20, 24], ["Novel diseases", "PROBLEM", 0, 14], ["SARS", "PROBLEM", 20, 24], ["isolation", "TREATMENT", 144, 153], ["diseases", "OBSERVATION", 6, 14]]], ["While these fluctuations are understandable, in the event of a biological attack, fear and hysteria will likely play a larger role than in naturally occurring outbreaks, which makes the stability of IPC recommendations that much more important.", [["hysteria", "DISEASE", 91, 99], ["a biological attack", "PROBLEM", 61, 80], ["fear", "PROBLEM", 82, 86], ["hysteria", "PROBLEM", 91, 99], ["IPC recommendations", "TREATMENT", 199, 218]]], ["It is crucial that future efforts include stronger processes to standardize infection control recommendations and guidelines during these critical times.Infection Control in Biodefense Efforts: Minimal Focus Despite Maximum ReturnBiodefense and global health security efforts work to strengthen capacity to respond to infectious disease threats.", [["infection", "DISEASE", 76, 85], ["standardize infection control recommendations", "TREATMENT", 64, 109], ["Maximum ReturnBiodefense", "TREATMENT", 216, 240], ["infectious disease threats", "PROBLEM", 318, 344], ["Minimal", "OBSERVATION_MODIFIER", 194, 201]]], ["Within these plans, there is often a considerable gap regarding the role of infection prevention and control and the programs within healthcare facilities.", [["infection", "DISEASE", 76, 85], ["infection prevention", "TREATMENT", 76, 96], ["infection", "OBSERVATION", 76, 85]]], ["The Health Sector Resilience Checklist for High-Consequence Infectious Diseases from the Johns Hopkins Center for Biosecurity points to the importance of infection control practices and their significance, but there is little overall mention of the programs within hospitals.", [["Infectious Diseases", "DISEASE", 60, 79], ["infection", "DISEASE", 154, 163], ["infection control practices", "TREATMENT", 154, 181], ["infection", "OBSERVATION", 154, 163]]], ["This checklist focuses on the adherence to infection control practices, like that of the Blue Ribbon Study Panel on Biodefense report, but tends to neglect the role of these programs.", [["infection", "DISEASE", 43, 52], ["infection control practices", "TREATMENT", 43, 70], ["the Blue Ribbon Study", "TEST", 85, 106], ["infection", "OBSERVATION", 43, 52]]], ["The same can be said of more recent pandemic influenza and hospital preparedness plans.", [["influenza", "DISEASE", 45, 54], ["hospital preparedness plans", "TREATMENT", 59, 86]]], ["Unfortunately, there tends to be a gap in the literature regarding IPC within biodefense efforts and although most focus on larger components (disease surveillance, PPE, medical countermeasures), the utilization of IPC programs should not go ignored.", [["larger components (disease surveillance", "PROBLEM", 124, 163], ["PPE", "TREATMENT", 165, 168], ["medical countermeasures", "TREATMENT", 170, 193], ["IPC programs", "TREATMENT", 215, 227], ["larger", "OBSERVATION_MODIFIER", 124, 130]]], ["There is a continuous trend of pointing to infection prevention and control processes and neglecting the programs responsible for ensuring they are followed.", [["infection", "DISEASE", 43, 52], ["infection prevention", "TREATMENT", 43, 63], ["infection", "OBSERVATION", 43, 52]]], ["The systemic gap in preparedness efforts citing infection prevention and control practices but failing to account for the program and role of infection preventionists reveals a fundamental lack of truly understanding the role of these programs and internal hospital operations.", [["infection", "DISEASE", 48, 57], ["infection", "DISEASE", 142, 151], ["The systemic gap", "PROBLEM", 0, 16], ["infection prevention", "TREATMENT", 48, 68], ["control practices", "TREATMENT", 73, 90], ["infection preventionists", "PROBLEM", 142, 166], ["internal hospital operations", "TREATMENT", 248, 276], ["systemic", "OBSERVATION_MODIFIER", 4, 12], ["gap", "OBSERVATION_MODIFIER", 13, 16], ["infection", "OBSERVATION", 48, 57]]], ["Biodefense efforts inherently include infection control practices as they are the foundation for preventing the spread of disease, but this gap regarding the inclusion of IPC programs does them a disservice.", [["infection", "DISEASE", 38, 47], ["infection control practices", "TREATMENT", 38, 65], ["disease", "PROBLEM", 122, 129], ["IPC programs", "TREATMENT", 171, 183], ["infection", "OBSERVATION", 38, 47], ["disease", "OBSERVATION", 122, 129]]], ["Hospitals already struggle with following IPC practices to reduce the spread of infection.", [["infection", "DISEASE", 80, 89], ["IPC practices", "TREATMENT", 42, 55], ["infection", "PROBLEM", 80, 89], ["infection", "OBSERVATION", 80, 89]]], ["If hospitals are already struggling with hand hygiene and PPE compliance, how will they manage bioterrorism acts or pandemics?Infection Control in Biodefense Efforts: Minimal Focus Despite Maximum ReturnThe problem is twofold: current compliance to infection control processes is often substandard, and the IPC programs are frequently under-utilized and/or -prioritized.", [["hand", "ANATOMY", 41, 45], ["infection", "DISEASE", 249, 258], ["hand", "ORGANISM_SUBDIVISION", 41, 45], ["PPE compliance", "TREATMENT", 58, 72], ["pandemics", "PROBLEM", 116, 125], ["infection control processes", "PROBLEM", 249, 276], ["the IPC programs", "TREATMENT", 303, 319], ["Minimal", "OBSERVATION_MODIFIER", 167, 174], ["infection", "OBSERVATION", 249, 258]]], ["Biodefense efforts should seek to increase infection prevention and control efforts and strengthen processes while building upon the existing IPC program infrastructure that can be an effective tool.", [["infection", "DISEASE", 43, 52], ["infection prevention", "TREATMENT", 43, 63], ["the existing IPC program infrastructure", "TREATMENT", 129, 168], ["infection", "OBSERVATION", 43, 52]]], ["Infection prevention and control is a significant resource in the biodefense arsenal and should be seen as an independent component, like surveillance and medical countermeasures.", [["Infection prevention", "TREATMENT", 0, 20], ["medical countermeasures", "TREATMENT", 155, 178], ["significant", "OBSERVATION_MODIFIER", 38, 49]]], ["These programs are already in place and while they focus on the day-to-day problems of HAIs, they can be utilized to better serve and strengthen the U.S. healthcare infrastructure and thus preparedness.", [["HAIs", "DISEASE", 87, 91], ["HAIs", "PROBLEM", 87, 91]]], ["Strengthening IPC programs and processes benefits health security whether it is a local outbreak, an act of bioterrorism, or a pandemic.Infection Control in Biodefense Efforts: Minimal Focus Despite Maximum ReturnHospitals are the frontline for biological events and their capacity to adequately detect and respond to such threats can either halt or help the spread of disease.", [["Strengthening IPC programs", "TREATMENT", 0, 26], ["a local outbreak", "PROBLEM", 80, 96], ["a pandemic", "PROBLEM", 125, 135], ["Maximum ReturnHospitals", "TREATMENT", 199, 222], ["biological events", "PROBLEM", 245, 262], ["their capacity", "PROBLEM", 267, 281], ["disease", "PROBLEM", 369, 376], ["Minimal", "OBSERVATION_MODIFIER", 177, 184]]], ["Infection prevention and control practices are existing guidelines and recommendations that seek to combat disease transmission during medical care.", [["Infection prevention", "TREATMENT", 0, 20], ["medical care", "TREATMENT", 135, 147]]], ["IPC programs within hospitals work to ensure staff are educated on and compliant with such practices to protect patients, visitors, and healthcare workers.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["IPC programs", "TREATMENT", 0, 12]]], ["These programs are also an integral source for infectious disease surveillance and a connective tissue within hospitals, making them a significant contributor to public health surveillance.", [["connective tissue", "ANATOMY", 85, 102], ["connective tissue", "TISSUE", 85, 102], ["infectious disease surveillance", "PROBLEM", 47, 78], ["public health surveillance", "TEST", 162, 188], ["infectious", "OBSERVATION", 47, 57], ["connective tissue", "OBSERVATION_MODIFIER", 85, 102]]], ["Outbreaks of SARS, MERS, Ebola virus disease, and multi-drug resistant microorganisms, have all revealed the importance of IPC and the devastating consequences of poor compliance.", [["SARS", "DISEASE", 13, 17], ["Ebola virus disease", "DISEASE", 25, 44], ["Ebola virus", "ORGANISM", 25, 36], ["Ebola virus", "SPECIES", 25, 36], ["Ebola virus", "SPECIES", 25, 36], ["SARS", "PROBLEM", 13, 17], ["MERS", "PROBLEM", 19, 23], ["Ebola virus disease", "PROBLEM", 25, 44], ["multi-drug resistant microorganisms", "PROBLEM", 50, 85], ["IPC", "PROBLEM", 123, 126], ["SARS", "OBSERVATION", 13, 17], ["poor compliance", "OBSERVATION", 163, 178]]], ["Continued failure to prioritize IPC programs and practices, as well as the role they serve within outbreaks and growing biological threats, will only serve to weaken preparedness and response efforts.", [["Continued failure", "PROBLEM", 0, 17], ["IPC programs", "TREATMENT", 32, 44], ["failure", "OBSERVATION", 10, 17]]], ["Defense against biological threats requires strong infection control practices, programs, and the ability to adequately employ these efforts prior to and during public health emergencies.", [["infection", "DISEASE", 51, 60], ["strong infection control practices", "TREATMENT", 44, 78], ["strong", "OBSERVATION_MODIFIER", 44, 50], ["infection", "OBSERVATION", 51, 60]]], ["Healthcare is a critical infrastructure, meaning that if hospitals are amplifiers for disease transmission and sources for negative patient outcomes, the impact can be devastating.", [["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["disease transmission", "PROBLEM", 86, 106]]], ["Infection prevention and control is an essential resource against all biological threats, regardless of their origin.", [["Infection prevention", "TREATMENT", 0, 20]]]], "98b8e765a8d5772af14a710bb86d87e0750a6586": [["INTRODUCTIONCoronaviruses, members of the family Coronaviridae and subfamily Coronavirinae, were initially considered epizoonotic in nature within avian and mammalian hosts (Peeri et al., 2020; Sahin et al., 2020) .", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 49, 62], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 77, 90], ["Coronaviridae", "PROTEIN", 49, 62], ["subfamily Coronavirinae", "PROTEIN", 67, 90]]], ["The transition of coronaviruses to human hosts has resulted in acute respiratory diseases in humans.", [["respiratory", "ANATOMY", 69, 80], ["respiratory diseases", "DISEASE", 69, 89], ["coronaviruses", "ORGANISM", 18, 31], ["human", "ORGANISM", 35, 40], ["humans", "ORGANISM", 93, 99], ["human", "SPECIES", 35, 40], ["humans", "SPECIES", 93, 99], ["human", "SPECIES", 35, 40], ["humans", "SPECIES", 93, 99], ["The transition of coronaviruses to human hosts", "PROBLEM", 0, 46], ["acute respiratory diseases in humans", "PROBLEM", 63, 99], ["coronaviruses", "OBSERVATION", 18, 31], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory diseases", "OBSERVATION", 69, 89]]], ["The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; cause of Coronavirus Disease 2019 or COVID-19) have been associated with extensive outbreaks in 2002 -2003 , clusters of disease from 2012 to 2020 (MERS) and an ongoing 2019-2020 COVID-19 pandemic (Menachery et al., 2017; Jiang et al., 2020; WHO, 2020; Xu et al., 2020) .", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 11, 49], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 64, 108], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 135, 173], ["Coronavirus Disease", "DISEASE", 198, 217], ["SARS-CoV-1", "ORGANISM", 51, 61], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 64, 108], ["MERS-CoV", "ORGANISM", 110, 118], ["SARS-CoV-2", "ORGANISM", 177, 187], ["CoV-1", "SPECIES", 56, 61], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1", "SPECIES", 4, 61], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 64, 118], ["Severe Acute Respiratory Syndrome Coronavirus 2", "SPECIES", 128, 175], ["SARS-CoV-2", "SPECIES", 177, 187], ["Coronavirus Disease 2019 or COVID-19", "SPECIES", 198, 234], ["The Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 0, 49], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["Middle East Respiratory Syndrome", "PROBLEM", 64, 96], ["Coronavirus", "PROBLEM", 97, 108], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 124, 173], ["SARS", "TEST", 177, 181], ["CoV", "TEST", 182, 185], ["Coronavirus Disease", "PROBLEM", 198, 217], ["COVID", "TEST", 226, 231], ["disease", "PROBLEM", 310, 317], ["Severe", "OBSERVATION_MODIFIER", 4, 10], ["Acute", "OBSERVATION_MODIFIER", 11, 16], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 17, 49], ["Middle", "ANATOMY_MODIFIER", 64, 70], ["Respiratory Syndrome", "OBSERVATION", 76, 96], ["Severe", "OBSERVATION_MODIFIER", 128, 134], ["Acute", "OBSERVATION_MODIFIER", 135, 140], ["Respiratory Syndrome", "OBSERVATION", 141, 161], ["Coronavirus Disease", "OBSERVATION", 198, 217], ["extensive", "OBSERVATION_MODIFIER", 262, 271], ["outbreaks", "OBSERVATION", 272, 281]]], ["The infectivity doses for human disease by SARS-CoV-2 and other coronaviruses have yet to be defined (Peeri et al., 2020; Sahin et al., 2020) .", [["SARS", "DISEASE", 43, 47], ["human", "ORGANISM", 26, 31], ["SARS-CoV-2", "ORGANISM", 43, 53], ["coronaviruses", "ORGANISM", 64, 77], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["SARS-CoV", "SPECIES", 43, 51], ["The infectivity doses", "TREATMENT", 0, 21], ["human disease", "PROBLEM", 26, 39], ["other coronaviruses", "PROBLEM", 58, 77]]], ["A dose-response model developed for SARS-CoV-1 indicated that 50% of the exposed individuals would develop illness when exposed to 280 plaque forming units of the virus (Watanabe et al., 2010) .", [["SARS", "DISEASE", 36, 40], ["illness", "DISEASE", 107, 114], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 36, 46], ["individuals", "ORGANISM", 81, 92], ["SARS-CoV-1", "SPECIES", 36, 46], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["illness", "PROBLEM", 107, 114]]], ["Given the gaps in our knowledge, the magnitude of the risk due to virally contaminated surfaces is uncertain and should be examined further.INTRODUCTIONCoronaviruses are positive-stranded RNA viruses with an envelope containing glycoprotein spikes.", [["virally contaminated surfaces", "PROBLEM", 66, 95], ["INTRODUCTIONCoronaviruses", "TEST", 140, 165], ["stranded RNA viruses", "PROBLEM", 179, 199], ["an envelope containing glycoprotein spikes", "PROBLEM", 205, 247], ["positive", "OBSERVATION", 170, 178], ["stranded RNA viruses", "OBSERVATION", 179, 199], ["glycoprotein spikes", "OBSERVATION", 228, 247]]], ["The 26-32 kb genomes of coronaviruses are some of the largest among RNA viruses.", [["coronaviruses", "ORGANISM", 24, 37], ["26-32 kb genomes", "DNA", 4, 20], ["coronaviruses", "PROBLEM", 24, 37], ["coronaviruses", "OBSERVATION", 24, 37], ["largest", "OBSERVATION_MODIFIER", 54, 61], ["RNA viruses", "OBSERVATION", 68, 79]]], ["While the targets of antiviral drugs against the coronavirus that causes COVID-19 could include its unique glycosylated spike and the M pro viral protease (Jin et al., 2020) (Figure 1) , curtailing the spread of the virus remains the first line of defense and a crucial step to reduce the spread of the disease.", [["coronavirus", "DISEASE", 49, 60], ["COVID-19", "CHEMICAL", 73, 81], ["coronavirus", "ORGANISM", 49, 60], ["COVID-19", "ORGANISM", 73, 81], ["M pro viral protease", "PROTEIN", 134, 154], ["coronavirus", "SPECIES", 49, 60], ["antiviral drugs", "TREATMENT", 21, 36], ["the coronavirus", "PROBLEM", 45, 60], ["COVID", "TEST", 73, 78], ["its unique glycosylated spike", "PROBLEM", 96, 125], ["the M pro viral protease", "TREATMENT", 130, 154], ["the virus", "PROBLEM", 212, 221], ["a crucial step", "TREATMENT", 260, 274], ["the disease", "PROBLEM", 299, 310], ["spread", "OBSERVATION_MODIFIER", 289, 295], ["disease", "OBSERVATION", 303, 310]]], ["Disinfectants and biocides effective against coronaviruses may work by inactivating the enveloped virus due to their affinity for the lipid-containing viral envelope, the capsid, and the genome (Pratelli, 2007) .", [["Disinfectants", "CHEMICAL", 0, 13], ["coronaviruses", "ORGANISM", 45, 58], ["Disinfectants", "TREATMENT", 0, 13], ["biocides", "TREATMENT", 18, 26], ["coronaviruses", "PROBLEM", 45, 58], ["the enveloped virus", "PROBLEM", 84, 103], ["the lipid", "TREATMENT", 130, 139], ["viral envelope", "PROBLEM", 151, 165], ["viral envelope", "OBSERVATION", 151, 165]]], ["The use of antimicrobials for hand sanitation (Hulkower et al., 2011) , fomite disinfection, and as nasal sprays and oral rinses (Eggers et al., 2015b; Graf et al., 2018) , may reduce human-to-human transmission of the virus.", [["hand", "ANATOMY", 30, 34], ["nasal", "ANATOMY", 100, 105], ["oral", "ANATOMY", 117, 121], ["hand", "ORGANISM_SUBDIVISION", 30, 34], ["oral", "ORGANISM_SUBDIVISION", 117, 121], ["human", "ORGANISM", 184, 189], ["human", "ORGANISM", 193, 198], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 193, 198], ["antimicrobials", "TREATMENT", 11, 25], ["hand sanitation", "TREATMENT", 30, 45], ["fomite disinfection", "TREATMENT", 72, 91], ["nasal sprays", "TREATMENT", 100, 112], ["oral rinses", "TREATMENT", 117, 128], ["the virus", "PROBLEM", 215, 224]]], ["The ongoing COVID-19 outbreak has resulted in shortages of commercial alcohol-based sanitizers, rubbing alcohol, and personal protective equipment (PPE); therefore, this review is intended to provide information regarding a range of alternative biocides effective in eliminating or reducing the presence of coronaviruses from fomites and other potential sources of cross contamination.SARS-CoV-2 TRANSMISSION AMONG FOOD WORKERS AND FOOD PROCESSING FACILITIESFood processing plants and retail facilities often contain a high density of workers working in close proximity.", [["alcohol", "CHEMICAL", 70, 77], ["alcohol", "CHEMICAL", 104, 111], ["SARS", "DISEASE", 385, 389], ["alcohol", "CHEMICAL", 70, 77], ["alcohol", "CHEMICAL", 104, 111], ["alcohol", "SIMPLE_CHEMICAL", 70, 77], ["alcohol", "SIMPLE_CHEMICAL", 104, 111], ["coronaviruses", "ORGANISM", 307, 320], ["The ongoing COVID", "TEST", 0, 17], ["alternative biocides", "TREATMENT", 233, 253], ["coronaviruses", "PROBLEM", 307, 320], ["cross contamination", "PROBLEM", 365, 384], ["coronaviruses", "OBSERVATION", 307, 320], ["high density", "OBSERVATION_MODIFIER", 519, 531]]], ["The rapid spread of the SARS-CoV-2 virus indicates that its transmission may be multifactorial (Otter et al., 2016) (Figures 2, 3) such as though aerosols, droplets and fomites.", [["SARS", "DISEASE", 24, 28], ["SARS-CoV-2 virus", "ORGANISM", 24, 40], ["CoV-2 virus", "SPECIES", 29, 40], ["SARS-CoV-2 virus", "SPECIES", 24, 40], ["the SARS-CoV-2 virus", "PROBLEM", 20, 40], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["spread", "OBSERVATION_MODIFIER", 10, 16], ["may be", "UNCERTAINTY", 73, 79]]], ["While many food processing facilities have hazard analysis critical control points (HACCP) plans that involve cleaning, sanitation and hand washing programs, several facilities have reported increased spread of SARS-CoV-2 among workers, resulting in shut downs and possible food shortages (Hart et al., 2020) .SARS-CoV-2 TRANSMISSION AMONG FOOD WORKERS AND FOOD PROCESSING FACILITIESTransmission of SARS-CoV-2 is different from that of foodborne bacterial pathogens and viruses, which are transmitted via the fecal-oral route.", [["hand", "ANATOMY", 135, 139], ["oral", "ANATOMY", 515, 519], ["SARS", "DISEASE", 211, 215], ["SARS", "DISEASE", 310, 314], ["SARS", "DISEASE", 399, 403], ["foodborne bacterial pathogens", "DISEASE", 436, 465], ["SARS-CoV-2", "ORGANISM", 211, 221], ["SARS-CoV-2", "ORGANISM", 399, 409], ["fecal", "ORGANISM_SUBDIVISION", 509, 514], ["oral", "ORGANISM_SUBDIVISION", 515, 519], ["SARS-CoV", "SPECIES", 211, 219], ["hand washing programs", "TREATMENT", 135, 156], ["SARS", "PROBLEM", 399, 403], ["foodborne bacterial pathogens", "PROBLEM", 436, 465], ["viruses", "PROBLEM", 470, 477], ["viruses", "OBSERVATION", 470, 477], ["fecal", "ANATOMY", 509, 514]]], ["The transmission of SARS-CoV-2 can not be controlled only through hand washing and sanitizer use and requires interventions that prevent aerosol and droplet based transmission of the virus.", [["hand", "ANATOMY", 66, 70], ["SARS", "DISEASE", 20, 24], ["SARS-CoV-2", "ORGANISM", 20, 30], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["hand washing", "TREATMENT", 66, 78], ["interventions", "TREATMENT", 110, 123], ["aerosol", "TREATMENT", 137, 144], ["the virus", "PROBLEM", 179, 188]]], ["A recent study of SARS-CoV-2 infected patients indicated that higher viral loads existed in the nose than the throat (Zou et al., 2020) .", [["nose", "ANATOMY", 96, 100], ["throat", "ANATOMY", 110, 116], ["SARS-CoV-2 infected", "DISEASE", 18, 37], ["SARS-CoV-2", "ORGANISM", 18, 28], ["patients", "ORGANISM", 38, 46], ["nose", "ORGANISM_SUBDIVISION", 96, 100], ["throat", "ORGANISM_SUBDIVISION", 110, 116], ["patients", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 18, 26], ["A recent study", "TEST", 0, 14], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["higher viral loads", "PROBLEM", 62, 80], ["viral loads", "OBSERVATION", 69, 80], ["nose", "ANATOMY", 96, 100], ["throat", "ANATOMY", 110, 116]]], ["Nasal shedding of virus particles was similar to that the influenza virus (Zou et al., 2020) , with both symptomatic and asymptomatic individuals having similar viral loads during the first 10 days of infection, after which individuals with severe illness have a 60 fold increase in viral load .", [["Nasal", "ANATOMY", 0, 5], ["influenza", "DISEASE", 58, 67], ["infection", "DISEASE", 201, 210], ["illness", "DISEASE", 248, 255], ["Nasal", "ORGAN", 0, 5], ["influenza virus", "ORGANISM", 58, 73], ["Nasal shedding of virus particles", "PROBLEM", 0, 33], ["the influenza virus", "PROBLEM", 54, 73], ["both symptomatic and asymptomatic individuals", "PROBLEM", 100, 145], ["similar viral loads", "PROBLEM", 153, 172], ["infection", "PROBLEM", 201, 210], ["severe illness", "PROBLEM", 241, 255], ["a 60 fold increase in viral load", "PROBLEM", 261, 293], ["virus particles", "OBSERVATION", 18, 33], ["symptomatic", "OBSERVATION_MODIFIER", 105, 116], ["viral loads", "OBSERVATION", 161, 172], ["infection", "OBSERVATION", 201, 210], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["60 fold", "OBSERVATION_MODIFIER", 263, 270], ["increase", "OBSERVATION_MODIFIER", 271, 279], ["viral load", "OBSERVATION", 283, 293]]], ["Control of respiratory transmission of SARS-CoV-2 through aerosols and droplets, as well as transmission by contact with contaminated fomites (Figure 3 ) requires synergy between conventional and novel techniques, including oral and nasal rinses with approved antimicrobials, as well as hand washing, donning of face masks and social isolation (Bali and Chaudhry, 2020) .SARS-CoV-2 TRANSMISSION AMONG FOOD WORKERS AND FOOD PROCESSING FACILITIESSARS-CoV-2, similar to SARS-CoV-1, can remain viable in aerosols for a duration of 3 h.", [["respiratory", "ANATOMY", 11, 22], ["oral", "ANATOMY", 224, 228], ["nasal", "ANATOMY", 233, 238], ["hand", "ANATOMY", 287, 291], ["SARS", "DISEASE", 39, 43], ["SARS", "DISEASE", 371, 375], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["oral", "ORGANISM_SUBDIVISION", 224, 228], ["-CoV-2", "ORGANISM", 448, 454], ["SARS-CoV-1", "ORGANISM", 467, 477], ["SARS-CoV-1", "SPECIES", 467, 477], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47], ["aerosols and droplets", "TREATMENT", 58, 79], ["synergy", "TREATMENT", 163, 170], ["conventional and novel techniques", "TREATMENT", 179, 212], ["oral and nasal rinses", "TREATMENT", 224, 245], ["antimicrobials", "TREATMENT", 260, 274], ["hand washing", "TREATMENT", 287, 299], ["face masks", "TREATMENT", 312, 322], ["respiratory", "ANATOMY", 11, 22]]], ["Recent studies on SARS-CoV-2 and previous studies on SARS-CoV-1 and MERS-CoV indicate that coronaviruses can survive on surfaces such as plastics and stainless steel for durations up to or exceeding 5 days (Sizun et al., 2000; Casanova et al., 2010; Van Doremalen et al., 2020) .", [["SARS-CoV-2", "ORGANISM", 18, 28], ["SARS-CoV-1", "ORGANISM", 53, 63], ["MERS-CoV", "ORGANISM", 68, 76], ["coronaviruses", "ORGANISM", 91, 104], ["CoV-1", "SPECIES", 58, 63], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV-1", "SPECIES", 53, 63], ["MERS-CoV", "SPECIES", 68, 76], ["Recent studies", "TEST", 0, 14], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["previous studies", "TEST", 33, 49], ["SARS", "TEST", 53, 57], ["CoV", "TEST", 58, 61], ["MERS", "PROBLEM", 68, 72], ["coronaviruses", "PROBLEM", 91, 104], ["plastics and stainless steel", "TREATMENT", 137, 165], ["coronaviruses", "OBSERVATION", 91, 104]]], ["Shorter survival of SARS-CoV-2 was observed on printed and tissue papers, but the virus was recovered from the surfaces of surgical masks after 7 days (Chin et al., 2020) .", [["tissue", "ANATOMY", 59, 65], ["SARS", "DISEASE", 20, 24], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["tissue", "TISSUE", 59, 65], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["the virus", "PROBLEM", 78, 87], ["surgical masks", "TREATMENT", 123, 137], ["SARS", "OBSERVATION", 20, 24], ["surgical masks", "OBSERVATION", 123, 137]]], ["Further recovery of SARS-CoV-2 from wood and fabric for up to 2 days indicates that commonly encountered surfaces can harbor SARS-CoV-2 (Casanova et al., 2010; Otter et al., 2016) .", [["wood", "ANATOMY", 36, 40], ["SARS", "DISEASE", 20, 24], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["wood", "ORGANISM_SUBDIVISION", 36, 40], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["SARS", "OBSERVATION", 20, 24]]], ["Studies using the endemic human coronavirus strain (HCoV) 229E indicate that the coronavirus may maintain infectivity for a week's duration on inert surfaces, while the transmissible gastroenteritis virus (TGEV), another coronavirus, survived for a month at 4 \u2022 C. Similarly, longer durations of virus recovery (14 days) were observed at 4 \u2022 C for SARS-CoV-2 (Chin et al., 2020) .", [["transmissible gastroenteritis", "DISEASE", 169, 198], ["coronavirus", "DISEASE", 221, 232], ["human coronavirus strain (HCoV) 229E", "ORGANISM", 26, 62], ["coronavirus", "ORGANISM", 81, 92], ["transmissible gastroenteritis virus", "ORGANISM", 169, 204], ["TGEV", "ORGANISM", 206, 210], ["human", "SPECIES", 26, 31], ["coronavirus", "SPECIES", 32, 43], ["coronavirus", "SPECIES", 81, 92], ["transmissible gastroenteritis virus", "SPECIES", 169, 204], ["human coronavirus", "SPECIES", 26, 43], ["HCoV", "SPECIES", 52, 56], ["transmissible gastroenteritis virus", "SPECIES", 169, 204], ["TGEV", "SPECIES", 206, 210], ["Studies", "TEST", 0, 7], ["the endemic human coronavirus strain", "PROBLEM", 14, 50], ["the coronavirus", "PROBLEM", 77, 92], ["inert surfaces", "TREATMENT", 143, 157], ["the transmissible gastroenteritis virus", "PROBLEM", 165, 204], ["virus recovery", "TREATMENT", 296, 310], ["SARS", "PROBLEM", 348, 352], ["CoV", "TEST", 353, 356], ["coronavirus", "OBSERVATION", 81, 92]]], ["Factors such as viral load and humidity also influence the survival of coronaviruses.", [["coronaviruses", "ORGANISM", 71, 84], ["viral load and humidity", "TREATMENT", 16, 39], ["coronaviruses", "PROBLEM", 71, 84]]], ["While intervention efforts such as quarantining, distancing of individuals, hand washing, and the disinfection of fomites, including food contact surfaces (WHO, 2020) have been suggested, the potential for mitigation strategies to reduce SARS-CoV-2 viral load, shedding in patients and survival in the environment and on contact surfaces need to be addressed.", [["hand", "ANATOMY", 76, 80], ["SARS", "DISEASE", 238, 242], ["hand", "ORGANISM_SUBDIVISION", 76, 80], ["SARS-CoV-2", "ORGANISM", 238, 248], ["patients", "ORGANISM", 273, 281], ["CoV-", "SPECIES", 243, 247], ["patients", "SPECIES", 273, 281], ["hand washing", "TREATMENT", 76, 88], ["mitigation strategies", "TREATMENT", 206, 227], ["SARS", "PROBLEM", 238, 242], ["CoV", "TEST", 243, 246]]], ["The objective of this review is to describe antimicrobial agents with virucidal activity against coronaviruses that can be effectively used for sanitation and disinfection of surfaces individually, or in combination to provide effective hurdles to the spread of SARS-CoV-2.", [["SARS", "DISEASE", 262, 266], ["coronaviruses", "ORGANISM", 97, 110], ["SARS-CoV-2", "ORGANISM", 262, 272], ["SARS-CoV", "SPECIES", 262, 270], ["antimicrobial agents", "TREATMENT", 44, 64], ["virucidal activity", "TREATMENT", 70, 88], ["coronaviruses", "PROBLEM", 97, 110], ["sanitation", "TREATMENT", 144, 154], ["disinfection of surfaces", "TREATMENT", 159, 183]]], ["Agents for the sanitation and disinfection of carriers, vehicles and fomites in food production, distribution, and retail settings (Sizun et al., 2000; Otter et al., 2016) are the primary focus.FOMITES AS VEHICLES AND RESERVOIRS OF CORONAVIRUSESFomites likely place a role in viral transmission because they can be contaminated with virus-containing secretions, such as aerosols or droplets, expelled through coughing or talking (Figure 2 ) (Hulkower et al., 2011; Menachery et al., 2017; Kampf et al., 2020) .", [["secretions", "ANATOMY", 350, 360], ["secretions", "ORGANISM_SUBSTANCE", 350, 360], ["Agents", "TREATMENT", 0, 6], ["the sanitation", "TREATMENT", 11, 25], ["disinfection of carriers", "TREATMENT", 30, 54], ["viral transmission", "TREATMENT", 276, 294], ["virus", "PROBLEM", 333, 338], ["secretions", "PROBLEM", 350, 360], ["coughing", "PROBLEM", 409, 417]]], ["During the 2002-2003 SARS-CoV-1 outbreak, 31 cases in three separate clusters were linked to a single index patient at National Taiwan University Hospital.", [["SARS", "DISEASE", 21, 25], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["SARS-CoV-1", "SPECIES", 21, 31]]], ["The third cluster included six healthcare workers with direct SARS patient contact, and six additional infected healthcare workers who had no direct contact with the patient.", [["SARS", "DISEASE", 62, 66], ["patient", "ORGANISM", 67, 74], ["patient", "ORGANISM", 166, 173], ["patient", "SPECIES", 67, 74], ["patient", "SPECIES", 166, 173]]], ["Contaminated fomites were a suspected route of transmission to the workers with no direct patient contact.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97]]], ["Out of 119 environmental samples collected throughout the hospital, nine were confirmed SARS-CoV-1 RNA positive (Chen et al., 2004) .FOMITES AS VEHICLES AND RESERVOIRS OF CORONAVIRUSESSeveral other surveys on coronaviruses such as SARS-CoV-1 and MERS-CoV have indicated that fomites, along with airborne routes, contribute to the spread of coronaviruses (Otter et al., 2016; Xiao et al., 2017) .", [["samples", "ANATOMY", 25, 32], ["coronaviruses", "DISEASE", 340, 353], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 88, 98], ["coronaviruses", "ORGANISM", 209, 222], ["SARS-CoV-1", "ORGANISM", 231, 241], ["MERS-CoV", "ORGANISM", 246, 254], ["coronaviruses", "ORGANISM", 340, 353], ["CoV-1", "SPECIES", 236, 241], ["SARS-CoV-1", "SPECIES", 88, 98], ["SARS-CoV-1", "SPECIES", 231, 241], ["MERS-CoV", "SPECIES", 246, 254], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["coronaviruses", "PROBLEM", 209, 222], ["SARS", "TEST", 231, 235], ["CoV", "TEST", 236, 239], ["MERS", "PROBLEM", 246, 250]]], ["Surface swabs of two hospitals treating MERS-CoV patients indicated that 42 out of 68 surfaces were positive for the coronavirus using reverse transcriptase polymerase chain reaction (RT-PCR).", [["MERS-CoV", "ORGANISM", 40, 48], ["patients", "ORGANISM", 49, 57], ["coronavirus", "ORGANISM", 117, 128], ["reverse transcriptase", "PROTEIN", 135, 156], ["patients", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 40, 48], ["Surface swabs", "TEST", 0, 13], ["the coronavirus", "PROBLEM", 113, 128], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 135, 182], ["RT-PCR", "TEST", 184, 190]]], ["The MERS-CoV was cultured from surfaces such as stethoscopes, doorknobs, bed guardrails, and elevators (Kim S.-H. et al., 2016) .", [["stethoscopes", "ANATOMY", 48, 60], ["doorknobs", "ANATOMY", 62, 71], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["MERS-CoV", "DNA", 4, 12], ["MERS-CoV", "SPECIES", 4, 12], ["stethoscopes", "TEST", 48, 60]]], ["Swabs of surfaces such as a refrigerator handle, table, and television remote control were positive for SARS-CoV-1 using RT-PCR in SARS units during an outbreak in Toronto (Dowell et al., 2004) .", [["SARS", "DISEASE", 104, 108], ["SARS", "DISEASE", 131, 135], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 104, 114], ["SARS-CoV-1", "SPECIES", 104, 114], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["RT-PCR", "TREATMENT", 121, 127]]], ["Several factors, including surface material, organic load, viral load, temperature, and environmental humidity may influence the survival of viral particles on surfaces (Kim S.-H. et al., 2016; Otter et al., 2016) .FOMITES AS VEHICLES AND RESERVOIRS OF CORONAVIRUSESA comparative study of the SARS-CoV-1 and SARS-CoV-2 examined viral stability kinetics in aerosols and on surfaces and determined that decay rates for both viruses were similar on many, but not all surfaces (Van Doremalen et al., 2020) .", [["surface", "ANATOMY", 27, 34], ["SARS", "DISEASE", 293, 297], ["SARS-CoV-1", "ORGANISM", 293, 303], ["SARS-CoV-2", "ORGANISM", 308, 318], ["SARS-CoV-1", "SPECIES", 293, 303], ["SARS-CoV", "SPECIES", 308, 316], ["Several factors", "PROBLEM", 0, 15], ["surface material", "PROBLEM", 27, 43], ["organic load", "TEST", 45, 57], ["viral load", "TEST", 59, 69], ["temperature", "TEST", 71, 82], ["environmental humidity", "TREATMENT", 88, 110], ["viral particles", "PROBLEM", 141, 156], ["comparative study", "TEST", 268, 285], ["the SARS", "TEST", 289, 297], ["CoV", "TEST", 298, 301], ["SARS", "PROBLEM", 308, 312], ["CoV", "TEST", 313, 316], ["viral stability kinetics", "PROBLEM", 328, 352], ["both viruses", "PROBLEM", 417, 429], ["organic load", "OBSERVATION", 45, 57], ["viral load", "OBSERVATION", 59, 69]]], ["Airborne titer reductions for both aerosolized viruses were <1 log 10 TCID 50 /mL after 3 h.", [["Airborne titer reductions", "TREATMENT", 0, 25], ["both aerosolized viruses", "PROBLEM", 30, 54]]], ["SARS-CoV-1 and SARS-CoV-2 were both detectable on plastic and stainless steel for up to 72 h; SARS-CoV-2 titers decreased from 10 3.7 to 10 0.6 TCID 50 /mL after 48 h on stainless steel and after 72 h on plastic.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-1", "ORGANISM", 0, 10], ["SARS-CoV-2", "ORGANISM", 15, 25], ["SARS-CoV-2", "DNA", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["SARS", "PROBLEM", 15, 19], ["CoV", "TEST", 20, 23], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["stainless steel", "TREATMENT", 170, 185]]], ["However, SARS-CoV-1 appears to have a significantly shorter half-life on cardboard, as the study found no detectable SARS-CoV-1 after 8 h, while viable SARS-CoV-2 was undetectable after 24 h (Van Doremalen et al., 2020) .", [["SARS", "DISEASE", 9, 13], ["SARS", "DISEASE", 152, 156], ["SARS-CoV-1", "ORGANISM", 9, 19], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 117, 127], ["SARS-CoV-2", "ORGANISM", 152, 162], ["SARS-CoV-1", "SPECIES", 9, 19], ["SARS-CoV", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 152, 160], ["the study", "TEST", 87, 96], ["detectable SARS", "PROBLEM", 106, 121], ["CoV", "TEST", 122, 125], ["CoV", "TEST", 157, 160]]], ["This suggests that the causative agent of the current COVID-19 pandemic might survive better on environmental surfaces than SARS-CoV-1; however, the authors did caution that considerable statistical dispersion occurred within studies examining cardboard (Van Doremalen et al., 2020) .", [["SARS", "DISEASE", 124, 128], ["COVID-19", "ORGANISM", 54, 62], ["SARS-CoV-1", "SPECIES", 124, 134], ["the current COVID", "TREATMENT", 42, 59]]], ["Coronaviruses (HCoV-229E and feline infectious peritonitis virus or FIPV) can remain infectious for long periods in water (>100 days in water at 4 \u2022 C and >10 days in water at 23 \u2022 C) and pasteurized settled sewage (2-4 days), suggesting contaminated water may be a potential vehicle for human exposure if aerosols are generated .", [["infectious peritonitis", "DISEASE", 36, 58], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["HCoV-229E", "ORGANISM", 15, 24], ["feline infectious peritonitis virus", "ORGANISM", 29, 64], ["human", "ORGANISM", 288, 293], ["feline infectious peritonitis virus", "SPECIES", 29, 64], ["human", "SPECIES", 288, 293], ["HCoV-229E and feline infectious peritonitis virus", "SPECIES", 15, 64], ["FIPV", "SPECIES", 68, 72], ["human", "SPECIES", 288, 293], ["Coronaviruses", "TEST", 0, 13], ["HCoV", "TEST", 15, 19], ["feline infectious peritonitis virus", "PROBLEM", 29, 64], ["FIPV", "PROBLEM", 68, 72]]], ["At 25 \u2022 C, the time required for a 99% reduction in reagent-grade water was 22 days and 17 days for two SARS surrogates, TGEV and MHV, respectively.", [["SARS", "DISEASE", 104, 108], ["TGEV", "ORGANISM", 121, 125], ["MHV", "ORGANISM", 130, 133], ["TGEV", "SPECIES", 121, 125], ["MHV", "SPECIES", 130, 133], ["a 99% reduction", "TREATMENT", 33, 48], ["reagent-grade water", "TREATMENT", 52, 71], ["two SARS surrogates", "TREATMENT", 100, 119]]], ["In settled sewage that was pasteurized to reduce competing microorganisms and then spiked with coronaviruses, times for a 99% reduction were 9 days for TGEV and 7 days for MHV.", [["TGEV", "ORGANISM", 152, 156], ["MHV", "ORGANISM", 172, 175], ["TGEV", "SPECIES", 152, 156], ["MHV", "SPECIES", 172, 175], ["competing microorganisms", "PROBLEM", 49, 73], ["coronaviruses", "PROBLEM", 95, 108], ["a 99% reduction", "TREATMENT", 120, 135], ["TGEV", "PROBLEM", 152, 156], ["MHV", "PROBLEM", 172, 175]]], ["However, in wastewater, domestic sewage, and dechlorinated tap water, inoculated SARS-CoV-1 persisted for 14 days at 4 \u2022 C but only for 2 days at 20 \u2022 C.FOMITES AS VEHICLES AND RESERVOIRS OF CORONAVIRUSESWhile several factors affect the survival and infectivity of SARS-CoV-2 such as the type of surface (stainless steel, plastics and cardboard), moisture level and contaminants (protein, saliva and fecal material), the risk of SARS-CoV-2 presence on food contact surfaces and packing materials remains high during a pandemic.", [["surface", "ANATOMY", 296, 303], ["SARS", "DISEASE", 81, 85], ["SARS", "DISEASE", 265, 269], ["SARS", "DISEASE", 429, 433], ["SARS-CoV-1", "ORGANISM", 81, 91], ["SARS-CoV-2", "ORGANISM", 265, 275], ["saliva", "ORGANISM_SUBSTANCE", 389, 395], ["fecal material", "MULTI-TISSUE_STRUCTURE", 400, 414], ["SARS-CoV-1", "SPECIES", 81, 91], ["SARS-CoV", "SPECIES", 265, 273], ["domestic sewage", "TREATMENT", 24, 39], ["dechlorinated tap water", "TREATMENT", 45, 68], ["CoV", "TEST", 86, 89], ["SARS", "PROBLEM", 265, 269], ["CoV", "PROBLEM", 270, 273], ["surface (stainless steel, plastics and cardboard", "TREATMENT", 296, 344], ["moisture level", "TEST", 347, 361], ["contaminants (protein, saliva and fecal material", "TREATMENT", 366, 414], ["SARS", "PROBLEM", 429, 433], ["CoV", "PROBLEM", 434, 437], ["packing materials", "TREATMENT", 478, 495], ["fecal", "ANATOMY", 400, 405]]], ["Infected individuals albeit asymptomatic could come in contact with food or packaging throughout the food supply chain; hence the use of mitigation strategies should also be considered from food production facility to consumer handling of the food product.IMPORTANCE OF JUDICIOUS BIOCIDE SELECTIONThough the current SARS-CoV-2 literature indicates that it is a respiratory virus and not a food safety concern, coronaviruses and other respiratory viruses have been known to survive on produce such as lettuce for several days (Y\u00e9piz-G\u00f3mez et al., 2013) .", [["respiratory virus", "DISEASE", 361, 378], ["respiratory viruses", "DISEASE", 434, 453], ["individuals", "ORGANISM", 9, 20], ["coronaviruses", "ORGANISM", 410, 423], ["lettuce", "ORGANISM_SUBDIVISION", 500, 507], ["lettuce", "SPECIES", 500, 507], ["asymptomatic", "PROBLEM", 28, 40], ["packaging", "TREATMENT", 76, 85], ["mitigation strategies", "TREATMENT", 137, 158], ["CoV", "TEST", 321, 324], ["a respiratory virus", "PROBLEM", 359, 378], ["coronaviruses", "PROBLEM", 410, 423], ["other respiratory viruses", "PROBLEM", 428, 453], ["respiratory virus", "OBSERVATION", 361, 378]]], ["SARS-CoV-2 has been isolated from feces, indicating that shedding through the gastrointestinal system occurs (Yeo et al., 2020) ; therefore, it is hypothesized that SARS-CoV-2 may also have an affinity for cells in the intestine and colon (Gu et al., 2020) .IMPORTANCE OF JUDICIOUS BIOCIDE SELECTIONWorkers in the food, retail, service, and health industries normally come in close contact with a large number of individuals during the work day.", [["feces", "ANATOMY", 34, 39], ["gastrointestinal system", "ANATOMY", 78, 101], ["cells", "ANATOMY", 206, 211], ["intestine", "ANATOMY", 219, 228], ["colon", "ANATOMY", 233, 238], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["feces", "ORGANISM_SUBSTANCE", 34, 39], ["gastrointestinal", "ORGAN", 78, 94], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 165, 175], ["cells", "CELL", 206, 211], ["intestine", "ORGAN", 219, 228], ["colon", "ORGAN", 233, 238], ["cells in the intestine and colon", "PROBLEM", 206, 238], ["feces", "OBSERVATION", 34, 39], ["gastrointestinal system", "ANATOMY", 78, 101], ["intestine", "ANATOMY", 219, 228], ["colon", "ANATOMY", 233, 238], ["Gu", "ANATOMY", 240, 242]]], ["Recent shut downs of meat processing facilities that have established sanitation programs due to spread of SARS-CoV-2 among workers indicates the importance for new control strategies to spread the transmission of the virus (Hart et al., 2020) .", [["SARS", "DISEASE", 107, 111], ["meat", "ORGANISM_SUBDIVISION", 21, 25], ["SARS-CoV-2", "ORGANISM", 107, 117], ["SARS-CoV", "SPECIES", 107, 115], ["sanitation programs", "TREATMENT", 70, 89], ["SARS", "PROBLEM", 107, 111], ["new control strategies", "TREATMENT", 161, 183]]], ["Hence efforts to minimize the risk of virus contamination of common contact surfaces and survival of the virus in droplets and aerosols in food manufacturing, production, and retail centers should be considered.", [["virus contamination", "PROBLEM", 38, 57], ["the virus in droplets", "PROBLEM", 101, 122], ["virus", "OBSERVATION", 38, 43], ["virus", "OBSERVATION", 105, 110], ["food manufacturing", "OBSERVATION", 139, 157]]], ["These efforts include the use of antimicrobial agents such as sanitizers and disinfectants on hands and fomites (Otter et al., 2016; Eggers, 2019) .", [["sanitizers", "CHEMICAL", 62, 72], ["sanitizers", "SIMPLE_CHEMICAL", 62, 72], ["hands", "ORGANISM_SUBDIVISION", 94, 99], ["antimicrobial agents", "TREATMENT", 33, 53], ["sanitizers", "TREATMENT", 62, 72]]], ["The improper selection and inadequate use of sanitizers and disinfectants plays a significant role in the cross transfer and spread of pathogens (Hirose et al., 2019) resulting in additional public health concerns.", [["sanitizers", "CHEMICAL", 45, 55], ["The improper selection", "PROBLEM", 0, 22], ["sanitizers", "TREATMENT", 45, 55], ["disinfectants", "TREATMENT", 60, 73], ["pathogens", "PROBLEM", 135, 144], ["improper selection", "OBSERVATION", 4, 22]]], ["Sanitizer choice and coronavirus susceptibility to current cleaning and sanitation practices within facilities is an important consideration.", [["Sanitizer", "CHEMICAL", 0, 9], ["coronavirus", "ORGANISM", 21, 32], ["coronavirus", "SPECIES", 21, 32], ["Sanitizer choice", "TREATMENT", 0, 16], ["coronavirus susceptibility", "PROBLEM", 21, 47], ["current cleaning", "TREATMENT", 51, 67], ["sanitation practices", "TREATMENT", 72, 92], ["important consideration", "UNCERTAINTY", 117, 140]]], ["For instance, coronaviruses such as the mouse hepatitis virus (MHV) and TGEV are less susceptible to 1:100 hypochlorite than they are to 70% ethanol (Hulkower et al., 2011) .", [["mouse hepatitis virus", "DISEASE", 40, 61], ["hypochlorite", "CHEMICAL", 107, 119], ["ethanol", "CHEMICAL", 141, 148], ["hypochlorite", "CHEMICAL", 107, 119], ["ethanol", "CHEMICAL", 141, 148], ["coronaviruses", "ORGANISM", 14, 27], ["mouse hepatitis virus", "ORGANISM", 40, 61], ["MHV", "ORGANISM", 63, 66], ["TGEV", "ORGANISM", 72, 76], ["hypochlorite", "SIMPLE_CHEMICAL", 107, 119], ["ethanol", "SIMPLE_CHEMICAL", 141, 148], ["mouse", "SPECIES", 40, 45], ["hepatitis virus", "SPECIES", 46, 61], ["TGEV", "SPECIES", 72, 76], ["mouse hepatitis virus", "SPECIES", 40, 61], ["MHV", "SPECIES", 63, 66], ["TGEV", "SPECIES", 72, 76], ["coronaviruses", "PROBLEM", 14, 27], ["the mouse hepatitis virus", "PROBLEM", 36, 61], ["TGEV", "PROBLEM", 72, 76], ["coronaviruses", "OBSERVATION", 14, 27]]], ["Over-dilution of sanitizers and insufficient product contact time are critical factors that should be taken into account when targeting the elimination of coronaviruses from fomites (Boyce, 2016) .IMPORTANCE OF JUDICIOUS BIOCIDE SELECTIONThe presence of SARS-CoV-2 in human feces (Xiao et al., 2020) highlights the importance of incorportating cleaning and disinfection regimens in toilets and restrooms as well as developing protocols to prevent aerosolization of virus particles during flushing.", [["SARS", "DISEASE", 254, 258], ["coronaviruses", "ORGANISM", 155, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 254, 264], ["human", "ORGANISM", 268, 273], ["feces", "ORGANISM_SUBSTANCE", 274, 279], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["sanitizers", "TREATMENT", 17, 27], ["coronaviruses", "PROBLEM", 155, 168], ["SARS", "PROBLEM", 254, 258], ["incorportating cleaning", "TREATMENT", 329, 352], ["disinfection regimens", "TREATMENT", 357, 378], ["restrooms", "TREATMENT", 394, 403], ["developing protocols", "TREATMENT", 415, 435], ["virus particles", "PROBLEM", 465, 480], ["virus", "OBSERVATION", 465, 470]]], ["The use of quartenary ammonium (alkyl dimethyl benzyl ammonium chloride) and peracetic acid was effective in coliphage MS2 redution on surfaces after flushing (Sassi et al., 2018) .", [["quartenary ammonium", "CHEMICAL", 11, 30], ["alkyl dimethyl benzyl ammonium chloride", "CHEMICAL", 32, 71], ["peracetic acid", "CHEMICAL", 77, 91], ["quartenary ammonium", "CHEMICAL", 11, 30], ["alkyl dimethyl benzyl ammonium chloride", "CHEMICAL", 32, 71], ["peracetic acid", "CHEMICAL", 77, 91], ["quartenary ammonium", "SIMPLE_CHEMICAL", 11, 30], ["alkyl dimethyl benzyl ammonium chloride", "SIMPLE_CHEMICAL", 32, 71], ["peracetic acid", "SIMPLE_CHEMICAL", 77, 91], ["quartenary ammonium (alkyl dimethyl benzyl ammonium chloride", "TREATMENT", 11, 71], ["peracetic acid", "TREATMENT", 77, 91], ["coliphage MS2", "OBSERVATION_MODIFIER", 109, 122]]], ["The use of biocides effective against SARS-CoV-2 in toilet bowls apart from cleaning could be considered in light of the information presented in this review.Estimation of Virucidal ActivityVirucidal activity can be determined by suspension tests as well as carrier tests that mimic surfaces and evaluate the performance of biocides in the presence of organic loads through the addition of serum.", [["serum", "ANATOMY", 390, 395], ["SARS", "DISEASE", 38, 42], ["SARS-CoV-2", "ORGANISM", 38, 48], ["serum", "ORGANISM_SUBSTANCE", 390, 395], ["SARS-CoV", "SPECIES", 38, 46], ["biocides", "TREATMENT", 11, 19], ["SARS", "PROBLEM", 38, 42], ["CoV-2 in toilet bowls", "TREATMENT", 43, 64], ["cleaning", "TREATMENT", 76, 84], ["Virucidal ActivityVirucidal activity", "TREATMENT", 172, 208], ["suspension tests", "TEST", 230, 246], ["carrier tests", "TEST", 258, 271], ["biocides", "TREATMENT", 324, 332], ["organic loads", "PROBLEM", 352, 365]]], ["Viral reduction is determined by infectivity assays where treated viruses are compared to untreated controls for the reduction in viral cytopathic effects (CPE) on tissue culture monolayers.", [["tissue culture monolayers", "ANATOMY", 164, 189], ["Viral reduction", "DISEASE", 0, 15], ["tissue culture monolayers", "CELL", 164, 189], ["Viral reduction", "PROBLEM", 0, 15], ["infectivity assays", "PROBLEM", 33, 51], ["treated viruses", "PROBLEM", 58, 73], ["the reduction", "PROBLEM", 113, 126], ["viral cytopathic effects", "PROBLEM", 130, 154], ["tissue culture monolayers", "TEST", 164, 189], ["viral cytopathic effects", "OBSERVATION", 130, 154]]], ["Surviving fractions determined through Log 10 reductions are enumerated either by viral plaque assays, a most probable number (MPN) assay, or by determining the 50% titration endpoint for infectivity (known as tissue culture infectious dose 50% or TCID 50 assay).", [["plaque", "ANATOMY", 88, 94], ["tissue", "ANATOMY", 210, 216], ["MPN", "DISEASE", 127, 130], ["tissue", "TISSUE", 210, 216], ["Surviving fractions", "PROBLEM", 0, 19], ["viral plaque assays", "PROBLEM", 82, 101], ["infectivity", "PROBLEM", 188, 199], ["tissue culture", "TEST", 210, 224], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["plaque", "OBSERVATION", 88, 94]]], ["Plaque forming units (PFU) are proportional to TCID 50 titer by a factor of 0.56 (Wulff et al., 2012) .", [["Plaque", "ANATOMY", 0, 6], ["TCID", "TEST", 47, 51], ["a factor", "TEST", 64, 72]]], ["RT-PCR for the estimation of viral nucleic acid using threshold cycle (Ct value) has also been used to determine viral load.", [["nucleic acid", "CHEMICAL", 35, 47], ["RT-PCR", "TEST", 0, 6], ["the estimation", "TEST", 11, 25], ["viral nucleic acid", "TEST", 29, 47], ["threshold cycle", "TEST", 54, 69], ["Ct value", "TEST", 71, 79], ["viral load", "PROBLEM", 113, 123]]], ["Reduction factors are calculated using the difference in the quotient of the infection titer before and after exposure to the antimicrobial agent (Rabenau et al., 2005b) According to the Environmental Protection Agency (EPA), an acceptable disinfectant claim requires a 4 log 10 reduction in the human norovirus surrogate, feline calicivirus (FCV) (EPA, 2017) .", [["infection", "DISEASE", 77, 86], ["feline calicivirus", "DISEASE", 323, 341], ["human", "ORGANISM", 296, 301], ["norovirus", "ORGANISM", 302, 311], ["feline calicivirus", "ORGANISM", 323, 341], ["FCV", "ORGANISM", 343, 346], ["human", "SPECIES", 296, 301], ["feline calicivirus", "SPECIES", 323, 341], ["human norovirus", "SPECIES", 296, 311], ["feline calicivirus", "SPECIES", 323, 341], ["FCV", "SPECIES", 343, 346], ["Reduction factors", "PROBLEM", 0, 17], ["the infection titer", "PROBLEM", 73, 92], ["the antimicrobial agent", "TREATMENT", 122, 145], ["a 4 log 10 reduction", "TREATMENT", 268, 288], ["the human norovirus surrogate", "TREATMENT", 292, 321], ["infection", "OBSERVATION", 77, 86]]], ["European countries recommend the use of other viral surrogates such as murine norovirus (MNV) or adenovirus type 5 (AdV-5) for testing (Rabenau et al., 2014) .", [["murine norovirus", "ORGANISM", 71, 87], ["MNV", "ORGANISM", 89, 92], ["adenovirus type 5", "ORGANISM", 97, 114], ["AdV-5", "ORGANISM", 116, 121], ["murine", "SPECIES", 71, 77], ["murine norovirus", "SPECIES", 71, 87], ["MNV", "SPECIES", 89, 92], ["adenovirus type 5 (AdV-5", "SPECIES", 97, 121], ["other viral surrogates", "TREATMENT", 40, 62], ["murine norovirus", "PROBLEM", 71, 87], ["adenovirus type", "TREATMENT", 97, 112]]], ["Criticisms for suspension tests include that they do not mimic \"real world\" conditions, which should be taken into consideration while determining virucide selection for disinfection of surfaces soiled with organic matter and other substances that could reduce efficacy.", [["suspension tests", "TEST", 15, 31], ["disinfection of surfaces", "TREATMENT", 170, 194], ["organic matter", "TREATMENT", 207, 221]]], ["Results regarding the virucidal activity of disinfectants using non-enveloped surrogates translate well to the more susceptible enveloped viruses, such as coronaviruses.", [["coronaviruses", "ORGANISM", 155, 168], ["disinfectants", "TREATMENT", 44, 57], ["non-enveloped surrogates", "TREATMENT", 64, 88], ["coronaviruses", "PROBLEM", 155, 168], ["viruses", "OBSERVATION", 138, 145]]], ["Several factors such as target strain, testing of biocide against virus in suspension vs. drying and use of protein supplementation play important roles in influencing viral particle stability and loss of infectivity during the determination of virucidal activity (Rabenau et al., 2005a) .Estimation of Virucidal ActivityAlcohol based sanitizers can be used on skin, for the disinfection of fomites and on certain food contact surfaces (Table 1) .", [["skin", "ANATOMY", 361, 365], ["biocide", "CHEMICAL", 50, 57], ["Alcohol", "CHEMICAL", 321, 328], ["skin", "ORGAN", 361, 365], ["Several factors", "PROBLEM", 0, 15], ["target strain", "PROBLEM", 24, 37], ["biocide", "TREATMENT", 50, 57], ["virus in suspension", "TREATMENT", 66, 85], ["protein supplementation", "TREATMENT", 108, 131], ["influencing viral particle stability", "PROBLEM", 156, 192], ["loss of infectivity", "PROBLEM", 197, 216], ["Virucidal ActivityAlcohol based sanitizers", "TREATMENT", 303, 345], ["the disinfection of fomites", "TREATMENT", 371, 398], ["viral particle stability", "OBSERVATION", 168, 192], ["skin", "ANATOMY", 361, 365]]], ["Alcohol acts on viral envelopes to denature proteins and is not significantly impaired by organic matter contamination .", [["Alcohol", "CHEMICAL", 0, 7], ["Alcohol", "CHEMICAL", 0, 7], ["Alcohol", "SIMPLE_CHEMICAL", 0, 7], ["denature proteins", "PROTEIN", 35, 52], ["denature proteins", "PROBLEM", 35, 52], ["organic matter contamination", "PROBLEM", 90, 118], ["not", "UNCERTAINTY", 60, 63], ["significantly impaired", "OBSERVATION_MODIFIER", 64, 86], ["organic matter", "OBSERVATION", 90, 104]]], ["Ethyl alcohol (ethanol), isopropyl alcohol (isopropanol or rubbing alcohol), and 2,4 dichlorobenzyl alcohol are classes of alcohol that have been shown to possess antimicrobial properties, although their concentrations and ranges of activity differ (Lambert, 2004) .Estimation of Virucidal ActivityHand sanitizers and rubs containing alcohol (75-85% v/v) effectively reduce the infectivity of coronaviruses in in vitro tests.", [["Ethyl alcohol", "CHEMICAL", 0, 13], ["ethanol", "CHEMICAL", 15, 22], ["isopropyl alcohol", "CHEMICAL", 25, 42], ["isopropanol", "CHEMICAL", 44, 55], ["rubbing alcohol", "CHEMICAL", 59, 74], ["2,4 dichlorobenzyl alcohol", "CHEMICAL", 81, 107], ["alcohol", "CHEMICAL", 123, 130], ["alcohol", "CHEMICAL", 334, 341], ["Ethyl alcohol", "CHEMICAL", 0, 13], ["ethanol", "CHEMICAL", 15, 22], ["isopropyl alcohol", "CHEMICAL", 25, 42], ["isopropanol", "CHEMICAL", 44, 55], ["alcohol", "CHEMICAL", 67, 74], ["2,4 dichlorobenzyl alcohol", "CHEMICAL", 81, 107], ["alcohol", "CHEMICAL", 123, 130], ["alcohol", "CHEMICAL", 334, 341], ["Ethyl alcohol", "SIMPLE_CHEMICAL", 0, 13], ["ethanol", "SIMPLE_CHEMICAL", 15, 22], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 25, 42], ["isopropanol", "SIMPLE_CHEMICAL", 44, 55], ["rubbing alcohol", "SIMPLE_CHEMICAL", 59, 74], ["2,4 dichlorobenzyl alcohol", "SIMPLE_CHEMICAL", 81, 107], ["alcohol", "SIMPLE_CHEMICAL", 123, 130], ["alcohol", "SIMPLE_CHEMICAL", 334, 341], ["coronaviruses", "ORGANISM", 393, 406], ["antimicrobial properties", "TREATMENT", 163, 187], ["the infectivity of coronaviruses", "PROBLEM", 374, 406], ["vitro tests", "TEST", 413, 424], ["Virucidal Activity", "OBSERVATION", 280, 298]]], ["Against SARS-CoV-2, both the World Health Organization sanitizer formulation 1 [85% ethanol (v/v), 0.725% glycerol (v/v) and 0.125% hydrogen peroxide (v/v)] and formulation 2 [75% isopropanol (w/w), 0.725% glycerol (v/v) and 0.125% hydrogen peroxide (v/v)] resulted in complete inactivation from an initial viral titer of 8 log 10 (TCID 50 /ml).", [["SARS", "DISEASE", 8, 12], ["ethanol", "CHEMICAL", 84, 91], ["glycerol", "CHEMICAL", 106, 114], ["hydrogen peroxide", "CHEMICAL", 132, 149], ["isopropanol", "CHEMICAL", 180, 191], ["glycerol", "CHEMICAL", 206, 214], ["hydrogen peroxide", "CHEMICAL", 232, 249], ["ethanol", "CHEMICAL", 84, 91], ["glycerol", "CHEMICAL", 106, 114], ["hydrogen peroxide", "CHEMICAL", 132, 149], ["isopropanol", "CHEMICAL", 180, 191], ["glycerol", "CHEMICAL", 206, 214], ["hydrogen peroxide", "CHEMICAL", 232, 249], ["ethanol", "SIMPLE_CHEMICAL", 84, 91], ["glycerol", "SIMPLE_CHEMICAL", 106, 114], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 132, 149], ["v/v)", "SIMPLE_CHEMICAL", 151, 155], ["isopropanol", "SIMPLE_CHEMICAL", 180, 191], ["glycerol", "SIMPLE_CHEMICAL", 206, 214], ["v/v", "SIMPLE_CHEMICAL", 216, 219], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 232, 249], ["v/v)", "SIMPLE_CHEMICAL", 251, 255], ["Organization sanitizer formulation", "TREATMENT", 42, 76], ["ethanol (v/v)", "TREATMENT", 84, 97], ["glycerol (v/v)", "TREATMENT", 106, 120], ["0.125% hydrogen peroxide (v/v)", "TREATMENT", 125, 155], ["formulation", "TREATMENT", 161, 172], ["glycerol (v/v)", "TREATMENT", 206, 220], ["0.125% hydrogen peroxide", "TREATMENT", 225, 249], ["an initial viral titer", "TEST", 296, 318]]], ["Tests of both ethanol and isopropanol within the same study (along with 0.125% hydrogen peroxide) against SARS-CoV-2 were effective in inactivating the virus within 30 s, even when used at a concentration of 30% (Kratzel et al., 2020) , Products based on 80, 85, and 95% ethanol without dilution inactivated SARS-CoV-1 to below the limit of detection (RF \u2265 4) within 30 s of exposure (Rabenau et al., 2005b) .", [["ethanol", "CHEMICAL", 14, 21], ["isopropanol", "CHEMICAL", 26, 37], ["hydrogen peroxide", "CHEMICAL", 79, 96], ["SARS-CoV-2", "CHEMICAL", 106, 116], ["ethanol", "CHEMICAL", 271, 278], ["SARS", "DISEASE", 308, 312], ["ethanol", "CHEMICAL", 14, 21], ["isopropanol", "CHEMICAL", 26, 37], ["hydrogen peroxide", "CHEMICAL", 79, 96], ["ethanol", "CHEMICAL", 271, 278], ["ethanol", "SIMPLE_CHEMICAL", 14, 21], ["isopropanol", "SIMPLE_CHEMICAL", 26, 37], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 79, 96], ["ethanol", "SIMPLE_CHEMICAL", 271, 278], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV-1", "SPECIES", 308, 318], ["Tests", "TEST", 0, 5], ["isopropanol", "TREATMENT", 26, 37], ["the same study", "TEST", 45, 59], ["0.125% hydrogen peroxide", "TREATMENT", 72, 96], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["the virus", "PROBLEM", 148, 157], ["CoV", "TEST", 313, 316]]], ["High concentrations of ethanol (95% and 85%) based hand sanitizers have also been useful in reducing SARS-CoV-1 by 5.5 log 10 (TCID 50 /ml) within an exposure time of 30 s (Rabenau et al., 2005b) .Estimation of Virucidal ActivityEthanol at a concentration of 70% resulted in a 3 log 10 reduction of coronaviruses (TGEV and MHV) after an exposure duration of a minute.", [["hand", "ANATOMY", 51, 55], ["ethanol", "CHEMICAL", 23, 30], ["SARS", "DISEASE", 101, 105], ["ActivityEthanol", "CHEMICAL", 221, 236], ["ethanol", "CHEMICAL", 23, 30], ["ethanol", "SIMPLE_CHEMICAL", 23, 30], ["Virucidal ActivityEthanol", "SIMPLE_CHEMICAL", 211, 236], ["coronaviruses", "ORGANISM", 299, 312], ["TGEV", "ORGANISM", 314, 318], ["SARS-CoV-1", "SPECIES", 101, 111], ["TGEV", "SPECIES", 314, 318], ["MHV", "SPECIES", 323, 326], ["ethanol", "TEST", 23, 30], ["based hand sanitizers", "PROBLEM", 45, 66], ["CoV", "TEST", 106, 109], ["Virucidal ActivityEthanol", "TREATMENT", 211, 236], ["coronaviruses (TGEV and MHV", "TREATMENT", 299, 326], ["concentrations", "OBSERVATION_MODIFIER", 5, 19]]], ["Hand sanitizers with 62% ethanol resulted in a reduction factor of 4 log 10 of TGEV and a 2.7 log 10 reduction of MHV (Hulkower et al., 2011) .", [["ethanol", "CHEMICAL", 25, 32], ["ethanol", "CHEMICAL", 25, 32], ["ethanol", "SIMPLE_CHEMICAL", 25, 32], ["TGEV", "ORGANISM", 79, 83], ["MHV", "ORGANISM", 114, 117], ["TGEV", "SPECIES", 79, 83], ["MHV", "SPECIES", 114, 117], ["Hand sanitizers", "TREATMENT", 0, 15], ["a reduction factor", "TREATMENT", 45, 63]]], ["Alcohol-based formulations containing 3.2% povidone-iodine and 78% alcohol reported 99.99% (4 log 10 reduction) inactivation of the modified vaccinia virus Ankara (MVA), a reference virus for virucidal hand disinfectants, under clean and dirty conditions after a 15 s contact time (Eggers et al., 2015a) indicating that these sanitizers might also be effective against other enveloped viruses such as coronaviruses.", [["hand", "ANATOMY", 202, 206], ["Alcohol", "CHEMICAL", 0, 7], ["povidone-iodine", "CHEMICAL", 43, 58], ["alcohol", "CHEMICAL", 67, 74], ["Alcohol", "CHEMICAL", 0, 7], ["povidone-iodine", "CHEMICAL", 43, 58], ["alcohol", "CHEMICAL", 67, 74], ["Alcohol", "SIMPLE_CHEMICAL", 0, 7], ["povidone-iodine", "SIMPLE_CHEMICAL", 43, 58], ["alcohol", "SIMPLE_CHEMICAL", 67, 74], ["vaccinia virus Ankara", "ORGANISM", 141, 162], ["MVA", "ORGANISM", 164, 167], ["coronaviruses", "ORGANISM", 401, 414], ["vaccinia virus", "SPECIES", 141, 155], ["vaccinia virus", "SPECIES", 141, 155], ["Alcohol-based formulations", "TREATMENT", 0, 26], ["povidone", "TREATMENT", 43, 51], ["iodine", "TREATMENT", 52, 58], ["the modified vaccinia virus", "TREATMENT", 128, 155], ["a reference virus", "TREATMENT", 170, 187], ["virucidal hand disinfectants", "TREATMENT", 192, 220], ["these sanitizers", "TREATMENT", 320, 336], ["other enveloped viruses", "PROBLEM", 369, 392], ["coronaviruses", "PROBLEM", 401, 414], ["viruses", "OBSERVATION", 385, 392]]], ["When evaluated on inanimate surfaces like metal, glass, or plastic, 78-95% ethanol inactivated the coronaviruses SARS-CoV-1, MERS-CoV, and MHV to reduction factor \u22654 in 30 s (Kampf et al., 2020) .", [["ethanol", "CHEMICAL", 75, 82], ["SARS", "DISEASE", 113, 117], ["ethanol", "CHEMICAL", 75, 82], ["ethanol", "SIMPLE_CHEMICAL", 75, 82], ["coronaviruses", "ORGANISM", 99, 112], ["MERS-CoV", "ORGANISM", 125, 133], ["MHV", "ORGANISM", 139, 142], ["SARS-CoV-1", "SPECIES", 113, 123], ["MERS-CoV", "SPECIES", 125, 133], ["MHV", "SPECIES", 139, 142], ["the coronaviruses SARS", "TEST", 95, 117], ["CoV", "TEST", 118, 121], ["MHV to reduction factor", "TREATMENT", 139, 162], ["MHV", "ANATOMY", 139, 142]]], ["The use of amyl metacresol (0.6 mg) and dichlorobenzyl alcohol (1.2 mg) at pH of 2.3 in throat lozenges resulted in negligible antiviral activity against human coronavirus OC43 (hCoV OC43) (Morokutti-Kurz et al., 2017) in in vitro tests.Povidone Iodine and Povidone Iodone Based ProductsPovidone Iodone (PVP-I) has been used for skin, nasal, and oral cavity disinfection ( Table 1) .", [["throat", "ANATOMY", 88, 94], ["skin", "ANATOMY", 329, 333], ["nasal", "ANATOMY", 335, 340], ["oral cavity", "ANATOMY", 346, 357], ["amyl metacresol", "CHEMICAL", 11, 26], ["dichlorobenzyl alcohol", "CHEMICAL", 40, 62], ["Povidone Iodine", "CHEMICAL", 237, 252], ["Povidone Iodone", "CHEMICAL", 257, 272], ["ProductsPovidone Iodone", "CHEMICAL", 279, 302], ["PVP-I", "CHEMICAL", 304, 309], ["amyl metacresol", "CHEMICAL", 11, 26], ["dichlorobenzyl alcohol", "CHEMICAL", 40, 62], ["Povidone Iodine", "CHEMICAL", 237, 252], ["Povidone Iodone", "CHEMICAL", 257, 272], ["ProductsPovidone Iodone", "CHEMICAL", 279, 302], ["PVP-I", "CHEMICAL", 304, 309], ["amyl metacresol", "SIMPLE_CHEMICAL", 11, 26], ["dichlorobenzyl alcohol", "SIMPLE_CHEMICAL", 40, 62], ["throat", "ORGANISM_SUBDIVISION", 88, 94], ["human", "ORGANISM", 154, 159], ["coronavirus OC43", "ORGANISM", 160, 176], ["hCoV OC43", "CELL", 178, 187], ["Povidone Iodine", "SIMPLE_CHEMICAL", 237, 252], ["Povidone Iodone", "SIMPLE_CHEMICAL", 257, 272], ["ProductsPovidone Iodone", "SIMPLE_CHEMICAL", 279, 302], ["PVP-I", "SIMPLE_CHEMICAL", 304, 309], ["skin", "ORGAN", 329, 333], ["nasal", "ORGANISM_SUBDIVISION", 335, 340], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 346, 357], ["human", "SPECIES", 154, 159], ["coronavirus", "SPECIES", 160, 171], ["human coronavirus", "SPECIES", 154, 171], ["amyl metacresol", "TREATMENT", 11, 26], ["dichlorobenzyl alcohol", "TREATMENT", 40, 62], ["throat lozenges", "TREATMENT", 88, 103], ["negligible antiviral activity", "PROBLEM", 116, 145], ["human coronavirus OC43", "PROBLEM", 154, 176], ["vitro tests", "TEST", 225, 236], ["Povidone Iodine", "TREATMENT", 237, 252], ["Povidone Iodone", "TREATMENT", 257, 272], ["ProductsPovidone Iodone (PVP-I)", "TREATMENT", 279, 310], ["skin, nasal, and oral cavity disinfection", "PROBLEM", 329, 370], ["antiviral activity", "OBSERVATION", 127, 145], ["skin", "ANATOMY", 329, 333], ["nasal", "ANATOMY", 335, 340], ["oral cavity", "ANATOMY", 346, 357]]], ["PVP-I is an iodophore with broad spectrum antimicrobial activity against bacteria, fungi, and viruses.", [["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "CHEMICAL", 0, 5], ["iodophore", "CHEMICAL", 12, 21], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["iodophore", "SIMPLE_CHEMICAL", 12, 21], ["an iodophore", "TREATMENT", 9, 21], ["broad spectrum antimicrobial activity", "TREATMENT", 27, 64], ["bacteria", "PROBLEM", 73, 81], ["fungi", "PROBLEM", 83, 88], ["viruses", "PROBLEM", 94, 101], ["viruses", "OBSERVATION", 94, 101]]], ["PVP-I forms I 2 and hypoiodous acid (HOI), which oxidizes nucleic acids and membranes (Lachapelle et al., 2013) .", [["membranes", "ANATOMY", 76, 85], ["PVP-I forms I 2 and hypoiodous acid", "CHEMICAL", 0, 35], ["HOI", "CHEMICAL", 37, 40], ["nucleic acids", "CHEMICAL", 58, 71], ["PVP", "CHEMICAL", 0, 3], ["hypoiodous acid", "CHEMICAL", 20, 35], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["I 2", "GENE_OR_GENE_PRODUCT", 12, 15], ["hypoiodous acid", "SIMPLE_CHEMICAL", 20, 35], ["HOI", "SIMPLE_CHEMICAL", 37, 40], ["nucleic acids", "SIMPLE_CHEMICAL", 58, 71], ["membranes", "CELLULAR_COMPONENT", 76, 85], ["PVP", "TEST", 0, 3], ["hypoiodous acid (HOI)", "PROBLEM", 20, 41]]], ["PVP-I is used for the disinfection of skin when formulated into scrubs or hand washes and for oral cavities through oral sprays and mouth rinses (Nagatake et al., 2002; Kariwa et al., 2004; Durani and Leaper, 2008) .", [["skin", "ANATOMY", 38, 42], ["hand", "ANATOMY", 74, 78], ["oral cavities", "ANATOMY", 94, 107], ["oral", "ANATOMY", 116, 120], ["mouth", "ANATOMY", 132, 137], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["skin", "ORGAN", 38, 42], ["hand", "ORGANISM_SUBDIVISION", 74, 78], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["cavities", "MULTI-TISSUE_STRUCTURE", 99, 107], ["oral", "ORGANISM_SUBDIVISION", 116, 120], ["PVP", "TREATMENT", 0, 3], ["the disinfection of skin", "TREATMENT", 18, 42], ["hand washes", "TREATMENT", 74, 85], ["oral cavities through oral sprays", "TREATMENT", 94, 127], ["skin", "ANATOMY", 38, 42], ["mouth", "ANATOMY", 132, 137]]], ["Nasal spray of PVP-I has been used for the post-operative control of Staphylococcus aureus infections and could potentially be used to reduce nasal harborage and dispersal of SARS-CoV-2 (Phillips et al., 2014) .", [["Nasal", "ANATOMY", 0, 5], ["nasal", "ANATOMY", 142, 147], ["PVP-I", "CHEMICAL", 15, 20], ["Staphylococcus aureus infections", "DISEASE", 69, 101], ["SARS", "DISEASE", 175, 179], ["PVP-I", "CHEMICAL", 15, 20], ["PVP-I", "SIMPLE_CHEMICAL", 15, 20], ["Staphylococcus aureus", "ORGANISM", 69, 90], ["nasal", "ORGANISM_SUBDIVISION", 142, 147], ["Staphylococcus aureus", "SPECIES", 69, 90], ["Staphylococcus aureus", "SPECIES", 69, 90], ["SARS-CoV", "SPECIES", 175, 183], ["Nasal spray of PVP", "TREATMENT", 0, 18], ["Staphylococcus aureus infections", "PROBLEM", 69, 101], ["nasal harborage", "TREATMENT", 142, 157], ["Staphylococcus aureus", "OBSERVATION", 69, 90]]], ["The exposure of SARS-CoV-2 (7.8 of log 10 (TCID 50 /ml) to 7.5% of PVP-I resulted in the virus titer dropping below levels of detection after 5 min (Chin et al., 2020) .", [["SARS", "DISEASE", 16, 20], ["PVP-I", "CHEMICAL", 67, 72], ["PVP", "CHEMICAL", 67, 70], ["SARS-CoV-2", "ORGANISM", 16, 26], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "TEST", 16, 20], ["CoV", "TEST", 21, 24], ["PVP", "TREATMENT", 67, 70], ["the virus titer", "TEST", 85, 100], ["virus", "OBSERVATION", 89, 94]]], ["The use of PVP-I at a concentration of 7.5% (surgical scrub), 4% (hand wash), and 1% + 8.3% alcohol (mouth rinse) against MERS-CoV resulted in a 99.99% reduction in virus populations after 15 s in both clean and soiled conditions (Bovine serum albumin and erythrocytes).", [["hand", "ANATOMY", 66, 70], ["serum", "ANATOMY", 238, 243], ["erythrocytes", "ANATOMY", 256, 268], ["PVP-I", "CHEMICAL", 11, 16], ["alcohol", "CHEMICAL", 92, 99], ["PVP-I", "CHEMICAL", 11, 16], ["alcohol", "CHEMICAL", 92, 99], ["PVP-I", "SIMPLE_CHEMICAL", 11, 16], ["alcohol", "SIMPLE_CHEMICAL", 92, 99], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 122, 130], ["Bovine", "ORGANISM", 231, 237], ["serum", "ORGANISM_SUBSTANCE", 238, 243], ["albumin", "GENE_OR_GENE_PRODUCT", 244, 251], ["erythrocytes", "CELL", 256, 268], ["erythrocytes", "CELL_TYPE", 256, 268], ["Bovine", "SPECIES", 231, 237], ["MERS-CoV", "SPECIES", 122, 130], ["Bovine", "SPECIES", 231, 237], ["PVP-I at a concentration", "TREATMENT", 11, 35], ["CoV", "PROBLEM", 127, 130], ["a 99.99% reduction in virus populations", "TREATMENT", 143, 182], ["Bovine serum albumin", "TEST", 231, 251], ["erythrocytes", "TEST", 256, 268]]], ["Virucidal activity of PVP-I was observed against MERS-CoV even after a 1:10 dilution, though a higher duration of exposure (30 s) was required for the oral rinse that contained 1% PVP-I + 8.3% alcohol (Eggers et al., 2015b) .Povidone Iodine and Povidone Iodone Based ProductsAntiviral activity of PVP-I containing products (0.23-1%) was observed against SARS-CoV-1.", [["oral", "ANATOMY", 151, 155], ["PVP-I", "CHEMICAL", 22, 27], ["PVP-I", "CHEMICAL", 180, 185], ["alcohol", "CHEMICAL", 193, 200], ["Povidone Iodine", "CHEMICAL", 225, 240], ["Povidone Iodone", "CHEMICAL", 245, 260], ["PVP-I", "CHEMICAL", 297, 302], ["PVP-I", "CHEMICAL", 22, 27], ["PVP-I", "CHEMICAL", 180, 185], ["alcohol", "CHEMICAL", 193, 200], ["Povidone Iodine", "CHEMICAL", 225, 240], ["Povidone Iodone", "CHEMICAL", 245, 260], ["PVP-I", "CHEMICAL", 297, 302], ["PVP-I", "SIMPLE_CHEMICAL", 22, 27], ["MERS-CoV", "ORGANISM", 49, 57], ["oral", "ORGANISM_SUBDIVISION", 151, 155], ["PVP-I", "SIMPLE_CHEMICAL", 180, 185], ["alcohol", "SIMPLE_CHEMICAL", 193, 200], ["Povidone Iodine", "SIMPLE_CHEMICAL", 225, 240], ["Povidone Iodone", "SIMPLE_CHEMICAL", 245, 260], ["PVP-I", "SIMPLE_CHEMICAL", 297, 302], ["SARS-CoV-1", "ORGANISM", 354, 364], ["MERS-CoV", "SPECIES", 49, 57], ["SARS-CoV-1", "SPECIES", 354, 364], ["the oral rinse", "TREATMENT", 147, 161], ["Povidone Iodine", "TREATMENT", 225, 240], ["Povidone Iodone", "TREATMENT", 245, 260], ["Antiviral activity of PVP-I containing products", "TREATMENT", 275, 322]]], ["Exposure of SARS-CoV-1 to PVP-I containing products reduced a viral load of 1.17 \u00d7 10 6 TCID 50 /ml to below levels of detection within a duration of 2 min (Kariwa et al., 2004) .", [["SARS", "DISEASE", 12, 16], ["PVP-I", "CHEMICAL", 26, 31], ["PVP", "CHEMICAL", 26, 29], ["PVP-I", "SIMPLE_CHEMICAL", 26, 31], ["SARS-CoV-1", "SPECIES", 12, 22], ["SARS", "PROBLEM", 12, 16], ["CoV", "TEST", 17, 20], ["PVP", "TREATMENT", 26, 29], ["a viral load", "TEST", 60, 72], ["SARS", "OBSERVATION", 12, 16]]], ["PVP-I was also effective when used against human rotavirus, a non-enveloped virus that causes diarrhea, on disk of stainless steel and plastics, indicating its effectiveness as a surface sanitizer .", [["surface", "ANATOMY", 179, 186], ["PVP-I", "CHEMICAL", 0, 5], ["diarrhea", "DISEASE", 94, 102], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "SIMPLE_CHEMICAL", 0, 5], ["human", "ORGANISM", 43, 48], ["rotavirus", "ORGANISM", 49, 58], ["human", "SPECIES", 43, 48], ["human rotavirus", "SPECIES", 43, 58], ["PVP", "TEST", 0, 3], ["human rotavirus", "PROBLEM", 43, 58], ["a non-enveloped virus", "PROBLEM", 60, 81], ["diarrhea", "PROBLEM", 94, 102], ["disk of stainless steel", "TREATMENT", 107, 130], ["plastics", "TREATMENT", 135, 143], ["a surface sanitizer", "TREATMENT", 177, 196], ["diarrhea", "OBSERVATION", 94, 102]]], ["The efficacy of PVP-I against test bacterial pathogens (skin contaminant surrogates) did not decrease when tested on an inert surface (Durani and Leaper, 2008) , indicating that PVP-I could be used for hand washing and disinfection of skin, surfaces and the oral tract, and as a substitute or replacement for alcohol-based products (Durani and Leaper, 2008) .", [["skin", "ANATOMY", 56, 60], ["surface", "ANATOMY", 126, 133], ["hand", "ANATOMY", 202, 206], ["skin", "ANATOMY", 235, 239], ["oral tract", "ANATOMY", 258, 268], ["PVP-I", "CHEMICAL", 16, 21], ["PVP-I", "CHEMICAL", 178, 183], ["alcohol", "CHEMICAL", 309, 316], ["PVP-I", "CHEMICAL", 16, 21], ["PVP-I", "CHEMICAL", 178, 183], ["alcohol", "CHEMICAL", 309, 316], ["PVP-I", "SIMPLE_CHEMICAL", 16, 21], ["skin", "ORGAN", 56, 60], ["PVP-I", "SIMPLE_CHEMICAL", 178, 183], ["hand", "ORGANISM_SUBDIVISION", 202, 206], ["skin", "ORGAN", 235, 239], ["oral tract", "ORGANISM_SUBDIVISION", 258, 268], ["alcohol", "SIMPLE_CHEMICAL", 309, 316], ["PVP", "TREATMENT", 16, 19], ["test bacterial pathogens", "PROBLEM", 30, 54], ["PVP", "TREATMENT", 178, 181], ["hand washing", "TREATMENT", 202, 214], ["disinfection of skin, surfaces and the oral tract", "PROBLEM", 219, 268], ["a substitute or replacement", "TREATMENT", 277, 304], ["skin", "ANATOMY", 56, 60], ["skin", "ANATOMY", 235, 239], ["oral tract", "ANATOMY", 258, 268]]], ["While PVP-I can stain surfaces, it is water soluble and stains can be washed away or removed with a damp cloth.", [["PVP-I", "CHEMICAL", 6, 11], ["PVP-I", "CHEMICAL", 6, 11], ["PVP-I", "GENE_OR_GENE_PRODUCT", 6, 11], ["a damp cloth", "TREATMENT", 98, 110], ["damp cloth", "OBSERVATION", 100, 110]]], ["PVP-I' virucidal efficacy against coronaviruses at concentrations as low as 0.23%, rapid efficacy at 15 s, and residual efficacy in combination with isopropyl alcohol or ethanol make it an excellent choice for disinfecting skin, oral cavities, and fomite surfaces (Eggers et al., 2015b; Kampf et al., 2020) .", [["skin", "ANATOMY", 223, 227], ["oral cavities", "ANATOMY", 229, 242], ["PVP-I", "CHEMICAL", 0, 5], ["isopropyl alcohol", "CHEMICAL", 149, 166], ["ethanol", "CHEMICAL", 170, 177], ["PVP", "CHEMICAL", 0, 3], ["isopropyl alcohol", "CHEMICAL", 149, 166], ["ethanol", "CHEMICAL", 170, 177], ["PVP-I", "SIMPLE_CHEMICAL", 0, 5], ["coronaviruses", "ORGANISM", 34, 47], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 149, 166], ["ethanol", "SIMPLE_CHEMICAL", 170, 177], ["skin", "ORGAN", 223, 227], ["oral cavities", "MULTI-TISSUE_STRUCTURE", 229, 242], ["PVP", "TEST", 0, 3], ["coronaviruses", "PROBLEM", 34, 47], ["isopropyl alcohol", "TREATMENT", 149, 166], ["disinfecting skin, oral cavities", "PROBLEM", 210, 242], ["skin", "ANATOMY", 223, 227], ["oral cavities", "ANATOMY", 229, 242]]], ["The combination of PVP-I with alcohol as a disinfectant could reduce the amount of alcohol required and could serve as a useful substitute or supplement to alcohol use.Quaternary Ammonium Compounds and Quaternary Ammonium Compound Based DisinfectantsQuaternary Ammonium Compounds (QACs) are popular sanitizers that can be used on certain food contact surfaces as well as fomites ( Table 1) .", [["PVP-I", "CHEMICAL", 19, 24], ["alcohol", "CHEMICAL", 30, 37], ["alcohol", "CHEMICAL", 83, 90], ["alcohol", "CHEMICAL", 156, 163], ["Ammonium", "CHEMICAL", 179, 187], ["Ammonium", "CHEMICAL", 213, 221], ["DisinfectantsQuaternary Ammonium", "CHEMICAL", 237, 269], ["PVP-I", "CHEMICAL", 19, 24], ["alcohol", "CHEMICAL", 30, 37], ["alcohol", "CHEMICAL", 83, 90], ["alcohol", "CHEMICAL", 156, 163], ["Ammonium", "CHEMICAL", 179, 187], ["Quaternary Ammonium", "CHEMICAL", 202, 221], ["Ammonium", "CHEMICAL", 261, 269], ["PVP-I", "SIMPLE_CHEMICAL", 19, 24], ["alcohol", "SIMPLE_CHEMICAL", 30, 37], ["alcohol", "SIMPLE_CHEMICAL", 83, 90], ["alcohol", "SIMPLE_CHEMICAL", 156, 163], ["Ammonium Compounds", "SIMPLE_CHEMICAL", 179, 197], ["Quaternary Ammonium Compound", "SIMPLE_CHEMICAL", 202, 230], ["DisinfectantsQuaternary Ammonium Compounds", "SIMPLE_CHEMICAL", 237, 279], ["QACs", "SIMPLE_CHEMICAL", 281, 285], ["a disinfectant", "TREATMENT", 41, 55], ["Quaternary Ammonium Compounds", "TREATMENT", 168, 197], ["Quaternary Ammonium Compound", "TREATMENT", 202, 230], ["DisinfectantsQuaternary Ammonium Compounds (QACs)", "TREATMENT", 237, 286], ["popular sanitizers", "TREATMENT", 291, 309], ["Ammonium Compounds", "OBSERVATION", 179, 197]]], ["QACs are cationic detergents with membrane active properties, and their antimicrobial activity is due in part to their ability to disrupt the lipid membrane of a microorganism (Rabenau et al., 2005b; Pratelli, 2007; Kumar et al., 2017) .", [["membrane", "ANATOMY", 34, 42], ["lipid membrane", "ANATOMY", 142, 156], ["QACs", "SIMPLE_CHEMICAL", 0, 4], ["membrane", "CELLULAR_COMPONENT", 34, 42], ["lipid membrane", "CELLULAR_COMPONENT", 142, 156], ["cationic detergents", "TREATMENT", 9, 28], ["membrane active properties", "TREATMENT", 34, 60]]], ["The effectiveness of QACs is very formulation specific and this affects the range of organisms to which they are effective and the time needed to be effective against a specific organism (Gerba, 2015) The exposure of SARS-CoV-2 (7.8 of log 10 TCID 50 /ml) to 0.10% (100 ppm) of benazlkonium chloride resulted in viral titer reduction below levels of detection after 5 min (Chin et al.) .", [["SARS", "DISEASE", 217, 221], ["benazlkonium chloride", "CHEMICAL", 278, 299], ["benazlkonium chloride", "CHEMICAL", 278, 299], ["QACs", "SIMPLE_CHEMICAL", 21, 25], ["benazlkonium chloride", "SIMPLE_CHEMICAL", 278, 299], ["SARS-CoV", "SPECIES", 217, 225], ["QACs", "TREATMENT", 21, 25], ["SARS", "TEST", 217, 221], ["CoV", "TEST", 222, 225], ["benazlkonium chloride", "TREATMENT", 278, 299], ["viral titer reduction", "TREATMENT", 312, 333], ["viral titer", "OBSERVATION", 312, 323]]], ["An analysis of the efficacy of household disinfectants against murine hepatitis virus (MHV), a surrogate for SARS-CoV-1, indicated that a formulation of 0.10% (100 ppm) quarternary compound with 79% ethanol resulted in a 3 log 10 (TCID 50 /ml) reduction after a 30 s exposure time (Dellanno et al., 2009 ).", [["murine hepatitis virus", "DISEASE", 63, 85], ["ethanol", "CHEMICAL", 199, 206], ["ethanol", "CHEMICAL", 199, 206], ["murine hepatitis virus", "ORGANISM", 63, 85], ["MHV", "ORGANISM", 87, 90], ["SARS-CoV-1", "ORGANISM", 109, 119], ["ethanol", "SIMPLE_CHEMICAL", 199, 206], ["murine", "SPECIES", 63, 69], ["hepatitis virus", "SPECIES", 70, 85], ["murine hepatitis virus", "SPECIES", 63, 85], ["MHV", "SPECIES", 87, 90], ["SARS-CoV-1", "SPECIES", 109, 119], ["An analysis", "TEST", 0, 11], ["household disinfectants", "TREATMENT", 31, 54], ["murine hepatitis virus", "PROBLEM", 63, 85], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117]]], ["The use of 1% (1,000 ppm) benzalkoniumchloride (a QAC) and 1% (1,000 ppm) chlorhexadine digluconate (a polybiguanide) against SARS-CoV resulted in a loss of culturability of the virus, though detection of viral RNA through PCR occurred 30 min after exposure (Ansaldi et al., 2004) .", [["benzalkoniumchloride", "CHEMICAL", 26, 46], ["QAC", "CHEMICAL", 50, 53], ["chlorhexadine digluconate", "CHEMICAL", 74, 99], ["polybiguanide", "CHEMICAL", 103, 116], ["SARS", "DISEASE", 126, 130], ["benzalkoniumchloride", "CHEMICAL", 26, 46], ["chlorhexadine digluconate", "CHEMICAL", 74, 99], ["polybiguanide", "CHEMICAL", 103, 116], ["benzalkoniumchloride", "SIMPLE_CHEMICAL", 26, 46], ["QAC", "SIMPLE_CHEMICAL", 50, 53], ["chlorhexadine digluconate", "SIMPLE_CHEMICAL", 74, 99], ["polybiguanide", "SIMPLE_CHEMICAL", 103, 116], ["SARS-CoV", "ORGANISM", 126, 134], ["viral RNA", "RNA", 205, 214], ["SARS-CoV", "SPECIES", 126, 134], ["benzalkoniumchloride (a QAC)", "TREATMENT", 26, 54], ["chlorhexadine digluconate", "TREATMENT", 74, 99], ["a polybiguanide)", "TREATMENT", 101, 117], ["SARS", "PROBLEM", 126, 130], ["CoV", "PROBLEM", 131, 134], ["a loss of culturability", "PROBLEM", 147, 170], ["the virus", "PROBLEM", 174, 183], ["viral RNA through PCR", "PROBLEM", 205, 226]]], ["The formulations and test conditions used by Kampf et al. (2020) indicated a low efficacy against MERS-CoV.", [["MERS-CoV", "ORGANISM", 98, 106], ["MERS-CoV", "SPECIES", 98, 106], ["The formulations", "TREATMENT", 0, 16], ["test conditions", "TEST", 21, 36], ["low efficacy", "OBSERVATION_MODIFIER", 77, 89]]], ["The use of ethanol along with QACs usually has been associated with effective antimicrobial activity against coronaviruses (Sattar, 2004) .Hydrogen PeroxideHydrogen peroxide is commonly used to disinfect food contact surfaces, as a fumigant and as a sanitizer (Table 1 ) (Kumar et al., 2017) .", [["ethanol", "CHEMICAL", 11, 18], ["QACs", "CHEMICAL", 30, 34], ["Hydrogen", "CHEMICAL", 139, 147], ["PeroxideHydrogen peroxide", "CHEMICAL", 148, 173], ["ethanol", "CHEMICAL", 11, 18], ["Hydrogen PeroxideHydrogen peroxide", "CHEMICAL", 139, 173], ["ethanol", "SIMPLE_CHEMICAL", 11, 18], ["QACs", "SIMPLE_CHEMICAL", 30, 34], ["coronaviruses", "ORGANISM", 109, 122], ["Hydrogen PeroxideHydrogen peroxide", "SIMPLE_CHEMICAL", 139, 173], ["ethanol", "TREATMENT", 11, 18], ["QACs", "TREATMENT", 30, 34], ["coronaviruses", "PROBLEM", 109, 122], ["Hydrogen PeroxideHydrogen peroxide", "TREATMENT", 139, 173]]], ["Studies have shown that hydrogen peroxide is effective against SARS-CoV and its surrogates.", [["hydrogen peroxide", "CHEMICAL", 24, 41], ["SARS-CoV", "DISEASE", 63, 71], ["hydrogen peroxide", "CHEMICAL", 24, 41], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 24, 41], ["SARS-CoV", "ORGANISM", 63, 71], ["SARS-CoV", "SPECIES", 63, 71], ["Studies", "TEST", 0, 7], ["hydrogen peroxide", "TREATMENT", 24, 41], ["SARS", "PROBLEM", 63, 67], ["hydrogen peroxide", "OBSERVATION", 24, 41]]], ["Exposure of a coronavirus surrogate (TGEV) dried on stainless steel to hydrogen peroxide vapor (20 \u00b5l) for 2-3 h resulted in approximately a 5 log 10 (TCID 50 /ml) reduction (Goyal et al., 2014) .", [["hydrogen peroxide", "CHEMICAL", 71, 88], ["hydrogen peroxide", "CHEMICAL", 71, 88], ["coronavirus", "ORGANISM", 14, 25], ["TGEV", "ORGANISM", 37, 41], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 71, 88], ["coronavirus", "SPECIES", 14, 25], ["TGEV", "SPECIES", 37, 41], ["a coronavirus surrogate (TGEV", "TREATMENT", 12, 41], ["stainless steel to hydrogen peroxide vapor", "TREATMENT", 52, 94]]], ["A limitation to this study was that the hydrogen peroxide vapor was examined on clean surfaces; therefore, further studies examining the impact of organic material and soil are necessary to determine its efficacy in a range of environments and situations.", [["hydrogen peroxide", "CHEMICAL", 40, 57], ["hydrogen peroxide", "CHEMICAL", 40, 57], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 40, 57], ["this study", "TEST", 16, 26], ["the hydrogen peroxide vapor", "TREATMENT", 36, 63], ["further studies", "TEST", 107, 122], ["organic material", "PROBLEM", 147, 163]]], ["Another study using a commercial product (ACCEL TB) containing liquid hydrogen peroxide with surfactants was effective (>4 log 10 TCID 50 /ml reduction) at a concentration of 0.5% with an incubation time of 1 min against HCoV-229E (Omidbakhsh and Sattar, 2006 ).", [["hydrogen peroxide", "CHEMICAL", 70, 87], ["surfactants", "CHEMICAL", 93, 104], ["HCoV-229E", "CHEMICAL", 221, 230], ["hydrogen peroxide", "CHEMICAL", 70, 87], ["liquid hydrogen peroxide", "SIMPLE_CHEMICAL", 63, 87], ["HCoV-229E", "CELL", 221, 230], ["HCoV-229E", "SPECIES", 221, 230], ["Another study", "TEST", 0, 13], ["a commercial product (ACCEL TB)", "TREATMENT", 20, 51], ["liquid hydrogen peroxide", "TREATMENT", 63, 87], ["surfactants", "TREATMENT", 93, 104], ["HCoV", "TEST", 221, 225]]], ["However, limited information exists regarding the virucidal activity of hydrogen peroxide on other types of surfaces.Sodium HypochloriteSodium hypochlorite (NaOCl; chlorine bleach) has been used as disinfectant for the past century in water and on food contact surfaces (Table 1 ; Kumar et al., 2017) .", [["hydrogen peroxide", "CHEMICAL", 72, 89], ["Sodium HypochloriteSodium hypochlorite", "CHEMICAL", 117, 155], ["NaOCl", "CHEMICAL", 157, 162], ["chlorine", "CHEMICAL", 164, 172], ["hydrogen peroxide", "CHEMICAL", 72, 89], ["Sodium HypochloriteSodium hypochlorite", "CHEMICAL", 117, 155], ["NaOCl", "CHEMICAL", 157, 162], ["chlorine", "CHEMICAL", 164, 172], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 72, 89], ["Sodium HypochloriteSodium hypochlorite", "SIMPLE_CHEMICAL", 117, 155], ["NaOCl", "SIMPLE_CHEMICAL", 157, 162], ["chlorine", "SIMPLE_CHEMICAL", 164, 172], ["hydrogen peroxide", "TREATMENT", 72, 89], ["Sodium HypochloriteSodium hypochlorite (NaOCl", "TREATMENT", 117, 162], ["chlorine bleach", "TREATMENT", 164, 179]]], ["Hypochlorous acid (HOCl) and the hypochlorite ion contribute the majority of the disinfectant activity associated with bleach-containing products, with the former compound contributing the most biocidal activity (Kott et al., 1975; Rutala and Weber, 1997) .", [["Hypochlorous acid", "CHEMICAL", 0, 17], ["HOCl", "CHEMICAL", 19, 23], ["hypochlorite", "CHEMICAL", 33, 45], ["Hypochlorous acid", "CHEMICAL", 0, 17], ["HOCl", "CHEMICAL", 19, 23], ["hypochlorite", "CHEMICAL", 33, 45], ["Hypochlorous acid", "SIMPLE_CHEMICAL", 0, 17], ["HOCl", "SIMPLE_CHEMICAL", 19, 23], ["hypochlorite", "SIMPLE_CHEMICAL", 33, 45], ["Hypochlorous acid (HOCl", "PROBLEM", 0, 23], ["the hypochlorite ion", "TREATMENT", 29, 49], ["the disinfectant activity", "PROBLEM", 77, 102], ["bleach-containing products", "TREATMENT", 119, 145], ["acid", "OBSERVATION_MODIFIER", 13, 17], ["disinfectant activity", "OBSERVATION", 81, 102]]], ["However, while chlorine-derived compounds do exhibit significant efficacy against coronaviruses on non-porous surfaces, organic matter and porous materials diminish virucidal activity because of the quenching of free chlorine (Geller et al., 2012) .", [["chlorine", "CHEMICAL", 15, 23], ["chlorine", "CHEMICAL", 217, 225], ["chlorine", "CHEMICAL", 15, 23], ["chlorine", "CHEMICAL", 217, 225], ["chlorine", "SIMPLE_CHEMICAL", 15, 23], ["coronaviruses", "ORGANISM", 82, 95], ["chlorine", "SIMPLE_CHEMICAL", 217, 225], ["coronaviruses on non-porous surfaces", "PROBLEM", 82, 118], ["organic matter and porous materials", "PROBLEM", 120, 155], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["organic matter", "OBSERVATION_MODIFIER", 120, 134]]], ["Common practice in the food industry is to adjust alkaline chlorine formulations to ca. pH 7 using a food grade acid when it is used at higher concentrations to increase dissociation into the more potent antimicrobial compound HOCl.", [["chlorine", "CHEMICAL", 59, 67], ["HOCl", "CHEMICAL", 227, 231], ["chlorine", "CHEMICAL", 59, 67], ["HOCl", "CHEMICAL", 227, 231], ["alkaline chlorine", "SIMPLE_CHEMICAL", 50, 67], ["HOCl", "SIMPLE_CHEMICAL", 227, 231], ["alkaline chlorine formulations", "TREATMENT", 50, 80], ["pH", "TEST", 88, 90], ["a food grade acid", "TREATMENT", 99, 116]]], ["However, pH adjustment is less common in healthcare and household environments and does not occur in literature examining the virucidal activity of bleach in these settings (Kott et al., 1975) .Sodium HypochloriteThe exposure of SARS-CoV-2 (7.8 of log 10 (TCID50/ml) to 1:49 (\u223c150 ppm) and 1:99 (\u223c75 ppm) household bleach resulted in the virus titer being reduced below levels of detection after 5 min (Chin et al., 2020) .", [["Sodium Hypochlorite", "CHEMICAL", 194, 213], ["SARS", "DISEASE", 229, 233], ["Sodium Hypochlorite", "CHEMICAL", 194, 213], ["Sodium Hypochlorite", "SIMPLE_CHEMICAL", 194, 213], ["SARS-CoV-2", "ORGANISM", 229, 239], ["SARS-CoV", "SPECIES", 229, 237], ["Sodium Hypochlorite", "TREATMENT", 194, 213], ["SARS", "TEST", 229, 233], ["CoV", "TEST", 234, 237], ["the virus titer", "PROBLEM", 334, 349], ["Hypochlorite", "OBSERVATION", 201, 213]]], ["To elucidate the target of antiviral activity, bovine coronavirus was exposed to 100,000 ppm NaOCl (pH 11.5) for 1 min.", [["NaOCl", "CHEMICAL", 93, 98], ["NaOCl", "CHEMICAL", 93, 98], ["bovine", "ORGANISM", 47, 53], ["coronavirus", "ORGANISM", 54, 65], ["NaOCl", "SIMPLE_CHEMICAL", 93, 98], ["bovine", "SPECIES", 47, 53], ["bovine coronavirus", "SPECIES", 47, 65], ["antiviral activity", "TREATMENT", 27, 45], ["bovine coronavirus", "PROBLEM", 47, 65], ["pH", "TEST", 100, 102], ["antiviral activity", "OBSERVATION", 27, 45]]], ["Real-time reverse transcriptase PCR (rRT-PCR) and Western Blot indicated that total RNA and nucleoprotein degradation occurred in that time period.", [["reverse transcriptase", "PROTEIN", 10, 31], ["transcriptase PCR", "TEST", 18, 35], ["rRT", "TEST", 37, 40], ["Western Blot", "TEST", 50, 62], ["total RNA", "PROBLEM", 78, 87], ["nucleoprotein degradation", "PROBLEM", 92, 117], ["nucleoprotein degradation", "OBSERVATION", 92, 117]]], ["When the concentration was reduced to 10,000 ppm NaOCl, a 10 min treatment was required to achieve complete nucleoprotein degradation, although there was <1 log 10 reduction in total RNA units observed (Bieker, 2006) .", [["NaOCl", "CHEMICAL", 49, 54], ["NaOCl", "CHEMICAL", 49, 54], ["NaOCl", "SIMPLE_CHEMICAL", 49, 54], ["NaOCl", "TREATMENT", 49, 54], ["a 10 min treatment", "TREATMENT", 56, 74], ["complete nucleoprotein degradation", "PROBLEM", 99, 133], ["total RNA units", "TREATMENT", 177, 192]]], ["HCoV-229E challenged with 5,000 ppm NaOCl for 10 min on an inanimate surface underwent a ca.", [["surface", "ANATOMY", 69, 76], ["HCoV-229E", "CHEMICAL", 0, 9], ["NaOCl", "CHEMICAL", 36, 41], ["NaOCl", "CHEMICAL", 36, 41], ["HCoV-229E", "CELL", 0, 9], ["NaOCl", "SIMPLE_CHEMICAL", 36, 41], ["HCoV-229E", "SPECIES", 0, 9], ["HCoV", "TEST", 0, 4], ["NaOCl", "TREATMENT", 36, 41], ["ca", "OBSERVATION", 89, 91]]], ["3 log10 (TCID50/ml) reduction, which failed to meet EPA standards for virucidal activity for a disinfectant claim (Tyan et al., 2018) .", [["reduction", "TREATMENT", 20, 29]]], ["However, when treatment levels were increased to 2,100 ppm NaOCl) on stainless steel coupons, a \u22654.5 log 10 TCID50/mL reduction was achieved after 30 s against the SARS-CoV-1 surrogate, MHV (Dellanno et al., 2009) .", [["NaOCl", "CHEMICAL", 59, 64], ["SARS", "DISEASE", 164, 168], ["NaOCl", "CHEMICAL", 59, 64], ["NaOCl", "SIMPLE_CHEMICAL", 59, 64], ["MHV", "ORGANISM", 186, 189], ["SARS-CoV-1", "SPECIES", 164, 174], ["MHV", "SPECIES", 186, 189], ["treatment levels", "TEST", 14, 30], ["stainless steel coupons", "TREATMENT", 69, 92], ["TCID50/mL reduction", "TREATMENT", 108, 127], ["the SARS", "TEST", 160, 168], ["CoV", "TEST", 169, 172]]], ["Much lower concentrations were required in seeded hospital wastewater; SARS-CoV-1 was inactivated by exposure to 10 ppm NaOCl (0.4 ppm free chlorine) after 10 min exposure, while inactivation occurred within 1 min in 20 ppm NaOCl (0.5 ppm free chlorine; Kott et al., 1975; Rutala and Weber, 1997; Kapil et al., 2004; Wang et al., 2005; Dellanno et al., 2009; Geller et al., 2012; Kumar et al., 2017; Chin et al., 2020) .Peroxyacetic Acid and Acetic AcidUses of peroxyacetic acid (PAA) include the sanitation of food contact surfaces and for post-harvest produce washing.", [["SARS-CoV-1", "CHEMICAL", 71, 81], ["NaOCl", "CHEMICAL", 120, 125], ["chlorine", "CHEMICAL", 140, 148], ["NaOCl", "CHEMICAL", 224, 229], ["chlorine", "CHEMICAL", 244, 252], ["Peroxyacetic Acid", "CHEMICAL", 420, 437], ["peroxyacetic acid", "CHEMICAL", 461, 478], ["PAA", "CHEMICAL", 480, 483], ["NaOCl", "CHEMICAL", 120, 125], ["chlorine", "CHEMICAL", 140, 148], ["NaOCl", "CHEMICAL", 224, 229], ["chlorine", "CHEMICAL", 244, 252], ["Peroxyacetic Acid", "CHEMICAL", 420, 437], ["Acetic AcidUses", "CHEMICAL", 442, 457], ["peroxyacetic acid", "CHEMICAL", 461, 478], ["PAA", "CHEMICAL", 480, 483], ["NaOCl", "SIMPLE_CHEMICAL", 120, 125], ["chlorine", "SIMPLE_CHEMICAL", 140, 148], ["NaOCl", "SIMPLE_CHEMICAL", 224, 229], ["Peroxyacetic Acid", "SIMPLE_CHEMICAL", 420, 437], ["Acetic AcidUses", "SIMPLE_CHEMICAL", 442, 457], ["peroxyacetic acid", "SIMPLE_CHEMICAL", 461, 478], ["PAA", "SIMPLE_CHEMICAL", 480, 483], ["Much lower concentrations", "PROBLEM", 0, 25], ["NaOCl", "TREATMENT", 120, 125], ["Peroxyacetic Acid", "TREATMENT", 420, 437], ["Acetic AcidUses", "TREATMENT", 442, 457], ["peroxyacetic acid (PAA)", "TREATMENT", 461, 484], ["post-harvest produce washing", "TREATMENT", 541, 569]]], ["The antimicrobial action of PAA involves the production of reactive oxygen species (ROS) (Vandekinderen et al., 2009) .", [["PAA", "CHEMICAL", 28, 31], ["oxygen", "CHEMICAL", 68, 74], ["ROS", "CHEMICAL", 84, 87], ["PAA", "CHEMICAL", 28, 31], ["oxygen", "CHEMICAL", 68, 74], ["PAA", "SIMPLE_CHEMICAL", 28, 31], ["reactive oxygen species", "SIMPLE_CHEMICAL", 59, 82], ["ROS", "SIMPLE_CHEMICAL", 84, 87], ["The antimicrobial action of PAA", "TREATMENT", 0, 31], ["reactive oxygen species", "PROBLEM", 59, 82], ["antimicrobial", "OBSERVATION_MODIFIER", 4, 17], ["reactive", "OBSERVATION_MODIFIER", 59, 67], ["oxygen species", "OBSERVATION", 68, 82]]], ["ROS oxidize sulfhydryl and disulfide bonds, which in bacteria leads to increased cell wall permeability, impacted enzymatic transport systems, and disrupted cell membranes (Vandekinderen et al., 2009) .", [["cell wall", "ANATOMY", 81, 90], ["cell membranes", "ANATOMY", 157, 171], ["ROS", "CHEMICAL", 0, 3], ["sulfhydryl", "CHEMICAL", 12, 22], ["sulfhydryl", "CHEMICAL", 12, 22], ["disulfide", "CHEMICAL", 27, 36], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["sulfhydryl", "SIMPLE_CHEMICAL", 12, 22], ["disulfide bonds", "SIMPLE_CHEMICAL", 27, 42], ["cell wall", "TISSUE", 81, 90], ["cell membranes", "CELLULAR_COMPONENT", 157, 171], ["ROS oxidize sulfhydryl", "TREATMENT", 0, 22], ["disulfide bonds", "PROBLEM", 27, 42], ["bacteria", "PROBLEM", 53, 61], ["increased cell wall permeability", "PROBLEM", 71, 103], ["impacted enzymatic transport systems", "PROBLEM", 105, 141], ["disrupted cell membranes", "PROBLEM", 147, 171], ["disulfide bonds", "OBSERVATION", 27, 42], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["cell", "OBSERVATION", 81, 85], ["wall", "ANATOMY_MODIFIER", 86, 90], ["permeability", "OBSERVATION_MODIFIER", 91, 103], ["impacted", "OBSERVATION_MODIFIER", 105, 113], ["enzymatic transport systems", "OBSERVATION", 114, 141], ["disrupted cell membranes", "OBSERVATION", 147, 171]]], ["While PAA has shown effectiveness on bacterial pathogens on food and food contact surfaces, it has varied impact on foodborne viruses, notably human norovirus (NoV) and hepatitis A virus (HAV), both non-enveloped viruses which tend to be more resistant to antimicrobials than enveloped viruses (Watanabe et al., 1989; Barker et al., 2001) .", [["PAA", "CHEMICAL", 6, 9], ["foodborne viruses", "DISEASE", 116, 133], ["human norovirus (NoV) and hepatitis A", "DISEASE", 143, 180], ["PAA", "CHEMICAL", 6, 9], ["PAA", "SIMPLE_CHEMICAL", 6, 9], ["human norovirus (NoV)", "ORGANISM", 143, 164], ["hepatitis A virus", "ORGANISM", 169, 186], ["HAV", "ORGANISM", 188, 191], ["human", "SPECIES", 143, 148], ["hepatitis A virus", "SPECIES", 169, 186], ["human norovirus", "SPECIES", 143, 158], ["NoV", "SPECIES", 160, 163], ["hepatitis A virus", "SPECIES", 169, 186], ["HAV", "SPECIES", 188, 191], ["bacterial pathogens", "PROBLEM", 37, 56], ["foodborne viruses", "PROBLEM", 116, 133], ["human norovirus", "PROBLEM", 143, 158], ["hepatitis A virus (HAV)", "PROBLEM", 169, 192], ["both non-enveloped viruses", "PROBLEM", 194, 220], ["antimicrobials", "TREATMENT", 256, 270], ["bacterial", "OBSERVATION_MODIFIER", 37, 46], ["pathogens", "OBSERVATION", 47, 56], ["foodborne viruses", "OBSERVATION", 116, 133], ["non-enveloped", "OBSERVATION_MODIFIER", 199, 212], ["viruses", "OBSERVATION", 213, 220]]], ["A PAAbased biocide (100 ppm PAA) used to wash lettuce had no significant disinfection effect on viral titers of HAV and murine norovirus (MNV) (Fraisse et al., 2011) .", [["PAAbased biocide", "CHEMICAL", 2, 18], ["PAA", "CHEMICAL", 28, 31], ["PAA", "CHEMICAL", 28, 31], ["PAAbased", "SIMPLE_CHEMICAL", 2, 10], ["HAV", "ORGANISM", 112, 115], ["murine norovirus", "ORGANISM", 120, 136], ["MNV", "ORGANISM", 138, 141], ["murine", "SPECIES", 120, 126], ["lettuce", "SPECIES", 46, 53], ["HAV", "SPECIES", 112, 115], ["murine norovirus", "SPECIES", 120, 136], ["MNV", "SPECIES", 138, 141], ["A PAAbased biocide (100 ppm PAA)", "TREATMENT", 0, 32], ["significant disinfection effect", "PROBLEM", 61, 92], ["viral titers", "TEST", 96, 108], ["HAV", "PROBLEM", 112, 115], ["murine norovirus", "PROBLEM", 120, 136], ["no", "UNCERTAINTY", 58, 60], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["disinfection", "OBSERVATION", 73, 85], ["viral titers", "OBSERVATION_MODIFIER", 96, 108]]], ["Higher concentrations of PAA (>100 ppm) may be necessary to reduce nonenveloped viruses on surfaces, foods, and fomites, and research regarding the effectiveness of PAA on coronaviruses is limited.", [["PAA", "CHEMICAL", 25, 28], ["PAA", "CHEMICAL", 165, 168], ["PAA", "CHEMICAL", 25, 28], ["PAA", "CHEMICAL", 165, 168], ["PAA", "SIMPLE_CHEMICAL", 25, 28], ["PAA", "SIMPLE_CHEMICAL", 165, 168], ["coronaviruses", "ORGANISM", 172, 185], ["PAA", "TEST", 25, 28], ["PAA on coronaviruses", "PROBLEM", 165, 185], ["viruses", "OBSERVATION", 80, 87], ["coronaviruses", "OBSERVATION", 172, 185]]], ["A 0.035% (35 ppm) solution of PAA inhibited SARS-CoV-1 replication in cell culture with <2 min of contact time (Ansaldi et al., 2004) , while the same concentration did not affect the viral genome after 30 min of exposure (Ansaldi et al., 2004) .", [["cell culture", "ANATOMY", 70, 82], ["PAA", "CHEMICAL", 30, 33], ["SARS", "DISEASE", 44, 48], ["PAA", "CHEMICAL", 30, 33], ["PAA", "SIMPLE_CHEMICAL", 30, 33], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 44, 54], ["cell culture", "CELL", 70, 82], ["viral genome", "DNA", 184, 196], ["SARS-CoV-1", "SPECIES", 44, 54], ["A 0.035% (35 ppm) solution", "TREATMENT", 0, 26], ["PAA", "TEST", 30, 33], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["cell culture", "TEST", 70, 82], ["viral genome", "OBSERVATION", 184, 196]]], ["Another study suggested that SARS-CoV-1 can be inactivated with 500 to 1,000 ppm of PAA (Wang et al., 2005) .", [["SARS", "DISEASE", 29, 33], ["PAA", "CHEMICAL", 84, 87], ["PAA", "CHEMICAL", 84, 87], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 29, 39], ["PAA", "SIMPLE_CHEMICAL", 84, 87], ["SARS-CoV-1", "SPECIES", 29, 39], ["Another study", "TEST", 0, 13], ["SARS", "PROBLEM", 29, 33]]], ["The EPA has listed several PAA-based sanitizers and disinfectants that can be used against SARS-CoV-2, in addition to other viruses (https://www.epa.gov/pesticide-registration/list-ndisinfectants-use-against-sars-cov-2; accessed March 24, 2020).Peroxyacetic Acid and Acetic AcidWine vinegar (6% acetic acid) was effective in inactivating SARS-CoV-1 by a reduction factor of 3 log 10 within an exposure duration of 30s (Rabenau et al., 2005a) providing both processers and consumers with an option for food contact surface disinfection.Chlorine DioxideChlorine dioxide (ClO 2 ) is a gas at room temperature and is easily dissolved in water, although concentrations in water diminish rapidly (Gates et al., 2009) .", [["surface", "ANATOMY", 514, 521], ["EPA", "CHEMICAL", 4, 7], ["PAA", "CHEMICAL", 27, 30], ["SARS", "DISEASE", 91, 95], ["Peroxyacetic Acid", "CHEMICAL", 245, 262], ["Acetic AcidWine vinegar", "CHEMICAL", 267, 290], ["acetic acid", "CHEMICAL", 295, 306], ["SARS", "DISEASE", 338, 342], ["Chlorine", "CHEMICAL", 535, 543], ["DioxideChlorine dioxide", "CHEMICAL", 544, 567], ["ClO 2", "CHEMICAL", 569, 574], ["EPA", "CHEMICAL", 4, 7], ["PAA", "CHEMICAL", 27, 30], ["Peroxyacetic Acid", "CHEMICAL", 245, 262], ["Acetic AcidWine", "CHEMICAL", 267, 282], ["acetic acid", "CHEMICAL", 295, 306], ["Chlorine DioxideChlorine dioxide", "CHEMICAL", 535, 567], ["ClO 2", "CHEMICAL", 569, 574], ["EPA", "SIMPLE_CHEMICAL", 4, 7], ["PAA", "SIMPLE_CHEMICAL", 27, 30], ["SARS-CoV-2", "ORGANISM", 91, 101], ["Peroxyacetic Acid", "SIMPLE_CHEMICAL", 245, 262], ["Acetic AcidWine vinegar", "SIMPLE_CHEMICAL", 267, 290], ["acetic acid", "SIMPLE_CHEMICAL", 295, 306], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 338, 348], ["Chlorine DioxideChlorine dioxide", "SIMPLE_CHEMICAL", 535, 567], ["ClO 2", "SIMPLE_CHEMICAL", 569, 574], ["water", "SIMPLE_CHEMICAL", 633, 638], ["water", "SIMPLE_CHEMICAL", 667, 672], ["SARS-CoV", "SPECIES", 91, 99], ["SARS-CoV-1", "SPECIES", 338, 348], ["several PAA-based sanitizers", "TREATMENT", 19, 47], ["disinfectants", "TREATMENT", 52, 65], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["other viruses", "PROBLEM", 118, 131], ["Peroxyacetic Acid", "TREATMENT", 245, 262], ["Acetic AcidWine vinegar", "TREATMENT", 267, 290], ["6% acetic acid", "TREATMENT", 292, 306], ["CoV", "TEST", 343, 346], ["a reduction factor", "TEST", 352, 370], ["Chlorine DioxideChlorine dioxide", "TREATMENT", 535, 567], ["dissolved", "OBSERVATION", 620, 629]]], ["It is an effective disinfectant in both gas and liquid states, making it a versatile biocidal agent (Gates et al., 2009; Morino et al., 2011) .", [["effective", "OBSERVATION_MODIFIER", 9, 18], ["disinfectant", "OBSERVATION", 19, 31]]], ["A ClO 2 solution at concentrations yielding 2.19 ppm free chlorine in wastewater has been reported to inactivate SARS-CoV-1 (Wang et al., 2005; Miura and Shibata, 2010) , which makes it a less efficacious disinfectant against the virus than chlorine, which was effective at 0.5 ppm free chlorine.", [["ClO 2", "CHEMICAL", 2, 7], ["chlorine", "CHEMICAL", 58, 66], ["SARS", "DISEASE", 113, 117], ["chlorine", "CHEMICAL", 241, 249], ["chlorine", "CHEMICAL", 287, 295], ["ClO 2", "CHEMICAL", 2, 7], ["chlorine", "CHEMICAL", 58, 66], ["chlorine", "CHEMICAL", 241, 249], ["chlorine", "CHEMICAL", 287, 295], ["ClO 2", "SIMPLE_CHEMICAL", 2, 7], ["chlorine", "SIMPLE_CHEMICAL", 58, 66], ["chlorine", "SIMPLE_CHEMICAL", 241, 249], ["chlorine", "SIMPLE_CHEMICAL", 287, 295], ["SARS-CoV-1", "SPECIES", 113, 123], ["A ClO 2 solution at concentrations", "TREATMENT", 0, 34], ["ppm free chlorine in wastewater", "TREATMENT", 49, 80], ["the virus", "PROBLEM", 226, 235], ["chlorine", "TREATMENT", 241, 249]]], ["To achieve complete inactivation of the virus in wastewater, ClO 2 at 20 ppm required a 5 min contact time.", [["ClO 2", "CHEMICAL", 61, 66], ["ClO 2", "CHEMICAL", 61, 66], ["ClO 2", "SIMPLE_CHEMICAL", 61, 66], ["the virus", "PROBLEM", 36, 45]]], ["However, a 10 ppm solution only achieved a 55.3-68.4% inactivation of the virus (Wang et al., 2005) .Chlorine DioxideClO 2 is an active virucidal agent in its gaseous state.", [["Chlorine", "CHEMICAL", 101, 109], ["DioxideClO 2", "CHEMICAL", 110, 122], ["Chlorine DioxideClO 2", "CHEMICAL", 101, 122], ["Chlorine DioxideClO 2", "SIMPLE_CHEMICAL", 101, 122], ["a 10 ppm solution", "TREATMENT", 9, 26], ["the virus", "PROBLEM", 70, 79], ["Chlorine DioxideClO", "TREATMENT", 101, 120], ["an active virucidal agent", "TREATMENT", 126, 151], ["active", "OBSERVATION_MODIFIER", 129, 135], ["virucidal", "OBSERVATION", 136, 145], ["gaseous state", "OBSERVATION", 159, 172]]], ["When placed in an environment with chlorine dioxide at concentrations of 0.05 ppm, Influenza A virus (an enveloped virus) on wet glass slides was reduced from > 6 log 10 TCID 50 to below the limit of detection (<0.5 log 10 TCID 50 ) within 3 h, while the control (air) titers remained unchanged after 5 h exposure (Morino et al., 2011) .", [["chlorine dioxide", "CHEMICAL", 35, 51], ["chlorine dioxide", "CHEMICAL", 35, 51], ["chlorine dioxide", "SIMPLE_CHEMICAL", 35, 51], ["Influenza A virus", "ORGANISM", 83, 100], ["Influenza A virus", "SPECIES", 83, 100], ["Influenza A virus", "SPECIES", 83, 100], ["chlorine dioxide", "TREATMENT", 35, 51], ["Influenza A virus", "PROBLEM", 83, 100], ["wet glass slides", "TEST", 125, 141], ["the control (air) titers", "TEST", 251, 275], ["unchanged", "OBSERVATION_MODIFIER", 285, 294]]], ["Complete inactivation of SARS-CoV surrogate MHV strain A59 after 12 h exposure to 0.16 ppmv/min ClO 2 gas has been reported, with titers reduced 3.5 times after 6 h exposure .", [["SARS", "DISEASE", 25, 29], ["ClO 2 gas", "CHEMICAL", 96, 105], ["ClO 2", "CHEMICAL", 96, 101], ["SARS-CoV", "ORGANISM", 25, 33], ["MHV strain A59", "ORGANISM", 44, 58], ["SARS-CoV", "SPECIES", 25, 33], ["MHV", "SPECIES", 44, 47], ["SARS", "PROBLEM", 25, 29], ["CoV surrogate MHV strain A59", "TREATMENT", 30, 58], ["ClO 2 gas", "TEST", 96, 105]]], ["ClO 2 can also be safely used in low concentrations around animals and people to control airborne viruses.", [["ClO 2", "CHEMICAL", 0, 5], ["ClO 2", "CHEMICAL", 0, 5], ["ClO 2", "GENE_OR_GENE_PRODUCT", 0, 5], ["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["low concentrations", "OBSERVATION_MODIFIER", 33, 51], ["airborne viruses", "OBSERVATION", 89, 105]]], ["Mice housed in an environment with 0.032 ppm ClO 2 were exposed to aerosolized influenza virus A and compared to mice housed in fresh air with no ClO 2 .", [["ClO 2", "CHEMICAL", 45, 50], ["ClO 2", "CHEMICAL", 146, 151], ["Mice", "ORGANISM", 0, 4], ["mice", "ORGANISM", 113, 117], ["Mice", "SPECIES", 0, 4], ["influenza virus", "SPECIES", 79, 94], ["mice", "SPECIES", 113, 117], ["influenza virus A", "SPECIES", 79, 96], ["mice", "SPECIES", 113, 117], ["0.032 ppm ClO", "TREATMENT", 35, 48], ["aerosolized influenza virus A", "PROBLEM", 67, 96]]], ["After 3 days, pulmonary titers in the control group were 6.7 TCID 50 , significantly higher than the 2.6 TCID 50 observed within the mice exposed to ClO 2 (Miura and Shibata, 2010) .", [["pulmonary", "ANATOMY", 14, 23], ["ClO 2", "CHEMICAL", 149, 154], ["ClO 2", "CHEMICAL", 149, 154], ["pulmonary", "ORGAN", 14, 23], ["mice", "ORGANISM", 133, 137], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 133, 137], ["pulmonary titers", "TEST", 14, 30], ["ClO", "TEST", 149, 152], ["pulmonary", "ANATOMY", 14, 23], ["titers", "OBSERVATION", 24, 30]]], ["Gaseous oxidizers should be used according the federal regulations and should be monitored to prevent inadvertent exposure to personnel (CDC, 1978) .OzoneOzone is a naturally occurring configuration of three oxygen atoms and has a half-life of about 1 h at room temperature; degradation results in spontaneous oxygen gas formation (Kumar et al., 2017) .", [["OzoneOzone", "CHEMICAL", 149, 159], ["oxygen", "CHEMICAL", 208, 214], ["oxygen", "CHEMICAL", 310, 316], ["OzoneOzone", "CHEMICAL", 149, 159], ["oxygen", "CHEMICAL", 208, 214], ["oxygen", "CHEMICAL", 310, 316], ["OzoneOzone", "SIMPLE_CHEMICAL", 149, 159], ["oxygen atoms", "SIMPLE_CHEMICAL", 208, 220], ["oxygen", "SIMPLE_CHEMICAL", 310, 316], ["Gaseous oxidizers", "TREATMENT", 0, 17], ["OzoneOzone", "TREATMENT", 149, 159], ["three oxygen atoms", "TREATMENT", 202, 220], ["spontaneous oxygen gas formation", "PROBLEM", 298, 330], ["spontaneous", "OBSERVATION_MODIFIER", 298, 309], ["oxygen gas", "OBSERVATION", 310, 320]]], ["A powerful oxidant, ozone has unique biological properties and can be used as a gas at recommended levels with monitoring and can also be dispersed in water.", [["ozone", "CHEMICAL", 20, 25], ["ozone", "CHEMICAL", 20, 25], ["ozone", "SIMPLE_CHEMICAL", 20, 25], ["a gas", "TEST", 78, 83]]], ["Viral susceptibility to ozone varies.", [["ozone", "CHEMICAL", 24, 29], ["ozone", "CHEMICAL", 24, 29], ["ozone", "SIMPLE_CHEMICAL", 24, 29], ["Viral susceptibility to ozone varies", "PROBLEM", 0, 36], ["ozone varies", "OBSERVATION", 24, 36]]], ["Enveloped viruses such as coronaviruses might be more sensitive than non-enveloped viruses due to the interaction of ozone with the lipid layer envelopes (Kumar et al., 2016) .", [["lipid layer", "ANATOMY", 132, 143], ["ozone", "CHEMICAL", 117, 122], ["ozone", "CHEMICAL", 117, 122], ["coronaviruses", "ORGANISM", 26, 39], ["ozone", "SIMPLE_CHEMICAL", 117, 122], ["Enveloped viruses", "PROBLEM", 0, 17], ["coronaviruses", "PROBLEM", 26, 39], ["non-enveloped viruses", "PROBLEM", 69, 90], ["viruses", "OBSERVATION", 10, 17]]], ["Zhang et al. (2004) reported that a high concentration of 27.73 ppm ozone inactivated SARS-CoV-1 in 4 min.", [["ozone", "CHEMICAL", 68, 73], ["SARS", "DISEASE", 86, 90], ["ozone", "CHEMICAL", 68, 73], ["ozone", "SIMPLE_CHEMICAL", 68, 73], ["SARS-CoV-1", "SPECIES", 86, 96]]], ["The medium (17.82 ppm) and low (4.86 ppm) concentrations could also inactivate SARS-Cov-1 with different speeds and efficacy (Zhang et al., 2004) .", [["SARS", "DISEASE", 79, 83], ["SARS", "TEST", 79, 83], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["In another study, maximum anti-viral efficacy of ozone required a short period of high humidity (>90% relative humidity) after the attainment of peak ozone gas concentration (20-25 ppm) (Hudson et al., 2007) .", [["ozone", "CHEMICAL", 49, 54], ["ozone", "CHEMICAL", 150, 155], ["ozone", "CHEMICAL", 49, 54], ["ozone", "CHEMICAL", 150, 155], ["ozone", "SIMPLE_CHEMICAL", 49, 54], ["ozone", "SIMPLE_CHEMICAL", 150, 155], ["another study", "TEST", 3, 16], ["high humidity", "TREATMENT", 82, 95], ["peak ozone gas concentration", "TEST", 145, 173]]], ["Mouse coronavirus (MCoV) on different surfaces (glass, plastic, and stainless steel) and in the presence of biological fluids was inactivated by ozone by at least 3 log 10 in the laboratory and in simulated field trials (Hudson et al., 2007 (Hudson et al., , 2009 .", [["ozone", "CHEMICAL", 145, 150], ["ozone", "CHEMICAL", 145, 150], ["Mouse coronavirus", "ORGANISM", 0, 17], ["MCoV", "ORGANISM", 19, 23], ["ozone", "SIMPLE_CHEMICAL", 145, 150], ["Mouse", "SPECIES", 0, 5], ["Mouse coronavirus", "SPECIES", 0, 17], ["MCoV", "SPECIES", 19, 23], ["Mouse coronavirus", "PROBLEM", 0, 17], ["different surfaces (glass, plastic, and stainless steel)", "TREATMENT", 28, 84], ["biological fluids", "TREATMENT", 108, 125], ["stainless steel", "OBSERVATION_MODIFIER", 68, 83], ["fluids", "OBSERVATION", 119, 125]]], ["Ozone can be harmful to personnel when inhaled and should be used according to federal regulations (CDC, 2019) .", [["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "SIMPLE_CHEMICAL", 0, 5]]], ["Precautions should be taken to monitor ozone levels in air to avoid inadvertent exposure to personnel (CDC, 2019).Ultraviolet LightUltraviolet (UV) light has three classifications (UVA, UVB, and UVC) based on wavelength and is known to cause pyrimidine dimers and breakage in nucleic acids (Tseng and Li, 2005) .", [["ozone", "CHEMICAL", 39, 44], ["UVA", "CHEMICAL", 181, 184], ["UVB", "CHEMICAL", 186, 189], ["pyrimidine", "CHEMICAL", 242, 252], ["nucleic acids", "CHEMICAL", 276, 289], ["ozone", "CHEMICAL", 39, 44], ["pyrimidine", "CHEMICAL", 242, 252], ["ozone", "SIMPLE_CHEMICAL", 39, 44], ["pyrimidine dimers", "SIMPLE_CHEMICAL", 242, 259], ["nucleic acids", "SIMPLE_CHEMICAL", 276, 289], ["Precautions", "TREATMENT", 0, 11], ["ozone levels", "TEST", 39, 51], ["Ultraviolet LightUltraviolet (UV)", "TREATMENT", 114, 147], ["UVB", "TREATMENT", 186, 189], ["UVC", "TREATMENT", 195, 198], ["pyrimidine dimers", "PROBLEM", 242, 259], ["breakage in nucleic acids", "PROBLEM", 264, 289], ["UVC", "ANATOMY", 195, 198], ["pyrimidine dimers", "OBSERVATION", 242, 259], ["breakage", "OBSERVATION_MODIFIER", 264, 272]]], ["This dimerization disrupts transcriptional and translational processes, affecting cellular function and can thus also interfere with viral replication.", [["cellular", "ANATOMY", 82, 90], ["cellular", "CELL", 82, 90], ["viral replication", "TREATMENT", 133, 150], ["cellular function", "OBSERVATION", 82, 99]]], ["UV light treatment can be employed to target three transmission forms of viral particles: (1) in droplets, (2) aerosolized, and (3) on fomites; however, the inactivation of coronaviruses via UV light can be challenging as inactivation rates vary based on wavelength and the length of the RNA transcript (Stern and Sefton, 1982) .", [["droplets", "ANATOMY", 97, 105], ["coronaviruses", "ORGANISM", 173, 186], ["RNA transcript", "RNA", 288, 302], ["UV light treatment", "TREATMENT", 0, 18], ["viral particles", "PROBLEM", 73, 88], ["coronaviruses via UV light", "TREATMENT", 173, 199], ["viral particles", "OBSERVATION", 73, 88]]], ["Generally, inactivation rates increase with the length of the RNA transcript (Stern and Sefton, 1982) .", [["RNA transcript", "RNA", 62, 76]]], ["Also, UV target sizes for viral messenger RNA (mRNA) are typically directly related to that of the genomic-size RNA (Yokomori et al., 1992) .Ultraviolet LightUVC light (254 nm) with an intensity of 4,016 \u00b5W/cm 2 inactivated SARS-CoV-1 in a liquid medium at a 3 cm distance for 15 min, while UVA light had no effect on viability (Darnell et al., 2004) .", [["UVA", "CHEMICAL", 291, 294], ["viral messenger RNA", "RNA", 26, 45], ["mRNA", "RNA", 47, 51], ["UV target sizes", "TREATMENT", 6, 21], ["viral messenger RNA (mRNA)", "PROBLEM", 26, 52], ["Ultraviolet LightUVC light", "TREATMENT", 141, 167], ["an intensity", "TEST", 182, 194], ["SARS", "TEST", 224, 228], ["CoV", "TEST", 229, 232], ["a liquid medium", "TREATMENT", 238, 253], ["target", "OBSERVATION_MODIFIER", 9, 15], ["sizes", "OBSERVATION_MODIFIER", 16, 21], ["viral messenger RNA", "OBSERVATION", 26, 45], ["size", "OBSERVATION_MODIFIER", 107, 111]]], ["UV light, in combination with riboflavin, a B vitamin, reduced MERS-CoV titer below the limit of detection of 2.18 log 10 PFU/mL from an initial concentration of 7.5 log 10 PFU/mL (Keil et al., 2016) .", [["riboflavin", "CHEMICAL", 30, 40], ["B vitamin", "CHEMICAL", 44, 53], ["riboflavin", "CHEMICAL", 30, 40], ["vitamin", "CHEMICAL", 46, 53], ["riboflavin", "SIMPLE_CHEMICAL", 30, 40], ["B vitamin", "SIMPLE_CHEMICAL", 44, 53], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 63, 71], ["MERS-CoV", "SPECIES", 63, 71], ["UV light", "TREATMENT", 0, 8], ["riboflavin", "TREATMENT", 30, 40], ["a B vitamin", "TREATMENT", 42, 53], ["CoV titer", "TEST", 68, 77]]], ["Other studies have examined the effectiveness of UV light on aerosolized viral particles.", [["Other studies", "TEST", 0, 13], ["UV light", "TREATMENT", 49, 57], ["aerosolized viral particles", "TREATMENT", 61, 88], ["viral particles", "OBSERVATION", 73, 88]]], ["SARS-CoV-1 in an aerosolized form treated with UV light illustrated a greater susceptibility (Z-value ratio of air to liquid of 85.7) compared to that of the virus in liquid media (Walker and Ko, 2007) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["UV light", "TREATMENT", 47, 55], ["a greater susceptibility", "PROBLEM", 68, 92]]], ["While UV light (134 \u00b5W/cm 2 ) for a duration of 15 min was effective in significantly reducing the infectivity of SARS-CoV-1 from 7.57 to 2.25 log 10 TCID 50 /mL, the treatment did not completely eliminate the virus (Kariwa et al., 2006) .", [["SARS", "DISEASE", 114, 118], ["SARS-CoV-1", "ORGANISM", 114, 124], ["SARS-CoV-1", "SPECIES", 114, 124], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["the treatment", "TREATMENT", 163, 176], ["the virus", "PROBLEM", 206, 215]]], ["UV light should be used according to federal regulations and during hours when operations have ceased to prevent inadvertent exposure to personnel (21 CFR 880.6600) (FDA, 2019).MetalsVery few studies have examined the effectiveness of metals against viruses.", [["metals", "CHEMICAL", 235, 241], ["UV light", "TREATMENT", 0, 8], ["operations", "TREATMENT", 79, 89], ["viruses", "PROBLEM", 250, 257]]], ["In a study by Bright et al. (2009) , zeolite powders amended with silver and/or silver/copper ions resulted in reductions of 1.08 log 10 TCID 50 /ml (3.5% Ag, 6.5% Cu), 0.43 log 10 TCID 50 /ml (20% Ag) and 0.50 log 10 TCID 50 /ml (0.6% Ag, 14% Zn, 80% ZnO) of HCoV-229E after 1 h in a saline suspension (Bright et al., 2009) .", [["silver", "CHEMICAL", 66, 72], ["silver", "CHEMICAL", 80, 86], ["copper", "CHEMICAL", 87, 93], ["Cu", "CHEMICAL", 164, 166], ["Ag", "CHEMICAL", 198, 200], ["Ag", "CHEMICAL", 236, 238], ["Zn", "CHEMICAL", 244, 246], ["ZnO", "CHEMICAL", 252, 255], ["HCoV-229E", "CHEMICAL", 260, 269], ["zeolite", "CHEMICAL", 37, 44], ["silver", "CHEMICAL", 66, 72], ["silver", "CHEMICAL", 80, 86], ["copper", "CHEMICAL", 87, 93], ["Ag", "CHEMICAL", 155, 157], ["Cu", "CHEMICAL", 164, 166], ["Ag", "CHEMICAL", 198, 200], ["Ag", "CHEMICAL", 236, 238], ["Zn", "CHEMICAL", 244, 246], ["ZnO", "CHEMICAL", 252, 255], ["HCoV-229E", "CHEMICAL", 260, 269], ["zeolite powders", "SIMPLE_CHEMICAL", 37, 52], ["silver", "SIMPLE_CHEMICAL", 66, 72], ["silver/copper ions", "SIMPLE_CHEMICAL", 80, 98], ["Zn", "SIMPLE_CHEMICAL", 244, 246], ["HCoV-229E", "SIMPLE_CHEMICAL", 260, 269], ["a study", "TEST", 3, 10], ["zeolite powders", "TREATMENT", 37, 52], ["silver and/or silver/copper ions", "TREATMENT", 66, 98], ["HCoV", "TREATMENT", 260, 264], ["a saline suspension", "TREATMENT", 283, 302]]], ["Silver/copper zeolites were the most effective, with an observed 2.06 log 10 TCID 50 reduction after 4 h and a 5.13 log 10 TCID 50 reduction within 24 h.", [["Silver", "CHEMICAL", 0, 6], ["copper", "CHEMICAL", 7, 13], ["Silver", "CHEMICAL", 0, 6], ["copper", "CHEMICAL", 7, 13], ["Silver", "SIMPLE_CHEMICAL", 0, 6], ["copper zeolites", "SIMPLE_CHEMICAL", 7, 22], ["Silver/copper zeolites", "TREATMENT", 0, 22]]], ["A 3.18 log 10 reduction was observed for FIPV (feline coronavirus) after 4 h (Bright et al., 2009) .", [["feline coronavirus", "DISEASE", 47, 65], ["feline coronavirus", "ORGANISM", 47, 65], ["feline coronavirus", "SPECIES", 47, 65], ["FIPV", "SPECIES", 41, 45], ["feline coronavirus", "SPECIES", 47, 65], ["A 3.18 log 10 reduction", "TREATMENT", 0, 23], ["FIPV (feline coronavirus", "TREATMENT", 41, 65]]], ["The long duration required for inactivation of coronaviruses by metals such as silver and copper indicate that they might be ineffective in food production operations when used individually as rapid disinfection is required.MetalsSilver has been shown to have antiviral activity against numerous viruses including the enveloped HIV, HSV-1, herpes vesicular stomatitis virus (HSTV), and vaccinia virus, and the non-enveloped papovaviruses and adenovirus (AdV) (Silvestry-Rodriguez et al., 2007) .", [["silver", "CHEMICAL", 79, 85], ["copper", "CHEMICAL", 90, 96], ["MetalsSilver", "CHEMICAL", 224, 236], ["herpes vesicular stomatitis", "DISEASE", 340, 367], ["silver", "CHEMICAL", 79, 85], ["copper", "CHEMICAL", 90, 96], ["coronaviruses", "ORGANISM", 47, 60], ["metals", "SIMPLE_CHEMICAL", 64, 70], ["silver", "SIMPLE_CHEMICAL", 79, 85], ["copper", "SIMPLE_CHEMICAL", 90, 96], ["MetalsSilver", "SIMPLE_CHEMICAL", 224, 236], ["enveloped HIV", "ORGANISM", 318, 331], ["HSV-1", "ORGANISM", 333, 338], ["herpes vesicular stomatitis virus", "ORGANISM", 340, 373], ["HSTV", "ORGANISM", 375, 379], ["vaccinia virus", "ORGANISM", 386, 400], ["non-enveloped papovaviruses", "ORGANISM", 410, 437], ["adenovirus", "ORGANISM", 442, 452], ["AdV", "ORGANISM", 454, 457], ["HIV", "SPECIES", 328, 331], ["HSV-1", "SPECIES", 333, 338], ["herpes vesicular stomatitis virus", "SPECIES", 340, 373], ["vaccinia virus", "SPECIES", 386, 400], ["HIV", "SPECIES", 328, 331], ["HSV-1", "SPECIES", 333, 338], ["HSTV", "SPECIES", 375, 379], ["vaccinia virus", "SPECIES", 386, 400], ["AdV", "SPECIES", 454, 457], ["coronaviruses", "PROBLEM", 47, 60], ["food production operations", "TREATMENT", 140, 166], ["rapid disinfection", "TREATMENT", 193, 211], ["antiviral activity", "TREATMENT", 260, 278], ["numerous viruses", "PROBLEM", 287, 303], ["the enveloped HIV", "PROBLEM", 314, 331], ["HSV", "TEST", 333, 336], ["herpes vesicular stomatitis virus (HSTV)", "PROBLEM", 340, 380], ["vaccinia virus", "PROBLEM", 386, 400], ["the non-enveloped papovaviruses", "PROBLEM", 406, 437], ["adenovirus", "PROBLEM", 442, 452], ["viruses", "OBSERVATION", 296, 303], ["vesicular stomatitis", "ANATOMY", 347, 367], ["vaccinia virus", "OBSERVATION", 386, 400]]], ["The use of silver as a coating on food contact surfaces and processing equipment could be considered for further testing and validation as silver ions have also been demonstrated to inactivate the non-enveloped poliovirus (PV) and coliphages (Yahya et al., 1992) and synergistic antiviral activity in the presence of oxidizing agents.", [["silver", "CHEMICAL", 11, 17], ["silver ions", "CHEMICAL", 139, 150], ["silver", "CHEMICAL", 11, 17], ["silver", "CHEMICAL", 139, 145], ["silver", "SIMPLE_CHEMICAL", 11, 17], ["silver ions", "SIMPLE_CHEMICAL", 139, 150], ["non-enveloped poliovirus", "ORGANISM", 197, 221], ["PV", "SPECIES", 223, 225], ["silver", "TREATMENT", 11, 17], ["processing equipment", "TREATMENT", 60, 80], ["further testing", "TEST", 105, 120], ["validation as silver ions", "TREATMENT", 125, 150], ["the non-enveloped poliovirus", "PROBLEM", 193, 221], ["synergistic antiviral activity", "TREATMENT", 267, 297], ["oxidizing agents", "TREATMENT", 317, 333], ["antiviral activity", "OBSERVATION", 279, 297], ["oxidizing agents", "OBSERVATION", 317, 333]]], ["Similarly, silver has been shown to have synergistic antimicrobial activity against MS-2 bacteriophage when used in conjunction with UV light (Butkus et al., 2004) .Plant-Based AntimicrobialsSeveral plant-based compounds, though not biocides, could be effective in reducing the infectivity of SARS-CoV-2 by inhibiting or blocking viral attachment to host cells.", [["cells", "ANATOMY", 355, 360], ["silver", "CHEMICAL", 11, 17], ["SARS", "DISEASE", 293, 297], ["silver", "CHEMICAL", 11, 17], ["silver", "SIMPLE_CHEMICAL", 11, 17], ["MS-2 bacteriophage", "CELL", 84, 102], ["SARS-CoV-2", "ORGANISM", 293, 303], ["host cells", "CELL", 350, 360], ["host cells", "CELL_TYPE", 350, 360], ["SARS-CoV", "SPECIES", 293, 301], ["synergistic antimicrobial activity", "PROBLEM", 41, 75], ["MS-2 bacteriophage", "PROBLEM", 84, 102], ["Antimicrobials", "TREATMENT", 177, 191], ["Several plant-based compounds", "PROBLEM", 191, 220], ["SARS", "PROBLEM", 293, 297], ["CoV", "TEST", 298, 301], ["blocking viral attachment to host cells", "PROBLEM", 321, 360], ["synergistic", "OBSERVATION_MODIFIER", 41, 52], ["antimicrobial activity", "OBSERVATION", 53, 75], ["plant", "OBSERVATION_MODIFIER", 199, 204], ["-based", "OBSERVATION_MODIFIER", 204, 210], ["compounds", "OBSERVATION_MODIFIER", 211, 220], ["host cells", "OBSERVATION", 350, 360]]], ["Phytocompounds, betulinic acid and savinin (Wen et al., 2007) and essential oils from Laurus nobilis (from berries), Thuja orientalis (from fruit), and Juniperus oxycedrus ssp. oxycedrus (from berries) (Loizzo et al., 2008) have been shown to be effective against SARS-CoV-1.Plant-Based AntimicrobialsIota-carrageenan, a generally regarded as safe (GRAS) polymer derived from red seaweed (Rhodophyceae) is a commonly used food thickener that has demonstrated inhibitory activity against coronaviruses and other respiratory viruses (Graf et al., 2018) .", [["berries", "ANATOMY", 107, 114], ["berries", "ANATOMY", 193, 200], ["Phytocompounds", "CHEMICAL", 0, 14], ["betulinic acid", "CHEMICAL", 16, 30], ["savinin", "CHEMICAL", 35, 42], ["oxycedrus", "CHEMICAL", 177, 186], ["SARS", "DISEASE", 264, 268], ["Iota-carrageenan", "CHEMICAL", 301, 317], ["red seaweed", "CHEMICAL", 376, 387], ["Rhodophyceae", "CHEMICAL", 389, 401], ["respiratory viruses", "DISEASE", 511, 530], ["Phytocompounds", "CHEMICAL", 0, 14], ["betulinic acid", "CHEMICAL", 16, 30], ["savinin", "CHEMICAL", 35, 42], ["Phytocompounds", "SIMPLE_CHEMICAL", 0, 14], ["betulinic acid", "SIMPLE_CHEMICAL", 16, 30], ["savinin", "SIMPLE_CHEMICAL", 35, 42], ["oils", "TISSUE", 76, 80], ["Laurus nobilis", "ORGANISM", 86, 100], ["berries", "ORGANISM_SUBDIVISION", 107, 114], ["Thuja orientalis", "ORGANISM", 117, 133], ["fruit", "ORGANISM_SUBDIVISION", 140, 145], ["Juniperus oxycedrus ssp", "ORGANISM", 152, 175], ["oxycedrus", "SIMPLE_CHEMICAL", 177, 186], ["berries", "ORGANISM_SUBDIVISION", 193, 200], ["SARS-CoV-1", "ORGANISM", 264, 274], ["Iota-carrageenan", "SIMPLE_CHEMICAL", 301, 317], ["red seaweed", "ORGANISM", 376, 387], ["Rhodophyceae", "SIMPLE_CHEMICAL", 389, 401], ["coronaviruses", "ORGANISM", 487, 500], ["Laurus nobilis", "SPECIES", 86, 100], ["Thuja orientalis", "SPECIES", 117, 133], ["Juniperus oxycedrus ssp", "SPECIES", 152, 175], ["oxycedrus", "SPECIES", 177, 186], ["Laurus nobilis", "SPECIES", 86, 100], ["Thuja orientalis", "SPECIES", 117, 133], ["Juniperus oxycedrus ssp", "SPECIES", 152, 175], ["SARS-CoV-1", "SPECIES", 264, 274], ["red seaweed", "SPECIES", 376, 387], ["Phytocompounds", "TEST", 0, 14], ["betulinic acid", "TEST", 16, 30], ["Laurus nobilis", "PROBLEM", 86, 100], ["Thuja orientalis", "PROBLEM", 117, 133], ["Juniperus oxycedrus ssp", "PROBLEM", 152, 175], ["Antimicrobials", "TREATMENT", 287, 301], ["coronaviruses", "PROBLEM", 487, 500], ["other respiratory viruses", "PROBLEM", 505, 530], ["Laurus nobilis", "ANATOMY", 86, 100], ["Juniperus oxycedrus", "OBSERVATION", 152, 171], ["respiratory viruses", "ANATOMY", 511, 530]]], ["Iota-carrageenan forms a protective barrier on mucosa when used as a nasal spray, preventing the attachment of the virus to cell surface (Grassauer et al., 2008) .", [["mucosa", "ANATOMY", 47, 53], ["nasal", "ANATOMY", 69, 74], ["cell surface", "ANATOMY", 124, 136], ["Iota-carrageenan", "CHEMICAL", 0, 16], ["Iota-carrageenan", "SIMPLE_CHEMICAL", 0, 16], ["mucosa", "MULTI-TISSUE_STRUCTURE", 47, 53], ["cell surface", "CELLULAR_COMPONENT", 124, 136], ["Iota-carrageenan", "TREATMENT", 0, 16], ["a protective barrier on mucosa", "TREATMENT", 23, 53], ["a nasal spray", "TREATMENT", 67, 80]]], ["Against human coronavirus OC43 (HCoV OC43), iota-carrageenan had an MIC of 0.024 \u00b5g/mL (Graf et al., 2018) .", [["iota-carrageenan", "CHEMICAL", 44, 60], ["iota-carrageenan", "CHEMICAL", 44, 60], ["human", "ORGANISM", 8, 13], ["coronavirus OC43", "ORGANISM", 14, 30], ["HCoV OC43", "ORGANISM", 32, 41], ["iota-carrageenan", "SIMPLE_CHEMICAL", 44, 60], ["human", "SPECIES", 8, 13], ["coronavirus", "SPECIES", 14, 25], ["human coronavirus", "SPECIES", 8, 25], ["HCoV", "SPECIES", 32, 36], ["an MIC", "TEST", 65, 71]]], ["Iota-carrageenan has demonstrated inhibitory activity against respiratory viruses such as Influenza A H1N1 (Wang et al., 2011) and reduced the viral load in nasal secretions of children displaying acute symptoms of common cold (Fazekas et al., 2012) .", [["nasal secretions", "ANATOMY", 157, 173], ["Iota-carrageenan", "CHEMICAL", 0, 16], ["respiratory viruses", "DISEASE", 62, 81], ["Influenza A H1N1", "DISEASE", 90, 106], ["Iota-carrageenan", "SIMPLE_CHEMICAL", 0, 16], ["Influenza A H1N1", "ORGANISM", 90, 106], ["nasal secretions", "ORGANISM_SUBDIVISION", 157, 173], ["children", "ORGANISM", 177, 185], ["Influenza A H1N1", "SPECIES", 90, 106], ["children", "SPECIES", 177, 185], ["Influenza A H1N1", "SPECIES", 90, 106], ["inhibitory activity", "PROBLEM", 34, 53], ["respiratory viruses", "PROBLEM", 62, 81], ["Influenza A H1N1", "PROBLEM", 90, 106], ["reduced the viral load in nasal secretions", "PROBLEM", 131, 173], ["acute symptoms", "PROBLEM", 197, 211], ["common cold", "PROBLEM", 215, 226], ["viral load", "OBSERVATION", 143, 153], ["nasal", "ANATOMY", 157, 162], ["acute", "OBSERVATION_MODIFIER", 197, 202]]], ["Common colds in humans can be caused by viruses such as human rhinovirus (hRV), human coronavirus (hCoV), parainfluenza (PIV), influenza (infA and infB), respiratory syncytial virus (RSV), adenovirus(ADV), enterovirus (EV), and metapneumovirus (MPV) (Koenighofer et al., 2014) .", [["colds", "DISEASE", 7, 12], ["human rhinovirus (hRV), human coronavirus (hCoV), parainfluenza (PIV), influenza", "DISEASE", 56, 136], ["respiratory syncytial virus (RSV), adenovirus(ADV), enterovirus (EV), and metapneumovirus", "DISEASE", 154, 243], ["humans", "ORGANISM", 16, 22], ["human rhinovirus", "ORGANISM", 56, 72], ["hRV", "ORGANISM", 74, 77], ["human coronavirus", "ORGANISM", 80, 97], ["hCoV", "ORGANISM", 99, 103], ["parainfluenza (PIV)", "ORGANISM", 106, 125], ["influenza", "ORGANISM", 127, 136], ["infA and infB),", "ORGANISM", 138, 153], ["respiratory syncytial virus", "ORGANISM", 154, 181], ["RSV", "ORGANISM", 183, 186], ["adenovirus", "ORGANISM", 189, 199], ["ADV", "ORGANISM", 200, 203], ["enterovirus", "ORGANISM", 206, 217], ["metapneumovirus", "ORGANISM", 228, 243], ["humans", "SPECIES", 16, 22], ["human", "SPECIES", 56, 61], ["rhinovirus", "SPECIES", 62, 72], ["human", "SPECIES", 80, 85], ["coronavirus", "SPECIES", 86, 97], ["parainfluenza", "SPECIES", 106, 119], ["respiratory syncytial virus (RSV", "SPECIES", 154, 186], ["humans", "SPECIES", 16, 22], ["human rhinovirus", "SPECIES", 56, 72], ["hRV", "SPECIES", 74, 77], ["human coronavirus", "SPECIES", 80, 97], ["hCoV", "SPECIES", 99, 103], ["PIV", "SPECIES", 121, 124], ["respiratory syncytial virus", "SPECIES", 154, 181], ["RSV", "SPECIES", 183, 186], ["adenovirus", "SPECIES", 189, 199], ["ADV", "SPECIES", 200, 203], ["EV", "SPECIES", 219, 221], ["MPV", "SPECIES", 245, 248], ["Common colds in humans", "PROBLEM", 0, 22], ["viruses", "PROBLEM", 40, 47], ["human rhinovirus (hRV)", "PROBLEM", 56, 78], ["human coronavirus (hCoV)", "PROBLEM", 80, 104], ["parainfluenza", "PROBLEM", 106, 119], ["PIV", "TEST", 121, 124], ["influenza", "PROBLEM", 127, 136], ["infB", "PROBLEM", 147, 151], ["respiratory syncytial virus (RSV)", "PROBLEM", 154, 187], ["adenovirus(ADV)", "PROBLEM", 189, 204], ["enterovirus", "PROBLEM", 206, 217], ["metapneumovirus", "PROBLEM", 228, 243], ["colds", "OBSERVATION", 7, 12], ["viruses", "OBSERVATION", 40, 47], ["respiratory syncytial", "ANATOMY", 154, 175]]], ["Exploration of the use of iota-carrageenan (0.12%) nasal spray to prevent common colds caused by these viruses indicated that patients using iota-carrageenan nasal sprays had significantly reduced durations of symptoms, relapses, and viral titers with highest efficacy against hCoV (Koenighofer et al., 2014) .", [["nasal", "ANATOMY", 51, 56], ["nasal", "ANATOMY", 158, 163], ["iota-carrageenan", "CHEMICAL", 26, 42], ["colds", "DISEASE", 81, 86], ["iota-carrageenan", "CHEMICAL", 141, 157], ["iota-carrageenan", "CHEMICAL", 26, 42], ["iota-carrageenan", "SIMPLE_CHEMICAL", 26, 42], ["nasal", "ORGANISM_SUBDIVISION", 51, 56], ["patients", "ORGANISM", 126, 134], ["hCoV", "SIMPLE_CHEMICAL", 277, 281], ["patients", "SPECIES", 126, 134], ["hCoV", "SPECIES", 277, 281], ["iota-carrageenan", "TREATMENT", 26, 42], ["nasal spray", "TREATMENT", 51, 62], ["common colds", "PROBLEM", 74, 86], ["these viruses", "PROBLEM", 97, 110], ["iota-carrageenan nasal sprays", "TREATMENT", 141, 170], ["symptoms", "PROBLEM", 210, 218], ["relapses", "PROBLEM", 220, 228], ["viral titers", "PROBLEM", 234, 246], ["viruses", "OBSERVATION", 103, 110]]], ["Relapses among patients treated with iota-carrageenan nasal sprays were observed less frequently in groups infected with hrv and hCoV (Koenighofer et al., 2014) .", [["nasal", "ANATOMY", 54, 59], ["iota-carrageenan", "CHEMICAL", 37, 53], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["Relapses", "PROBLEM", 0, 8], ["iota-carrageenan nasal sprays", "TREATMENT", 37, 66]]], ["The use of iotacarrageenan nasal sprays could be used as a method to prevent infection transmission among workers in food processing facilities.", [["nasal", "ANATOMY", 27, 32], ["iotacarrageenan", "CHEMICAL", 11, 26], ["infection", "DISEASE", 77, 86], ["iotacarrageenan", "CHEMICAL", 11, 26], ["iotacarrageenan", "SIMPLE_CHEMICAL", 11, 26], ["iotacarrageenan nasal sprays", "TREATMENT", 11, 39], ["a method", "TREATMENT", 57, 65], ["infection", "PROBLEM", 77, 86]]], ["Iota-carrageenan is GRAS certified (21 CFR 172.620) and is approved for use in foods, cosmetics and pharmaceuticals (Hebar et al., 2015) .Plant-Based AntimicrobialsThere are numerous groups of plant compounds/components that have been shown to have antimicrobial activity including saponins, thiosulfinates, glucosinolates, terpenoids, and polyphenols.", [["Iota-carrageenan", "CHEMICAL", 0, 16], ["CFR 172.620", "CHEMICAL", 39, 50], ["thiosulfinates, glucosinolates, terpenoids, and polyphenols", "CHEMICAL", 292, 351], ["saponins", "CHEMICAL", 282, 290], ["thiosulfinates", "CHEMICAL", 292, 306], ["glucosinolates", "CHEMICAL", 308, 322], ["terpenoids", "CHEMICAL", 324, 334], ["polyphenols", "CHEMICAL", 340, 351], ["Iota-carrageenan", "SIMPLE_CHEMICAL", 0, 16], ["saponins", "SIMPLE_CHEMICAL", 282, 290], ["thiosulfinates", "SIMPLE_CHEMICAL", 292, 306], ["glucosinolates", "SIMPLE_CHEMICAL", 308, 322], ["terpenoids", "SIMPLE_CHEMICAL", 324, 334], ["polyphenols", "SIMPLE_CHEMICAL", 340, 351], ["Antimicrobials", "TREATMENT", 150, 164], ["plant compounds/components", "PROBLEM", 193, 219], ["antimicrobial activity", "TREATMENT", 249, 271], ["saponins", "TREATMENT", 282, 290], ["thiosulfinates", "TREATMENT", 292, 306], ["glucosinolates", "TREATMENT", 308, 322], ["terpenoids", "TREATMENT", 324, 334], ["polyphenols", "TREATMENT", 340, 351], ["numerous", "OBSERVATION_MODIFIER", 174, 182], ["groups", "OBSERVATION_MODIFIER", 183, 189], ["plant compounds", "OBSERVATION", 193, 208], ["antimicrobial activity", "OBSERVATION", 249, 271]]], ["Many of these have been shown to have efficacy against various enveloped viruses such as herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2), bovine herpesviruses (BHV), bovine viral diarrhea virus (BVDV), human immunodeficiency virus (HIV), dengue virus (DENV), junin virus (JUNV), yellow fever virus (YFV), human respiratory syncytial virus (HRSV), influenza A virus (INFV-A; H1N1, H3N2, H5N1, and H9N2 strains), Newcastle disease virus (NDV), viral hemorrhagic septicemia virus (VHSV), human cytomegalovirus (HCMV), and measles virus (MeV) indicating possible efficacy against coronaviruses (reviewed by Goyal and Cannon, 2006; Bright and Gilling, 2016) .CONCLUSIONThe high infectivity of the COVID-19 coronavirus, SARS-CoV-2, has caused rapid person to person transmission resulting in a pandemic that has posed multifarious challenges to the food industry.", [["herpes simplex viruses", "DISEASE", 89, 111], ["bovine herpesviruses", "DISEASE", 145, 165], ["bovine viral diarrhea virus (BVDV), human immunodeficiency virus (HIV), dengue virus (DENV)", "DISEASE", 173, 264], ["yellow fever", "DISEASE", 286, 298], ["respiratory syncytial virus", "DISEASE", 318, 345], ["influenza A virus", "DISEASE", 354, 371], ["H3N2, H5N1, and H9N2 strains", "DISEASE", 387, 415], ["Newcastle disease", "DISEASE", 418, 435], ["viral hemorrhagic septicemia", "DISEASE", 449, 477], ["human cytomegalovirus (HCMV), and measles virus", "DISEASE", 492, 539], ["SARS-CoV-2", "CHEMICAL", 721, 731], ["herpes simplex viruses types 1", "ORGANISM", 89, 119], ["HSV-1", "ORGANISM", 127, 132], ["HSV-2", "ORGANISM", 137, 142], ["bovine herpesviruses (BHV", "ORGANISM", 145, 170], ["bovine viral diarrhea virus", "ORGANISM", 173, 200], ["BVDV", "ORGANISM", 202, 206], ["human immunodeficiency virus", "ORGANISM", 209, 237], ["HIV", "ORGANISM", 239, 242], ["dengue virus", "ORGANISM", 245, 257], ["DENV", "ORGANISM", 259, 263], ["junin virus", "ORGANISM", 266, 277], ["JUNV", "ORGANISM", 279, 283], ["yellow fever virus", "ORGANISM", 286, 304], ["YFV", "ORGANISM", 306, 309], ["human respiratory syncytial virus", "ORGANISM", 312, 345], ["HRSV", "ORGANISM", 347, 351], ["influenza A virus", "ORGANISM", 354, 371], ["INFV-A; H1N1, H3N2, H5N1", "ORGANISM", 373, 397], ["H9N2 strains", "ORGANISM", 403, 415], ["Newcastle disease virus", "ORGANISM", 418, 441], ["NDV", "ORGANISM", 443, 446], ["viral hemorrhagic septicemia virus", "ORGANISM", 449, 483], ["VHSV", "ORGANISM", 485, 489], ["human", "ORGANISM", 492, 497], ["cytomegalovirus", "ORGANISM", 498, 513], ["HCMV", "ORGANISM", 515, 519], ["measles virus", "ORGANISM", 526, 539], ["coronaviruses", "ORGANISM", 583, 596], ["COVID-19 coronavirus", "ORGANISM", 699, 719], ["SARS-CoV-2", "ORGANISM", 721, 731], ["herpes simplex viruses", "SPECIES", 89, 111], ["HSV-1", "SPECIES", 127, 132], ["HSV-2", "SPECIES", 137, 142], ["bovine", "SPECIES", 145, 151], ["bovine", "SPECIES", 173, 179], ["viral diarrhea virus", "SPECIES", 180, 200], ["BVDV", "SPECIES", 202, 206], ["human immunodeficiency virus", "SPECIES", 209, 237], ["(HIV", "SPECIES", 238, 242], ["dengue virus", "SPECIES", 245, 257], ["junin virus", "SPECIES", 266, 277], ["yellow fever virus", "SPECIES", 286, 304], ["human", "SPECIES", 312, 317], ["respiratory syncytial virus", "SPECIES", 318, 345], ["HRSV", "SPECIES", 347, 351], ["influenza A virus", "SPECIES", 354, 371], ["H9N2", "SPECIES", 403, 407], ["Newcastle disease virus", "SPECIES", 418, 441], ["NDV", "SPECIES", 443, 446], ["viral hemorrhagic septicemia virus", "SPECIES", 449, 483], ["VHSV", "SPECIES", 485, 489], ["human", "SPECIES", 492, 497], ["cytomegalovirus", "SPECIES", 498, 513], ["measles virus", "SPECIES", 526, 539], ["19 coronavirus", "SPECIES", 705, 719], ["person", "SPECIES", 750, 756], ["person", "SPECIES", 760, 766], ["herpes simplex viruses", "SPECIES", 89, 111], ["HSV-1", "SPECIES", 127, 132], ["HSV-2", "SPECIES", 137, 142], ["bovine", "SPECIES", 145, 151], ["BHV", "SPECIES", 167, 170], ["bovine viral diarrhea virus", "SPECIES", 173, 200], ["BVDV", "SPECIES", 202, 206], ["human immunodeficiency virus", "SPECIES", 209, 237], ["HIV", "SPECIES", 239, 242], ["dengue virus", "SPECIES", 245, 257], ["DENV", "SPECIES", 259, 263], ["junin virus", "SPECIES", 266, 277], ["JUNV", "SPECIES", 279, 283], ["yellow fever virus", "SPECIES", 286, 304], ["YFV", "SPECIES", 306, 309], ["human respiratory syncytial virus", "SPECIES", 312, 345], ["HRSV", "SPECIES", 347, 351], ["influenza A virus", "SPECIES", 354, 371], ["INFV-A", "SPECIES", 373, 379], ["Newcastle disease virus", "SPECIES", 418, 441], ["NDV", "SPECIES", 443, 446], ["viral hemorrhagic septicemia virus", "SPECIES", 449, 483], ["VHSV", "SPECIES", 485, 489], ["human cytomegalovirus", "SPECIES", 492, 513], ["HCMV", "SPECIES", 515, 519], ["measles virus", "SPECIES", 526, 539], ["COVID-19 coronavirus", "SPECIES", 699, 719], ["SARS-CoV", "SPECIES", 721, 729], ["various enveloped viruses", "PROBLEM", 55, 80], ["herpes simplex viruses types", "PROBLEM", 89, 117], ["HSV", "TEST", 127, 130], ["HSV", "TEST", 137, 140], ["bovine herpesviruses", "PROBLEM", 145, 165], ["BHV", "TEST", 167, 170], ["bovine viral diarrhea virus", "PROBLEM", 173, 200], ["BVDV", "PROBLEM", 202, 206], ["human immunodeficiency virus", "PROBLEM", 209, 237], ["HIV", "PROBLEM", 239, 242], ["dengue virus (DENV", "PROBLEM", 245, 263], ["junin virus (JUNV)", "PROBLEM", 266, 284], ["yellow fever virus", "PROBLEM", 286, 304], ["human respiratory syncytial virus", "PROBLEM", 312, 345], ["HRSV", "PROBLEM", 347, 351], ["influenza A virus", "PROBLEM", 354, 371], ["INFV", "TEST", 373, 377], ["H1N1", "PROBLEM", 381, 385], ["H3N2", "PROBLEM", 387, 391], ["H5N1", "PROBLEM", 393, 397], ["H9N2 strains", "PROBLEM", 403, 415], ["Newcastle disease virus", "PROBLEM", 418, 441], ["NDV", "PROBLEM", 443, 446], ["viral hemorrhagic septicemia virus", "PROBLEM", 449, 483], ["VHSV", "PROBLEM", 485, 489], ["human cytomegalovirus (HCMV)", "PROBLEM", 492, 520], ["measles virus", "PROBLEM", 526, 539], ["coronaviruses", "PROBLEM", 583, 596], ["the COVID", "TEST", 695, 704], ["coronavirus", "PROBLEM", 708, 719], ["viruses", "OBSERVATION", 73, 80], ["junin virus", "OBSERVATION", 266, 277], ["respiratory syncytial", "ANATOMY", 318, 339], ["viral", "OBSERVATION_MODIFIER", 449, 454], ["hemorrhagic", "OBSERVATION_MODIFIER", 455, 466], ["septicemia", "OBSERVATION", 467, 477], ["cytomegalovirus", "OBSERVATION", 498, 513], ["possible", "UNCERTAINTY", 557, 565], ["high infectivity", "OBSERVATION_MODIFIER", 675, 691]]], ["Though not transmitted through food, infections caused by SARS-CoV-2 have resulted in the closing of food processing plants due to infections among essential workers.", [["infections", "DISEASE", 37, 47], ["SARS", "DISEASE", 58, 62], ["infections", "DISEASE", 131, 141], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV", "SPECIES", 58, 66], ["infections", "PROBLEM", 37, 47], ["SARS", "PROBLEM", 58, 62], ["infections", "PROBLEM", 131, 141], ["infections", "OBSERVATION", 37, 47]]], ["Furthermore food contact surfaces and food packaging materials could serve as fomites for SARS-CoV-2, highlighting the importance of biocide use to mitigate the spread of the virus.CONCLUSIONCurrently used methods to reduce the transmission of the virus involve the use of masks, social distancing as well as the use of USEPA approved disinfecting and sanitizing agents.", [["SARS", "DISEASE", 90, 94], ["SARS-CoV", "SPECIES", 90, 98], ["food packaging materials", "TREATMENT", 38, 62], ["SARS", "PROBLEM", 90, 94], ["biocide use", "TREATMENT", 133, 144], ["the virus", "PROBLEM", 171, 180], ["methods", "TREATMENT", 206, 213], ["the virus", "PROBLEM", 244, 253], ["USEPA", "TREATMENT", 320, 325], ["sanitizing agents", "TREATMENT", 352, 369]]], ["These practices have not been fully successful in preventing transmission of SARS-CoV-2 in several food processing facilities.", [["SARS", "DISEASE", 77, 81], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "SPECIES", 77, 85], ["SARS", "PROBLEM", 77, 81]]], ["The information presented in this review indicates that SARS-CoV-2 can be transmitted through the air, feces, soiled surfaces and could occur on surfaces that are frequently touched.", [["feces", "ANATOMY", 103, 108], ["SARS", "DISEASE", 56, 60], ["SARS-CoV-2", "ORGANISM", 56, 66], ["feces", "ORGANISM_SUBDIVISION", 103, 108], ["SARS", "PROBLEM", 56, 60], ["air", "OBSERVATION", 98, 101]]], ["Our review indicates that ethanol at high concentrations (>70%), povidone iodine, hypochlorite and QACs when combined with alcohol are efficacious against SARS-CoV-2 for surface disinfection. hydrogen peroxide vapor, chlorine dioxide, ozone and UV could be applied to reduce viral load present in aerosols with appropriate precautions to prevent exposure of personnel to these antimicrobials.CONCLUSIONWhile hand washing and the use of sanitizers is a commonly implemented practice in food production plants, the dispersal of the SARS-CoV-2 virus from often asymptomatic individuals carrying high viral loads in their nasal epithelium requires the exploration of new practices such as the use of nasal sprays to minimize person to person transmission of the virus.", [["surface", "ANATOMY", 170, 177], ["hand", "ANATOMY", 408, 412], ["nasal epithelium", "ANATOMY", 618, 634], ["nasal", "ANATOMY", 696, 701], ["ethanol", "CHEMICAL", 26, 33], ["povidone iodine", "CHEMICAL", 65, 80], ["hypochlorite", "CHEMICAL", 82, 94], ["QACs", "CHEMICAL", 99, 103], ["alcohol", "CHEMICAL", 123, 130], ["SARS", "DISEASE", 155, 159], ["hydrogen peroxide", "CHEMICAL", 192, 209], ["chlorine dioxide", "CHEMICAL", 217, 233], ["ozone", "CHEMICAL", 235, 240], ["UV", "CHEMICAL", 245, 247], ["SARS", "DISEASE", 530, 534], ["ethanol", "CHEMICAL", 26, 33], ["povidone iodine", "CHEMICAL", 65, 80], ["hypochlorite", "CHEMICAL", 82, 94], ["alcohol", "CHEMICAL", 123, 130], ["hydrogen peroxide", "CHEMICAL", 192, 209], ["chlorine dioxide", "CHEMICAL", 217, 233], ["ozone", "CHEMICAL", 235, 240], ["ethanol", "SIMPLE_CHEMICAL", 26, 33], ["povidone iodine", "SIMPLE_CHEMICAL", 65, 80], ["hypochlorite", "SIMPLE_CHEMICAL", 82, 94], ["QACs", "SIMPLE_CHEMICAL", 99, 103], ["alcohol", "SIMPLE_CHEMICAL", 123, 130], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 192, 209], ["chlorine dioxide", "SIMPLE_CHEMICAL", 217, 233], ["ozone", "SIMPLE_CHEMICAL", 235, 240], ["SARS-CoV-2 virus", "ORGANISM", 530, 546], ["nasal epithelium", "TISSUE", 618, 634], ["CoV-2 virus", "SPECIES", 535, 546], ["person", "SPECIES", 721, 727], ["person", "SPECIES", 731, 737], ["SARS-CoV", "SPECIES", 155, 163], ["SARS-CoV-2 virus", "SPECIES", 530, 546], ["ethanol at high concentrations", "TREATMENT", 26, 56], ["povidone iodine", "TREATMENT", 65, 80], ["hypochlorite", "TREATMENT", 82, 94], ["QACs", "TREATMENT", 99, 103], ["SARS", "PROBLEM", 155, 159], ["CoV", "TEST", 160, 163], ["surface disinfection", "PROBLEM", 170, 190], ["hydrogen peroxide vapor", "TREATMENT", 192, 215], ["chlorine dioxide", "TREATMENT", 217, 233], ["ozone", "TREATMENT", 235, 240], ["UV", "TREATMENT", 245, 247], ["viral load", "PROBLEM", 275, 285], ["appropriate precautions", "TREATMENT", 311, 334], ["these antimicrobials", "TREATMENT", 371, 391], ["hand washing", "TREATMENT", 408, 420], ["sanitizers", "TREATMENT", 436, 446], ["the SARS", "TEST", 526, 534], ["CoV", "TEST", 535, 538], ["2 virus", "PROBLEM", 539, 546], ["asymptomatic individuals", "PROBLEM", 558, 582], ["high viral loads in their nasal epithelium", "PROBLEM", 592, 634], ["the exploration", "TEST", 644, 659], ["new practices", "TREATMENT", 663, 676], ["nasal sprays", "TREATMENT", 696, 708], ["the virus", "PROBLEM", 754, 763], ["washing", "OBSERVATION", 413, 420], ["high viral loads", "OBSERVATION", 592, 608], ["nasal epithelium", "ANATOMY", 618, 634]]], ["The review presents information on antimicrobials and plant-based compounds that could be explored to curtail transmission of SARS-CoV-2.", [["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "ORGANISM", 126, 136], ["SARS-CoV", "SPECIES", 126, 134], ["antimicrobials", "TREATMENT", 35, 49], ["plant-based compounds", "TREATMENT", 54, 75], ["CoV", "TEST", 131, 134]]], ["Plant derived iota carrageenan could prevent viral attachment to cells and reduce viral loads in the nasal epithelium.", [["cells", "ANATOMY", 65, 70], ["nasal epithelium", "ANATOMY", 101, 117], ["carrageenan", "CHEMICAL", 19, 30], ["iota carrageenan", "ORGANISM", 14, 30], ["cells", "CELL", 65, 70], ["nasal epithelium", "TISSUE", 101, 117], ["Plant derived iota carrageenan", "TREATMENT", 0, 30], ["viral attachment to cells", "PROBLEM", 45, 70], ["viral loads in the nasal epithelium", "PROBLEM", 82, 117], ["viral loads", "OBSERVATION", 82, 93], ["nasal epithelium", "ANATOMY", 101, 117]]], ["Povidone iodine has also been used in nasal sprays and might serve as an additional preventative measure to control the person-person transmission of SARS-CoV-2.CONCLUSIONThe use of a multiple hurdles to control the spread of pathogenic microorganisms is a common practice in the food industry and hence the implementation of several mitigation strategies can be adapted by the food industry.", [["nasal", "ANATOMY", 38, 43], ["Povidone iodine", "CHEMICAL", 0, 15], ["Povidone iodine", "CHEMICAL", 0, 15], ["Povidone iodine", "SIMPLE_CHEMICAL", 0, 15], ["person", "SPECIES", 120, 126], ["person", "SPECIES", 127, 133], ["Povidone iodine", "TREATMENT", 0, 15], ["nasal sprays", "TREATMENT", 38, 50], ["an additional preventative measure", "TREATMENT", 70, 104], ["a multiple hurdles", "TREATMENT", 182, 200], ["pathogenic microorganisms", "PROBLEM", 226, 251], ["several mitigation strategies", "TREATMENT", 326, 355]]], ["Biocides effective against SARS-CoV-2 on moist/soiled surfaces, air and skin is a requirement of high priority for transmission control.", [["skin", "ANATOMY", 72, 76], ["Biocides", "CHEMICAL", 0, 8], ["SARS", "DISEASE", 27, 31], ["SARS-CoV-2", "ORGANISM", 27, 37], ["skin", "ORGAN", 72, 76], ["SARS-CoV", "SPECIES", 27, 35], ["Biocides", "TREATMENT", 0, 8], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["moist/soiled surfaces", "TREATMENT", 41, 62], ["high priority", "TREATMENT", 97, 110], ["transmission control", "TREATMENT", 115, 135], ["air", "OBSERVATION", 64, 67], ["skin", "ANATOMY", 72, 76]]], ["Food processing facilities should practice the judicious and optimal use of biocides to avert the development of antimicrobial resistance in non-target bacterial pathogens during the SARS-CoV-2 pandemic.CONCLUSIONThe review provides the food industry with information about sanitizers and disinfectants with virucidal and inhibitory activity against SARS-CoV-2 or surrogates on food contact surfaces, liquids, aerosols and skin.", [["skin", "ANATOMY", 423, 427], ["SARS", "DISEASE", 183, 187], ["sanitizers", "SIMPLE_CHEMICAL", 274, 284], ["SARS-CoV-2", "ORGANISM", 350, 360], ["skin", "ORGAN", 423, 427], ["SARS-CoV", "SPECIES", 183, 191], ["SARS-CoV", "SPECIES", 350, 358], ["biocides", "TREATMENT", 76, 84], ["antimicrobial resistance", "PROBLEM", 113, 137], ["non-target bacterial pathogens", "PROBLEM", 141, 171], ["the SARS", "TEST", 179, 187], ["CoV", "TEST", 188, 191], ["sanitizers", "TREATMENT", 274, 284], ["disinfectants", "TREATMENT", 289, 302], ["virucidal", "TREATMENT", 308, 317], ["SARS", "PROBLEM", 350, 354], ["antimicrobial resistance", "OBSERVATION", 113, 137], ["bacterial pathogens", "OBSERVATION", 152, 171], ["skin", "ANATOMY", 423, 427]]], ["The integration of the recommended disinfectants and infection-prevention approaches would prevent SARS-CoV-2 dissemination in food production, manufacturing and retail facilities and among personnel.", [["infection", "DISEASE", 53, 62], ["SARS", "DISEASE", 99, 103], ["disinfectants", "TREATMENT", 35, 48], ["infection", "PROBLEM", 53, 62], ["prevention approaches", "TREATMENT", 63, 84], ["SARS", "PROBLEM", 99, 103], ["CoV", "PROBLEM", 104, 107], ["infection", "OBSERVATION", 53, 62]]]], "PMC6269171": [["IntroductionRespiratory infections, including tuberculosis, represent one of the leading causes of morbidity and mortality across the world.", [["IntroductionRespiratory infections", "DISEASE", 0, 34], ["tuberculosis", "DISEASE", 46, 58], ["IntroductionRespiratory infections", "PROBLEM", 0, 34], ["tuberculosis", "PROBLEM", 46, 58], ["morbidity", "PROBLEM", 99, 108], ["infections", "OBSERVATION", 24, 34], ["tuberculosis", "OBSERVATION", 46, 58], ["morbidity", "OBSERVATION", 99, 108]]], ["They represent the deadliest communicable diseases causing 3.0 million deaths worldwide in 2016 [1].", [["communicable diseases", "DISEASE", 29, 50], ["deaths", "DISEASE", 71, 77]]], ["The burden of respiratory infections can be unbearable for some health systems: they represent one of the most common reasons for doctor visits, regardless of age and sex [2].IntroductionAlthough respiratory infections have been identified as a mandatory topic in the education and training of respiratory physicians, the specialty has been faced with several challenges to implement training.", [["respiratory", "ANATOMY", 14, 25], ["respiratory", "ANATOMY", 196, 207], ["respiratory infections", "DISEASE", 14, 36], ["respiratory infections", "DISEASE", 196, 218], ["respiratory infections", "PROBLEM", 14, 36], ["respiratory infections", "PROBLEM", 196, 218], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["respiratory", "ANATOMY", 14, 25], ["infections", "OBSERVATION", 26, 36], ["respiratory", "ANATOMY", 196, 207], ["infections", "OBSERVATION", 208, 218]]], ["There are ongoing discussions surrounding what is included and excluded epidemiologically within the parameters of respiratory infections.", [["respiratory", "ANATOMY", 115, 126], ["respiratory infections", "DISEASE", 115, 137], ["respiratory infections", "PROBLEM", 115, 137], ["respiratory", "ANATOMY", 115, 126], ["infections", "OBSERVATION", 127, 137]]], ["Thus it is no surprise that, at present, the vast majority of European countries do not yet have a formal system for educating respiratory physicians, at a specialty level, on the knowledge and skills considered essential in the diagnosis, treatment and prevention of respiratory infections.", [["respiratory", "ANATOMY", 268, 279], ["respiratory infections", "DISEASE", 268, 290], ["treatment", "TREATMENT", 240, 249], ["respiratory infections", "PROBLEM", 268, 290], ["no surprise", "UNCERTAINTY", 11, 22], ["respiratory", "ANATOMY", 268, 279], ["infections", "OBSERVATION", 280, 290]]], ["Furthermore, European countries have very different resources dedicated to the continuing development of respiratory professionals.IntroductionKeeping these educational and training challenges in mind, the European Respiratory Society (ERS) decided to support a group of experts in respiratory infections to define the core knowledge and skills considered essential to manage respiratory infections.", [["respiratory", "ANATOMY", 282, 293], ["respiratory", "ANATOMY", 376, 387], ["respiratory infections", "DISEASE", 282, 304], ["respiratory infections", "DISEASE", 376, 398], ["training challenges", "TREATMENT", 173, 192], ["respiratory infections", "PROBLEM", 282, 304], ["respiratory infections", "PROBLEM", 376, 398], ["respiratory professionals", "OBSERVATION", 105, 130], ["respiratory", "ANATOMY", 282, 293], ["infections", "OBSERVATION", 294, 304], ["infections", "OBSERVATION", 388, 398]]], ["The ERS respiratory infections educational task force was founded in 2014 and included 13 experts from six European countries (Italy, Germany, UK, the Netherlands, Spain and Greece).", [["respiratory", "ANATOMY", 8, 19], ["respiratory infections", "DISEASE", 8, 30], ["The ERS respiratory infections", "PROBLEM", 0, 30], ["respiratory", "ANATOMY", 8, 19], ["infections", "OBSERVATION", 20, 30]]], ["The task force had two main aims: 1) to develop a syllabus to guide the national training and education of respiratory physicians in the field of respiratory infections, and 2) to help structure ERS educational activities on respiratory infections.Target audienceAs previously outlined [3], the target audience for the syllabus are qualified respiratory physicians with a special interest in respiratory infections.", [["respiratory", "ANATOMY", 146, 157], ["respiratory", "ANATOMY", 225, 236], ["respiratory", "ANATOMY", 392, 403], ["respiratory infections", "DISEASE", 146, 168], ["respiratory infections", "DISEASE", 225, 247], ["respiratory infections", "DISEASE", 392, 414], ["the national training", "TREATMENT", 68, 89], ["respiratory infections", "PROBLEM", 146, 168], ["respiratory infections", "PROBLEM", 225, 247], ["respiratory infections", "PROBLEM", 392, 414], ["respiratory", "ANATOMY", 146, 157], ["infections", "OBSERVATION", 158, 168], ["respiratory", "ANATOMY", 225, 236], ["infections", "OBSERVATION", 237, 247], ["respiratory", "ANATOMY", 392, 403], ["infections", "OBSERVATION", 404, 414]]], ["Based on the situational analysis and the Delphi surveys, the target audience also includes infectious diseases specialists, intensive care unit specialists, internists, trainees, researchers and microbiologists, working in public hospitals or holding an academic position.MethodsThe approach, methods, and processes used in this project have been adapted from the ERS developed educational harmonisation framework, which, to date, has been used in the development of seven postgraduate curricula (www.ersnet.org/professional-development/ers-curriculum-design-a-summary-of-projects) and four specialised skills-based training programmes [4].MethodsTo develop the syllabus, a list of key topics was identified by the expert task force.", [["infectious diseases", "DISEASE", 92, 111], ["the situational analysis", "TEST", 9, 33], ["the Delphi surveys", "TEST", 38, 56]]], ["A modified Delphi technique was applied to these topics to reach consensus.", [["A modified Delphi technique", "TREATMENT", 0, 27]]], ["The Delphi technique is a group facilitation method that seeks to obtain consensus on the opinions of experts through a series of structured questionnaires [5].", [["a group facilitation method", "TREATMENT", 24, 51]]], ["Research and methods outlined by Heiko [6] were used to guide the decisions taken at various stages of this study, for example survey design, undertaking data collection and analysis.MethodsThe Delphi process was phased in three rounds (figure 1).", [["this study", "TEST", 103, 113], ["undertaking data collection", "TEST", 142, 169], ["analysis", "TEST", 174, 182], ["Delphi process", "OBSERVATION", 194, 208]]], ["Members of ERS Assembly 10 (respiratory infections) and national experts were asked to complete an online questionnaire, which was then processed by the ERS office.", [["respiratory infections", "DISEASE", 28, 50]]], ["Respondents were asked to rate in terms of agreement whether sections should be included (mandatory or optional) or excluded.", [["sections", "ANATOMY", 61, 69]]], ["A Likert scale from 1 (strongly disagree) to 5 (strongly agree) was chosen to ensure measurement reliability over the three different Delphi rounds.", [["A Likert scale", "TEST", 0, 14]]], ["Agreement was operationalised through a majority of responses in the top two points of the scale (measured as the sum of frequencies of agree and strongly agree responses).", [["the scale", "TEST", 87, 96]]], ["In Delphi studies consensus is considered a necessary, but not sufficient, condition for agreement concerning the inclusion of items [6].", [["Delphi studies", "TEST", 3, 17]]], ["Stability was defined as \u201cthe consistency of responses between successive rounds of a study\u201d [7].", [["a study", "TEST", 84, 91]]], ["Both consensus and stability dimensions were investigated in the study.Final syllabusThe content of the syllabus was organised in 14 modules, which were considered important and necessary topics or aspects forming the basis of the respiratory infections domain (table 1).", [["respiratory", "ANATOMY", 231, 242], ["respiratory infections", "DISEASE", 231, 253], ["the study", "TEST", 61, 70], ["the respiratory infections domain", "PROBLEM", 227, 260], ["stability", "OBSERVATION_MODIFIER", 19, 28], ["dimensions", "OBSERVATION_MODIFIER", 29, 39], ["content", "OBSERVATION_MODIFIER", 89, 96], ["syllabus", "ANATOMY", 104, 112], ["14 modules", "OBSERVATION_MODIFIER", 130, 140], ["respiratory", "ANATOMY", 231, 242], ["infections", "OBSERVATION", 243, 253]]]], "PMC7155910": [["The Safety of the Patient ::: To the Editor:Patients with COVID-19 may experience myocardial injury and multiple organ failure, which causes hemodynamic instability coinciding with low oxygen saturation.", [["myocardial", "ANATOMY", 82, 92], ["organ", "ANATOMY", 113, 118], ["myocardial injury", "DISEASE", 82, 99], ["organ failure", "DISEASE", 113, 126], ["oxygen", "CHEMICAL", 185, 191], ["oxygen", "CHEMICAL", 185, 191], ["Patients", "ORGANISM", 44, 52], ["myocardial", "MULTI-TISSUE_STRUCTURE", 82, 92], ["organ", "ORGAN", 113, 118], ["oxygen", "SIMPLE_CHEMICAL", 185, 191], ["Patient", "SPECIES", 18, 25], ["Patients", "SPECIES", 44, 52], ["COVID", "TEST", 58, 63], ["myocardial injury", "PROBLEM", 82, 99], ["multiple organ failure", "PROBLEM", 104, 126], ["hemodynamic instability", "PROBLEM", 141, 164], ["low oxygen saturation", "PROBLEM", 181, 202], ["myocardial", "ANATOMY", 82, 92], ["injury", "OBSERVATION", 93, 99], ["multiple", "OBSERVATION_MODIFIER", 104, 112], ["organ", "ANATOMY", 113, 118], ["failure", "OBSERVATION", 119, 126], ["hemodynamic instability", "OBSERVATION", 141, 164], ["low", "OBSERVATION_MODIFIER", 181, 184], ["oxygen saturation", "OBSERVATION", 185, 202]]], ["The patient\u2019s oxygen reserve is very poor, especially for those who are critically ill.", [["oxygen", "CHEMICAL", 14, 20], ["critically ill", "DISEASE", 72, 86], ["oxygen", "CHEMICAL", 14, 20], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 14, 20], ["patient", "SPECIES", 4, 11], ["critically ill", "PROBLEM", 72, 86], ["oxygen reserve", "OBSERVATION", 14, 28]]], ["This makes intubation a huge challenge.The Safety of the Patient ::: To the Editor:Based on our experience, rapid sequence induction is recommended.", [["Patient", "SPECIES", 57, 64], ["intubation a huge challenge", "TREATMENT", 11, 38], ["rapid sequence induction", "TEST", 108, 132]]], ["To avoid virus scattering, assisted mask ventilation should be avoided.", [["virus scattering", "TREATMENT", 9, 25], ["assisted mask ventilation", "TREATMENT", 27, 52]]], ["If positive mask ventilation is needed based on clinical judgment, we recommended covering the area around the patient\u2019s mouth and nose with wet gauze to help prevent virus spreading.", [["mouth", "ANATOMY", 121, 126], ["nose", "ANATOMY", 131, 135], ["patient", "ORGANISM", 111, 118], ["mouth", "ORGANISM_SUBDIVISION", 121, 126], ["nose", "ORGANISM_SUBDIVISION", 131, 135], ["patient", "SPECIES", 111, 118], ["positive mask ventilation", "TREATMENT", 3, 28], ["clinical judgment", "TEST", 48, 65], ["wet gauze", "TREATMENT", 141, 150], ["virus spreading", "PROBLEM", 167, 182], ["mouth", "ANATOMY", 121, 126], ["nose", "ANATOMY", 131, 135], ["virus", "OBSERVATION", 167, 172]]], ["We believe that muscle relaxants need to be used in such a situation.The Safety of the Patient ::: To the Editor:Tracheal intubation should be performed by an experienced anesthesiologist with an experienced assistant (preferably also an anesthesiologist) and a nurse, to maximize patient safety (fig. 1) and to manage the severe hypoxemia and circulatory failure that might occur.", [["muscle", "ANATOMY", 16, 22], ["Tracheal", "ANATOMY", 113, 121], ["circulatory", "ANATOMY", 344, 355], ["hypoxemia", "DISEASE", 330, 339], ["circulatory failure", "DISEASE", 344, 363], ["muscle", "ORGAN", 16, 22], ["Tracheal", "ORGAN", 113, 121], ["patient", "ORGANISM", 281, 288], ["Patient", "SPECIES", 87, 94], ["patient", "SPECIES", 281, 288], ["muscle relaxants", "TREATMENT", 16, 32], ["Tracheal intubation", "TREATMENT", 113, 132], ["the severe hypoxemia", "PROBLEM", 319, 339], ["circulatory failure", "PROBLEM", 344, 363], ["muscle", "ANATOMY", 16, 22], ["Tracheal", "ANATOMY", 113, 121], ["severe", "OBSERVATION_MODIFIER", 323, 329], ["hypoxemia", "OBSERVATION", 330, 339], ["circulatory failure", "OBSERVATION", 344, 363]]], ["Muscle relaxants are highly recommended.5 The video laryngoscope should be placed as soon as muscle relaxation is achieved, and tracheal intubation should be accomplished and confirmed as soon as possible (less than 15 to 20 s).", [["Muscle", "ANATOMY", 0, 6], ["muscle", "ANATOMY", 93, 99], ["tracheal", "ANATOMY", 128, 136], ["Muscle", "ORGAN", 0, 6], ["muscle", "ORGAN", 93, 99], ["tracheal", "ORGAN", 128, 136], ["Muscle relaxants", "TREATMENT", 0, 16], ["The video laryngoscope", "TREATMENT", 42, 64], ["tracheal intubation", "TREATMENT", 128, 147], ["tracheal", "ANATOMY", 128, 136]]], ["Confirming the depth of the endotracheal tube is extremely difficult using auscultation while wearing isolation suits.", [["endotracheal tube", "ANATOMY", 28, 45], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 28, 45], ["the endotracheal tube", "TREATMENT", 24, 45], ["auscultation", "TEST", 75, 87], ["isolation suits", "TREATMENT", 102, 117], ["depth", "OBSERVATION_MODIFIER", 15, 20], ["endotracheal tube", "OBSERVATION", 28, 45]]], ["It is recommended instead to observe bilateral chest expansion, ventilator breathing waveform, and respiratory parameters.", [["chest", "ANATOMY", 47, 52], ["respiratory", "ANATOMY", 99, 110], ["chest", "ORGANISM_SUBDIVISION", 47, 52], ["bilateral chest expansion", "TEST", 37, 62], ["ventilator breathing waveform", "TEST", 64, 93], ["respiratory parameters", "TEST", 99, 121], ["bilateral", "ANATOMY_MODIFIER", 37, 46], ["chest", "ANATOMY", 47, 52], ["expansion", "OBSERVATION", 53, 62], ["ventilator breathing", "OBSERVATION", 64, 84]]], ["End-tidal CO2 is a better indicator of successful tracheal intubation, as oxygen saturation is not always increased immediately after intubation in these patients, because the oxygen exchange is significantly impaired.The Safety of the Patient ::: To the Editor:Cricoid compression or displacement is needed when exposure of the cord is difficult and the patient\u2019s fasting time is unknown; it is critical that suction is readily available.", [["tracheal", "ANATOMY", 50, 58], ["cord", "ANATOMY", 329, 333], ["CO2", "CHEMICAL", 10, 13], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 176, 182], ["CO2", "CHEMICAL", 10, 13], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 176, 182], ["tracheal", "MULTI-TISSUE_STRUCTURE", 50, 58], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["patients", "ORGANISM", 154, 162], ["oxygen", "SIMPLE_CHEMICAL", 176, 182], ["cord", "ORGAN", 329, 333], ["patient", "ORGANISM", 355, 362], ["patients", "SPECIES", 154, 162], ["Patient", "SPECIES", 236, 243], ["patient", "SPECIES", 355, 362], ["End-tidal CO2", "TEST", 0, 13], ["successful tracheal intubation", "TREATMENT", 39, 69], ["oxygen saturation", "TEST", 74, 91], ["intubation", "TREATMENT", 134, 144], ["the oxygen exchange", "TEST", 172, 191], ["Cricoid compression", "PROBLEM", 262, 281], ["displacement", "PROBLEM", 285, 297], ["tidal CO2", "OBSERVATION", 4, 13], ["tracheal", "ANATOMY", 50, 58], ["intubation", "OBSERVATION", 59, 69], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["oxygen exchange", "OBSERVATION", 176, 191], ["significantly", "OBSERVATION_MODIFIER", 195, 208], ["impaired", "OBSERVATION", 209, 217], ["Cricoid", "ANATOMY", 262, 269], ["compression", "OBSERVATION", 270, 281], ["displacement", "OBSERVATION", 285, 297], ["cord", "ANATOMY", 329, 333]]], ["Repeated tracheal intubation attempts could potentially increase virus spread, so a laryngeal mask should be inserted after an intubation failure.", [["tracheal", "ANATOMY", 9, 17], ["laryngeal", "ANATOMY", 84, 93], ["tracheal", "MULTI-TISSUE_STRUCTURE", 9, 17], ["laryngeal", "ORGAN", 84, 93], ["Repeated tracheal intubation", "TREATMENT", 0, 28], ["increase virus spread", "PROBLEM", 56, 77], ["a laryngeal mask", "TREATMENT", 82, 98], ["an intubation failure", "PROBLEM", 124, 145], ["tracheal", "ANATOMY", 9, 17], ["intubation", "OBSERVATION", 18, 28], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["virus", "OBSERVATION", 65, 70], ["laryngeal", "ANATOMY", 84, 93], ["intubation failure", "OBSERVATION", 127, 145]]], ["Fogging of goggles is a serious problem during rapid intubation, which can make intubation and airway management a major challenge for the care provider.", [["airway", "ANATOMY", 95, 101], ["airway", "MULTI-TISSUE_STRUCTURE", 95, 101], ["a serious problem", "PROBLEM", 22, 39], ["rapid intubation", "TREATMENT", 47, 63], ["intubation", "TREATMENT", 80, 90], ["airway management", "TREATMENT", 95, 112], ["goggles", "OBSERVATION", 11, 18], ["serious", "OBSERVATION_MODIFIER", 24, 31], ["airway", "ANATOMY", 95, 101]]], ["Poor visibility also increases the risk for potential injury and infection.", [["infection", "DISEASE", 65, 74], ["potential injury", "PROBLEM", 44, 60], ["infection", "PROBLEM", 65, 74], ["risk for", "UNCERTAINTY", 35, 43], ["potential", "OBSERVATION_MODIFIER", 44, 53], ["injury", "OBSERVATION", 54, 60], ["infection", "OBSERVATION", 65, 74]]], ["One solution to the problem of fogging may be to cover the inner side of the goggles with a layer of antifogging agent, such as transparent hand sanitizer.The Safety of the Care Providers ::: To the Editor:In a recent report related to 138 confirmed COVID-19 cases, 41.3% were considered acquired infection from the hospital, and more than 70% of these patients were healthcare providers.5 A high level of vigilance is necessary to prevent contracting the infection when intubation is performed.", [["hand", "ANATOMY", 140, 144], ["infection", "DISEASE", 297, 306], ["infection", "DISEASE", 456, 465], ["hand", "ORGANISM_SUBDIVISION", 140, 144], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 353, 361], ["a layer of antifogging agent", "TREATMENT", 90, 118], ["transparent hand sanitizer", "TREATMENT", 128, 154], ["COVID", "TEST", 250, 255], ["acquired infection", "PROBLEM", 288, 306], ["the infection", "PROBLEM", 452, 465], ["intubation", "TREATMENT", 471, 481], ["goggles", "OBSERVATION", 77, 84], ["infection", "OBSERVATION", 297, 306], ["infection", "OBSERVATION", 456, 465]]], ["Standard Level 3 protection5 should be worn by individuals performing the intubation, as shown in figure 1.", [["Standard Level 3 protection5", "TREATMENT", 0, 28], ["the intubation", "TREATMENT", 70, 84]]], ["The recommended Level 3 protection process is as follows: hand disinfection \u2192 head cap \u2192 protective mask N95 1860 \u2192 surgical masks \u2192 isolation gown \u2192 disposable latex gloves \u2192 goggles \u2192 protective clothing \u2192 disposable latex gloves \u2192 shoe covers \u2192 disposable gown \u2192 disposable latex gloves \u2192 full head hood.", [["hand", "ANATOMY", 58, 62], ["head", "ANATOMY", 78, 82], ["head", "ANATOMY", 297, 301], ["hand", "ORGANISM_SUBDIVISION", 58, 62], ["head", "ORGANISM_SUBDIVISION", 78, 82], ["head", "ORGANISM_SUBDIVISION", 297, 301], ["Level 3 protection process", "TREATMENT", 16, 42], ["hand disinfection", "TREATMENT", 58, 75], ["head cap", "TREATMENT", 78, 86], ["protective mask", "TREATMENT", 89, 104], ["surgical masks", "TREATMENT", 116, 130], ["isolation gown", "TREATMENT", 133, 147], ["disposable latex gloves", "TREATMENT", 150, 173], ["protective clothing", "TREATMENT", 186, 205], ["disposable latex gloves", "TREATMENT", 208, 231], ["disposable gown", "TREATMENT", 248, 263], ["disposable latex gloves", "TREATMENT", 266, 289], ["head", "ANATOMY", 297, 301]]], ["Double masks with N95 1860 filter inside, gowns, and double gloves should be worn by the intubation team.", [["Double masks", "TREATMENT", 0, 12], ["gowns", "TREATMENT", 42, 47], ["double gloves", "TREATMENT", 53, 66]]], ["The person who is performing the intubation should wear a third pair of gloves and remove them immediately after intubation.The Safety of the Care Providers ::: To the Editor:Goggles and full protective headgear are necessary during intubation, as shown in figure 1.", [["person", "SPECIES", 4, 10], ["the intubation", "TREATMENT", 29, 43], ["a third pair of gloves", "TREATMENT", 56, 78], ["intubation", "TREATMENT", 113, 123], ["Goggles", "TREATMENT", 175, 182], ["full protective headgear", "TREATMENT", 187, 211], ["intubation", "TREATMENT", 233, 243]]], ["A powered air-purifying respirator system is recommended during the intubation of COVID-19 patients.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["A powered air-purifying respirator system", "TREATMENT", 0, 41]]], ["The outer layer of the protective device is removed after direct patient contact and before touching any equipment or furniture in other areas of the room; hand cleansing with disinfectant-containing alcohol is also necessary.", [["outer layer", "ANATOMY", 4, 15], ["hand", "ANATOMY", 156, 160], ["alcohol", "CHEMICAL", 200, 207], ["alcohol", "CHEMICAL", 200, 207], ["patient", "ORGANISM", 65, 72], ["hand", "ORGANISM_SUBDIVISION", 156, 160], ["alcohol", "SIMPLE_CHEMICAL", 200, 207], ["patient", "SPECIES", 65, 72], ["the protective device", "TREATMENT", 19, 40], ["any equipment", "TREATMENT", 101, 114], ["hand cleansing", "TREATMENT", 156, 170], ["disinfectant", "TREATMENT", 176, 188], ["outer", "OBSERVATION_MODIFIER", 4, 9], ["layer", "OBSERVATION_MODIFIER", 10, 15], ["protective device", "OBSERVATION", 23, 40]]], ["Endotracheal intubation guided by a video laryngoscope with a disposable cover is recommended.", [["Endotracheal", "ANATOMY", 0, 12], ["Endotracheal intubation", "TREATMENT", 0, 23], ["a video laryngoscope", "TREATMENT", 34, 54], ["a disposable cover", "TREATMENT", 60, 78]]], ["Fiber optic intubation is feasible, but disinfection of the fibro bronchoscope system is inconvenient.", [["Fiber optic intubation", "TREATMENT", 0, 22], ["the fibro bronchoscope system", "TREATMENT", 56, 85]]], ["The disposable cover should be removed and exchanged for a new disposable protective device after each intubation before moving to the next patient who needs intubation.", [["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["The disposable cover", "TREATMENT", 0, 20], ["a new disposable protective device", "TREATMENT", 57, 91], ["each intubation", "TREATMENT", 98, 113], ["intubation", "TREATMENT", 158, 168]]], ["The contaminated instruments must not be taken from the contaminated area to a clean area.", [["The contaminated instruments", "TREATMENT", 0, 28], ["contaminated", "OBSERVATION", 4, 16], ["clean", "OBSERVATION", 79, 84]]], ["Particular care is necessary for the removal of potentially contaminated gloves, gowns, masks, and head covers; this contaminated clothing is disposed of as infectious materials.The Safety of the Care Providers ::: To the Editor:In the nonperioperative area, in the event of a difficult intubation, additional personnel and tools may not be immediately available.", [["head", "ANATOMY", 99, 103], ["head", "ORGANISM_SUBDIVISION", 99, 103], ["the removal", "TREATMENT", 33, 44], ["contaminated gloves", "TREATMENT", 60, 79], ["gowns", "TREATMENT", 81, 86], ["masks", "TREATMENT", 88, 93], ["head covers", "TREATMENT", 99, 110], ["this contaminated clothing", "TREATMENT", 112, 138], ["a difficult intubation", "TREATMENT", 275, 297], ["head", "ANATOMY", 99, 103], ["infectious", "OBSERVATION", 157, 167]]], ["A backup plan needs to be established.", [["A backup plan", "TREATMENT", 0, 13]]], ["We have a laryngeal mask readily available.", [["laryngeal", "ANATOMY", 10, 19], ["laryngeal", "ORGAN", 10, 19], ["a laryngeal mask", "TREATMENT", 8, 24], ["laryngeal", "ANATOMY", 10, 19]]], ["In the event of a failed intubation attempt, a laryngeal mask should be used as a temporary bridging method.", [["laryngeal", "ANATOMY", 47, 56], ["laryngeal", "ORGAN", 47, 56], ["a failed intubation attempt", "TREATMENT", 16, 43], ["a laryngeal mask", "TREATMENT", 45, 61], ["a temporary bridging method", "TREATMENT", 80, 107], ["laryngeal", "ANATOMY", 47, 56]]], ["Under these circumstances a bedside tracheostomy should be considered as early as possible.The Safety of the Care Providers ::: To the Editor:In conclusion, special consideration is needed to ensure the highest safety when intubating patients who have COVID-19.Research Support ::: To the Editor:Support was provided solely from institutional and/or departmental sources.Competing Interests ::: To the Editor:The authors declare no competing interests.", [["COVID-19", "CHEMICAL", 252, 260], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 234, 242], ["a bedside tracheostomy", "TREATMENT", 26, 48], ["COVID", "TEST", 252, 257], ["tracheostomy", "OBSERVATION", 36, 48]]]], "PMC7377665": [["IntroductionThe \ufb01rst case of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, and was reported in December 2019.", [["coronavirus disease", "DISEASE", 29, 48], ["COVID-19", "CHEMICAL", 55, 63], ["coronavirus", "ORGANISM", 29, 40], ["coronavirus disease", "PROBLEM", 29, 48], ["COVID", "TEST", 55, 60], ["coronavirus disease", "OBSERVATION", 29, 48]]], ["On January 16, 2020, the \ufb01rst reports of COVID-19 were of\ufb01cially announced by Japan\u2019s Ministry of Health, Labour, and Welfare.", [["COVID", "TEST", 41, 46]]], ["The COVID-19 pandemic is the largest health care crisis of this century.", [["largest", "OBSERVATION_MODIFIER", 29, 36]]], ["A large number of health care workers have died following infection with this virus.", [["infection", "DISEASE", 58, 67], ["infection", "PROBLEM", 58, 67], ["this virus", "PROBLEM", 73, 83], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["infection", "OBSERVATION", 58, 67]]], ["As a consequence, elective surgery was markedly reduced or stopped in the orthopedic department of the hospital, despite its importance in preserving the quality of life and activities of daily living.", [["elective surgery", "TREATMENT", 18, 34], ["reduced", "OBSERVATION_MODIFIER", 48, 55]]], ["A number of lines of evidence indicate that transmission of the virus by asymptomatic patients is possible and that this may have hastened the spread of COVID-19 [1-2].", [["COVID-19", "CHEMICAL", 153, 161], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["the virus", "PROBLEM", 60, 69], ["COVID", "TEST", 153, 158]]], ["Therefore, the management of asymptomatic patients to reduce the infection risk to physicians and medical staff is important to allow orthopedic surgery to be performed safely.", [["infection", "DISEASE", 65, 74], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["the infection risk", "PROBLEM", 61, 79], ["orthopedic surgery", "TREATMENT", 134, 152], ["infection", "OBSERVATION", 65, 74]]], ["Some guidelines for orthopedic procedures have been reported [3-5].", [["orthopedic procedures", "TREATMENT", 20, 41]]], ["Kanagawa Prefecture has the third-highest number of infected patients in Japan.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["infected", "OBSERVATION", 52, 60]]], ["The number of COVID-19-infected patients in Chigasaki City has been relatively small as compared to other cities in Kanagawa Prefecture.", [["COVID-19-infected", "DISEASE", 14, 31], ["COVID-19", "ORGANISM", 14, 22], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 14, 19], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["relatively", "OBSERVATION_MODIFIER", 68, 78], ["small", "OBSERVATION_MODIFIER", 79, 84]]], ["A strategy for the management of orthopedic surgery, including elective surgery, during the pandemic, was needed to maintain orthopedic surgery practice during and after this pandemic.IntroductionLoop-mediated isothermal amplification (LAMP) with simple visual detection of amplification provides rapid analysis in field applications [6].", [["orthopedic surgery", "TREATMENT", 33, 51], ["elective surgery", "TREATMENT", 63, 79], ["orthopedic surgery", "TREATMENT", 125, 143], ["this pandemic", "PROBLEM", 170, 183], ["IntroductionLoop-mediated isothermal amplification", "TREATMENT", 184, 234], ["simple visual detection", "TEST", 247, 270], ["rapid analysis", "TEST", 297, 311]]], ["LAMP was first established as a rapid and reliable method for amplifying a small amount of target sequence at a single reaction temperature, eliminating the requirement for sophisticated thermal cycling equipment.", [["LAMP", "TEST", 0, 4], ["a single reaction temperature", "PROBLEM", 110, 139], ["sophisticated thermal cycling equipment", "TREATMENT", 173, 212]]], ["Previous studies have reported that the LAMP method is useful to detect COVID-19 [7].", [["COVID-19", "CHEMICAL", 72, 80], ["Previous studies", "TEST", 0, 16], ["the LAMP method", "TEST", 36, 51], ["COVID", "TEST", 72, 77]]], ["We hypothesized that the LAMP method would be useful for screening for COVID-19 in asymptomatic patients undergoing orthopedic surgery.Materials and methodsPatients and methodsMaterials and methodsSyonantobu Hospital is located in Chigasaki City in the south-central Kanagawa Prefecture (Figure 1).Materials and methodsThe number of COVID patients were counted by Public Health Centers at six cities: Yokohama, Kawasaki, Sagamihara, Yokosuka, Chigasaki, and Fujisawa City and by public health and welfare offices at four cities, including Kamakura, Atsugi, Hiratsuka, and Odawara.", [["patients", "ORGANISM", 96, 104], ["Patients", "ORGANISM", 156, 164], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 96, 104], ["Patients", "SPECIES", 156, 164], ["patients", "SPECIES", 339, 347], ["the LAMP method", "TEST", 21, 36], ["screening", "TEST", 57, 66], ["COVID", "TEST", 71, 76], ["orthopedic surgery", "TREATMENT", 116, 134], ["Kamakura", "TREATMENT", 539, 547], ["Hiratsuka", "TREATMENT", 557, 566]]], ["We estimated COVID-19 patient numbers in 10 areas of Kanagawa Prefecture from February 12 to May 24, 2020, using information from the Kanagawa Prefecture official home page [8].", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["COVID", "TEST", 13, 18]]], ["We also calculated the approximate incidence of COVID cases in populations in each area.Materials and methodsThis study was approved by the Shonantobu Institutional Review Board (approval number 2020-005).", [["COVID", "DISEASE", 48, 53], ["COVID cases", "TREATMENT", 48, 59], ["This study", "TEST", 109, 119]]], ["Informed consent was obtained from all individual participants.", [["participants", "SPECIES", 50, 62]]], ["A total of 21 patients (age 21-90 y) without symptoms of fever, shortness of breath, or desaturation were included.", [["fever", "DISEASE", 57, 62], ["shortness of breath", "DISEASE", 64, 83], ["desaturation", "DISEASE", 88, 100], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["symptoms", "PROBLEM", 45, 53], ["fever", "PROBLEM", 57, 62], ["shortness of breath", "PROBLEM", 64, 83], ["desaturation", "PROBLEM", 88, 100], ["fever", "OBSERVATION", 57, 62]]], ["Patients underwent LAMP screening using a commercial kit (Loopamp\u00ae, Eiken Chemical Co., Ltd, Tokyo, Japan) for COVID-19 detection one day before surgery.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["LAMP screening", "TEST", 19, 33], ["surgery", "TREATMENT", 145, 152]]], ["Nasopharyngeal samples were used to detect COVID-19.", [["Nasopharyngeal samples", "ANATOMY", 0, 22], ["Nasopharyngeal samples", "CANCER", 0, 22], ["COVID-19", "DNA", 43, 51], ["Nasopharyngeal samples", "TEST", 0, 22], ["COVID", "TEST", 43, 48]]], ["Total viral ribonucleic acid (RNA) was extracted from the specimens using the RNA extraction kit (QIAamp Viral RNA Mini Kit, Qiagen, Hilden, Germany) according to the manufacturer's instructions.", [["specimens", "ANATOMY", 58, 67], ["ribonucleic acid", "CHEMICAL", 12, 28], ["viral ribonucleic acid", "RNA", 6, 28], ["Total viral ribonucleic acid (RNA", "PROBLEM", 0, 33], ["the specimens", "TEST", 54, 67], ["the RNA extraction", "TREATMENT", 74, 92], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["ribonucleic acid", "OBSERVATION", 12, 28]]], ["Isolated RNA reacted with enzyme mix (avian myeloblastosis virus (AMV) reverse transcriptase and Bst DNA polymerase) and primer mix at 62.5\u00b0C for 35 min according to the manufacture\u2019s protocol.", [["avian myeloblastosis virus", "ORGANISM", 38, 64], ["(AMV) reverse transcriptase", "GENE_OR_GENE_PRODUCT", 65, 92], ["Bst", "GENE_OR_GENE_PRODUCT", 97, 100], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["avian myeloblastosis virus (AMV) reverse transcriptase", "PROTEIN", 38, 92], ["Bst DNA polymerase", "PROTEIN", 97, 115], ["avian myeloblastosis virus", "SPECIES", 38, 64], ["avian myeloblastosis virus", "SPECIES", 38, 64], ["AMV", "SPECIES", 66, 69], ["Isolated RNA", "PROBLEM", 0, 12], ["enzyme mix", "TEST", 26, 36], ["avian myeloblastosis virus", "PROBLEM", 38, 64], ["Bst DNA polymerase", "TEST", 97, 115], ["primer mix", "TEST", 121, 131], ["myeloblastosis virus", "OBSERVATION", 44, 64]]], ["Turbidity measurement was carried out at an optical density of 650 nm, and the reaction was considered positive when the turbidity values were >0.1.ResultsEpidemiologyResultsIn Japan, the weekly rate of infection gradually increased from February 2-9 to April 5-11.", [["infection", "DISEASE", 203, 212], ["Turbidity measurement", "TEST", 0, 21], ["the reaction", "PROBLEM", 75, 87], ["the turbidity values", "TEST", 117, 137], ["infection", "PROBLEM", 203, 212], ["650 nm", "OBSERVATION_MODIFIER", 63, 69], ["infection", "OBSERVATION", 203, 212]]], ["After the declaration of the state of emergency, the number of newly infected patients gradually decreased in Kanagawa Prefecture (Figures 2A-2B).ResultsMost cases in Kanagawa Prefecture were concentrated in Yokohama and Kawasaki Cities (Table 1; 530 and 269 patients, respectively).", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 259, 267], ["newly", "OBSERVATION_MODIFIER", 63, 68], ["infected", "OBSERVATION", 69, 77], ["gradually", "OBSERVATION_MODIFIER", 87, 96], ["decreased", "OBSERVATION_MODIFIER", 97, 106]]], ["Twenty-seven cases were observed in Chigasaki City; this rate was lower than that in the other nine areas (Table 1).ResultsIncidence of COVID-19 in patients scheduled to undergo orthopedic surgeryResultsNone of the 21 patients we tested was positive for COVID-19.", [["COVID-19", "CHEMICAL", 136, 144], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 218, 226], ["this rate", "TEST", 52, 61], ["COVID", "TEST", 136, 141], ["orthopedic surgery", "TREATMENT", 178, 196], ["COVID", "TEST", 254, 259], ["surgery", "OBSERVATION", 189, 196]]], ["All underwent orthopedic surgery.", [["orthopedic surgery", "TREATMENT", 14, 32], ["orthopedic", "ANATOMY", 14, 24], ["surgery", "OBSERVATION", 25, 32]]], ["Nine patients requiring fracture repair and one patient with a spinal tumor underwent emergency surgery.", [["spinal tumor", "ANATOMY", 63, 75], ["fracture", "DISEASE", 24, 32], ["spinal tumor", "DISEASE", 63, 75], ["patients", "ORGANISM", 5, 13], ["patient", "ORGANISM", 48, 55], ["spinal tumor", "CANCER", 63, 75], ["patients", "SPECIES", 5, 13], ["patient", "SPECIES", 48, 55], ["fracture repair", "TREATMENT", 24, 39], ["a spinal tumor", "PROBLEM", 61, 75], ["emergency surgery", "TREATMENT", 86, 103], ["fracture repair", "OBSERVATION", 24, 39], ["spinal", "ANATOMY", 63, 69], ["tumor", "OBSERVATION", 70, 75]]], ["Eleven cases, including one each with osteoarthritis, ligament tear, and meniscus tear, underwent elective surgery following negative COVID-19 screening.", [["ligament", "ANATOMY", 54, 62], ["meniscus", "ANATOMY", 73, 81], ["osteoarthritis", "DISEASE", 38, 52], ["ligament tear", "DISEASE", 54, 67], ["meniscus tear", "DISEASE", 73, 86], ["ligament", "TISSUE", 54, 62], ["meniscus", "TISSUE", 73, 81], ["osteoarthritis", "PROBLEM", 38, 52], ["ligament tear", "PROBLEM", 54, 67], ["meniscus tear", "PROBLEM", 73, 86], ["elective surgery", "TREATMENT", 98, 114], ["screening", "TEST", 143, 152], ["osteoarthritis", "OBSERVATION", 38, 52], ["ligament tear", "OBSERVATION", 54, 67], ["meniscus tear", "OBSERVATION", 73, 86]]], ["The clinical characteristics of the patients are listed in Table 2.ResultsAll patients remained asymptomatic after orthopedic surgery during the two to four weeks follow-up.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 78, 86], ["asymptomatic", "PROBLEM", 96, 108], ["orthopedic surgery", "TREATMENT", 115, 133]]], ["No physicians or medical staff developed symptoms of COVID-19.DiscussionThe global COVID-19 pandemic is caused by the SARS-CoV-2 virus and has so caused several million infections, with hundreds of thousands of deaths around the world.", [["COVID", "DISEASE", 53, 58], ["infections", "DISEASE", 169, 179], ["deaths", "DISEASE", 211, 217], ["COVID-19", "CHEMICAL", 53, 61], ["SARS-CoV-2 virus", "ORGANISM", 118, 134], ["CoV-2 virus", "SPECIES", 123, 134], ["SARS-CoV-2 virus", "SPECIES", 118, 134], ["symptoms", "PROBLEM", 41, 49], ["COVID", "TEST", 53, 58], ["The global COVID", "TEST", 72, 88], ["pandemic", "PROBLEM", 92, 100], ["the SARS-CoV-2 virus", "PROBLEM", 114, 134], ["several million infections", "PROBLEM", 153, 179], ["several", "OBSERVATION_MODIFIER", 153, 160], ["million", "OBSERVATION_MODIFIER", 161, 168], ["infections", "OBSERVATION", 169, 179]]], ["Previous studies have reported on emergency orthopedic surgery during a pandemic.", [["Previous studies", "TEST", 0, 16], ["emergency orthopedic surgery", "TREATMENT", 34, 62]]], ["A recent study reported that the occurrence of COVID-19 pneumonia in patients with a fracture can result in severe adverse outcomes and increase mortality [9].", [["pneumonia", "DISEASE", 56, 65], ["fracture", "DISEASE", 85, 93], ["COVID-19", "ORGANISM", 47, 55], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["A recent study", "TEST", 0, 14], ["COVID-19 pneumonia", "PROBLEM", 47, 65], ["a fracture", "PROBLEM", 83, 93], ["severe adverse outcomes", "PROBLEM", 108, 131], ["increase mortality", "PROBLEM", 136, 154], ["pneumonia", "OBSERVATION", 56, 65], ["fracture", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 108, 114]]], ["Surgery was performed following pneumonia and COVID-19 testing under pandemic conditions and significantly improved outcomes.", [["pneumonia", "DISEASE", 32, 41], ["Surgery", "TREATMENT", 0, 7], ["pneumonia", "PROBLEM", 32, 41], ["COVID", "TEST", 46, 51], ["pneumonia", "OBSERVATION", 32, 41]]], ["Upper extremity numbness was resolved in patients with a spinal tumor [10].", [["extremity", "ANATOMY", 6, 15], ["spinal tumor", "ANATOMY", 57, 69], ["Upper extremity numbness", "DISEASE", 0, 24], ["spinal tumor", "DISEASE", 57, 69], ["Upper extremity", "ORGANISM_SUBDIVISION", 0, 15], ["patients", "ORGANISM", 41, 49], ["spinal tumor", "CANCER", 57, 69], ["patients", "SPECIES", 41, 49], ["Upper extremity numbness", "PROBLEM", 0, 24], ["a spinal tumor", "PROBLEM", 55, 69], ["extremity", "ANATOMY", 6, 15], ["numbness", "OBSERVATION", 16, 24], ["spinal", "ANATOMY", 57, 63], ["tumor", "OBSERVATION", 64, 69]]], ["In contrast, the widespread recommendation to postpone elective operations in the US during the pandemic has produced a large population of patients with hip and knee osteoarthritis who are unable to receive their recommended surgical treatment [11].", [["hip", "ANATOMY", 154, 157], ["knee", "ANATOMY", 162, 166], ["osteoarthritis", "DISEASE", 167, 181], ["patients", "ORGANISM", 140, 148], ["hip", "ORGANISM_SUBDIVISION", 154, 157], ["knee", "ORGANISM_SUBDIVISION", 162, 166], ["patients", "SPECIES", 140, 148], ["postpone elective operations", "TREATMENT", 46, 74], ["the US", "TEST", 78, 84], ["hip and knee osteoarthritis", "PROBLEM", 154, 181], ["surgical treatment", "TREATMENT", 226, 244], ["large", "OBSERVATION_MODIFIER", 120, 125], ["population", "OBSERVATION", 126, 136], ["hip", "ANATOMY", 154, 157], ["knee", "ANATOMY", 162, 166], ["osteoarthritis", "OBSERVATION", 167, 181]]], ["In our cases, we performed both emergency and elective surgery following COVID-19 screening with LAMP during a declared state of emergency in Japan.", [["elective surgery", "TREATMENT", 46, 62], ["COVID", "TEST", 73, 78], ["LAMP", "TREATMENT", 97, 101]]], ["No complications were observed after surgery in any patient.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["complications", "PROBLEM", 3, 16], ["surgery", "TREATMENT", 37, 44], ["complications", "OBSERVATION", 3, 16]]], ["During the study period, 1324 COVID-19 cases were reported in Kanagawa Prefecture.", [["COVID", "TEST", 30, 35]]], ["However, COVID-19 cases in Chigasaki City, where our hospital is located, were lower than in other cities.", [["lower", "OBSERVATION_MODIFIER", 79, 84]]], ["Our experience with LAMP screening may provide a strategy to begin orthopedic surgery, including elective surgery, in asymptomatic patients with orthopedic problems in a post-pandemic future.DiscussionA previous study found the colorimetric LAMP assay provided 100% agreement with quantitative reverse transcription-polymerase chain reaction (RT-qPCR) results across a range of Cq values and rapidly detects COVID-19 [7].", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["LAMP screening", "TEST", 20, 34], ["orthopedic surgery", "TREATMENT", 67, 85], ["elective surgery", "TREATMENT", 97, 113], ["orthopedic problems", "PROBLEM", 145, 164], ["previous study", "TEST", 203, 217], ["the colorimetric LAMP assay", "TEST", 224, 251], ["quantitative reverse transcription", "TEST", 281, 315], ["polymerase chain reaction", "PROBLEM", 316, 341], ["RT-qPCR", "TEST", 343, 350], ["Cq values", "TEST", 378, 387], ["COVID", "TEST", 408, 413]]], ["Here, we used the LAMP method as a rapid detection tool to test asymptomatic patients with orthopedic problems.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["the LAMP method", "TREATMENT", 14, 29], ["a rapid detection tool", "TEST", 33, 55], ["orthopedic problems", "PROBLEM", 91, 110]]], ["A LAMP assay screening may be important to ensure the safety of the medical staff and other patients.DiscussionSome studies have reported that concerns have been raised about the poor sensitivity of nucleic acid-based tests.", [["nucleic acid", "CHEMICAL", 199, 211], ["patients", "ORGANISM", 92, 100], ["nucleic acid", "SIMPLE_CHEMICAL", 199, 211], ["patients", "SPECIES", 92, 100], ["A LAMP assay screening", "TEST", 0, 22], ["nucleic acid", "TEST", 199, 211]]], ["The sensitivity of PCR was this might be as low as 59% [12].", [["PCR", "TEST", 19, 22]]], ["Therefore, further investigations with larger sample sizes are needed to clarify the usefulness of the LAMP method to identify a COVID-19 infection in patients requiring orthopedic surgery in the post-pandemic future.ConclusionsA total of 21 patients gave permission to undergo LAMP screening the day before orthopedic surgery.", [["infection", "DISEASE", 138, 147], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 242, 250], ["further investigations", "TEST", 11, 33], ["larger sample sizes", "TREATMENT", 39, 58], ["the LAMP method", "TEST", 99, 114], ["a COVID-19 infection", "PROBLEM", 127, 147], ["orthopedic surgery", "TREATMENT", 170, 188], ["LAMP screening", "TEST", 278, 292], ["orthopedic surgery", "TREATMENT", 308, 326], ["infection", "OBSERVATION", 138, 147]]], ["None of the patients we tested was positive for COVID-19.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 48, 53]]], ["All patients remained asymptomatic during the two to four weeks of postoperative follow-up.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["asymptomatic", "PROBLEM", 22, 34], ["asymptomatic", "OBSERVATION", 22, 34]]], ["No physicians or medical staff developed COVID-19 symptoms.", [["COVID-19 symptoms", "PROBLEM", 41, 58]]], ["LAMP screening may provide a strategy to begin orthopedic surgery, including elective surgery, in asymptomatic patients with orthopedic problems in a post-pandemic future.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["LAMP screening", "TEST", 0, 14], ["orthopedic surgery", "TREATMENT", 47, 65], ["elective surgery", "TREATMENT", 77, 93], ["orthopedic problems", "PROBLEM", 125, 144]]]], "48d99a6bf233596d6c4f460689e9af0d0ee42e73": [["To the Editor:The ongoing pandemic of the Coronavirus infection (COVID-19) and its restrictive measures may lead to widespread fear, anxiety and panic, which can escalate into further negative psychological reactions, including adjustment disorder, depression and changes in sexual behaviour [1] .", [["Coronavirus infection", "DISEASE", 42, 63], ["anxiety", "DISEASE", 133, 140], ["panic", "DISEASE", 145, 150], ["adjustment disorder", "DISEASE", 228, 247], ["depression", "DISEASE", 249, 259], ["the Coronavirus infection", "PROBLEM", 38, 63], ["COVID", "TEST", 65, 70], ["its restrictive measures", "TREATMENT", 79, 103], ["anxiety", "PROBLEM", 133, 140], ["panic", "PROBLEM", 145, 150], ["further negative psychological reactions", "PROBLEM", 176, 216], ["adjustment disorder", "PROBLEM", 228, 247], ["depression", "PROBLEM", 249, 259], ["changes in sexual behaviour", "PROBLEM", 264, 291], ["Coronavirus", "OBSERVATION_MODIFIER", 42, 53], ["infection", "OBSERVATION", 54, 63]]], ["Clinical depression is often associated with a reduction in sexual interest and sexual response, an association that may be more marked in women than in men [2] .To the Editor:In this report, we present the preliminary results of an online survey conducted during the quarantine in Italy.", [["depression", "DISEASE", 9, 19], ["women", "ORGANISM", 139, 144], ["men", "ORGANISM", 153, 156], ["women", "SPECIES", 139, 144], ["men", "SPECIES", 153, 156], ["Clinical depression", "PROBLEM", 0, 19], ["depression", "OBSERVATION", 9, 19]]], ["We aimed to assess the impact of the quarantine due to COVID-19 on psychological (in particular anxiety and depression symptoms) and sexual well-being.", [["anxiety", "DISEASE", 96, 103], ["depression", "DISEASE", 108, 118], ["COVID", "TEST", 55, 60], ["anxiety", "PROBLEM", 96, 103], ["depression symptoms", "PROBLEM", 108, 127]]], ["The sample was drawn through posts on social networks (Instagram \u00ae and Facebook \u00ae ) and the survey was administered online through Google Forms.", [["The sample", "TEST", 0, 10]]], ["Participants completed the survey with questions about their sexual habits they had before and during the quarantine ( Table 1 ).", [["Participants", "SPECIES", 0, 12]]], ["The Beck Depression Inventory (BDI-II) [3] in its Italian validated version [4] and the Beck Anxiety Inventory (BAI) [5] in the Italian validated version [4] were used.", [["The Beck Depression Inventory", "PROBLEM", 0, 29]]], ["Moreover, sexual satisfaction was evaluated by asking the question \"Overall, how satisfied are you with your sex life during quarantine on a scale ranging from 1 (not at all satisfied) to 5 (extremely satisfied)?\" and people were asked \"Have you been quarantined as positive for COVID-19?\".", [["people", "ORGANISM", 218, 224], ["people", "SPECIES", 218, 224]]], ["The survey also investigated items about autoerotism during and before quarantine.", [["autoerotism", "PROBLEM", 41, 52]]], ["Supplementary Table 1 shows the questions of the survey.To the Editor:A total of 1515 respondents were involved in the study.", [["respondents", "ORGANISM", 86, 97], ["the study", "TEST", 115, 124]]], ["None of the participants were quarantined as positive for COVID-19.", [["participants", "ORGANISM", 12, 24], ["participants", "SPECIES", 12, 24], ["COVID", "TEST", 58, 63]]], ["Median age was 21.0 (interquartile range [IQR]: 19.0-25.0), median BDI score was 10.0 (IQR: 5.0-16.0) and median BAI score was 11.0 (IQR: 6.0-20.0).", [["Median age", "TEST", 0, 10], ["IQR", "TEST", 42, 45], ["median BDI score", "TEST", 60, 76], ["IQR", "TEST", 87, 90], ["median BAI score", "TEST", 106, 122], ["IQR", "TEST", 133, 136]]], ["Moreover, 602 (39.74%) respondents answered that quarantine increased autoerotism more than before.", [["autoerotism", "DISEASE", 70, 81], ["quarantine increased autoerotism", "PROBLEM", 49, 81], ["increased", "OBSERVATION_MODIFIER", 60, 69]]], ["Although only 7.46% of the participants reported \"no satisfaction\" before the quarantine, 53.53% complained about that during the quarantine (p < 0.01).", [["participants", "ORGANISM", 27, 39], ["participants", "SPECIES", 27, 39]]], ["We found that women had greater depression (BDI-male: 8.", [["depression", "DISEASE", 32, 42], ["women", "ORGANISM", 14, 19], ["women", "SPECIES", 14, 19], ["greater depression", "PROBLEM", 24, 42]]], ["At the multivariate logistic regression analysis, we found that age (odds ratio [OR]: 0.96; p < 0.01) and BDI (OR: 1.07; p < 0.01) in male and age (OR: 0.96; p < 0.01), BDI (OR: 1.03; p < 0.01) and \"knowing people positive at COVID\" (OR: 0.78; 0.05) in women were significant predictors of sexual dissatisfaction.To the Editor:We interestingly found that more than 40% of the respondents reported an increased sexual desire during the quarantine, compared to baseline.", [["increased sexual desire", "DISEASE", 400, 423], ["people", "ORGANISM", 207, 213], ["women", "ORGANISM", 253, 258], ["people", "SPECIES", 207, 213], ["women", "SPECIES", 253, 258], ["ratio", "TEST", 74, 79], ["p", "TEST", 92, 93], ["BDI", "TEST", 106, 109], ["p", "TEST", 121, 122], ["p", "TEST", 158, 159], ["BDI", "TEST", 169, 172], ["p", "TEST", 184, 185], ["sexual dissatisfaction", "PROBLEM", 290, 312], ["sexual dissatisfaction", "OBSERVATION", 290, 312], ["increased", "OBSERVATION_MODIFIER", 400, 409]]], ["Moreover, sexual satisfaction significantly decreased during the quarantine, with more than half of the respondents describing a complete absence of sexual satisfaction, compared with only 7.46% of people before the lockdown.", [["people", "ORGANISM", 198, 204], ["people", "SPECIES", 198, 204], ["sexual satisfaction", "PROBLEM", 10, 29], ["decreased", "OBSERVATION_MODIFIER", 44, 53]]], ["These results can be partly explained by a self-reported increase of autoerotism in 40% of the participants and a high prevalence of pornography use between the responders; in fact, it is widely accepted that pornography use is associated with decreased sexual satisfaction [6] .To the Editor:The limitations of this online survey include the sampling process, the lack of validated questionnaires about sexual activity and the recall bias for questions assessing sexual function before the quarantine.", [["autoerotism", "DISEASE", 69, 80], ["participants", "SPECIES", 95, 107], ["autoerotism", "PROBLEM", 69, 80], ["increase", "OBSERVATION_MODIFIER", 57, 65]]], ["We found that lower age and higher depression score were significant predictors of sexual dissatisfaction in both genders.", [["depression", "DISEASE", 35, 45], ["higher depression score", "PROBLEM", 28, 51], ["sexual dissatisfaction", "PROBLEM", 83, 105], ["lower", "OBSERVATION_MODIFIER", 14, 19]]], ["Interestingly, we found that women who knew patients positive for COVID-19 were at a reduced risk of sexual satisfaction, may be due to the mitigation of stress secondary to a better knowledge of the disease itself.", [["women", "ORGANISM", 29, 34], ["patients", "ORGANISM", 44, 52], ["women", "SPECIES", 29, 34], ["patients", "SPECIES", 44, 52], ["COVID", "TEST", 66, 71], ["sexual satisfaction", "PROBLEM", 101, 120], ["stress", "PROBLEM", 154, 160], ["the disease itself", "PROBLEM", 196, 214], ["disease", "OBSERVATION", 200, 207]]], ["Further analyses and longer follow-up after the quarantine are required in order to confirm these preliminary results and to investigate different changes in sexual health.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Compliance with ethical standardsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["Further analyses", "TEST", 0, 16], ["different changes in sexual health", "PROBLEM", 137, 171], ["ethical standards", "TREATMENT", 188, 205], ["ethical standards", "TREATMENT", 301, 318]]]], "PMC7523171": [["IntroductionCoronavirus disease 2019 (COVID-19), a viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a pandemic affecting different aspects of acute ischemic stroke (AIS) care.1 In addition to a delay in AIS care, such as endovascular thrombectomy (EVT), there has been a significant decline in AIS hospitalizations and procedures.2\u20135 Previous studies demonstrated an association between COIVD-19 and poor outcome in patients presenting with AIS.6 7IntroductionThe effect of COIVD-19 on the clinical outcomes of EVT-treated patients has not been adequately assessed in a diverse sample of United States' hospitals.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["viral infection", "DISEASE", 51, 66], ["acute respiratory syndrome coronavirus", "DISEASE", 84, 122], ["acute ischemic stroke", "DISEASE", 197, 218], ["AIS", "DISEASE", 220, 223], ["AIS", "DISEASE", 258, 261], ["AIS", "DISEASE", 349, 352], ["AIS", "DISEASE", 496, 499], ["COIVD-19", "CHEMICAL", 529, 537], ["COIVD-19", "CHEMICAL", 529, 537], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 77, 124], ["SARS-CoV-2", "ORGANISM", 126, 136], ["COIVD-19", "GENE_OR_GENE_PRODUCT", 442, 450], ["patients", "ORGANISM", 471, 479], ["COIVD-19", "GENE_OR_GENE_PRODUCT", 529, 537], ["EVT", "CELL", 566, 569], ["patients", "ORGANISM", 578, 586], ["patients", "SPECIES", 471, 479], ["patients", "SPECIES", 578, 586], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 77, 122], ["SARS-CoV-2", "SPECIES", 126, 136], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a viral infection", "PROBLEM", 49, 66], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 77, 122], ["SARS-CoV", "TEST", 126, 134], ["a pandemic", "PROBLEM", 155, 165], ["acute ischemic stroke", "PROBLEM", 197, 218], ["a delay in AIS care", "TREATMENT", 247, 266], ["endovascular thrombectomy", "TREATMENT", 276, 301], ["a significant decline in AIS hospitalizations", "PROBLEM", 324, 369], ["procedures", "TREATMENT", 374, 384], ["Previous studies", "TEST", 389, 405], ["COIVD", "TEST", 442, 447], ["AIS", "PROBLEM", 496, 499], ["COIVD", "TEST", 529, 534], ["viral infection", "OBSERVATION", 51, 66], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory syndrome", "OBSERVATION", 90, 110], ["pandemic", "OBSERVATION", 157, 165], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["ischemic", "OBSERVATION_MODIFIER", 203, 211], ["stroke", "OBSERVATION", 212, 218], ["thrombectomy", "OBSERVATION", 289, 301], ["significant", "OBSERVATION_MODIFIER", 326, 337], ["decline", "OBSERVATION_MODIFIER", 338, 345]]], ["Furthermore, it is unclear if the outcome of EVT-treated AIS patients with comorbid COVID-19 is different than AIS patients with COVID-19 who do not undergo EVT, such as lacunar stroke or non-occlusive atherosclerotic stroke.", [["lacunar", "ANATOMY", 170, 177], ["atherosclerotic", "ANATOMY", 202, 217], ["AIS", "DISEASE", 57, 60], ["lacunar stroke", "DISEASE", 170, 184], ["atherosclerotic stroke", "DISEASE", 202, 224], ["EVT", "CELL", 45, 48], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 115, 123], ["EVT", "TEST", 45, 48], ["comorbid COVID", "TEST", 75, 89], ["COVID", "TEST", 129, 134], ["EVT", "TREATMENT", 157, 160], ["lacunar stroke", "PROBLEM", 170, 184], ["non-occlusive atherosclerotic stroke", "PROBLEM", 188, 224], ["EVT", "OBSERVATION", 157, 160], ["lacunar", "OBSERVATION_MODIFIER", 170, 177], ["stroke", "OBSERVATION", 178, 184], ["non-occlusive", "OBSERVATION_MODIFIER", 188, 201], ["atherosclerotic", "OBSERVATION_MODIFIER", 202, 217], ["stroke", "OBSERVATION", 218, 224]]], ["In this study of AIS patients treated with EVT from April to July 2020, we compared the outcome of patients with confirmed COVID-19 to those without COVID-19.MethodsWe performed a retrospective analysis using the Vizient Clinical Data Base (CDB), a healthcare analytics platform employed by participating US hospitals.8 Data is entered into the CDB using a combination of the electronic medical record and administrative claim data for purposes of benchmarking clinical performance, costs, and outcomes.", [["AIS", "DISEASE", 17, 20], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 99, 107], ["COVID", "TEST", 123, 128], ["COVID", "TEST", 149, 154], ["a retrospective analysis", "TEST", 178, 202]]], ["The Vizient CDB is a validated administrative database used to answer diverse research questions.9 10 We identified patients whose date of hospital discharge was from April f1 to July 31 2020 and included those with ICD-10 codes for EVT and ischemic stroke (online supplemental table 1).11 12 The concordance between the clinical diagnosis of ischemic stroke and the used ICD-10 codes has previously been shown to be >95%11 and the codes for mechanical thrombectomy are specific to a procedure, making the use of the code without performing the procedure unlikely.", [["ischemic stroke", "DISEASE", 241, 256], ["ischemic stroke", "DISEASE", 343, 358], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["ICD", "TREATMENT", 216, 219], ["EVT", "PROBLEM", 233, 236], ["ischemic stroke", "PROBLEM", 241, 256], ["online supplemental table", "TREATMENT", 258, 283], ["ischemic stroke", "PROBLEM", 343, 358], ["the used ICD", "TREATMENT", 363, 375], ["mechanical thrombectomy", "TREATMENT", 442, 465], ["a procedure", "TREATMENT", 482, 493], ["the procedure", "TREATMENT", 541, 554], ["ischemic", "OBSERVATION_MODIFIER", 241, 249], ["stroke", "OBSERVATION", 250, 256], ["ischemic", "OBSERVATION_MODIFIER", 343, 351], ["stroke", "OBSERVATION", 352, 358], ["thrombectomy", "OBSERVATION", 453, 465]]], ["Patients<18 years of age and those who were in a hospice at the time of admission were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We stratified the cohort by the presence of comorbid COVID-19, determined by the ICD code U07.1, which is reserved for laboratory-confirmed SARS-CoV-2.13 IRB approval was not required for this retrospective study of deidentified data per University of Utah Institutional Review Board Guidelines.MethodsThe primary outcome was in-hospital death.", [["COVID", "DISEASE", 53, 58], ["death", "DISEASE", 338, 343], ["comorbid COVID", "TEST", 44, 58], ["SARS-CoV", "TEST", 140, 148], ["this retrospective study", "TEST", 188, 212]]], ["Favorable discharge, defined as a discharge to home or acute rehabilitation, was the secondary outcome.", [["acute rehabilitation", "TREATMENT", 55, 75]]], ["We report descriptive statistics stratified by COVID-19 status, and test for significant differences using the chi-squared test, student\u2019s t-test, or Wilcoxon rank-sum tests, as appropriate.", [["COVID", "TEST", 47, 52], ["test", "TEST", 68, 72], ["the chi-squared test", "TEST", 107, 127], ["student\u2019s t-test", "TEST", 129, 145], ["sum tests", "TEST", 164, 173]]], ["We also stratified hospitals by their monthly volume of AIS EVT cases with low volume (<5 cases/month), medium volume (5\u201310 cases/month), and high volume (>10 cases/month) stratum, and report the primary and secondary outcomes in the stratifications.", [["low volume", "PROBLEM", 75, 85], ["medium volume", "TEST", 104, 117]]], ["Consistent with Vizient regulations for deidentification, we have suppressed values for cell counts that are <10, which occurs after stratification.MethodsTo account for patient clustering by hospital and different patient volumes at individual hospitals, we fit mixed-effects (random intercept) logistic regression models to our outcomes with the hospital identifier as a random effect.", [["cell", "ANATOMY", 88, 92], ["cell", "CELL", 88, 92], ["patient", "ORGANISM", 170, 177], ["patient", "ORGANISM", 215, 222], ["patient", "SPECIES", 170, 177], ["patient", "SPECIES", 215, 222], ["Vizient regulations", "TREATMENT", 16, 35], ["deidentification", "PROBLEM", 40, 56], ["cell counts", "TEST", 88, 99], ["Methods", "TREATMENT", 148, 155]]], ["To assess the stability of the results, standard errors and bias-confidence intervals were estimated with 1000 cluster bootstrap replications.14\u201316 The mixed-effects model estimates a separate intercept for each hospital to account for between-hospital differences, such as hospital EVT volume.", [["cluster bootstrap replications", "TREATMENT", 111, 141]]], ["The models were adjusted for: Model 1: patient age, sex, race, ethnicity, and Elixhauser comorbidity score; and Model 2: patient age, sex, race, ethnicity, Elixhauser comorbidity score, acute respiratory failure requiring intubation, acute coronary syndrome, acute renal failure, pulmonary embolism, and hospital length of stay.MethodsAs a sensitivity analysis, we created a cohort of AIS patients who did not undergo EVT but had laboratory-confirmed COVID-19.", [["respiratory", "ANATOMY", 192, 203], ["coronary", "ANATOMY", 240, 248], ["renal", "ANATOMY", 265, 270], ["pulmonary", "ANATOMY", 280, 289], ["Elixhauser comorbidity", "DISEASE", 156, 178], ["acute respiratory failure", "DISEASE", 186, 211], ["acute coronary syndrome", "DISEASE", 234, 257], ["acute renal failure", "DISEASE", 259, 278], ["pulmonary embolism", "DISEASE", 280, 298], ["AIS", "DISEASE", 385, 388], ["patient", "ORGANISM", 39, 46], ["patient", "ORGANISM", 121, 128], ["renal", "ORGAN", 265, 270], ["pulmonary", "ORGAN", 280, 289], ["patients", "ORGANISM", 389, 397], ["patient", "SPECIES", 39, 46], ["patient", "SPECIES", 121, 128], ["patients", "SPECIES", 389, 397], ["Elixhauser comorbidity score", "PROBLEM", 156, 184], ["acute respiratory failure", "PROBLEM", 186, 211], ["intubation", "TREATMENT", 222, 232], ["acute coronary syndrome", "PROBLEM", 234, 257], ["acute renal failure", "PROBLEM", 259, 278], ["pulmonary embolism", "PROBLEM", 280, 298], ["a sensitivity analysis", "TEST", 338, 360], ["COVID", "TEST", 451, 456], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["respiratory failure", "OBSERVATION", 192, 211], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["coronary", "ANATOMY", 240, 248], ["syndrome", "OBSERVATION", 249, 257], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["renal", "ANATOMY", 265, 270], ["failure", "OBSERVATION", 271, 278], ["pulmonary", "ANATOMY", 280, 289], ["embolism", "OBSERVATION", 290, 298]]], ["We compared this cohort to the AIS EVT patients with COVID-19 and fitted our mixed effects' model adjusted for the covariates in Models 1 and 2.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 53, 58]]], ["All analysis was conducted in Stata 16.1 (StataCorp, College Station, TX) and we defined statistical significance as P<0.05.ResultsWe included data from 190 non-federal hospitals in 45 states who, from April 1 to July 31 2020, discharged 3165 AIS patients who underwent EVT.", [["AIS", "DISEASE", 243, 246], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["All analysis", "TEST", 0, 12], ["Stata", "TEST", 30, 35], ["TX", "TREATMENT", 70, 72]]], ["Comorbid SARS-CoV-2 infection was detected in 104/3,165 (3.3%) patients from 49/190 (25.8%) of included hospitals in 17/45 (37.8%) states.", [["SARS-CoV-2 infection", "DISEASE", 9, 29], ["SARS-CoV-2", "ORGANISM", 9, 19], ["patients", "ORGANISM", 63, 71], ["CoV-", "SPECIES", 14, 18], ["patients", "SPECIES", 63, 71], ["SARS-CoV-2", "SPECIES", 9, 19], ["Comorbid SARS", "PROBLEM", 0, 13], ["CoV", "TEST", 14, 17], ["2 infection", "PROBLEM", 18, 29], ["CoV", "OBSERVATION_MODIFIER", 14, 17], ["infection", "OBSERVATION", 20, 29]]], ["The mean (SD) and median (IQR) number of EVTs performed each month at the hospitals were 5.9 (4.0) and 5 (3.3\u20137.8).", [["The mean (SD) and median (IQR) number of EVTs", "TREATMENT", 0, 45]]], ["Because the number of hospitals in the dataset fluctuates by month, to compare the volume of AIS EVT patients we can focus on monthly data.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["monthly data", "TEST", 126, 138]]], ["In June, for example, the mean (SD) volume of AIS EVT patients was 6.0 (4.6) in hospitals without COVID-19 cases vs 6.1 (3.6) (P=0.943) in hospitals with COVID-19 cases.", [["AIS EVT", "ANATOMY", 46, 53], ["AIS", "DISEASE", 46, 49], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["AIS EVT", "TEST", 46, 53], ["COVID", "TEST", 98, 103], ["cases vs", "TEST", 107, 115], ["P", "TEST", 127, 128], ["COVID", "TEST", 154, 159]]], ["Patients with COVID-19 were younger, more likely to be male, black, or Hispanic, had higher rates of diabetes, but were less likely to be smokers or have atrial fibrillation.", [["atrial", "ANATOMY", 154, 160], ["diabetes", "DISEASE", 101, 109], ["atrial fibrillation", "DISEASE", 154, 173], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19], ["diabetes", "PROBLEM", 101, 109], ["atrial fibrillation", "PROBLEM", 154, 173], ["diabetes", "OBSERVATION", 101, 109], ["atrial", "ANATOMY", 154, 160], ["fibrillation", "OBSERVATION", 161, 173]]], ["The proportion of non-Hispanic black patients increased from 16.9% to 26.0%, and Hispanic patients increased from 5.6% to 19.2%, while non-Hispanic whites decreased from 65.4% to 26.0% (P<0.001).", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 90, 98], ["non-Hispanic whites", "TEST", 135, 154], ["non-Hispanic", "OBSERVATION_MODIFIER", 18, 30], ["black", "OBSERVATION_MODIFIER", 31, 36], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["increased", "OBSERVATION_MODIFIER", 99, 108]]], ["Patients with COVID-19 were also more likely to have acute respiratory failure requiring intubation, acute coronary syndrome, and acute renal failure, but not pulmonary embolism.", [["respiratory", "ANATOMY", 59, 70], ["coronary", "ANATOMY", 107, 115], ["renal", "ANATOMY", 136, 141], ["pulmonary", "ANATOMY", 159, 168], ["respiratory failure", "DISEASE", 59, 78], ["acute coronary syndrome", "DISEASE", 101, 124], ["acute renal failure", "DISEASE", 130, 149], ["pulmonary embolism", "DISEASE", 159, 177], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 136, 141], ["pulmonary", "ORGAN", 159, 168], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19], ["acute respiratory failure", "PROBLEM", 53, 78], ["intubation", "TREATMENT", 89, 99], ["acute coronary syndrome", "PROBLEM", 101, 124], ["acute renal failure", "PROBLEM", 130, 149], ["pulmonary embolism", "PROBLEM", 159, 177], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory failure", "OBSERVATION", 59, 78], ["intubation", "OBSERVATION", 89, 99], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["coronary", "ANATOMY", 107, 115], ["syndrome", "OBSERVATION", 116, 124], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["renal", "ANATOMY", 136, 141], ["failure", "OBSERVATION", 142, 149], ["not", "UNCERTAINTY", 155, 158], ["pulmonary", "ANATOMY", 159, 168], ["embolism", "OBSERVATION", 169, 177]]], ["The mean hospital length of stay was longer in patients with COVID-19 vs without (14.2 vs 9.1 days, P<0.001).ResultsThere were 409/3,165 (12.9%) patients who died in hospital and 1,942/3,165 (61.4%) who had a favorable discharge.", [["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 145, 153], ["COVID", "TEST", 61, 66], ["P", "TEST", 100, 101]]], ["Compared with EVT-treated patients without COVID-19, those with COVID-19 were more likely to die in hospital (29.8% vs 12.4%, P<0.001) and less likely to have favorable discharge (47.1% vs 61.8%, P=0.002).", [["EVT", "CELL", 14, 17], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["EVT", "TEST", 14, 17], ["COVID", "TEST", 43, 48], ["COVID", "TEST", 64, 69], ["P", "TEST", 126, 127], ["P", "TEST", 196, 197], ["less likely", "UNCERTAINTY", 139, 150]]], ["In the mixed-effects adjusted logistic regression models, comorbid COVID-19 remained highly associated with in-hospital death (table 2).", [["death", "DISEASE", 120, 125], ["comorbid COVID", "TEST", 58, 72]]], ["The OR for death related to comorbid COVID-19 in Model 1 was 4.48 (95% CI, 3.02 to 6.165) and in Model 2 was 3.37 (95% CI, 1.77 to 6.943).", [["death", "DISEASE", 11, 16], ["COVID", "DISEASE", 37, 42], ["death", "PROBLEM", 11, 16], ["comorbid COVID", "TEST", 28, 42], ["CI", "TEST", 71, 73], ["Model", "TEST", 97, 102], ["CI", "TEST", 119, 121]]], ["Comorbid COVID-19 was associated with lower odds of a favorable discharge in Model 1 (OR 0.43, 95% CI 0.30 to 0.61) and Model 2 (OR 0.58, 95% CI 0.36 to 0.91).ResultsThe primary and secondary outcomes for patients with and without COVID-19 are shown after age stratification in online supplemental table 2.", [["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["Comorbid COVID", "TEST", 0, 14], ["CI", "TEST", 99, 101], ["Model", "TEST", 120, 125], ["CI", "TEST", 142, 144], ["COVID", "TEST", 231, 236]]], ["The largest increase in the rate of death was seen in patients aged 51\u201364 and the lowest increase in patients aged 18\u201350.", [["death", "DISEASE", 36, 41], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 101, 109], ["death", "PROBLEM", 36, 41], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["lowest", "OBSERVATION_MODIFIER", 82, 88], ["increase", "OBSERVATION_MODIFIER", 89, 97]]], ["We also stratified hospitals by <5, 5\u201310, and >10 EVT cases a month and saw a significantly higher rate of death and lower rate of favorable discharge across the EVT volume stratifications (online supplemental table 3).ResultsIn the sensitivity analysis, comparing AIS patients with COVID-19 who did not undergo EVT (n=2139) to AIS EVT patients with COVID-19, there was no difference in the rate of in-hospital death (30.6% vs 29.8%, P=0.868), and AIS EVT patients had a higher rate of favorable discharge (32.4% vs 47.1%, P=0.002).", [["death", "DISEASE", 107, 112], ["death", "DISEASE", 411, 416], ["patients", "ORGANISM", 269, 277], ["patients", "ORGANISM", 336, 344], ["patients", "ORGANISM", 456, 464], ["patients", "SPECIES", 269, 277], ["patients", "SPECIES", 336, 344], ["patients", "SPECIES", 456, 464], ["death", "PROBLEM", 107, 112], ["the EVT volume stratifications", "TREATMENT", 158, 188], ["the sensitivity analysis", "TEST", 229, 253], ["COVID", "TEST", 283, 288], ["COVID", "TEST", 350, 355], ["P", "TEST", 434, 435], ["AIS EVT", "TEST", 448, 455], ["P", "TEST", 523, 524], ["no", "UNCERTAINTY", 370, 372]]], ["In the mixed-effects logistic regression models there was not a significant difference in death, but the AIS patients with COVID-19 who did not undergo EVT had a significantly lower odds of a favorable discharge in Model 2 (OR 0.55, 95% CI 0.34 to 0.89) (table 3).DiscussionIn this study of 3165 hospitalized AIS patients treated with EVT and discharged from April to July 2020, 3.3% of patients had comorbid COVID-19.", [["death", "DISEASE", 90, 95], ["AIS", "DISEASE", 309, 312], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 313, 321], ["patients", "ORGANISM", 387, 395], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 313, 321], ["patients", "SPECIES", 387, 395], ["a significant difference in death", "PROBLEM", 62, 95], ["COVID", "TEST", 123, 128], ["CI", "TEST", 237, 239], ["this study", "TEST", 277, 287], ["EVT", "TREATMENT", 335, 338], ["comorbid COVID", "TEST", 400, 414], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["difference", "OBSERVATION_MODIFIER", 76, 86], ["favorable", "OBSERVATION_MODIFIER", 192, 201]]], ["Despite adjusting for comorbidities, including respiratory failure requiring intubation, acute renal failure, and hospital length of stay, COVID-19 remained a significant predictor of mortality.", [["respiratory", "ANATOMY", 47, 58], ["renal", "ANATOMY", 95, 100], ["respiratory failure", "DISEASE", 47, 66], ["acute renal failure", "DISEASE", 89, 108], ["renal", "ORGAN", 95, 100], ["comorbidities", "PROBLEM", 22, 35], ["respiratory failure", "PROBLEM", 47, 66], ["intubation", "TREATMENT", 77, 87], ["acute renal failure", "PROBLEM", 89, 108], ["respiratory failure", "OBSERVATION", 47, 66], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["renal", "ANATOMY", 95, 100], ["failure", "OBSERVATION", 101, 108]]], ["We also found that COVID-19 was negatively associated with favorable discharge after EVT.", [["COVID-19", "CHEMICAL", 19, 27], ["COVID-19", "GENE_OR_GENE_PRODUCT", 19, 27], ["COVID-19", "DNA", 19, 27], ["COVID", "TEST", 19, 24]]], ["However, AIS EVT patients with COVID-19 had a near identical rate of death as 2139 AIS patients who did not undergo EVT but had COVID-19, suggesting the higher rate of adverse outcomes was inherent to COVID-19 infection.", [["death", "DISEASE", 69, 74], ["AIS", "DISEASE", 83, 86], ["COVID-19", "CHEMICAL", 201, 209], ["infection", "DISEASE", 210, 219], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 87, 95], ["COVID-19", "GENE_OR_GENE_PRODUCT", 201, 209], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 87, 95], ["COVID", "TEST", 31, 36], ["EVT", "TEST", 116, 119], ["COVID", "TEST", 128, 133], ["adverse outcomes", "PROBLEM", 168, 184], ["COVID", "TEST", 201, 206], ["19 infection", "PROBLEM", 207, 219], ["infection", "OBSERVATION", 210, 219]]], ["These results argue that eligible AIS patients with COVID-19 should receive EVT, given the overwhelming benefit of that intervention.17DiscussionSince the beginning of the COVID-19 outbreak, there has been accumulating evidence of an association between COVID-19, stroke, and worse outcomes after stroke, including large-vessel occlusion stroke.5 6 18\u201320 Unlike prior studies, we provide data on AIS EVT patients from a broad sample of 190 United States' hospitals in 45 states.", [["vessel", "ANATOMY", 321, 327], ["AIS", "DISEASE", 34, 37], ["stroke", "DISEASE", 264, 270], ["stroke", "DISEASE", 297, 303], ["occlusion stroke", "DISEASE", 328, 344], ["patients", "ORGANISM", 38, 46], ["vessel", "MULTI-TISSUE_STRUCTURE", 321, 327], ["patients", "ORGANISM", 404, 412], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 404, 412], ["COVID", "TEST", 52, 57], ["EVT", "TREATMENT", 76, 79], ["that intervention", "TREATMENT", 115, 132], ["COVID", "TEST", 254, 259], ["stroke", "PROBLEM", 264, 270], ["stroke", "PROBLEM", 297, 303], ["large-vessel occlusion stroke", "PROBLEM", 315, 344], ["Unlike prior studies", "TEST", 355, 375], ["stroke", "OBSERVATION", 264, 270], ["worse", "OBSERVATION_MODIFIER", 276, 281], ["large", "OBSERVATION_MODIFIER", 315, 320], ["vessel", "ANATOMY", 321, 327], ["occlusion", "OBSERVATION_MODIFIER", 328, 337], ["stroke", "OBSERVATION", 338, 344]]], ["However, because this sample is not generalizable to the United States, we cannot provide reliable data on the incidence and prevalence of COVID-19 in AIS patients undergoing EVT.DiscussionThe higher rate of mortality in patients with COVID-19 is not surprising since COVID-19 has been associated with other complications including acute respiratory failure, acute renal failure, and coagulopathy.21 The most likely explanation for our findings is that patients with COVID-19 were sicker and had more systemic complications than patients without COVID-19, which, in turn, led to worse outcome.", [["respiratory", "ANATOMY", 338, 349], ["renal", "ANATOMY", 365, 370], ["COVID-19", "CHEMICAL", 139, 147], ["AIS", "DISEASE", 151, 154], ["COVID-19", "CHEMICAL", 268, 276], ["acute respiratory failure", "DISEASE", 332, 357], ["acute renal failure", "DISEASE", 359, 378], ["coagulopathy", "DISEASE", 384, 396], ["COVID-19", "CHEMICAL", 235, 243], ["COVID-19", "CHEMICAL", 268, 276], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 221, 229], ["renal", "ORGAN", 365, 370], ["patients", "ORGANISM", 453, 461], ["patients", "ORGANISM", 529, 537], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 453, 461], ["patients", "SPECIES", 529, 537], ["COVID", "TEST", 139, 144], ["EVT", "TREATMENT", 175, 178], ["COVID", "TEST", 235, 240], ["COVID", "TEST", 268, 273], ["other complications", "PROBLEM", 302, 321], ["acute respiratory failure", "PROBLEM", 332, 357], ["acute renal failure", "PROBLEM", 359, 378], ["coagulopathy", "PROBLEM", 384, 396], ["COVID", "TEST", 467, 472], ["systemic complications", "PROBLEM", 501, 523], ["COVID", "TEST", 546, 551], ["acute", "OBSERVATION_MODIFIER", 332, 337], ["respiratory failure", "OBSERVATION", 338, 357], ["acute", "OBSERVATION_MODIFIER", 359, 364], ["renal", "ANATOMY", 365, 370], ["failure", "OBSERVATION", 371, 378], ["coagulopathy", "OBSERVATION", 384, 396], ["most likely explanation for", "UNCERTAINTY", 404, 431]]], ["In addition, COVID-19 may have delayed diagnosis and intervention22 due to the high rates of respiratory illness, sedation, and intubation in this group.", [["respiratory", "ANATOMY", 93, 104], ["respiratory illness", "DISEASE", 93, 112], ["COVID", "TEST", 13, 18], ["intervention22", "TREATMENT", 53, 67], ["respiratory illness", "PROBLEM", 93, 112], ["sedation", "TREATMENT", 114, 122], ["intubation", "TREATMENT", 128, 138], ["respiratory illness", "OBSERVATION", 93, 112]]], ["Although we do not have access to stroke-specific variables such as baseline severity and EVT procedural metrics, the rate of baseline medical comorbidities, as reflected in the Elixhauser comorbidity score, was not different between AIS EVT patient with or without COVID-19.", [["stroke", "DISEASE", 34, 40], ["patient", "ORGANISM", 242, 249], ["patient", "SPECIES", 242, 249], ["stroke", "PROBLEM", 34, 40], ["baseline severity", "PROBLEM", 68, 85], ["baseline medical comorbidities", "PROBLEM", 126, 156], ["COVID", "TEST", 266, 271], ["stroke", "OBSERVATION", 34, 40]]], ["However, it is possible that the AIS EVT patients with COVID-19 presented with more severe stroke and we were not able to capture that, which is a limitation of our analysis.18 20DiscussionOther notable findings of our study are the differences in baseline characteristics for the patients with COVID-19, who were younger than those without COVID-19, with 24.0% of the COVID-19 patients being under the age of 50 compared with 12.7% of patients without COVID-19.", [["stroke", "DISEASE", 91, 97], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 281, 289], ["patients", "ORGANISM", 378, 386], ["patients", "ORGANISM", 436, 444], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 281, 289], ["patients", "SPECIES", 378, 386], ["patients", "SPECIES", 436, 444], ["COVID", "TEST", 55, 60], ["more severe stroke", "PROBLEM", 79, 97], ["our analysis", "TEST", 161, 173], ["our study", "TEST", 215, 224], ["COVID", "TEST", 295, 300], ["COVID", "TEST", 341, 346], ["the COVID", "TEST", 365, 374], ["COVID", "TEST", 453, 458], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["stroke", "OBSERVATION", 91, 97]]], ["This finding could be due to the pro-thrombotic effects of COVID-1919,23 or because elderly patients with COVID-19 may have been deemed too unstable or unlikely to benefit from EVT.", [["COVID-1919,23", "CHEMICAL", 59, 72], ["COVID-1919,23", "CHEMICAL", 59, 72], ["COVID-1919,23", "SIMPLE_CHEMICAL", 59, 72], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["COVID", "TEST", 59, 64], ["COVID", "TEST", 106, 111], ["could be due to", "UNCERTAINTY", 13, 28], ["pro-thrombotic", "OBSERVATION", 33, 47], ["EVT", "OBSERVATION", 177, 180]]], ["The proportion of Hispanic ethnicity among the the COVID-19 patients more than tripled (from 5.6% to 19.2%) and the proportion of black patients almost doubled (from 16.9% to 26.0%), consistent with the health disparities that are well documented for COVID-19.24 25DiscussionOur study has several limitations, mostly related to the use of administrative data, which introduces the possibility of classification bias from improper coding of exposures or outcomes.", [["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 136, 144], ["the the COVID", "TEST", 43, 56], ["COVID", "TEST", 251, 256], ["Our study", "TEST", 275, 284], ["administrative data", "TEST", 339, 358], ["classification bias", "PROBLEM", 396, 415], ["Hispanic", "OBSERVATION_MODIFIER", 18, 26], ["ethnicity", "OBSERVATION", 27, 36], ["black", "OBSERVATION_MODIFIER", 130, 135], ["consistent with", "UNCERTAINTY", 183, 198]]], ["We do not know the location of vessel occlusion, stroke severity, time from stroke onset to EVT, or disease severity.", [["vessel", "ANATOMY", 31, 37], ["vessel occlusion", "DISEASE", 31, 47], ["stroke", "DISEASE", 49, 55], ["stroke", "DISEASE", 76, 82], ["vessel", "MULTI-TISSUE_STRUCTURE", 31, 37], ["vessel occlusion", "PROBLEM", 31, 47], ["stroke severity", "PROBLEM", 49, 64], ["EVT", "PROBLEM", 92, 95], ["disease severity", "PROBLEM", 100, 116], ["vessel", "ANATOMY", 31, 37], ["occlusion", "OBSERVATION", 38, 47]]], ["Therefore, the differences in outcomes between the studied groups could be related to factors that were not accounted for in this study.", [["this study", "TEST", 125, 135]]], ["Second, we identified COVID-19 patients with laboratory-confirmed SARS-CoV-2 infection: therefore, it is possible that asymptomatic patients with COVID-19 were included in the COVID-19 negative group.", [["SARS-CoV-2 infection", "DISEASE", 66, 86], ["patients", "ORGANISM", 31, 39], ["SARS-CoV-2", "ORGANISM", 66, 76], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 132, 140], ["COVID", "TEST", 22, 27], ["laboratory", "TEST", 45, 55], ["SARS", "PROBLEM", 66, 70], ["CoV-2 infection", "PROBLEM", 71, 86], ["COVID", "TEST", 146, 151], ["the COVID", "TEST", 172, 181], ["infection", "OBSERVATION", 77, 86]]], ["The conclusions of our study should also be interpreted in light of the limited sample size and are not generalizable to the United States, representing instead a selection of patients from hospitals with available data.", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["our study", "TEST", 19, 28]]], ["Finally, with the current data we are not able to evaluate the 90-day modified Rankin Scale score, which is a more informative measure of functional outcome after ischemic stroke.26 Despite these limitations, we provide important data on AIS patients treated with EVT in the context of laboratory-confirmed COVID-19 infection.ConclusionIn AIS patients treated with EVT, comorbid COVID-19 infection was associated with in-hospital death and a lower odds of favorable discharge compared with patients without COVID-19, but not compared with AIS patients with COVID-19 who did not undergo EVT.", [["ischemic stroke", "DISEASE", 163, 178], ["AIS", "DISEASE", 238, 241], ["infection", "DISEASE", 316, 325], ["COVID", "DISEASE", 379, 384], ["infection", "DISEASE", 388, 397], ["death", "DISEASE", 430, 435], ["AIS", "DISEASE", 539, 542], ["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 343, 351], ["patients", "ORGANISM", 490, 498], ["patients", "ORGANISM", 543, 551], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 343, 351], ["patients", "SPECIES", 490, 498], ["patients", "SPECIES", 543, 551], ["ischemic stroke", "PROBLEM", 163, 178], ["EVT", "TREATMENT", 264, 267], ["COVID", "TEST", 307, 312], ["infection", "PROBLEM", 316, 325], ["EVT", "TREATMENT", 365, 368], ["comorbid COVID", "TEST", 370, 384], ["infection", "PROBLEM", 388, 397], ["COVID", "TEST", 507, 512], ["COVID", "TEST", 557, 562], ["ischemic", "OBSERVATION_MODIFIER", 163, 171], ["stroke", "OBSERVATION", 172, 178], ["infection", "OBSERVATION", 316, 325], ["infection", "OBSERVATION", 388, 397], ["EVT", "OBSERVATION", 586, 589]]], ["AIS EVT patients with COVID-19 were younger, more likely to be male, black, or Hispanic, and have systemic complications.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["COVID", "TEST", 22, 27], ["systemic complications", "PROBLEM", 98, 120], ["systemic", "OBSERVATION_MODIFIER", 98, 106], ["complications", "OBSERVATION", 107, 120]]]], "PMC7115375": [["IntroductionSevere acute respiratory syndrome (SARS) is caused by a novel coronavirus known as SARS-associated coronavirus (SARS-CoV) and the investigation of the SARS-CoV immunity has garnered significant attention since the worldwide outbreak spreaded to 30 countries in 2003 [1], [2], [3].", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["coronavirus", "DISEASE", 74, 85], ["SARS-associated coronavirus", "DISEASE", 95, 122], ["SARS", "DISEASE", 124, 128], ["SARS", "DISEASE", 163, 167], ["coronavirus", "ORGANISM", 74, 85], ["SARS-associated coronavirus", "ORGANISM", 95, 122], ["SARS-CoV", "ORGANISM", 124, 132], ["SARS-CoV", "ORGANISM", 163, 171], ["coronavirus", "SPECIES", 74, 85], ["SARS-associated coronavirus", "SPECIES", 95, 122], ["SARS-CoV", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 163, 171], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["a novel coronavirus", "PROBLEM", 66, 85], ["SARS", "PROBLEM", 95, 99], ["coronavirus", "PROBLEM", 111, 122], ["the SARS", "PROBLEM", 159, 167], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["The SARS-CoV is an enveloped positive-stranded RNA virus encoding four major structural proteins, known as a spike glycoprotein (S), a small envelope protein (E), an integral membrane glycoprotein (M), and a nucleocapsid RNA-binding protein (N) [4].", [["membrane", "ANATOMY", 175, 183], ["SARS", "DISEASE", 4, 8], ["SARS-CoV", "ORGANISM", 4, 12], ["E", "GENE_OR_GENE_PRODUCT", 159, 160], ["nucleocapsid RNA-binding protein (N)", "GENE_OR_GENE_PRODUCT", 208, 244], ["major structural proteins", "PROTEIN", 71, 96], ["spike glycoprotein", "PROTEIN", 109, 127], ["S", "PROTEIN", 129, 130], ["small envelope protein", "PROTEIN", 135, 157], ["E", "PROTEIN", 159, 160], ["integral membrane glycoprotein", "PROTEIN", 166, 196], ["M", "PROTEIN", 198, 199], ["nucleocapsid RNA-binding protein", "PROTEIN", 208, 240], ["N", "PROTEIN", 242, 243], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["an enveloped positive", "PROBLEM", 16, 37], ["stranded RNA virus", "PROBLEM", 38, 56], ["a small envelope protein (E", "PROBLEM", 133, 160], ["an integral membrane glycoprotein", "TEST", 163, 196], ["a nucleocapsid RNA", "TEST", 206, 224], ["SARS", "OBSERVATION", 4, 8], ["stranded RNA virus", "OBSERVATION", 38, 56], ["small", "OBSERVATION_MODIFIER", 135, 140]]], ["Upon viral infection, the viral proteins expressed within the infected cells are degraded in the cytosol by proteasomes.", [["cells", "ANATOMY", 71, 76], ["cytosol", "ANATOMY", 97, 104], ["viral infection", "DISEASE", 5, 20], ["cells", "CELL", 71, 76], ["cytosol", "CELLULAR_COMPONENT", 97, 104], ["viral proteins", "PROTEIN", 26, 40], ["infected cells", "CELL_TYPE", 62, 76], ["proteasomes", "PROTEIN", 108, 119], ["viral infection", "PROBLEM", 5, 20], ["the viral proteins", "PROBLEM", 22, 40], ["the infected cells", "PROBLEM", 58, 76], ["viral", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 11, 20], ["viral proteins", "OBSERVATION", 26, 40], ["infected cells", "OBSERVATION", 62, 76]]], ["Peptides generated by the proteasomes are transported by the transporter associated with antigen processing (TAP) into the lumen of endoplasmic reticulum (ER), where an ER aminopeptidase produces the mature MHC class I\u2013peptide complex by trimming the peptide to eight or nine amino acids [5].", [["lumen", "ANATOMY", 123, 128], ["endoplasmic reticulum", "ANATOMY", 132, 153], ["ER", "ANATOMY", 155, 157], ["amino acids", "CHEMICAL", 276, 287], ["amino acids", "CHEMICAL", 276, 287], ["antigen", "GENE_OR_GENE_PRODUCT", 89, 96], ["TAP", "GENE_OR_GENE_PRODUCT", 109, 112], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 128], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 132, 153], ["ER", "GENE_OR_GENE_PRODUCT", 155, 157], ["ER aminopeptidase", "GENE_OR_GENE_PRODUCT", 169, 186], ["amino acids", "AMINO_ACID", 276, 287], ["proteasomes", "PROTEIN", 26, 37], ["TAP", "PROTEIN", 109, 112], ["ER", "PROTEIN", 155, 157], ["ER aminopeptidase", "PROTEIN", 169, 186], ["MHC class I\u2013peptide complex", "PROTEIN", 207, 234], ["antigen processing (TAP", "TREATMENT", 89, 112], ["an ER aminopeptidase", "TREATMENT", 166, 186], ["lumen", "ANATOMY_MODIFIER", 123, 128], ["endoplasmic reticulum", "ANATOMY", 132, 153]]], ["The resulting MHC class I\u2013peptide complex expressed on the surface of professional antigen presenting cells, such as dendritic cells, plays important roles in the activation of specific cytotoxic T-cells for infected cell killing.", [["surface", "ANATOMY", 59, 66], ["antigen presenting cells", "ANATOMY", 83, 107], ["dendritic cells", "ANATOMY", 117, 132], ["T-cells", "ANATOMY", 196, 203], ["cell", "ANATOMY", 217, 221], ["MHC class I\u2013peptide", "GENE_OR_GENE_PRODUCT", 14, 33], ["surface", "CELLULAR_COMPONENT", 59, 66], ["cells", "CELL", 102, 107], ["dendritic cells", "CELL", 117, 132], ["T-cells", "CELL", 196, 203], ["cell", "CELL", 217, 221], ["MHC class I\u2013peptide complex", "PROTEIN", 14, 41], ["professional antigen presenting cells", "CELL_TYPE", 70, 107], ["dendritic cells", "CELL_TYPE", 117, 132], ["cytotoxic T-cells", "CELL_TYPE", 186, 203], ["dendritic cells", "PROBLEM", 117, 132], ["infected cell killing", "PROBLEM", 208, 229], ["dendritic cells", "OBSERVATION", 117, 132], ["infected cell killing", "OBSERVATION", 208, 229]]], ["On the other hand, the MHC class I\u2013peptide complexes expressed on the virus infected cells is a \u201cmarker\u201d for being killed.", [["cells", "ANATOMY", 85, 90], ["cells", "CELL", 85, 90], ["MHC class I\u2013peptide complexes", "PROTEIN", 23, 52], ["virus infected cells", "CELL_TYPE", 70, 90], ["the virus infected cells", "PROBLEM", 66, 90]]], ["Therefore, formation of stable MHC class I\u2013peptide complexes is critical to elicit cytotoxic T-cell response to eliminate the infected cells.", [["T-cell", "ANATOMY", 93, 99], ["cells", "ANATOMY", 135, 140], ["T-cell", "CELL", 93, 99], ["cells", "CELL", 135, 140], ["MHC class I\u2013peptide complexes", "PROTEIN", 31, 60], ["infected cells", "CELL_TYPE", 126, 140], ["the infected cells", "PROBLEM", 122, 140], ["stable", "OBSERVATION_MODIFIER", 24, 30], ["infected cells", "OBSERVATION", 126, 140]]], ["Immunogenicity of a peptide sequence for the cytotoxic T-cell is determined by its binding affinity towards the human MHC class I molecule and its availability upon proteasome digestion of the parental protein.", [["T-cell", "ANATOMY", 55, 61], ["T-cell", "CELL", 55, 61], ["human", "ORGANISM", 112, 117], ["cytotoxic T-cell", "CELL_TYPE", 45, 61], ["human MHC class I molecule", "PROTEIN", 112, 138], ["proteasome", "PROTEIN", 165, 175], ["parental protein", "PROTEIN", 193, 209], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["a peptide sequence", "TEST", 18, 36], ["the cytotoxic T-cell", "PROBLEM", 41, 61]]], ["Subunit vaccines containing HLA-A0201 restricted SARS S and N protein peptides can trigger specific human cytotoxic T-cell response against SARS in vitro[12], [14].", [["T-cell", "ANATOMY", 116, 122], ["SARS", "DISEASE", 140, 144], ["HLA-A0201", "GENE_OR_GENE_PRODUCT", 28, 37], ["SARS S", "GENE_OR_GENE_PRODUCT", 49, 55], ["human", "ORGANISM", 100, 105], ["T-cell", "CELL", 116, 122], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["Subunit vaccines", "TREATMENT", 0, 16], ["HLA", "TREATMENT", 28, 31], ["restricted SARS S and N protein peptides", "TREATMENT", 38, 78], ["SARS", "PROBLEM", 140, 144]]], ["In the present study, we have identified a noval HLA-A0201 restricted peptide ::: Materials and methodsThe potential SARS N-protein peptide sequence for human MHC class I binding was searched by a HLA peptide binding prediction program, SYFPEITHI (http://www.syfpeithi.de) [22].", [["human", "ORGANISM", 153, 158], ["MHC class I", "GENE_OR_GENE_PRODUCT", 159, 170], ["human MHC class I", "PROTEIN", 153, 170], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["a noval HLA", "TEST", 41, 52], ["The potential SARS N-protein peptide sequence", "TREATMENT", 103, 148]]], ["Seven nine-amino acid peptides with high scores for human MHC class I binding (N139\u2013147 ALNTPKDHI, N160\u2013168 LQLPQGTTL, N220\u2013228 LALLLLDRL, N223\u2013231 LLLDRLNQL, N227\u2013235 RLNQLESKY, N317\u2013325 GMSRIGMEV, N352\u2013360 ILLNKHID) were synthesized by a solid-phase strategy using the Fmoc-based protocol on an automated peptide synthesizer.", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 11, 21], ["Fmoc", "CHEMICAL", 271, 275], ["human", "ORGANISM", 52, 57], ["MHC class I", "GENE_OR_GENE_PRODUCT", 58, 69], ["human MHC class I", "PROTEIN", 52, 69], ["N160", "PROTEIN", 99, 103], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["amino acid peptides", "TREATMENT", 11, 30], ["ALNTPKDHI", "TEST", 88, 97], ["LQLPQGTTL", "TEST", 108, 117], ["LALLLLDRL", "TEST", 128, 137], ["LLLDRLNQL", "TEST", 148, 157], ["RLNQLESKY", "TEST", 168, 177], ["GMSRIGMEV", "TEST", 188, 197], ["ILLNKHID", "TEST", 208, 216], ["the Fmoc-based protocol", "TREATMENT", 267, 290], ["an automated peptide synthesizer", "TREATMENT", 294, 326]]], ["The peptides were stored in dimethyl sulfoxide (DMSO, Sigma) at \u221280 \u00b0C until use.Expression of recombinant SARS N-protein ::: Materials and methodsThe DNA sequence encoding the N-protein was cloned into a expression vector pET22b (Novagen) and the recombinant N-protein is expressed in a Escherichia coli system BL21-condonplus (DE3)-RIL (Stratagene) followed by purification with Ni-NTA His-Bind Resin (Novagen).", [["dimethyl sulfoxide", "CHEMICAL", 28, 46], ["DMSO", "CHEMICAL", 48, 52], ["Ni-NTA", "CHEMICAL", 381, 387], ["dimethyl sulfoxide", "CHEMICAL", 28, 46], ["DMSO", "CHEMICAL", 48, 52], ["NTA", "CHEMICAL", 384, 387], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 28, 46], ["DMSO", "SIMPLE_CHEMICAL", 48, 52], ["Sigma", "SIMPLE_CHEMICAL", 54, 59], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["N-protein", "GENE_OR_GENE_PRODUCT", 177, 186], ["pET22b", "GENE_OR_GENE_PRODUCT", 223, 229], ["Novagen", "GENE_OR_GENE_PRODUCT", 231, 238], ["N-protein", "GENE_OR_GENE_PRODUCT", 260, 269], ["Escherichia coli", "ORGANISM", 288, 304], ["BL21-condonplus", "ORGANISM", 312, 327], ["DE3)-RIL", "GENE_OR_GENE_PRODUCT", 329, 337], ["Novagen", "GENE_OR_GENE_PRODUCT", 404, 411], ["recombinant SARS N-protein", "PROTEIN", 95, 121], ["DNA sequence", "DNA", 151, 163], ["N-protein", "PROTEIN", 177, 186], ["expression vector pET22b", "DNA", 205, 229], ["Novagen", "PROTEIN", 231, 238], ["recombinant N-protein", "PROTEIN", 248, 269], ["Novagen", "PROTEIN", 404, 411], ["Escherichia coli", "SPECIES", 288, 304], ["BL21-condonplus", "SPECIES", 312, 327], ["Escherichia coli", "SPECIES", 288, 304], ["BL21-condonplus", "SPECIES", 312, 327], ["The peptides", "TREATMENT", 0, 12], ["dimethyl sulfoxide (DMSO", "TREATMENT", 28, 52], ["The DNA sequence", "TEST", 147, 163], ["a expression vector pET22b", "TREATMENT", 203, 229], ["Novagen", "TREATMENT", 231, 238], ["the recombinant N-protein", "TREATMENT", 244, 269], ["a Escherichia coli system", "TREATMENT", 286, 311], ["condonplus (DE3)", "TREATMENT", 317, 333], ["RIL (Stratagene)", "TREATMENT", 334, 350], ["Ni-NTA", "TREATMENT", 381, 387], ["Bind Resin (Novagen)", "TREATMENT", 392, 412], ["Escherichia coli", "OBSERVATION", 288, 304]]], ["After protein purification, the purity and the quantity of the recombinant protein was analyzed by SDS-PAGE analysis.Establishment of a trigger cell-line expressing the SARS N-protein ::: Materials and methodsTo establish a N-protein expressing cell-line for the cytotoxicity assay, lung tissues from the HLA-A2.1Kb transgenic mice were isolated, minced and treated with collagenase (Gibco) at 100 U/ml for 30 min.", [["cell-line", "ANATOMY", 144, 153], ["cell-line", "ANATOMY", 245, 254], ["lung tissues", "ANATOMY", 283, 295], ["cell-line", "CELL", 144, 153], ["cell-line", "CELL", 245, 254], ["lung tissues", "TISSUE", 283, 295], ["mice", "ORGANISM", 327, 331], ["collagenase", "GENE_OR_GENE_PRODUCT", 371, 382], ["recombinant protein", "PROTEIN", 63, 82], ["trigger cell-line", "CELL_LINE", 136, 153], ["SARS N-protein", "PROTEIN", 169, 183], ["N-protein expressing cell-line", "CELL_LINE", 224, 254], ["collagenase", "PROTEIN", 371, 382], ["mice", "SPECIES", 327, 331], ["mice", "SPECIES", 327, 331], ["protein purification", "TREATMENT", 6, 26], ["the purity", "TEST", 28, 38], ["the recombinant protein", "TEST", 59, 82], ["PAGE analysis", "TEST", 103, 116], ["a trigger cell", "TREATMENT", 134, 148], ["a N-protein expressing cell-line", "TREATMENT", 222, 254], ["the cytotoxicity assay", "TEST", 259, 281], ["the HLA", "TEST", 301, 308], ["Kb transgenic mice", "TREATMENT", 313, 331], ["collagenase (Gibco)", "TREATMENT", 371, 390], ["lung", "ANATOMY", 283, 287]]], ["Tissue samples were seeded on a plate and cultured for 1 week, fibroblasts were then collected and immortalized by transduction of a recombinant retrovirus containing the SARS N gene and the HPV16 E6-E7 genes [23].", [["Tissue samples", "ANATOMY", 0, 14], ["fibroblasts", "ANATOMY", 63, 74], ["Tissue samples", "CANCER", 0, 14], ["fibroblasts", "CELL", 63, 74], ["retrovirus", "ORGANISM", 145, 155], ["SARS N", "GENE_OR_GENE_PRODUCT", 171, 177], ["E6-E7", "GENE_OR_GENE_PRODUCT", 197, 202], ["fibroblasts", "CELL_TYPE", 63, 74], ["SARS N gene", "DNA", 171, 182], ["HPV16 E6-E7 genes", "DNA", 191, 208], ["Tissue samples", "TEST", 0, 14], ["a plate", "TEST", 30, 37], ["fibroblasts", "PROBLEM", 63, 74], ["a recombinant retrovirus", "TREATMENT", 131, 155], ["the HPV16 E6", "TEST", 187, 199]]], ["Expression of the N-protein in the lung fibroblast cell-line was confirmed by RT-PCR (with primers: N: sense: 5\u2032-ATGTCTGATAATGG-3\u2032, antisense: 5\u2032-TTATGCCTGAGTTG-3\u2032; E6E7: sense: 5\u2032-ATGTATAAAACTAAGGG CGTAACC-3\u2032, antisense: 5\u2032-TTATGGTTTCTGAGAACAGATGG-3\u2032), and the cell-line is named as N/E6E7/A2.1Kb.Binding assay of the N-protein peptide towards the human MHC class I in T2-cell ::: Materials and methodsThe T2-cell (174 \u00d7 CEM.T2), which are HLA-A2 positive, but deficient for the TAP protein for endogenous antigen presentation, were cultured according to the procedure stated in the ATCC manual.", [["lung fibroblast cell-line", "ANATOMY", 35, 60], ["cell-line", "ANATOMY", 262, 271], ["T2-cell", "ANATOMY", 370, 377], ["T2-cell", "ANATOMY", 407, 414], ["CEM", "ANATOMY", 422, 425], ["N-protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["lung fibroblast cell-line", "CELL", 35, 60], ["cell-line", "CELL", 262, 271], ["human", "ORGANISM", 349, 354], ["MHC class I", "GENE_OR_GENE_PRODUCT", 355, 366], ["T2-cell", "CELL", 370, 377], ["T2-cell", "CELL", 407, 414], ["HLA-A2", "GENE_OR_GENE_PRODUCT", 441, 447], ["TAP", "GENE_OR_GENE_PRODUCT", 480, 483], ["N-protein", "PROTEIN", 18, 27], ["lung fibroblast cell-line", "CELL_LINE", 35, 60], ["E6E7", "DNA", 165, 169], ["N/E6E7/A2.1Kb", "DNA", 284, 297], ["human MHC class I", "PROTEIN", 349, 366], ["T2-cell", "CELL_LINE", 370, 377], ["T2-cell", "CELL_LINE", 407, 414], ["174 \u00d7 CEM", "CELL_LINE", 416, 425], ["T2", "CELL_LINE", 426, 428], ["TAP protein", "PROTEIN", 480, 491], ["human", "SPECIES", 349, 354], ["human", "SPECIES", 349, 354], ["the N-protein in the lung fibroblast cell-line", "TREATMENT", 14, 60], ["sense", "TEST", 103, 108], ["ATGTCTGATAATGG", "TEST", 113, 127], ["antisense", "TEST", 132, 141], ["TTATGCCTGAGTTG", "TEST", 146, 160], ["sense", "TEST", 171, 176], ["ATGTATAAAACTAAGGG", "TEST", 181, 198], ["CGTAACC", "TEST", 199, 206], ["antisense", "TEST", 211, 220], ["TTATGGTTTCTGAGAACAGATGG", "TEST", 225, 248], ["Binding assay", "TEST", 298, 311], ["the N-protein peptide", "TREATMENT", 315, 336], ["HLA", "TEST", 441, 444], ["the TAP protein", "TEST", 476, 491], ["endogenous antigen presentation", "PROBLEM", 496, 527], ["the procedure", "TREATMENT", 556, 569], ["lung", "ANATOMY", 35, 39], ["fibroblast cell", "OBSERVATION", 40, 55]]], ["To determine whether the selected N-protein peptides could bind to the human MHC class I molecule, the T2-cells (1 \u00d7 105) were pulsed with each of the N-protein peptides (10 \u03bcg/ml) in the presence of 5 \u03bcg/ml human \u03b22-microglobulin (Sigma) for 4 h.", [["T2-cells", "ANATOMY", 103, 111], ["human", "ORGANISM", 71, 76], ["T2-cells", "CELL", 103, 111], ["human", "ORGANISM", 208, 213], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 214, 230], ["Sigma", "SIMPLE_CHEMICAL", 232, 237], ["human MHC class I molecule", "PROTEIN", 71, 97], ["T2-cells", "CELL_LINE", 103, 111], ["human \u03b22-microglobulin", "PROTEIN", 208, 230], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 208, 213], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 208, 213], ["the selected N-protein peptides", "TREATMENT", 21, 52], ["the T2-cells", "TEST", 99, 111], ["the N-protein peptides", "TREATMENT", 147, 169]]], ["After peptide pulsing, the T2-cells were washed twice with cold PBS containing 2% FBS and then stained with a mouse anti-human HLA-A2 antibody (BB7.2) followed by a goat anti-mouse IgG FITC antibody (Zymed).", [["T2-cells", "ANATOMY", 27, 35], ["FBS", "ANATOMY", 82, 85], ["FITC", "CHEMICAL", 185, 189], ["T2-cells", "CELL", 27, 35], ["FBS", "ORGANISM_SUBSTANCE", 82, 85], ["mouse", "ORGANISM", 110, 115], ["HLA-A2 antibody", "GENE_OR_GENE_PRODUCT", 127, 142], ["goat", "ORGANISM", 165, 169], ["Zymed", "GENE_OR_GENE_PRODUCT", 200, 205], ["T2-cells", "CELL_LINE", 27, 35], ["mouse anti-human HLA-A2 antibody", "PROTEIN", 110, 142], ["BB7", "PROTEIN", 144, 147], ["goat anti-mouse IgG FITC antibody", "PROTEIN", 165, 198], ["Zymed", "PROTEIN", 200, 205], ["mouse", "SPECIES", 110, 115], ["goat", "SPECIES", 165, 169], ["anti-mouse", "SPECIES", 170, 180], ["mouse", "SPECIES", 110, 115], ["goat", "SPECIES", 165, 169], ["peptide pulsing", "TREATMENT", 6, 21], ["cold PBS", "TREATMENT", 59, 67], ["2% FBS", "TEST", 79, 85], ["a mouse anti-human HLA", "TEST", 108, 130], ["BB7", "TEST", 144, 147], ["a goat anti-mouse IgG FITC antibody", "TEST", 163, 198]]], ["The peptide bound T2-cells were fixed with 1% paraformaldehyde (Sigma) and subjected to flow cytometry to measure the relative amount of MHC class I/peptide complexes formed.", [["T2-cells", "ANATOMY", 18, 26], ["paraformaldehyde", "CHEMICAL", 46, 62], ["T2-cells", "CELL", 18, 26], ["paraformaldehyde", "SIMPLE_CHEMICAL", 46, 62], ["Sigma", "SIMPLE_CHEMICAL", 64, 69], ["T2-cells", "CELL_LINE", 18, 26], ["MHC class I/peptide complexes", "PROTEIN", 137, 166], ["The peptide bound T2", "TEST", 0, 20], ["flow cytometry", "TEST", 88, 102], ["flow cytometry", "OBSERVATION", 88, 102], ["amount", "OBSERVATION_MODIFIER", 127, 133]]], ["The results were presented as the fluorescent index (FI) calculated by the mean fluorescence intensity (MFI) of T2 cells using the formula:FI=MFI (T2+peptide)MFI (T2 only)\u22121", [["T2 cells", "ANATOMY", 112, 120], ["T2 cells", "CELL", 112, 120], ["T2 cells", "CELL_LINE", 112, 120], ["the fluorescent index", "TEST", 30, 51], ["the mean fluorescence intensity", "TEST", 71, 102], ["MFI (T2+peptide)", "TREATMENT", 142, 158]]]], "PMC3722178": [["IntroductionRespiratory tract cells are structurally and functionally different in the upper respiratory tract (nasal and sinusoidal epithelia), conducting airways (tracheal and bronchial epithelia), and alveoli (alveolar epithelia).", [["IntroductionRespiratory tract cells", "ANATOMY", 0, 35], ["upper respiratory tract", "ANATOMY", 87, 110], ["nasal", "ANATOMY", 112, 117], ["sinusoidal epithelia", "ANATOMY", 122, 142], ["airways", "ANATOMY", 156, 163], ["tracheal", "ANATOMY", 165, 173], ["bronchial epithelia", "ANATOMY", 178, 197], ["alveoli", "ANATOMY", 204, 211], ["alveolar epithelia", "ANATOMY", 213, 231], ["IntroductionRespiratory tract cells", "CELL", 0, 35], ["upper", "ORGANISM_SUBDIVISION", 87, 92], ["respiratory tract", "ORGANISM_SUBDIVISION", 93, 110], ["nasal", "ORGANISM_SUBDIVISION", 112, 117], ["sinusoidal epithelia", "TISSUE", 122, 142], ["airways", "MULTI-TISSUE_STRUCTURE", 156, 163], ["tracheal", "MULTI-TISSUE_STRUCTURE", 165, 173], ["bronchial epithelia", "TISSUE", 178, 197], ["alveoli", "MULTI-TISSUE_STRUCTURE", 204, 211], ["alveolar epithelia", "TISSUE", 213, 231], ["IntroductionRespiratory tract cells", "CELL_TYPE", 0, 35], ["IntroductionRespiratory tract cells", "PROBLEM", 0, 35], ["the upper respiratory tract (nasal and sinusoidal epithelia", "PROBLEM", 83, 142], ["conducting airways (tracheal and bronchial epithelia)", "PROBLEM", 145, 198], ["alveoli (alveolar epithelia", "PROBLEM", 204, 231], ["tract cells", "OBSERVATION", 24, 35], ["functionally", "OBSERVATION_MODIFIER", 57, 69], ["different", "OBSERVATION_MODIFIER", 70, 79], ["upper", "ANATOMY_MODIFIER", 87, 92], ["respiratory tract", "ANATOMY", 93, 110], ["nasal", "ANATOMY", 112, 117], ["sinusoidal epithelia", "OBSERVATION", 122, 142], ["airways", "ANATOMY", 156, 163], ["tracheal", "ANATOMY", 165, 173], ["bronchial epithelia", "ANATOMY", 178, 197], ["alveoli", "ANATOMY_MODIFIER", 204, 211], ["alveolar", "ANATOMY_MODIFIER", 213, 221], ["epithelia", "ANATOMY_MODIFIER", 222, 231]]], ["Because they are the natural target cells for respiratory virus infection, primary human respiratory epithelial cell cultures provide the ideal in vitro systems for investigation of cell factors required for growth of respiratory human viruses, for analysis of their interactions with viruses and their innate immune responses to infection, and for isolation and propagation of novel respiratory pathogens.", [["cells", "ANATOMY", 36, 41], ["respiratory epithelial cell cultures", "ANATOMY", 89, 125], ["cell", "ANATOMY", 182, 186], ["respiratory virus infection", "DISEASE", 46, 73], ["infection", "DISEASE", 330, 339], ["respiratory pathogens", "DISEASE", 384, 405], ["cells", "CELL", 36, 41], ["respiratory virus", "ORGANISM", 46, 63], ["human", "ORGANISM", 83, 88], ["respiratory epithelial cell cultures", "CELL", 89, 125], ["cell", "CELL", 182, 186], ["human", "ORGANISM", 230, 235], ["natural target cells", "CELL_TYPE", 21, 41], ["primary human respiratory epithelial cell cultures", "CELL_LINE", 75, 125], ["cell factors", "PROTEIN", 182, 194], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 230, 235], ["respiratory virus infection", "PROBLEM", 46, 73], ["primary human respiratory epithelial cell cultures", "TEST", 75, 125], ["cell factors", "PROBLEM", 182, 194], ["respiratory human viruses", "PROBLEM", 218, 243], ["viruses", "PROBLEM", 285, 292], ["infection", "PROBLEM", 330, 339], ["isolation", "TREATMENT", 349, 358], ["novel respiratory pathogens", "PROBLEM", 378, 405], ["respiratory epithelial cell", "OBSERVATION", 89, 116], ["respiratory human viruses", "OBSERVATION", 218, 243], ["respiratory pathogens", "OBSERVATION", 384, 405]]], ["The alveolar epithelium consists of both alveolar type I cells (ATI), which make up 95% of the surface area of the lung, are terminally differentiated, non-dividing, and function in gas exchange and fluid homeostasis; and alveolar type II cells (ATII), which produce surfactant proteins and lipids, divide and differentiate to replace damaged ATI cells, participate in fluid homeostasis, and contribute to the innate defenses of the lung [1], [2], [3], [4].", [["alveolar epithelium", "ANATOMY", 4, 23], ["alveolar type I cells", "ANATOMY", 41, 62], ["surface area", "ANATOMY", 95, 107], ["lung", "ANATOMY", 115, 119], ["fluid", "ANATOMY", 199, 204], ["alveolar type II cells", "ANATOMY", 222, 244], ["ATII", "ANATOMY", 246, 250], ["ATI cells", "ANATOMY", 343, 352], ["fluid", "ANATOMY", 369, 374], ["lung", "ANATOMY", 433, 437], ["alveolar epithelium", "TISSUE", 4, 23], ["alveolar type I cells", "CELL", 41, 62], ["ATI", "GENE_OR_GENE_PRODUCT", 64, 67], ["lung", "ORGAN", 115, 119], ["fluid", "ORGANISM_SUBSTANCE", 199, 204], ["alveolar type II cells", "CELL", 222, 244], ["ATII", "CELL", 246, 250], ["lipids", "SIMPLE_CHEMICAL", 291, 297], ["ATI cells", "CELL", 343, 352], ["fluid", "ORGANISM_SUBSTANCE", 369, 374], ["lung", "ORGAN", 433, 437], ["[2]", "SIMPLE_CHEMICAL", 443, 446], ["[3]", "SIMPLE_CHEMICAL", 448, 451], ["[4]", "SIMPLE_CHEMICAL", 453, 456], ["alveolar type I cells", "CELL_TYPE", 41, 62], ["ATI", "CELL_TYPE", 64, 67], ["alveolar type II cells", "CELL_TYPE", 222, 244], ["ATII", "CELL_TYPE", 246, 250], ["surfactant proteins", "PROTEIN", 267, 286], ["ATI cells", "CELL_TYPE", 343, 352], ["gas exchange", "TEST", 182, 194], ["fluid homeostasis", "TEST", 199, 216], ["alveolar type II cells", "PROBLEM", 222, 244], ["surfactant proteins", "TREATMENT", 267, 286], ["lipids", "TREATMENT", 291, 297], ["damaged ATI cells", "PROBLEM", 335, 352], ["fluid homeostasis", "TEST", 369, 386], ["alveolar", "ANATOMY_MODIFIER", 4, 12], ["epithelium", "ANATOMY_MODIFIER", 13, 23], ["both", "ANATOMY_MODIFIER", 36, 40], ["alveolar", "ANATOMY_MODIFIER", 41, 49], ["type I cells", "OBSERVATION", 50, 62], ["surface", "OBSERVATION_MODIFIER", 95, 102], ["area", "OBSERVATION_MODIFIER", 103, 107], ["lung", "ANATOMY", 115, 119], ["terminally", "OBSERVATION_MODIFIER", 125, 135], ["differentiated", "OBSERVATION_MODIFIER", 136, 150], ["gas exchange", "OBSERVATION", 182, 194], ["fluid homeostasis", "OBSERVATION", 199, 216], ["alveolar type II cells", "OBSERVATION", 222, 244], ["ATI cells", "OBSERVATION", 343, 352], ["fluid homeostasis", "OBSERVATION", 369, 386], ["lung", "ANATOMY", 433, 437]]], ["Our laboratory has developed a system to isolate and culture primary ATII cells from human lungs and under specialized culture conditions transdifferentiate the ATII cells into an ATI-like phenotype [5].IntroductionIn 2005 the fifth human coronavirus, HCoV-HKU1, was discovered by RT-PCR screening with conserved coronavirus primers on respiratory samples from adult patients with pneumonia that were negative for the severe acute respiratory syndrome coronavirus (SARS-CoV) [6].", [["ATII cells", "ANATOMY", 69, 79], ["lungs", "ANATOMY", 91, 96], ["ATII cells", "ANATOMY", 161, 171], ["respiratory samples", "ANATOMY", 336, 355], ["pneumonia", "DISEASE", 381, 390], ["acute respiratory syndrome coronavirus", "DISEASE", 425, 463], ["SARS", "DISEASE", 465, 469], ["ATII cells", "CELL", 69, 79], ["human", "ORGANISM", 85, 90], ["lungs", "ORGAN", 91, 96], ["ATII cells", "CELL", 161, 171], ["ATI", "GENE_OR_GENE_PRODUCT", 180, 183], ["human", "ORGANISM", 233, 238], ["coronavirus", "ORGANISM", 239, 250], ["HCoV", "GENE_OR_GENE_PRODUCT", 252, 256], ["HKU1", "GENE_OR_GENE_PRODUCT", 257, 261], ["coronavirus", "ORGANISM", 313, 324], ["patients", "ORGANISM", 367, 375], ["primary ATII cells", "CELL_TYPE", 61, 79], ["ATII cells", "CELL_TYPE", 161, 171], ["HCoV", "DNA", 252, 256], ["HKU1", "DNA", 257, 261], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 233, 238], ["coronavirus", "SPECIES", 239, 250], ["patients", "SPECIES", 367, 375], ["human", "SPECIES", 85, 90], ["human coronavirus", "SPECIES", 233, 250], ["severe acute respiratory syndrome coronavirus", "SPECIES", 418, 463], ["SARS-CoV", "SPECIES", 465, 473], ["culture primary ATII cells", "TEST", 53, 79], ["specialized culture conditions", "TEST", 107, 137], ["an ATI", "TEST", 177, 183], ["PCR screening", "TEST", 284, 297], ["conserved coronavirus primers", "PROBLEM", 303, 332], ["respiratory samples", "TEST", 336, 355], ["pneumonia", "PROBLEM", 381, 390], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 414, 463], ["ATII cells", "OBSERVATION", 69, 79], ["lungs", "ANATOMY", 91, 96], ["ATII cells", "OBSERVATION", 161, 171], ["pneumonia", "OBSERVATION", 381, 390], ["severe", "OBSERVATION_MODIFIER", 418, 424], ["acute", "OBSERVATION_MODIFIER", 425, 430], ["respiratory syndrome coronavirus", "OBSERVATION", 431, 463]]], ["To date, HCoV-HKU1 has been associated with both upper and lower respiratory tract illness in children and adults [7], [8], [9], [10], [11], [12].", [["lower respiratory tract", "ANATOMY", 59, 82], ["upper and lower respiratory tract illness", "DISEASE", 49, 90], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 9, 18], ["upper", "ORGANISM_SUBDIVISION", 49, 54], ["lower", "ORGANISM_SUBDIVISION", 59, 64], ["respiratory tract", "ORGANISM_SUBDIVISION", 65, 82], ["children", "ORGANISM", 94, 102], ["[8]", "SIMPLE_CHEMICAL", 119, 122], ["[9]", "SIMPLE_CHEMICAL", 124, 127], ["[10]", "SIMPLE_CHEMICAL", 129, 133], ["[11]", "SIMPLE_CHEMICAL", 135, 139], ["HCoV", "PROTEIN", 9, 13], ["HKU1", "PROTEIN", 14, 18], ["children", "SPECIES", 94, 102], ["HCoV", "TEST", 9, 13], ["both upper and lower respiratory tract illness", "PROBLEM", 44, 90], ["upper", "ANATOMY_MODIFIER", 49, 54], ["lower", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82]]], ["Until recently, research on HCoV-HKU1 has been limited because it could not be isolated from clinical specimens in continuous cell lines in vitro, and there are no reports of HCoV-HKU1 infecting animals.", [["specimens", "ANATOMY", 102, 111], ["cell lines", "ANATOMY", 126, 136], ["HCoV-HKU1", "CHEMICAL", 28, 37], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 28, 37], ["cell lines", "CELL", 126, 136], ["HCoV-HKU1", "ORGANISM", 175, 184], ["animals", "ORGANISM", 195, 202], ["HCoV", "PROTEIN", 28, 32], ["HKU1", "DNA", 33, 37], ["continuous cell lines", "CELL_LINE", 115, 136], ["HCoV", "SPECIES", 28, 32], ["HCoV", "SPECIES", 175, 179], ["HCoV", "TEST", 28, 32], ["clinical specimens", "TEST", 93, 111], ["continuous cell lines", "TREATMENT", 115, 136], ["HCoV", "PROBLEM", 175, 179], ["HKU1 infecting animals", "PROBLEM", 180, 202], ["cell lines", "OBSERVATION", 126, 136]]], ["Using primary human ciliated airway epithelial cell cultures, Pyrc et al isolated and propagated HCoV-HKU1, and more recently, Dijkman et al extended these observations to additional primary isolates of HCoV-HKU1 [13], [14].", [["airway epithelial cell cultures", "ANATOMY", 29, 60], ["human", "ORGANISM", 14, 19], ["airway epithelial cell cultures", "CELL", 29, 60], ["HCoV-HKU1", "CELL", 97, 106], ["HCoV", "ORGANISM", 203, 207], ["primary human ciliated airway epithelial cell cultures", "CELL_LINE", 6, 60], ["HCoV", "PROTEIN", 97, 101], ["HKU1", "PROTEIN", 102, 106], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["primary human ciliated airway epithelial cell cultures", "TEST", 6, 60], ["Pyrc et al", "TREATMENT", 62, 72], ["ciliated", "ANATOMY_MODIFIER", 20, 28], ["airway", "ANATOMY", 29, 35], ["epithelial cell", "OBSERVATION", 36, 51]]], ["Similarly, we developed a primary human bronchial-tracheal epithelial cell (HTBEC) culture system at the air-liquid interface (AL/I) and have successfully propagated HCoV-HKU1 from patient specimens.", [["bronchial-tracheal epithelial cell", "ANATOMY", 40, 74], ["HTBEC", "ANATOMY", 76, 81], ["HCoV-HKU1", "ANATOMY", 166, 175], ["specimens", "ANATOMY", 189, 198], ["human", "ORGANISM", 34, 39], ["bronchial-tracheal epithelial cell", "CELL", 40, 74], ["HTBEC", "CELL", 76, 81], ["HCoV-HKU1", "CELL", 166, 175], ["patient", "ORGANISM", 181, 188], ["primary human bronchial-tracheal epithelial cell (HTBEC) culture", "CELL_LINE", 26, 90], ["HCoV", "PROTEIN", 166, 170], ["HKU1", "DNA", 171, 175], ["human", "SPECIES", 34, 39], ["patient", "SPECIES", 181, 188], ["human", "SPECIES", 34, 39], ["HCoV", "SPECIES", 166, 170], ["a primary human bronchial-tracheal epithelial cell", "PROBLEM", 24, 74], ["culture system", "TEST", 83, 97], ["patient specimens", "TEST", 181, 198], ["bronchial", "ANATOMY", 40, 49], ["tracheal", "ANATOMY", 50, 58], ["epithelial cell", "OBSERVATION", 59, 74]]], ["In parallel to these advances, and as an alternative approach to study HCoV-HKU1, we reasoned that HCoV-HKU1, like SARS-CoV [15], may be able to infect and be serially propagated in human alveolar cells since this virus is known to cause pneumonia in a subset of patients.", [["alveolar cells", "ANATOMY", 188, 202], ["pneumonia", "DISEASE", 238, 247], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 71, 80], ["HCoV", "GENE_OR_GENE_PRODUCT", 99, 103], ["HKU1", "GENE_OR_GENE_PRODUCT", 104, 108], ["SARS-CoV [15", "ORGANISM", 115, 127], ["human", "ORGANISM", 182, 187], ["alveolar cells", "CELL", 188, 202], ["patients", "ORGANISM", 263, 271], ["HCoV", "PROTEIN", 71, 75], ["HKU1", "PROTEIN", 76, 80], ["HCoV", "PROTEIN", 99, 103], ["HKU1", "PROTEIN", 104, 108], ["human alveolar cells", "CELL_TYPE", 182, 202], ["human", "SPECIES", 182, 187], ["patients", "SPECIES", 263, 271], ["HCoV", "SPECIES", 71, 75], ["SARS-CoV", "SPECIES", 115, 123], ["human", "SPECIES", 182, 187], ["study HCoV", "TEST", 65, 75], ["HCoV", "TEST", 99, 103], ["HKU1", "PROBLEM", 104, 108], ["this virus", "PROBLEM", 209, 219], ["pneumonia", "PROBLEM", 238, 247], ["alveolar cells", "OBSERVATION", 188, 202], ["pneumonia", "OBSERVATION", 238, 247]]], ["Furthermore, we reasoned that infecting primary human alveolar cells would allow us to determine which subset of cells is susceptible to infection, and to characterize initial innate immune responses of alveolar epithelial cells to viruses that cause lower respiratory tract diseases.", [["alveolar cells", "ANATOMY", 54, 68], ["cells", "ANATOMY", 113, 118], ["alveolar epithelial cells", "ANATOMY", 203, 228], ["lower respiratory tract", "ANATOMY", 251, 274], ["infection", "DISEASE", 137, 146], ["respiratory tract diseases", "DISEASE", 257, 283], ["human", "ORGANISM", 48, 53], ["alveolar cells", "CELL", 54, 68], ["cells", "CELL", 113, 118], ["alveolar epithelial cells", "CELL", 203, 228], ["lower", "ORGANISM_SUBDIVISION", 251, 256], ["respiratory tract", "ORGANISM_SUBDIVISION", 257, 274], ["primary human alveolar cells", "CELL_TYPE", 40, 68], ["alveolar epithelial cells", "CELL_TYPE", 203, 228], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["infecting primary human alveolar cells", "PROBLEM", 30, 68], ["infection", "PROBLEM", 137, 146], ["alveolar epithelial cells", "PROBLEM", 203, 228], ["viruses", "PROBLEM", 232, 239], ["lower respiratory tract diseases", "PROBLEM", 251, 283], ["alveolar cells", "OBSERVATION", 54, 68], ["infection", "OBSERVATION", 137, 146], ["alveolar epithelial cells", "OBSERVATION", 203, 228], ["lower", "ANATOMY_MODIFIER", 251, 256], ["respiratory tract", "ANATOMY", 257, 274]]], ["Here we demonstrate that HCoV-HKU1 can infect and be serially propagated in primary human alveolar type II cells but not in alveolar type I-like cells or alveolar macrophages at the air-liquid interface.Isolation and Culture of Primary Cells from Human Lung ::: Materials and MethodsHuman alveolar macrophages and alveolar cells were isolated as previously described [5], [16], [17].", [["alveolar type II cells", "ANATOMY", 90, 112], ["alveolar type I-like cells", "ANATOMY", 124, 150], ["alveolar macrophages", "ANATOMY", 154, 174], ["Cells", "ANATOMY", 236, 241], ["Lung", "ANATOMY", 253, 257], ["alveolar macrophages", "ANATOMY", 289, 309], ["alveolar cells", "ANATOMY", 314, 328], ["HCoV", "GENE_OR_GENE_PRODUCT", 25, 29], ["HKU1", "GENE_OR_GENE_PRODUCT", 30, 34], ["human", "ORGANISM", 84, 89], ["alveolar type II cells", "CELL", 90, 112], ["alveolar type I-like cells", "CELL", 124, 150], ["alveolar macrophages", "CELL", 154, 174], ["air-liquid interface", "MULTI-TISSUE_STRUCTURE", 182, 202], ["Primary Cells", "CELL", 228, 241], ["Human", "ORGANISM", 247, 252], ["Lung", "ORGAN", 253, 257], ["MethodsHuman alveolar macrophages", "CELL", 276, 309], ["alveolar cells", "CELL", 314, 328], ["[16]", "SIMPLE_CHEMICAL", 372, 376], ["HCoV", "PROTEIN", 25, 29], ["HKU1", "PROTEIN", 30, 34], ["primary human alveolar type II cells", "CELL_TYPE", 76, 112], ["alveolar type I-like cells", "CELL_TYPE", 124, 150], ["alveolar macrophages", "CELL_TYPE", 154, 174], ["Primary Cells", "CELL_TYPE", 228, 241], ["MethodsHuman alveolar macrophages", "CELL_TYPE", 276, 309], ["alveolar cells", "CELL_TYPE", 314, 328], ["human", "SPECIES", 84, 89], ["Human", "SPECIES", 247, 252], ["HCoV", "SPECIES", 25, 29], ["human", "SPECIES", 84, 89], ["HCoV", "TEST", 25, 29], ["HKU1", "PROBLEM", 30, 34], ["alveolar macrophages", "PROBLEM", 154, 174], ["Isolation", "TEST", 203, 212], ["Culture", "TEST", 217, 224], ["MethodsHuman alveolar macrophages", "PROBLEM", 276, 309], ["alveolar cells", "PROBLEM", 314, 328], ["alveolar type II cells", "OBSERVATION", 90, 112], ["alveolar", "ANATOMY_MODIFIER", 124, 132], ["like cells", "OBSERVATION", 140, 150], ["alveolar macrophages", "OBSERVATION", 154, 174], ["air-liquid interface", "OBSERVATION", 182, 202], ["Primary Cells", "OBSERVATION", 228, 241], ["Lung", "ANATOMY", 253, 257], ["alveolar macrophages", "OBSERVATION", 289, 309], ["alveolar cells", "OBSERVATION", 314, 328]]], ["Briefly, de-identified donor lungs that were not suitable for transplant were obtained through the National Disease Research Interchange (Philadelphia, PA) and the International Institute for the Advancement of Medicine (Edison, NJ).", [["lungs", "ANATOMY", 29, 34], ["lungs", "ORGAN", 29, 34], ["transplant", "TREATMENT", 62, 72], ["lungs", "ANATOMY", 29, 34]]], ["The isolation of cells was conducted as previously described with the exception that the type II cells were positively selected using EpCAM (CD326) magnetic beads (Miltenyi, Auburn, CA).", [["cells", "ANATOMY", 17, 22], ["type II cells", "ANATOMY", 89, 102], ["cells", "CELL", 17, 22], ["type II cells", "CELL", 89, 102], ["EpCAM", "GENE_OR_GENE_PRODUCT", 134, 139], ["CD326", "SIMPLE_CHEMICAL", 141, 146], ["type II cells", "CELL_TYPE", 89, 102], ["EpCAM", "PROTEIN", 134, 139], ["CD326", "PROTEIN", 141, 146], ["Miltenyi", "PROTEIN", 164, 172], ["The isolation of cells", "TREATMENT", 0, 22], ["the type II cells", "PROBLEM", 85, 102], ["EpCAM (CD326) magnetic beads", "TREATMENT", 134, 162]]], ["Cells were plated in DMEM with 10% FBS on millicell inserts (Millipore, Bedford, MA) coated with a mixture of 80% rat tail collagen and 20% Matrigel (BD Biosciences, San Jose, CA).", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 35, 38], ["millicell", "ANATOMY", 42, 51], ["tail", "ANATOMY", 118, 122], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 35, 38], ["rat", "ORGANISM", 114, 117], ["collagen", "GENE_OR_GENE_PRODUCT", 123, 131], ["rat", "SPECIES", 114, 117], ["Cells", "TEST", 0, 5], ["DMEM", "TEST", 21, 25], ["FBS", "TEST", 35, 38], ["millicell inserts (Millipore", "TREATMENT", 42, 70], ["80% rat tail collagen", "TREATMENT", 110, 131]]], ["Cells were allowed to adhere to inserts for 2 days submerged in DMEM with 10% FBS, then cultured at an air-liquid interface in DMEM with 1% charcoal-stripped serum (CS-FBS) supplemented with keratinocyte growth factor (K) for 2 days, and then switched to media that additionally had isobutylmethylxanthine (I), 8-bromo-cAMP (A), and dexamethasone (D) for 2 days to achieve the ATII differentiated phenotype prior to infection (day 6 after plating).", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 78, 81], ["serum", "ANATOMY", 158, 163], ["FBS", "ANATOMY", 168, 171], ["ATII", "ANATOMY", 377, 381], ["charcoal", "CHEMICAL", 140, 148], ["K", "CHEMICAL", 219, 220], ["isobutylmethylxanthine", "CHEMICAL", 283, 305], ["8-bromo-cAMP", "CHEMICAL", 311, 323], ["dexamethasone", "CHEMICAL", 333, 346], ["infection", "DISEASE", 416, 425], ["isobutylmethylxanthine", "CHEMICAL", 283, 305], ["8-bromo-cAMP", "CHEMICAL", 311, 323], ["dexamethasone", "CHEMICAL", 333, 346], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 78, 81], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["FBS", "ORGANISM_SUBSTANCE", 168, 171], ["keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 191, 217], ["isobutylmethylxanthine", "SIMPLE_CHEMICAL", 283, 305], ["8-bromo-cAMP", "SIMPLE_CHEMICAL", 311, 323], ["A", "SIMPLE_CHEMICAL", 325, 326], ["dexamethasone", "SIMPLE_CHEMICAL", 333, 346], ["D", "SIMPLE_CHEMICAL", 348, 349], ["ATII", "CELL", 377, 381], ["keratinocyte growth factor", "PROTEIN", 191, 217], ["10% FBS", "TREATMENT", 74, 81], ["1% charcoal", "TREATMENT", 137, 148], ["keratinocyte growth factor", "TEST", 191, 217], ["media", "TREATMENT", 255, 260], ["isobutylmethylxanthine (I)", "TREATMENT", 283, 309], ["cAMP (A)", "TREATMENT", 319, 327], ["dexamethasone (D)", "TREATMENT", 333, 350], ["the ATII differentiated phenotype", "PROBLEM", 373, 406], ["infection", "PROBLEM", 416, 425], ["infection", "OBSERVATION", 416, 425]]], ["The alveolar macrophages and alveolar type I-like cells were cultured and characterized as reported previously [5], [16], [17].", [["alveolar macrophages", "ANATOMY", 4, 24], ["alveolar type I-like cells", "ANATOMY", 29, 55], ["alveolar macrophages", "CELL", 4, 24], ["alveolar type I-like cells", "CELL", 29, 55], ["[16]", "SIMPLE_CHEMICAL", 116, 120], ["[17]", "SIMPLE_CHEMICAL", 122, 126], ["alveolar macrophages", "CELL_TYPE", 4, 24], ["alveolar type I-like cells", "CELL_TYPE", 29, 55], ["The alveolar macrophages", "TEST", 0, 24], ["alveolar type I-like cells", "PROBLEM", 29, 55], ["alveolar", "ANATOMY_MODIFIER", 4, 12], ["macrophages", "ANATOMY", 13, 24], ["alveolar", "ANATOMY_MODIFIER", 29, 37]]], ["Briefly, to transdifferentiate type II cells to type I\u2013like cells, type II cells were plated on rat tail collagen\u2013coated dishes at a density of 0.5\u20131.0\u00d7105/cm2 in DMEM with 10% FBS (15).", [["type II cells", "ANATOMY", 31, 44], ["type I\u2013like cells", "ANATOMY", 48, 65], ["type II cells", "ANATOMY", 67, 80], ["type II cells", "CELL", 31, 44], ["type I\u2013like cells", "CELL", 48, 65], ["type II cells", "CELL", 67, 80], ["rat", "ORGANISM", 96, 99], ["FBS", "ORGANISM_SUBSTANCE", 177, 180], ["type II cells", "CELL_TYPE", 31, 44], ["type I\u2013like cells", "CELL_TYPE", 48, 65], ["type II cells", "CELL_TYPE", 67, 80], ["rat", "SPECIES", 96, 99], ["type II cells", "PROBLEM", 31, 44], ["type I\u2013like cells", "PROBLEM", 48, 65], ["type II cells", "PROBLEM", 67, 80], ["a density", "TEST", 131, 140], ["10% FBS", "TEST", 173, 180], ["density", "OBSERVATION_MODIFIER", 133, 140]]], ["After 24\u201348 h the medium was changed to 5% FBS without additives.", [["FBS", "ANATOMY", 43, 46], ["FBS", "ORGANISM_SUBSTANCE", 43, 46], ["5% FBS", "TREATMENT", 40, 46]]], ["Type I-like cell phenotype was documented by positive staining for receptor for advanced glycation end products (RAGE, R & D systems, Minneapolis, MN) and epithelial membrane protein 2 (EMP2, Sigma-Aldrich, Inc, St.Louis, MO).", [["Type I-like cell", "ANATOMY", 0, 16], ["epithelial membrane", "ANATOMY", 155, 174], ["RAGE", "GENE_OR_GENE_PRODUCT", 113, 117], ["R & D", "GENE_OR_GENE_PRODUCT", 119, 124], ["Minneapolis", "SIMPLE_CHEMICAL", 134, 145], ["epithelial membrane protein 2", "GENE_OR_GENE_PRODUCT", 155, 184], ["St.Louis", "ORGANISM", 212, 220], ["receptor for advanced glycation end products", "PROTEIN", 67, 111], ["RAGE", "PROTEIN", 113, 117], ["epithelial membrane protein 2", "PROTEIN", 155, 184], ["EMP2", "PROTEIN", 186, 190], ["Type I-like cell phenotype", "PROBLEM", 0, 26], ["advanced glycation end products", "TREATMENT", 80, 111], ["RAGE", "TEST", 113, 117], ["R & D systems", "TEST", 119, 132], ["epithelial membrane protein", "TEST", 155, 182], ["EMP2", "TEST", 186, 190], ["like cell phenotype", "OBSERVATION", 7, 26], ["epithelial membrane", "ANATOMY", 155, 174]]], ["For alveolar macrophages, the middle lobe of the lungs was perfused, and then lavaged with HEPES-buffered saline containing 2 mM EDTA and then HEPES-buffered saline alone.", [["alveolar macrophages", "ANATOMY", 4, 24], ["middle lobe", "ANATOMY", 30, 41], ["lungs", "ANATOMY", 49, 54], ["HEPES", "CHEMICAL", 91, 96], ["EDTA", "CHEMICAL", 129, 133], ["HEPES", "CHEMICAL", 143, 148], ["alveolar macrophages", "CELL", 4, 24], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 30, 41], ["lungs", "ORGAN", 49, 54], ["saline", "SIMPLE_CHEMICAL", 106, 112], ["EDTA", "SIMPLE_CHEMICAL", 129, 133], ["HEPES-buffered saline", "SIMPLE_CHEMICAL", 143, 164], ["alveolar macrophages", "CELL_TYPE", 4, 24], ["alveolar macrophages", "PROBLEM", 4, 24], ["HEPES", "TREATMENT", 91, 96], ["buffered saline", "TREATMENT", 97, 112], ["2 mM EDTA", "TREATMENT", 124, 133], ["HEPES-buffered saline", "TREATMENT", 143, 164], ["alveolar", "ANATOMY_MODIFIER", 4, 12], ["macrophages", "OBSERVATION", 13, 24], ["middle lobe", "ANATOMY", 30, 41], ["lungs", "ANATOMY", 49, 54], ["perfused", "OBSERVATION_MODIFIER", 59, 67]]], ["The macrophage purity of the adherent cells was nearly 100% and demonstrated by staining for CD 68 (DakoCytomation, Carpinteria,CA).", [["macrophage", "ANATOMY", 4, 14], ["adherent cells", "ANATOMY", 29, 43], ["macrophage", "CELL", 4, 14], ["cells", "CELL", 38, 43], ["CA", "GENE_OR_GENE_PRODUCT", 128, 130], ["adherent cells", "CELL_TYPE", 29, 43], ["CD 68", "PROTEIN", 93, 98], ["The macrophage purity", "TEST", 0, 21], ["the adherent cells", "TEST", 25, 43], ["CD", "TEST", 93, 95], ["DakoCytomation", "TEST", 100, 114], ["macrophage purity", "OBSERVATION", 4, 21], ["adherent cells", "OBSERVATION", 29, 43]]], ["The purity of the type II cells is demonstrated in Figure 1 and the level of surfactant protein expression has been published [5], [20], [25].Virus ::: Materials and MethodsClinical nasopharyngeal specimens containing HCoV-HKU1 RNA were identified from pediatric patients with respiratory symptoms and submitted for testing to the clinical virology laboratory at the Children\u2019s Hospital Colorado by xTag \u00ae Respiratory Virus Panel, RVP (Luminex Molecular Diagnostics, Toronto CN).", [["type II cells", "ANATOMY", 18, 31], ["nasopharyngeal specimens", "ANATOMY", 182, 206], ["respiratory", "ANATOMY", 277, 288], ["respiratory symptoms", "DISEASE", 277, 297], ["type II cells", "CELL", 18, 31], ["[20]", "SIMPLE_CHEMICAL", 131, 135], ["Virus", "ORGANISM", 142, 147], ["nasopharyngeal specimens", "CANCER", 182, 206], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 218, 227], ["patients", "ORGANISM", 263, 271], ["type II cells", "CELL_TYPE", 18, 31], ["surfactant protein", "PROTEIN", 77, 95], ["HCoV-HKU1 RNA", "RNA", 218, 231], ["patients", "SPECIES", 263, 271], ["Children", "SPECIES", 367, 375], ["HCoV", "SPECIES", 218, 222], ["surfactant protein expression", "TREATMENT", 77, 106], ["Materials", "TEST", 152, 161], ["MethodsClinical nasopharyngeal specimens", "TEST", 166, 206], ["HKU1 RNA", "PROBLEM", 223, 231], ["respiratory symptoms", "PROBLEM", 277, 297], ["Respiratory Virus Panel", "TEST", 406, 429], ["RVP", "TEST", 431, 434], ["type II", "OBSERVATION_MODIFIER", 18, 25], ["cells", "OBSERVATION", 26, 31], ["nasopharyngeal", "ANATOMY", 182, 196]]], ["Aliquots of samples positive for HCoV-HKU1 RNA were stored in M4 viral transport media (Remel Laboratories, Lenexa, KS) at \u221270\u00b0C. Isolates of HCoV-HKU1 from five different patients (HKU1/DEN/2010/10, HKU1/DEN/2010/12, HKU1/DEN/2010/13, HKU1/DEN/2010/18, and HKU1/DEN/2010/21) were used for this study.Virus Infection and Propagation ::: Materials and MethodsCells were inoculated with primary clinical isolates of HCoV-HKU1 or isolates of HCoV-HKU1 which had been passaged one time on primary, differentiated, human bronchial-tracheal epithelial cells (HTBEC) (P1 virus) (Lifeline Cell Technology, Walkersville, MD), at 1\u223610 dilution in DMEM with 1% bovine serum albumin (BSA).", [["Aliquots", "ANATOMY", 0, 8], ["samples", "ANATOMY", 12, 19], ["bronchial-tracheal epithelial cells", "ANATOMY", 516, 551], ["HTBEC", "ANATOMY", 553, 558], ["Cell", "ANATOMY", 581, 585], ["serum", "ANATOMY", 657, 662], ["Virus Infection", "DISEASE", 301, 316], ["HCoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["HKU1", "GENE_OR_GENE_PRODUCT", 38, 42], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 142, 151], ["patients", "ORGANISM", 172, 180], ["Virus", "ORGANISM", 301, 306], ["HCoV-HKU1", "CELL", 414, 423], ["HCoV-HKU1", "CELL", 439, 448], ["human", "ORGANISM", 510, 515], ["bronchial-tracheal epithelial cells", "CELL", 516, 551], ["HTBEC", "CELL", 553, 558], ["Lifeline Cell", "CELL", 572, 585], ["bovine", "ORGANISM", 650, 656], ["serum", "ORGANISM_SUBSTANCE", 657, 662], ["albumin", "GENE_OR_GENE_PRODUCT", 663, 670], ["BSA", "SIMPLE_CHEMICAL", 672, 675], ["HCoV-HKU1 RNA", "RNA", 33, 46], ["HCoV", "PROTEIN", 142, 146], ["HKU1", "DNA", 147, 151], ["human bronchial-tracheal epithelial cells", "CELL_TYPE", 510, 551], ["patients", "SPECIES", 172, 180], ["human", "SPECIES", 510, 515], ["bovine", "SPECIES", 650, 656], ["HCoV", "SPECIES", 33, 37], ["HCoV", "SPECIES", 142, 146], ["HKU1/DEN/2010/10, HKU1/DEN/2010/12, HKU1/DEN/2010/13, HKU1/DEN/2010/18", "SPECIES", 182, 252], ["HCoV", "SPECIES", 414, 418], ["HCoV", "SPECIES", 439, 443], ["human", "SPECIES", 510, 515], ["bovine", "SPECIES", 650, 656], ["Aliquots of samples", "TEST", 0, 19], ["HCoV", "TEST", 33, 37], ["HKU1 RNA", "PROBLEM", 38, 46], ["Isolates", "TEST", 130, 138], ["HCoV", "TEST", 142, 146], ["HKU1", "TEST", 147, 151], ["HKU1", "TEST", 182, 186], ["HKU1", "TEST", 200, 204], ["HKU1", "TEST", 218, 222], ["HKU1", "TEST", 236, 240], ["HKU1", "TEST", 258, 262], ["this study", "TEST", 290, 300], ["Virus Infection", "PROBLEM", 301, 316], ["MethodsCells", "TREATMENT", 351, 363], ["HCoV", "TEST", 414, 418], ["HKU1", "PROBLEM", 419, 423], ["HCoV", "TEST", 439, 443], ["HKU1", "PROBLEM", 444, 448], ["human bronchial-tracheal epithelial cells (HTBEC) (P1 virus", "PROBLEM", 510, 569], ["1% bovine serum albumin", "TREATMENT", 647, 670], ["Infection", "OBSERVATION", 307, 316], ["bronchial", "ANATOMY", 516, 525], ["tracheal", "ANATOMY", 526, 534], ["epithelial cells", "OBSERVATION", 535, 551]]], ["After 4 hour incubation, the inoculum was removed and cells were incubated at 34oC.", [["cells", "ANATOMY", 54, 59], ["cells", "CELL", 54, 59], ["the inoculum", "TREATMENT", 25, 37]]], ["For cells kept at an air-liquid interface (AL/I), the apical surface of the cells were washed every 24 hours with DMEM +1% BSA and collected for PCR analysis.", [["cells", "ANATOMY", 4, 9], ["apical surface", "ANATOMY", 54, 68], ["cells", "ANATOMY", 76, 81], ["cells", "CELL", 4, 9], ["apical surface", "CELLULAR_COMPONENT", 54, 68], ["cells", "CELL", 76, 81], ["BSA", "SIMPLE_CHEMICAL", 123, 126], ["cells", "PROBLEM", 4, 9], ["DMEM", "TEST", 114, 118], ["PCR analysis", "TEST", 145, 157], ["apical", "ANATOMY_MODIFIER", 54, 60], ["cells", "ANATOMY", 76, 81]]], ["For cells kept immersed, the media was collected and replaced every 24 hours.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["cells", "PROBLEM", 4, 9]]], ["Cell morphology was monitored daily to observe for any cytopathic effects.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell morphology", "TEST", 0, 15], ["any cytopathic effects", "PROBLEM", 51, 73]]], ["Three days after inoculation, cells were fixed with 100% methanol and viral antigens and cell markers were detected using immunostaining.", [["cells", "ANATOMY", 30, 35], ["cell", "ANATOMY", 89, 93], ["methanol", "CHEMICAL", 57, 65], ["methanol", "CHEMICAL", 57, 65], ["cells", "CELL", 30, 35], ["methanol", "SIMPLE_CHEMICAL", 57, 65], ["cell", "CELL", 89, 93], ["viral antigens", "PROTEIN", 70, 84], ["cell markers", "PROTEIN", 89, 101], ["cells", "TEST", 30, 35], ["100% methanol", "TREATMENT", 52, 65], ["viral antigens", "TREATMENT", 70, 84], ["cell markers", "TEST", 89, 101], ["immunostaining", "TEST", 122, 136]]], ["HCoV-HKU1 was detected in infected cells using a rabbit polyclonal antibody or a mouse-monoclonal antibody directed against the HCoV-HKU1 viral spike glycoprotein developed in our laboratory and visualized using a goat anti-rabbit or goat anti-mouse antibody conjugated to ALEXA 488 fluorophore (Life Technologies, Grand Island, NY).", [["cells", "ANATOMY", 35, 40], ["ALEXA 488", "CHEMICAL", 273, 282], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["HKU1", "GENE_OR_GENE_PRODUCT", 5, 9], ["cells", "CELL", 35, 40], ["rabbit", "ORGANISM", 49, 55], ["mouse", "ORGANISM", 81, 86], ["HCoV", "GENE_OR_GENE_PRODUCT", 128, 132], ["HKU1", "GENE_OR_GENE_PRODUCT", 133, 137], ["goat", "ORGANISM", 214, 218], ["anti-rabbit", "GENE_OR_GENE_PRODUCT", 219, 230], ["ALEXA 488 fluorophore", "SIMPLE_CHEMICAL", 273, 294], ["HCoV", "PROTEIN", 0, 4], ["HKU1", "PROTEIN", 5, 9], ["infected cells", "CELL_TYPE", 26, 40], ["rabbit polyclonal antibody", "PROTEIN", 49, 75], ["mouse-monoclonal antibody", "PROTEIN", 81, 106], ["HCoV", "PROTEIN", 128, 132], ["HKU1 viral spike glycoprotein", "PROTEIN", 133, 162], ["goat anti-rabbit or goat anti-mouse antibody", "PROTEIN", 214, 258], ["rabbit", "SPECIES", 49, 55], ["mouse", "SPECIES", 81, 86], ["goat", "SPECIES", 214, 218], ["anti-rabbit", "SPECIES", 219, 230], ["goat", "SPECIES", 234, 238], ["anti-mouse", "SPECIES", 239, 249], ["HCoV", "SPECIES", 0, 4], ["rabbit", "SPECIES", 49, 55], ["mouse", "SPECIES", 81, 86], ["HCoV", "SPECIES", 128, 132], ["goat", "SPECIES", 214, 218], ["anti-rabbit", "SPECIES", 219, 230], ["goat", "SPECIES", 234, 238], ["HCoV", "TEST", 0, 4], ["HKU1", "PROBLEM", 5, 9], ["infected cells", "PROBLEM", 26, 40], ["a rabbit polyclonal antibody", "TEST", 47, 75], ["a mouse-monoclonal antibody", "TREATMENT", 79, 106], ["the HCoV", "TEST", 124, 132], ["HKU1 viral spike glycoprotein", "PROBLEM", 133, 162], ["a goat anti-rabbit", "TREATMENT", 212, 230], ["goat anti-mouse antibody", "TREATMENT", 234, 258], ["infected cells", "OBSERVATION", 26, 40]]], ["Cells were also stained for cell type specific markers [ATII cells: SP-A (PE-10, a gift from Yoshio Kuroki, University of Sapporo, Japan), proSP-B (Millipore, Billerica, MA), TTF-1 (Leica Biosystems, Buffalo Grove, IL), and mouse IgM anti-Dobbs (Hu-280, a gift from Leland Dobbs, University of California \u2013 San Francisco); Basal cells: keratin-5 (Thermo Scientific, Pittsburgh, PA); Alveolar macrophages: CD68, (clone KP1, DAKO, Inc., Carpenteria, CA)].", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 28, 32], ["ATII cells", "ANATOMY", 56, 66], ["Basal cells", "ANATOMY", 323, 334], ["Alveolar macrophages", "ANATOMY", 383, 403], ["Cells", "CELL", 0, 5], ["cell", "CELL", 28, 32], ["ATII cells", "CELL", 56, 66], ["SP-A", "CELL", 68, 72], ["PE-10", "CELL", 74, 79], ["proSP-B", "CELL", 139, 146], ["TTF-1", "GENE_OR_GENE_PRODUCT", 175, 180], ["IL", "GENE_OR_GENE_PRODUCT", 215, 217], ["mouse", "ORGANISM", 224, 229], ["Basal cells", "CELL", 323, 334], ["keratin-5", "GENE_OR_GENE_PRODUCT", 336, 345], ["Alveolar macrophages", "CELL", 383, 403], ["CD68", "GENE_OR_GENE_PRODUCT", 405, 409], ["DAKO", "GENE_OR_GENE_PRODUCT", 423, 427], ["ATII cells", "CELL_TYPE", 56, 66], ["SP", "PROTEIN", 68, 70], ["IgM", "PROTEIN", 230, 233], ["Hu", "PROTEIN", 246, 248], ["Basal cells", "CELL_TYPE", 323, 334], ["Alveolar macrophages", "CELL_TYPE", 383, 403], ["CD68", "PROTEIN", 405, 409], ["mouse", "SPECIES", 224, 229], ["mouse", "SPECIES", 224, 229], ["Cells", "TEST", 0, 5], ["cell type specific markers", "TEST", 28, 54], ["ATII cells", "TEST", 56, 66], ["SP", "TEST", 68, 70], ["PE", "TEST", 74, 76], ["proSP", "TEST", 139, 144], ["TTF", "TEST", 175, 178], ["Leica Biosystems", "TEST", 182, 198], ["mouse IgM", "TEST", 224, 233], ["Hu", "TEST", 246, 248], ["keratin", "TEST", 336, 343], ["CD68", "TEST", 405, 409], ["clone KP1", "TEST", 412, 421], ["DAKO", "TEST", 423, 427], ["PE", "OBSERVATION", 74, 76], ["Alveolar macrophages", "ANATOMY", 383, 403]]], ["Immunostained cells were imaged using a Zeiss Axioskop 2 fluorescent microscope with Axiovision software and a Zeiss LSM 700 laser scanning confocal microscope with Zen software (National Jewish Cytometry Core).Viral RNA Extraction and Real-time Quantitative Polymerase Chain Reaction (qPCR) ::: Materials and MethodsViral RNA from pooled apical washes was extracted using Qiagen EZ1 Virus Mini Kits (Valencia, CA) on a BioRobot EZ1 Extractor (Qiagen, Valencia, CA) following the manufacturer\u2019s instructions.", [["cells", "ANATOMY", 14, 19], ["apical", "ANATOMY", 339, 345], ["cells", "CELL", 14, 19], ["Viral RNA", "RNA", 211, 220], ["MethodsViral RNA", "RNA", 310, 326], ["Immunostained cells", "TEST", 0, 19], ["Viral RNA Extraction", "TREATMENT", 211, 231], ["MethodsViral RNA", "TREATMENT", 310, 326], ["pooled apical washes", "TREATMENT", 332, 352], ["Qiagen EZ1 Virus", "TREATMENT", 373, 389], ["a BioRobot EZ1 Extractor", "TREATMENT", 418, 442], ["RNA Extraction", "OBSERVATION", 217, 231], ["apical", "ANATOMY_MODIFIER", 339, 345], ["washes", "OBSERVATION", 346, 352]]], ["Virus yield was determined by a quantitative real time RT-PCR (qRT-PCR) which targeted the HCoV-HKU1 polymerase 1b gene with comparison to copy number from a plasmid encoding the region recognized by this assay.", [["plasmid", "ANATOMY", 158, 165], ["Virus", "ORGANISM", 0, 5], ["HCoV-HKU1 polymerase 1b", "GENE_OR_GENE_PRODUCT", 91, 114], ["HCoV-HKU1 polymerase 1b gene", "DNA", 91, 119], ["plasmid", "DNA", 158, 165], ["Virus yield", "PROBLEM", 0, 11], ["PCR", "TEST", 58, 61], ["qRT", "TEST", 63, 66], ["PCR", "TEST", 67, 70], ["the HCoV", "TEST", 87, 95], ["a plasmid encoding the region", "TREATMENT", 156, 185]]], ["The RT-PCRs were performed using a 1-step reverse-transcription PCR master mix (RNA UltraSense One-Step Quantitative RT-PCR System, Invitrogen Life Technologies, Carlsbad, CA).", [["The RT-PCRs", "TEST", 0, 11], ["a 1-step reverse-transcription PCR master mix", "TREATMENT", 33, 78], ["Quantitative RT-PCR System", "TREATMENT", 104, 130]]], ["Reaction mixtures were prepared using a 500-nM final concentration of the forward primer (5\u2032-TGGTGGCTGGGACGATATGT-3\u2032), 250 nM of the reverse primer (5\u2032-GGCATAGCACGATCACACTTAGG-3\u2032), and 100 nM of the probe (5\u2032-6FAM-ATAATCCCAACCCATRAG- minor groove binder nonfluorescent quencher-3\u2032).", [["the forward primer", "TREATMENT", 70, 88], ["TGGTGGCTGGGACGATATGT", "TEST", 93, 113], ["GGCATAGCACGATCACACTTAGG", "TEST", 152, 175], ["ATAATCCCAACCCATRAG- minor groove binder nonfluorescent quencher", "TREATMENT", 214, 277]]], ["10 ul of RNA was added to 10 ul of master mix containing an additional 1.3 mM MgCl.", [["MgCl", "CHEMICAL", 78, 82], ["MgCl", "CHEMICAL", 78, 82], ["MgCl", "SIMPLE_CHEMICAL", 78, 82], ["RNA", "TREATMENT", 9, 12], ["an additional 1.3 mM MgCl", "TREATMENT", 57, 82], ["RNA", "OBSERVATION", 9, 12]]], ["RT-PCR was performed using the following cycling conditions: 50\u00b0C for 15 minutes, 95\u00b0C for 2 minutes, and 40 cycles of 95\u00b0C for 15 seconds, 60\u00b0C for 30 seconds [12].Cytokine Analysis ::: Materials and MethodsAt 72 hours post-infection, cells were harvested for RNA analysis using the RNeasy RNA extraction kit (Qiagen, Valencia, CA), cDNA synthesis using qScript cDNA SuperMix (Quanta BioSciences, Gaithersburg, MD).", [["cells", "ANATOMY", 236, 241], ["infection", "DISEASE", 225, 234], ["cells", "CELL", 236, 241], ["Cytokine", "PROTEIN", 165, 173], ["qScript cDNA SuperMix", "DNA", 355, 376], ["RT-PCR", "TEST", 0, 6], ["Cytokine Analysis", "TEST", 165, 182], ["MethodsAt", "TREATMENT", 201, 210], ["infection", "PROBLEM", 225, 234], ["RNA analysis", "TEST", 261, 273], ["the RNeasy RNA extraction", "TREATMENT", 280, 305], ["cDNA synthesis", "TREATMENT", 334, 348], ["infection", "OBSERVATION", 225, 234]]], ["To quantitate mRNAs encoding interferons, cytokines and chemokines, we used Taqman gene expression assays (Applied Biosystems, Life Technologies, Grand Island, NY) real-time PCR primers and probes [CXCL10 Hs00171042_m1, RANTES (CCL5) Hs00982282_m1, CYB Hs00168719_m1], or primers and probes synthesized in house: IFN-\u03b2 (forward primer: 5\u2032-CTTACAGGTTACCTCCGAAACTGAA-3\u2032, reverse primer: 5\u2032-TTGAAGAATGCTTGAAGCAATTGT-3\u2032, probe: ATCTCCTAGCCTGTGCCTCTGGGACTGT), IL-29 (forward primer: 5\u2032-GGGAACCTGTGTCTGAGAACGT-3\u2032, reverse primer: 5\u2032-GAGTAGGGCTCAGCGCATAAATA-3\u2032, probe: 5\u2032-CTGAGTCCACCTGACACCCCACACCT-3\u2032), and IL-6 (forward primer: 5\u2032-CCAGGAGCCCAGCTATGAAC-3\u2032, and reverse primer: 5\u2032- CCCAGGGAGAAGGCAACTG-3\u2032, probe: 5\u2032- CCTTCTCCACAAGCGCCTTCGGTT-3\u2032).", [["RANTES", "GENE_OR_GENE_PRODUCT", 220, 226], ["CCL5", "GENE_OR_GENE_PRODUCT", 228, 232], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 313, 318], ["IL-29", "GENE_OR_GENE_PRODUCT", 455, 460], ["IL-6", "GENE_OR_GENE_PRODUCT", 601, 605], ["mRNAs", "RNA", 14, 19], ["interferons", "PROTEIN", 29, 40], ["cytokines", "PROTEIN", 42, 51], ["chemokines", "PROTEIN", 56, 66], ["CXCL10 Hs00171042_m1", "DNA", 198, 218], ["RANTES (CCL5) Hs00982282_m1", "DNA", 220, 247], ["CYB Hs00168719_m1", "DNA", 249, 266], ["IFN", "PROTEIN", 313, 316], ["\u03b2", "PROTEIN", 317, 318], ["reverse primer", "DNA", 369, 383], ["IL-29", "DNA", 455, 460], ["reverse primer", "DNA", 508, 522], ["IL-6", "DNA", 601, 605], ["forward primer", "DNA", 607, 621], ["reverse primer", "DNA", 655, 669], ["mRNAs encoding interferons", "TREATMENT", 14, 40], ["cytokines and chemokines", "TREATMENT", 42, 66], ["Taqman gene expression assays", "TREATMENT", 76, 105], ["PCR primers", "TEST", 174, 185], ["CXCL10 Hs", "TEST", 198, 207], ["RANTES", "TEST", 220, 226], ["CCL5", "TEST", 228, 232], ["CYB", "TEST", 249, 252], ["Hs", "TEST", 253, 255], ["primers", "TEST", 272, 279], ["IFN", "TEST", 313, 316], ["CTTACAGGTTACCTCCGAAACTGAA", "TEST", 339, 364], ["TTGAAGAATGCTTGAAGCAATTGT", "TEST", 388, 412], ["IL", "TEST", 455, 457], ["GGGAACCTGTGTCTGAGAACGT", "TEST", 481, 503], ["GAGTAGGGCTCAGCGCATAAATA", "TEST", 527, 550], ["CTGAGTCCACCTGACACCCCACACCT", "TEST", 565, 591], ["IL", "TEST", 601, 603], ["CCAGGAGCCCAGCTATGAAC", "TEST", 626, 646], ["CCCAGGGAGAAGGCAACTG", "TEST", 675, 694], ["CCTTCTCCACAAGCGCCTTCGGTT", "TEST", 710, 734]]], ["15 uL reaction mixtures were prepared using 2 uL of cDNA, with a final probe concentration of 250 nM and primer concentration of 900 nM.", [["cDNA", "DNA", 52, 56], ["uL reaction mixtures", "TREATMENT", 3, 23], ["2 uL of cDNA", "TREATMENT", 44, 56], ["a final probe concentration", "TREATMENT", 63, 90], ["900 nM", "OBSERVATION_MODIFIER", 129, 135]]], ["Real-time PCR analysis was performed on Bio-Rad CFX96 instrument (Bio-Rad Laboratories, Hercules, CA) using the following cycling conditions: 50\u00b0C for 2 minutes, 95\u00b0C for 10 minutes, and 40 cycles of 95\u00b0C for 15 seconds and 60\u00b0C for 1 minute.", [["Real-time PCR analysis", "TEST", 0, 22], ["Bio", "TEST", 40, 43]]], ["Statistical analysis was performed using Prism software (GraphPad Software Inc., La Jolla, CA).", [["Statistical analysis", "TEST", 0, 20], ["Prism software", "TEST", 41, 55]]], ["Gene expression values were normalized to show expression relative to the cyclophilin B (CYB), a housekeeping gene.Ethics Statement ::: Materials and MethodsThe Committee for the Protection of Human Subjects at National Jewish Health has deemed the use of human lung donor cells as nonhuman subject research, since there is no risk to donors and all donors are de-identified.", [["lung donor cells", "ANATOMY", 262, 278], ["cyclophilin B", "GENE_OR_GENE_PRODUCT", 74, 87], ["CYB", "GENE_OR_GENE_PRODUCT", 89, 92], ["Human", "ORGANISM", 193, 198], ["human", "ORGANISM", 256, 261], ["lung donor cells", "CELL", 262, 278], ["donors", "ORGANISM", 335, 341], ["donors", "ORGANISM", 350, 356], ["cyclophilin B", "PROTEIN", 74, 87], ["CYB", "PROTEIN", 89, 92], ["housekeeping gene", "DNA", 97, 114], ["human lung donor cells", "CELL_TYPE", 256, 278], ["Human", "SPECIES", 193, 198], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["Gene expression values", "TEST", 0, 22], ["the cyclophilin B (CYB)", "TREATMENT", 70, 93], ["human lung donor cells", "TREATMENT", 256, 278], ["lung", "ANATOMY", 262, 266], ["donor cells", "OBSERVATION", 267, 278], ["no", "UNCERTAINTY", 324, 326]]], ["Use of the banked virus specimens and clinical data for this research was approved by the Colorado Multiple Institutional Review Board.Clinical Characteristics of HCoV-HKU1 Viruses ::: ResultsThe 5 clinical isolates of HCoV-HKU1 from Denver, CO, utilized in the study were part of a larger set of HCoV-HKU1 samples collected as part of a study on the epidemiology of CoV infections in pediatric patients detailed elsewhere [12], [18].", [["specimens", "ANATOMY", 24, 33], ["HCoV-HKU1 samples", "ANATOMY", 297, 314], ["CoV infections", "DISEASE", 367, 381], ["HCoV-HKU1", "ORGANISM", 219, 228], ["HCoV-HKU1 samples", "CANCER", 297, 314], ["CoV", "ORGANISM", 367, 370], ["patients", "ORGANISM", 395, 403], ["HKU1", "DNA", 224, 228], ["patients", "SPECIES", 395, 403], ["HCoV", "SPECIES", 219, 223], ["HCoV", "SPECIES", 297, 301], ["CoV", "SPECIES", 367, 370], ["the banked virus specimens", "TEST", 7, 33], ["clinical data", "TEST", 38, 51], ["HCoV", "TEST", 163, 167], ["the study", "TEST", 258, 267], ["a study", "TEST", 336, 343], ["CoV infections", "PROBLEM", 367, 381]]], ["The clinical details of the patients from whom the isolates were obtained are summarized in Table 1.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["the isolates", "TEST", 47, 59]]], ["All of these HCoV-HKU1 isolates were HCoV-HKU1 genotype A.HCoV-HKU1 Infection of Primary Human Alveolar Cells ::: ResultsTo determine which subset of primary human alveolar cells are susceptible to HCoV-HKU1 infection, human alveolar type I-like cells, alveolar type II cells, and alveolar macrophages were tested.", [["Alveolar Cells", "ANATOMY", 95, 109], ["alveolar cells", "ANATOMY", 164, 178], ["alveolar type I-like cells", "ANATOMY", 225, 251], ["alveolar type II cells", "ANATOMY", 253, 275], ["alveolar macrophages", "ANATOMY", 281, 301], ["infection", "DISEASE", 208, 217], ["HCoV", "GENE_OR_GENE_PRODUCT", 13, 17], ["HKU1", "GENE_OR_GENE_PRODUCT", 18, 22], ["HCoV", "GENE_OR_GENE_PRODUCT", 37, 41], ["Human", "ORGANISM", 89, 94], ["Alveolar Cells", "CELL", 95, 109], ["human", "ORGANISM", 158, 163], ["alveolar cells", "CELL", 164, 178], ["HCoV", "GENE_OR_GENE_PRODUCT", 198, 202], ["HKU1", "GENE_OR_GENE_PRODUCT", 203, 207], ["human", "ORGANISM", 219, 224], ["alveolar type I-like cells", "CELL", 225, 251], ["alveolar type II cells", "CELL", 253, 275], ["alveolar macrophages", "CELL", 281, 301], ["primary human alveolar cells", "CELL_TYPE", 150, 178], ["human alveolar type I-like cells", "CELL_TYPE", 219, 251], ["alveolar type II cells", "CELL_TYPE", 253, 275], ["alveolar macrophages", "CELL_TYPE", 281, 301], ["Human", "SPECIES", 89, 94], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 219, 224], ["HCoV", "SPECIES", 37, 41], ["human", "SPECIES", 158, 163], ["HCoV", "SPECIES", 198, 202], ["human", "SPECIES", 219, 224], ["these HCoV", "TEST", 7, 17], ["HKU1 isolates", "TEST", 18, 31], ["HCoV", "TEST", 37, 41], ["genotype A.HCoV", "TEST", 47, 62], ["primary human alveolar cells", "PROBLEM", 150, 178], ["HCoV", "TEST", 198, 202], ["HKU1 infection", "PROBLEM", 203, 217], ["human alveolar type I-like cells", "PROBLEM", 219, 251], ["alveolar type II cells", "PROBLEM", 253, 275], ["alveolar macrophages", "PROBLEM", 281, 301], ["Alveolar Cells", "OBSERVATION", 95, 109], ["alveolar cells", "OBSERVATION", 164, 178], ["infection", "OBSERVATION", 208, 217], ["alveolar", "ANATOMY_MODIFIER", 225, 233], ["alveolar", "ANATOMY_MODIFIER", 253, 261], ["type II cells", "OBSERVATION", 262, 275], ["alveolar macrophages", "OBSERVATION", 281, 301]]], ["In addition, two different conditions for cell growth were compared, submerged cultures versus cultures at the air-liquid interface (AL/I).", [["cell", "ANATOMY", 42, 46], ["cell", "CELL", 42, 46], ["cell growth", "PROBLEM", 42, 53], ["submerged cultures", "TEST", 69, 87], ["cultures", "TEST", 95, 103]]], ["Cultures were inoculated with primary clinical isolates of HCoV-HKU1 or passage 1 (P1) virus.", [["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 59, 68], ["HCoV", "SPECIES", 59, 63], ["Cultures", "TEST", 0, 8], ["HCoV", "TEST", 59, 63], ["HKU1", "PROBLEM", 64, 68], ["passage 1 (P1) virus", "PROBLEM", 72, 92]]], ["Titers of viral RNA in the wash from the apical surface of the cells were determined by qRT-PCR at the indicated time points, and cultures were fixed and immunolabeled with antibodies to the HCoV-HKU1 spike glycoprotein to identify infected cells.", [["apical surface", "ANATOMY", 41, 55], ["cells", "ANATOMY", 63, 68], ["cultures", "ANATOMY", 130, 138], ["cells", "ANATOMY", 241, 246], ["apical surface", "CELLULAR_COMPONENT", 41, 55], ["cells", "CELL", 63, 68], ["HCoV", "GENE_OR_GENE_PRODUCT", 191, 195], ["HKU1", "GENE_OR_GENE_PRODUCT", 196, 200], ["cells", "CELL", 241, 246], ["viral RNA", "RNA", 10, 19], ["antibodies", "PROTEIN", 173, 183], ["HCoV-HKU1 spike glycoprotein", "PROTEIN", 191, 219], ["infected cells", "CELL_TYPE", 232, 246], ["HCoV", "SPECIES", 191, 195], ["viral RNA", "PROBLEM", 10, 19], ["qRT", "TEST", 88, 91], ["PCR", "TEST", 92, 95], ["cultures", "TEST", 130, 138], ["antibodies", "TEST", 173, 183], ["the HCoV", "TEST", 187, 195], ["HKU1 spike glycoprotein", "PROBLEM", 196, 219], ["infected cells", "PROBLEM", 232, 246], ["viral RNA", "OBSERVATION", 10, 19], ["apical", "ANATOMY_MODIFIER", 41, 47], ["infected cells", "OBSERVATION", 232, 246]]], ["Neither the submerged nor air-liquid interface type 1-like cells nor alveolar macrophages were susceptible to infection by HCoV-HKU1 (Figure 2).", [["air-liquid interface type 1-like cells", "ANATOMY", 26, 64], ["alveolar macrophages", "ANATOMY", 69, 89], ["infection", "DISEASE", 110, 119], ["type 1-like cells", "CELL", 47, 64], ["alveolar macrophages", "CELL", 69, 89], ["alveolar macrophages", "CELL_TYPE", 69, 89], ["HCoV", "SPECIES", 123, 127], ["alveolar macrophages", "PROBLEM", 69, 89], ["infection", "PROBLEM", 110, 119], ["HCoV", "TEST", 123, 127], ["air-liquid interface", "OBSERVATION", 26, 46], ["alveolar macrophages", "OBSERVATION", 69, 89], ["infection", "OBSERVATION", 110, 119]]], ["In the submerged culture of type II cells only a few cells were infected with HCoV-HKU1.", [["type II cells", "ANATOMY", 28, 41], ["cells", "ANATOMY", 53, 58], ["type II cells", "CELL", 28, 41], ["cells", "CELL", 53, 58], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 78, 87], ["type II cells", "CELL_TYPE", 28, 41], ["HCoV", "PROTEIN", 78, 82], ["HKU1", "DNA", 83, 87], ["HCoV", "SPECIES", 78, 82], ["the submerged culture", "TEST", 3, 24], ["type II cells", "PROBLEM", 28, 41], ["a few cells", "PROBLEM", 47, 58], ["HCoV", "TEST", 78, 82], ["type II", "OBSERVATION_MODIFIER", 28, 35]]], ["In contrast, type II cells maintained at the air-liquid interface supported infection, although the level of infection varied with individual subjects.HCoV-HKU1 Infection of Primary Human Alveolar Cells ::: ResultsType II cells infected with HCoV-HKU1 showed formation of large syncytia indicating cell to cell spread may be a major factor for virus spread within the lung as it is for respiratory syncytial virus and parainfluenza viruses (Figures 2 and 3).", [["type II cells", "ANATOMY", 13, 26], ["Alveolar Cells", "ANATOMY", 188, 202], ["Type II cells", "ANATOMY", 214, 227], ["syncytia", "ANATOMY", 278, 286], ["cell", "ANATOMY", 298, 302], ["cell", "ANATOMY", 306, 310], ["lung", "ANATOMY", 368, 372], ["infection", "DISEASE", 76, 85], ["infection", "DISEASE", 109, 118], ["respiratory syncytial virus and parainfluenza viruses", "DISEASE", 386, 439], ["type II cells", "CELL", 13, 26], ["HCoV", "GENE_OR_GENE_PRODUCT", 151, 155], ["Human", "ORGANISM", 182, 187], ["Alveolar Cells", "CELL", 188, 202], ["Type II cells", "CELL", 214, 227], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 242, 251], ["syncytia", "CELL", 278, 286], ["cell", "CELL", 298, 302], ["cell", "CELL", 306, 310], ["lung", "ORGAN", 368, 372], ["respiratory syncytial virus", "ORGANISM", 386, 413], ["parainfluenza viruses", "ORGANISM", 418, 439], ["type II cells", "CELL_TYPE", 13, 26], ["Primary Human Alveolar Cells", "CELL_TYPE", 174, 202], ["Type II cells", "CELL_TYPE", 214, 227], ["HCoV", "PROTEIN", 242, 246], ["HKU1", "PROTEIN", 247, 251], ["Human", "SPECIES", 182, 187], ["respiratory syncytial virus", "SPECIES", 386, 413], ["parainfluenza", "SPECIES", 418, 431], ["HCoV", "SPECIES", 242, 246], ["respiratory syncytial virus", "SPECIES", 386, 413], ["type II cells", "PROBLEM", 13, 26], ["infection", "PROBLEM", 76, 85], ["infection", "PROBLEM", 109, 118], ["HCoV", "TEST", 151, 155], ["Type II cells", "PROBLEM", 214, 227], ["HCoV", "TEST", 242, 246], ["large syncytia", "PROBLEM", 272, 286], ["cell to cell spread", "PROBLEM", 298, 317], ["virus spread within the lung", "PROBLEM", 344, 372], ["respiratory syncytial virus", "PROBLEM", 386, 413], ["parainfluenza viruses", "PROBLEM", 418, 439], ["type II", "OBSERVATION_MODIFIER", 13, 20], ["cells", "OBSERVATION", 21, 26], ["air-liquid interface", "OBSERVATION", 45, 65], ["infection", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 109, 118], ["Infection", "OBSERVATION", 161, 170], ["Alveolar Cells", "OBSERVATION", 188, 202], ["large", "OBSERVATION_MODIFIER", 272, 277], ["syncytia indicating cell to cell spread", "OBSERVATION", 278, 317], ["virus", "OBSERVATION", 344, 349], ["lung", "ANATOMY", 368, 372], ["syncytial virus", "OBSERVATION", 398, 413]]], ["This pattern of susceptibility of ATII cells at the AL/I to HCoV-HKU1 infection was reproducible in most human donors, since cultures from 17 of 20 different donors tested were susceptible to infection with HCoV-HKU1, although cells from different donors demonstrated significant variation in the percent of HCoV-HKU1 infected cells.", [["ATII cells", "ANATOMY", 34, 44], ["cultures", "ANATOMY", 125, 133], ["cells", "ANATOMY", 227, 232], ["cells", "ANATOMY", 327, 332], ["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 192, 201], ["ATII cells", "CELL", 34, 44], ["HCoV", "GENE_OR_GENE_PRODUCT", 60, 64], ["HKU1", "GENE_OR_GENE_PRODUCT", 65, 69], ["human", "ORGANISM", 105, 110], ["donors", "ORGANISM", 111, 117], ["donors", "ORGANISM", 158, 164], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 207, 216], ["cells", "CELL", 227, 232], ["donors", "ORGANISM", 248, 254], ["HCoV-HKU1", "CELL", 308, 317], ["cells", "CELL", 327, 332], ["ATII cells", "CELL_LINE", 34, 44], ["HCoV", "PROTEIN", 207, 211], ["HKU1", "DNA", 212, 216], ["HCoV-HKU1 infected cells", "CELL_LINE", 308, 332], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["HCoV", "SPECIES", 207, 211], ["HCoV", "SPECIES", 308, 312], ["ATII cells", "PROBLEM", 34, 44], ["HCoV", "TEST", 60, 64], ["HKU1 infection", "PROBLEM", 65, 79], ["cultures", "TEST", 125, 133], ["different donors", "TEST", 148, 164], ["infection", "PROBLEM", 192, 201], ["HCoV", "TEST", 207, 211], ["HKU1", "PROBLEM", 212, 216], ["different donors", "TEST", 238, 254], ["significant variation", "PROBLEM", 268, 289], ["HCoV", "TEST", 308, 312], ["HKU1 infected cells", "PROBLEM", 313, 332], ["susceptibility", "OBSERVATION_MODIFIER", 16, 30], ["ATII cells", "OBSERVATION", 34, 44], ["infection", "OBSERVATION", 70, 79], ["most human", "OBSERVATION_MODIFIER", 100, 110], ["infection", "OBSERVATION", 192, 201], ["significant", "OBSERVATION_MODIFIER", 268, 279], ["variation", "OBSERVATION_MODIFIER", 280, 289], ["infected cells", "OBSERVATION", 318, 332]]], ["Similarly, all 5 of our clinical HCoV-HKU1 specimens were able to infect type II cells at the air-liquid interface.HCoV-HKU1 Infection of Primary Human Alveolar Cells ::: ResultsThe ATII cells had a morphological appearance of a cobblestone epithelial monolayer, typical for type II cells.", [["specimens", "ANATOMY", 43, 52], ["type II cells", "ANATOMY", 73, 86], ["Alveolar Cells", "ANATOMY", 152, 166], ["ATII cells", "ANATOMY", 182, 192], ["epithelial monolayer", "ANATOMY", 241, 261], ["type II cells", "ANATOMY", 275, 288], ["HCoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["HKU1", "ORGANISM", 38, 42], ["type II cells", "CELL", 73, 86], ["HCoV", "GENE_OR_GENE_PRODUCT", 115, 119], ["Human", "ORGANISM", 146, 151], ["Alveolar Cells", "CELL", 152, 166], ["ATII cells", "CELL", 182, 192], ["cobblestone epithelial monolayer", "CELL", 229, 261], ["type II cells", "CELL", 275, 288], ["type II cells", "CELL_TYPE", 73, 86], ["Primary Human Alveolar Cells", "CELL_TYPE", 138, 166], ["ATII cells", "CELL_LINE", 182, 192], ["cobblestone epithelial monolayer", "CELL_LINE", 229, 261], ["type II cells", "CELL_TYPE", 275, 288], ["Human", "SPECIES", 146, 151], ["our clinical HCoV", "TEST", 20, 37], ["HKU1 specimens", "PROBLEM", 38, 52], ["HCoV", "TEST", 115, 119], ["The ATII cells", "TEST", 178, 192], ["a cobblestone epithelial monolayer", "PROBLEM", 227, 261], ["type II cells", "PROBLEM", 275, 288], ["air-liquid interface", "OBSERVATION", 94, 114], ["Infection", "OBSERVATION", 125, 134], ["Alveolar Cells", "OBSERVATION", 152, 166], ["ATII cells", "OBSERVATION", 182, 192], ["cobblestone epithelial monolayer", "OBSERVATION", 229, 261], ["type II", "OBSERVATION_MODIFIER", 275, 282], ["cells", "OBSERVATION", 283, 288]]], ["These cells were fluorescently labeled with antibodies to surfactant protein A (SP-A), pro-surfactant protein B (proSP-B), thyroid transcription factor\u20131 (TTF-1), and a type II specific transmembrane protein (Hu-280) using an antibody obtained from Dr. Leland Dobbs, University of California, San Francisco [19] (Figure 1).", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["antibodies to surfactant protein A", "GENE_OR_GENE_PRODUCT", 44, 78], ["SP-A", "GENE_OR_GENE_PRODUCT", 80, 84], ["pro-surfactant protein B", "GENE_OR_GENE_PRODUCT", 87, 111], ["proSP-B", "GENE_OR_GENE_PRODUCT", 113, 120], ["thyroid transcription factor\u20131", "GENE_OR_GENE_PRODUCT", 123, 153], ["TTF-1", "GENE_OR_GENE_PRODUCT", 155, 160], ["Hu-280", "GENE_OR_GENE_PRODUCT", 209, 215], ["antibodies", "PROTEIN", 44, 54], ["surfactant protein A", "PROTEIN", 58, 78], ["SP", "PROTEIN", 80, 82], ["A", "PROTEIN", 83, 84], ["pro-surfactant protein B", "PROTEIN", 87, 111], ["proSP", "PROTEIN", 113, 118], ["B", "PROTEIN", 119, 120], ["thyroid transcription factor\u20131", "PROTEIN", 123, 153], ["TTF-1", "PROTEIN", 155, 160], ["type II specific transmembrane protein", "PROTEIN", 169, 207], ["Hu", "PROTEIN", 209, 211], ["280", "PROTEIN", 212, 215], ["antibodies", "TREATMENT", 44, 54], ["pro-surfactant protein B", "TEST", 87, 111], ["proSP", "TEST", 113, 118], ["thyroid transcription factor\u20131", "TEST", 123, 153], ["TTF", "TEST", 155, 158], ["a type II specific transmembrane protein", "PROBLEM", 167, 207], ["Hu", "TEST", 209, 211], ["an antibody", "TEST", 223, 234], ["thyroid", "ANATOMY", 123, 130]]], ["There were a few clumps of airway basal cells in these cultures.", [["airway basal cells", "ANATOMY", 27, 45], ["cultures", "ANATOMY", 55, 63], ["airway basal cells", "CELL", 27, 45], ["airway basal cells", "CELL_TYPE", 27, 45], ["a few clumps of airway basal cells", "PROBLEM", 11, 45], ["these cultures", "TEST", 49, 63], ["few", "OBSERVATION_MODIFIER", 13, 16], ["clumps", "OBSERVATION_MODIFIER", 17, 23], ["airway", "ANATOMY", 27, 33], ["basal cells", "OBSERVATION", 34, 45]]], ["These cells stained for keratin 5 but were not infected by HCoV-HKU1.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["keratin 5", "GENE_OR_GENE_PRODUCT", 24, 33], ["HCoV", "GENE_OR_GENE_PRODUCT", 59, 63], ["HKU1", "GENE_OR_GENE_PRODUCT", 64, 68], ["keratin 5", "PROTEIN", 24, 33], ["HCoV", "PROTEIN", 59, 63], ["HKU1", "PROTEIN", 64, 68], ["HCoV", "SPECIES", 59, 63], ["These cells", "TEST", 0, 11], ["keratin", "TEST", 24, 31]]], ["Other than the formation of large syncytia, cytopathic effects (CPE) were not detectable in any of the type II cell culture at the AL/I.Kinetics of HCoV-HKU1 Replication in Type II Human Alveolar Cells at AL/I ::: ResultsTo examine the kinetics of HCoV-HKU1 replication in type II alveolar cells, primary clinical specimens containing HCoV-HKU1 RNA were used to inoculate the apical surface of type II alveolar cells for 4 hrs and then returned to the AL/I again.", [["syncytia", "ANATOMY", 34, 42], ["cell", "ANATOMY", 111, 115], ["Alveolar Cells", "ANATOMY", 187, 201], ["type II alveolar cells", "ANATOMY", 273, 295], ["specimens", "ANATOMY", 314, 323], ["apical surface", "ANATOMY", 376, 390], ["type II alveolar cells", "ANATOMY", 394, 416], ["cell", "CELL", 111, 115], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 148, 157], ["Human", "ORGANISM", 181, 186], ["Alveolar Cells", "CELL", 187, 201], ["HCoV", "GENE_OR_GENE_PRODUCT", 248, 252], ["HKU1", "GENE_OR_GENE_PRODUCT", 253, 257], ["type II alveolar cells", "CELL", 273, 295], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 335, 344], ["apical surface", "CELLULAR_COMPONENT", 376, 390], ["type II alveolar cells", "CELL", 394, 416], ["type II cell culture", "CELL_LINE", 103, 123], ["HCoV", "PROTEIN", 148, 152], ["HKU1", "DNA", 153, 157], ["Type II Human Alveolar Cells", "CELL_LINE", 173, 201], ["HCoV", "PROTEIN", 248, 252], ["HKU1", "DNA", 253, 257], ["type II alveolar cells", "CELL_TYPE", 273, 295], ["HCoV-HKU1 RNA", "RNA", 335, 348], ["type II alveolar cells", "CELL_TYPE", 394, 416], ["Human", "SPECIES", 181, 186], ["HCoV", "SPECIES", 248, 252], ["HCoV", "SPECIES", 335, 339], ["large syncytia", "PROBLEM", 28, 42], ["cytopathic effects (CPE", "PROBLEM", 44, 67], ["Kinetics of HCoV", "TREATMENT", 136, 152], ["HCoV", "TEST", 248, 252], ["HKU1 replication", "PROBLEM", 253, 269], ["type II alveolar cells", "PROBLEM", 273, 295], ["primary clinical specimens", "TEST", 297, 323], ["HCoV-HKU1 RNA", "TREATMENT", 335, 348], ["large", "OBSERVATION_MODIFIER", 28, 33], ["syncytia", "OBSERVATION", 34, 42], ["cytopathic", "OBSERVATION_MODIFIER", 44, 54], ["Alveolar Cells", "OBSERVATION", 187, 201], ["type II", "OBSERVATION_MODIFIER", 273, 280], ["alveolar cells", "OBSERVATION", 281, 295], ["apical", "ANATOMY_MODIFIER", 376, 382], ["alveolar cells", "OBSERVATION", 402, 416]]], ["Apical surfaces were washed 24, 48, 72, 96, and 120 hrs post inoculation and assayed for HCoV-HKU1 RNA by qRT-PCR.", [["Apical surfaces", "ANATOMY", 0, 15], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 89, 98], ["HCoV-HKU1 RNA", "RNA", 89, 102], ["HCoV", "SPECIES", 89, 93], ["Apical surfaces", "TEST", 0, 15], ["inoculation", "TEST", 61, 72], ["HCoV", "TEST", 89, 93], ["HKU1 RNA", "PROBLEM", 94, 102], ["qRT", "TEST", 106, 109], ["PCR", "TEST", 110, 113], ["surfaces", "ANATOMY_MODIFIER", 7, 15]]], ["Viral genome copies increased approximately 1000 fold during the course of the infection indicating productive infection and replication (Figure 4a).Kinetics of HCoV-HKU1 Replication in Type II Human Alveolar Cells at AL/I ::: ResultsTo determine if human alveolar cells could be utilized to propagate HCoV-HKU1, apical surfaces were inoculated and incubated for 4 hr at 34oC with a clinical sample of HCoV-HKU1 and then removed.", [["Alveolar Cells", "ANATOMY", 200, 214], ["alveolar cells", "ANATOMY", 256, 270], ["HCoV-HKU1", "ANATOMY", 302, 311], ["apical surfaces", "ANATOMY", 313, 328], ["sample", "ANATOMY", 392, 398], ["infection", "DISEASE", 79, 88], ["infection", "DISEASE", 111, 120], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 161, 170], ["Human", "ORGANISM", 194, 199], ["Alveolar Cells", "CELL", 200, 214], ["human", "ORGANISM", 250, 255], ["alveolar cells", "CELL", 256, 270], ["HCoV-HKU1", "CELL", 302, 311], ["apical surfaces", "MULTI-TISSUE_STRUCTURE", 313, 328], ["HCoV-HKU1", "CELL", 402, 411], ["Viral genome copies", "DNA", 0, 19], ["HCoV", "PROTEIN", 161, 165], ["HKU1", "DNA", 166, 170], ["Type II Human Alveolar Cells", "CELL_LINE", 186, 214], ["human alveolar cells", "CELL_TYPE", 250, 270], ["HCoV", "PROTEIN", 302, 306], ["Human", "SPECIES", 194, 199], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 250, 255], ["HCoV", "SPECIES", 302, 306], ["HCoV", "SPECIES", 402, 406], ["Viral genome copies", "PROBLEM", 0, 19], ["the infection", "PROBLEM", 75, 88], ["productive infection", "PROBLEM", 100, 120], ["Kinetics of HCoV", "TREATMENT", 149, 165], ["human alveolar cells", "PROBLEM", 250, 270], ["HCoV", "TEST", 302, 306], ["apical surfaces", "PROBLEM", 313, 328], ["HKU1", "TREATMENT", 407, 411], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["approximately", "OBSERVATION_MODIFIER", 30, 43], ["1000 fold", "OBSERVATION_MODIFIER", 44, 53], ["infection", "OBSERVATION", 79, 88], ["productive", "OBSERVATION_MODIFIER", 100, 110], ["infection", "OBSERVATION", 111, 120], ["Alveolar Cells", "OBSERVATION", 200, 214], ["alveolar cells", "OBSERVATION", 256, 270], ["apical", "ANATOMY_MODIFIER", 313, 319]]], ["The apical surfaces were then washed every 24 hr for the next 5 days.", [["apical surfaces", "ANATOMY", 4, 19], ["The apical surfaces", "TREATMENT", 0, 19], ["apical", "ANATOMY_MODIFIER", 4, 10], ["surfaces", "OBSERVATION_MODIFIER", 11, 19]]], ["Serial passage of HCoV-HKU1 infection was performed by inoculating na\u00efve cultures with 100 \u00b5L of the day 5 (120 hr post inoculation) apical wash from the previous passage.", [["cultures", "ANATOMY", 73, 81], ["infection", "DISEASE", 28, 37], ["HCoV", "GENE_OR_GENE_PRODUCT", 18, 22], ["HKU1", "GENE_OR_GENE_PRODUCT", 23, 27], ["na\u00efve cultures", "CELL_LINE", 67, 81], ["HCoV", "SPECIES", 18, 22], ["HKU1 infection", "PROBLEM", 23, 37], ["inoculating na\u00efve cultures", "TEST", 55, 81], ["apical wash", "PROBLEM", 133, 144], ["infection", "OBSERVATION", 28, 37], ["apical", "OBSERVATION_MODIFIER", 133, 139], ["wash", "OBSERVATION", 140, 144]]], ["Viral genome copy numbers were maintained over the course of three passages (Figure 4b).", [["Viral genome copy numbers", "TEST", 0, 25]]], ["Immunofluorescence assays (IFA) with antibodies to the HCoV-HKU1 spike glycoprotein performed at 120 hours confirmed the presence of infected cells at the end of each passage.", [["cells", "ANATOMY", 142, 147], ["HCoV", "GENE_OR_GENE_PRODUCT", 55, 59], ["HKU1", "GENE_OR_GENE_PRODUCT", 60, 64], ["cells", "CELL", 142, 147], ["antibodies", "PROTEIN", 37, 47], ["HCoV", "PROTEIN", 55, 59], ["HKU1 spike glycoprotein", "PROTEIN", 60, 83], ["infected cells", "CELL_TYPE", 133, 147], ["HCoV", "SPECIES", 55, 59], ["Immunofluorescence assays", "TEST", 0, 25], ["IFA", "TEST", 27, 30], ["antibodies", "TEST", 37, 47], ["the HCoV", "TEST", 51, 59], ["HKU1 spike glycoprotein", "PROBLEM", 60, 83], ["infected cells", "PROBLEM", 133, 147], ["infected cells", "OBSERVATION", 133, 147]]], ["These experiments demonstrated that genome copies detected in the apical wash were infectious and did not represent defective particles, confirming that HCoV-HKU1 was truly replicating in type II alveolar cells at the AL/I.Innate Immune Response Elicited by HCoV-HKU1 Infection in Type II Human Alveolar Cells ::: ResultsBecause alveolar type II cells at the air-liquid interface were highly susceptible to HCoV-HKU1 infection, we could measure changes in the level of expression of select genes of the innate immune system in these cells in response to HCoV-HKU1 infection.", [["apical", "ANATOMY", 66, 72], ["type II alveolar cells", "ANATOMY", 188, 210], ["Alveolar Cells", "ANATOMY", 295, 309], ["alveolar type II cells", "ANATOMY", 329, 351], ["cells", "ANATOMY", 533, 538], ["infection", "DISEASE", 417, 426], ["infection", "DISEASE", 564, 573], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 153, 162], ["type II alveolar cells", "CELL", 188, 210], ["HCoV-HKU1", "ORGANISM", 258, 267], ["Human", "ORGANISM", 289, 294], ["Alveolar Cells", "CELL", 295, 309], ["alveolar type II cells", "CELL", 329, 351], ["HCoV", "GENE_OR_GENE_PRODUCT", 407, 411], ["HKU1", "GENE_OR_GENE_PRODUCT", 412, 416], ["cells", "CELL", 533, 538], ["HCoV", "GENE_OR_GENE_PRODUCT", 554, 558], ["HKU1", "GENE_OR_GENE_PRODUCT", 559, 563], ["HCoV", "PROTEIN", 153, 157], ["HKU1", "PROTEIN", 158, 162], ["type II alveolar cells", "CELL_TYPE", 188, 210], ["Type II Human Alveolar Cells", "CELL_LINE", 281, 309], ["alveolar type II cells", "CELL_TYPE", 329, 351], ["Human", "SPECIES", 289, 294], ["HCoV", "SPECIES", 407, 411], ["HCoV", "SPECIES", 554, 558], ["genome copies", "PROBLEM", 36, 49], ["the apical wash", "PROBLEM", 62, 77], ["infectious", "PROBLEM", 83, 93], ["defective particles", "PROBLEM", 116, 135], ["HCoV", "TEST", 153, 157], ["HKU1", "PROBLEM", 158, 162], ["type II alveolar cells", "PROBLEM", 188, 210], ["HCoV", "TEST", 258, 262], ["HKU1 Infection", "PROBLEM", 263, 277], ["alveolar type II cells", "PROBLEM", 329, 351], ["HCoV", "PROBLEM", 407, 411], ["HKU1 infection", "PROBLEM", 412, 426], ["HCoV", "TEST", 554, 558], ["HKU1 infection", "PROBLEM", 559, 573], ["apical", "ANATOMY_MODIFIER", 66, 72], ["infectious", "OBSERVATION", 83, 93], ["defective particles", "OBSERVATION", 116, 135], ["alveolar cells", "OBSERVATION", 196, 210], ["Infection", "OBSERVATION", 268, 277], ["Alveolar Cells", "OBSERVATION", 295, 309], ["alveolar", "ANATOMY_MODIFIER", 329, 337], ["II cells", "OBSERVATION", 343, 351], ["air-liquid interface", "OBSERVATION", 359, 379], ["infection", "OBSERVATION", 417, 426], ["infection", "OBSERVATION", 564, 573]]], ["At 72 hours post inoculation, HCoV-HKU1 infection induced markedly increased levels of mRNAs encoding type III interferons (IL29), interferon-responsive genes (CXCL10), proinflammatory chemokines (CCL5 and CXCL10), and IL-6.", [["infection", "DISEASE", 40, 49], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 30, 39], ["type III interferons", "GENE_OR_GENE_PRODUCT", 102, 122], ["IL29", "GENE_OR_GENE_PRODUCT", 124, 128], ["interferon", "GENE_OR_GENE_PRODUCT", 131, 141], ["CXCL10", "GENE_OR_GENE_PRODUCT", 160, 166], ["CCL5", "GENE_OR_GENE_PRODUCT", 197, 201], ["CXCL10", "GENE_OR_GENE_PRODUCT", 206, 212], ["IL-6", "GENE_OR_GENE_PRODUCT", 219, 223], ["mRNAs", "RNA", 87, 92], ["type III interferons", "PROTEIN", 102, 122], ["IL29", "PROTEIN", 124, 128], ["interferon-responsive genes", "DNA", 131, 158], ["CXCL10", "DNA", 160, 166], ["proinflammatory chemokines", "PROTEIN", 169, 195], ["CCL5", "PROTEIN", 197, 201], ["CXCL10", "PROTEIN", 206, 212], ["IL-6", "PROTEIN", 219, 223], ["HCoV", "SPECIES", 30, 34], ["inoculation", "TEST", 17, 28], ["HCoV", "TEST", 30, 34], ["HKU1 infection", "PROBLEM", 35, 49], ["markedly increased levels", "PROBLEM", 58, 83], ["mRNAs encoding type III interferons (IL29)", "TREATMENT", 87, 129], ["interferon-responsive genes", "TREATMENT", 131, 158], ["proinflammatory chemokines", "TEST", 169, 195], ["CCL5", "TEST", 197, 201], ["CXCL10", "TEST", 206, 212], ["infection", "OBSERVATION", 40, 49], ["markedly", "OBSERVATION_MODIFIER", 58, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["There was no significant increase in IFN\u03b2, the only type I interferon reported to be expressed by alveolar type II cells [20] (Figure 5a).", [["alveolar type II cells", "ANATOMY", 98, 120], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 37, 41], ["type I interferon", "GENE_OR_GENE_PRODUCT", 52, 69], ["alveolar type II cells", "CELL", 98, 120], ["IFN\u03b2", "PROTEIN", 37, 41], ["type I interferon", "PROTEIN", 52, 69], ["alveolar type II cells", "CELL_TYPE", 98, 120], ["significant increase in IFN\u03b2", "PROBLEM", 13, 41], ["type I interferon", "PROBLEM", 52, 69], ["alveolar type II cells", "PROBLEM", 98, 120], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["alveolar", "ANATOMY", 98, 106]]], ["The levels of relative cellular gene expression varied significantly between human donors tested (Figure 5b).", [["cellular", "ANATOMY", 23, 31], ["cellular", "CELL", 23, 31], ["human", "ORGANISM", 77, 82], ["donors", "ORGANISM", 83, 89], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["relative cellular gene expression", "PROBLEM", 14, 47], ["cellular gene expression", "OBSERVATION", 23, 47]]], ["Thus, human alveolar type II cells induce significant innate, anti-viral responses to infection with HCoV-HKU1, but the extent of these responses varied in different humans with different levels of infection.DiscussionThis is the first study to demonstrate infection of primary human alveolar type II cells at the AL/I with primary clinical specimens containing HCoV-HKU1 RNA.", [["alveolar type II cells", "ANATOMY", 12, 34], ["alveolar type II cells", "ANATOMY", 284, 306], ["specimens", "ANATOMY", 341, 350], ["infection", "DISEASE", 86, 95], ["infection", "DISEASE", 198, 207], ["infection", "DISEASE", 257, 266], ["human", "ORGANISM", 6, 11], ["alveolar type II cells", "CELL", 12, 34], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 101, 110], ["humans", "ORGANISM", 166, 172], ["human", "ORGANISM", 278, 283], ["alveolar type II cells", "CELL", 284, 306], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 362, 371], ["human alveolar type II cells", "CELL_TYPE", 6, 34], ["primary human alveolar type II cells", "CELL_TYPE", 270, 306], ["HCoV-HKU1 RNA", "RNA", 362, 375], ["human", "SPECIES", 6, 11], ["humans", "SPECIES", 166, 172], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 6, 11], ["HCoV", "SPECIES", 101, 105], ["humans", "SPECIES", 166, 172], ["human", "SPECIES", 278, 283], ["HCoV", "SPECIES", 362, 366], ["human alveolar type II cells", "PROBLEM", 6, 34], ["infection", "PROBLEM", 86, 95], ["HCoV", "TEST", 101, 105], ["HKU1", "TREATMENT", 106, 110], ["infection", "PROBLEM", 198, 207], ["the first study", "TEST", 226, 241], ["infection", "PROBLEM", 257, 266], ["primary human alveolar type II cells", "PROBLEM", 270, 306], ["primary clinical specimens", "TEST", 324, 350], ["HKU1 RNA", "PROBLEM", 367, 375], ["alveolar", "ANATOMY", 12, 20], ["infection", "OBSERVATION", 198, 207], ["infection", "OBSERVATION", 257, 266], ["alveolar type", "OBSERVATION", 284, 297]]], ["Human alveolar type II cells maintained at an air-liquid interface were highly susceptible to HCoV-HKU1 infection, but alveolar macrophages and type I-like cells were not susceptible to HCoV-HKU1.", [["alveolar type II cells", "ANATOMY", 6, 28], ["alveolar macrophages", "ANATOMY", 119, 139], ["type I-like cells", "ANATOMY", 144, 161], ["infection", "DISEASE", 104, 113], ["Human", "ORGANISM", 0, 5], ["alveolar type II cells", "CELL", 6, 28], ["HCoV", "GENE_OR_GENE_PRODUCT", 94, 98], ["HKU1", "GENE_OR_GENE_PRODUCT", 99, 103], ["alveolar macrophages", "CELL", 119, 139], ["type I-like cells", "CELL", 144, 161], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 186, 195], ["Human alveolar type II cells", "CELL_TYPE", 0, 28], ["alveolar macrophages", "CELL_TYPE", 119, 139], ["type I-like cells", "CELL_TYPE", 144, 161], ["HCoV", "PROTEIN", 186, 190], ["HKU1", "PROTEIN", 191, 195], ["Human", "SPECIES", 0, 5], ["HCoV", "SPECIES", 94, 98], ["HCoV", "SPECIES", 186, 190], ["Human alveolar type II cells", "PROBLEM", 0, 28], ["HCoV", "PROBLEM", 94, 98], ["HKU1 infection", "PROBLEM", 99, 113], ["alveolar macrophages", "PROBLEM", 119, 139], ["type I-like cells", "PROBLEM", 144, 161], ["HCoV", "TEST", 186, 190], ["alveolar", "ANATOMY", 6, 14], ["II cells", "OBSERVATION", 20, 28], ["air-liquid", "OBSERVATION", 46, 56], ["infection", "OBSERVATION", 104, 113], ["alveolar macrophages", "OBSERVATION", 119, 139]]], ["This supports our hypothesis that primary human alveolar cells can be a suitable culture system for isolation and propagation of novel human respiratory viruses that cause lower respiratory tract disease and which display a stringent degree of cell, tissue, and host specificity.", [["alveolar cells", "ANATOMY", 48, 62], ["lower respiratory tract", "ANATOMY", 172, 195], ["cell", "ANATOMY", 244, 248], ["tissue", "ANATOMY", 250, 256], ["respiratory viruses", "DISEASE", 141, 160], ["lower respiratory tract disease", "DISEASE", 172, 203], ["human", "ORGANISM", 42, 47], ["alveolar cells", "CELL", 48, 62], ["human", "ORGANISM", 135, 140], ["respiratory viruses", "ORGANISM", 141, 160], ["lower", "ORGANISM_SUBDIVISION", 172, 177], ["respiratory tract", "ORGANISM_SUBDIVISION", 178, 195], ["cell", "CELL", 244, 248], ["tissue", "TISSUE", 250, 256], ["primary human alveolar cells", "CELL_TYPE", 34, 62], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 42, 47], ["human respiratory viruses", "SPECIES", 135, 160], ["primary human alveolar cells", "PROBLEM", 34, 62], ["a suitable culture system", "TEST", 70, 95], ["isolation", "TREATMENT", 100, 109], ["novel human respiratory viruses", "PROBLEM", 129, 160], ["lower respiratory tract disease", "PROBLEM", 172, 203], ["a stringent degree of cell, tissue", "PROBLEM", 222, 256], ["alveolar cells", "OBSERVATION", 48, 62], ["respiratory viruses", "OBSERVATION", 141, 160], ["lower", "ANATOMY_MODIFIER", 172, 177], ["respiratory tract", "ANATOMY", 178, 195], ["stringent degree", "OBSERVATION_MODIFIER", 224, 240], ["cell", "OBSERVATION", 244, 248]]], ["Utilization of this culture system is appealing because it most closely represents the in vivo physiological conditions of the lung [2], [21].", [["lung", "ANATOMY", 127, 131], ["lung", "ORGAN", 127, 131], ["this culture system", "TEST", 15, 34], ["lung", "ANATOMY", 127, 131]]], ["The type II culture system allows identification of which terminal human respiratory epithelial cells are susceptible to infection and might provide insight into the spread of infections from the conducting airways required for the development of pneumonia and the acute respiratory distress syndrome (ARDS).DiscussionThese results are agreement with what is known about the SARS-CoV, another beta-coronavirus (lineage b) that causes more severe lower respiratory tract disease than HCoV-HKU1.", [["respiratory epithelial cells", "ANATOMY", 73, 101], ["airways", "ANATOMY", 207, 214], ["respiratory", "ANATOMY", 271, 282], ["lower respiratory tract", "ANATOMY", 446, 469], ["infection", "DISEASE", 121, 130], ["infections", "DISEASE", 176, 186], ["pneumonia", "DISEASE", 247, 256], ["acute respiratory distress syndrome", "DISEASE", 265, 300], ["ARDS", "DISEASE", 302, 306], ["SARS", "DISEASE", 375, 379], ["lower respiratory tract disease", "DISEASE", 446, 477], ["human", "ORGANISM", 67, 72], ["respiratory epithelial cells", "CELL", 73, 101], ["airways", "MULTI-TISSUE_STRUCTURE", 207, 214], ["SARS-CoV", "ORGANISM", 375, 383], ["tract", "ORGANISM_SUBDIVISION", 464, 469], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 483, 492], ["terminal human respiratory epithelial cells", "CELL_TYPE", 58, 101], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["SARS-CoV", "SPECIES", 375, 383], ["HCoV", "SPECIES", 483, 487], ["The type II culture system", "TEST", 0, 26], ["terminal human respiratory epithelial cells", "PROBLEM", 58, 101], ["infection", "PROBLEM", 121, 130], ["infections", "PROBLEM", 176, 186], ["pneumonia", "PROBLEM", 247, 256], ["the acute respiratory distress syndrome", "PROBLEM", 261, 300], ["ARDS", "PROBLEM", 302, 306], ["the SARS-CoV", "PROBLEM", 371, 383], ["more severe lower respiratory tract disease", "PROBLEM", 434, 477], ["respiratory epithelial cells", "OBSERVATION", 73, 101], ["infection", "OBSERVATION", 121, 130], ["infections", "OBSERVATION", 176, 186], ["airways", "ANATOMY", 207, 214], ["pneumonia", "OBSERVATION", 247, 256], ["acute", "OBSERVATION_MODIFIER", 265, 270], ["respiratory distress syndrome", "OBSERVATION", 271, 300], ["severe", "OBSERVATION_MODIFIER", 439, 445], ["lower", "ANATOMY_MODIFIER", 446, 451], ["respiratory tract", "ANATOMY", 452, 469]]], ["Autopsy studies of patients with SARS-CoV demonstrated expression of viral antigen in type II pneumocytes [22], [23], [24], and previous studies in our laboratory showed that in vitro cultures of human alveolar type II cells at the AL/I are susceptible to infection with SARS-CoV [15], [25].", [["type II pneumocytes", "ANATOMY", 86, 105], ["alveolar type II cells", "ANATOMY", 202, 224], ["SARS", "DISEASE", 33, 37], ["infection", "DISEASE", 256, 265], ["SARS", "DISEASE", 271, 275], ["patients", "ORGANISM", 19, 27], ["SARS-CoV", "ORGANISM", 33, 41], ["human", "ORGANISM", 196, 201], ["alveolar type II cells", "CELL", 202, 224], ["SARS-CoV", "ORGANISM", 271, 279], ["viral antigen", "PROTEIN", 69, 82], ["type II pneumocytes", "CELL_TYPE", 86, 105], ["in vitro cultures", "CELL_LINE", 175, 192], ["human alveolar type II cells", "CELL_TYPE", 196, 224], ["patients", "SPECIES", 19, 27], ["human", "SPECIES", 196, 201], ["SARS-CoV", "SPECIES", 33, 41], ["human", "SPECIES", 196, 201], ["SARS-CoV", "SPECIES", 271, 279], ["Autopsy studies", "TEST", 0, 15], ["SARS", "PROBLEM", 33, 37], ["viral antigen in type II pneumocytes", "PROBLEM", 69, 105], ["previous studies", "TEST", 128, 144], ["our laboratory", "TEST", 148, 162], ["vitro cultures", "TEST", 178, 192], ["human alveolar type II cells", "PROBLEM", 196, 224], ["infection", "PROBLEM", 256, 265], ["SARS", "TEST", 271, 275], ["CoV", "TEST", 276, 279], ["alveolar", "ANATOMY", 202, 210], ["infection", "OBSERVATION", 256, 265]]], ["Similarly, a recent study using human lung organ cultures demonstrated that various subtypes of human influenza A viruses, which varied in their pathogenic potential, all preferentially infected type II alveolar cells, with minimal infection of alveolar macrophages and no infection of alveolar type I cells [21].", [["lung organ cultures", "ANATOMY", 38, 57], ["type II alveolar cells", "ANATOMY", 195, 217], ["alveolar macrophages", "ANATOMY", 245, 265], ["alveolar type I cells", "ANATOMY", 286, 307], ["influenza A viruses", "DISEASE", 102, 121], ["infection", "DISEASE", 232, 241], ["infection", "DISEASE", 273, 282], ["human", "ORGANISM", 32, 37], ["lung organ cultures", "CELL", 38, 57], ["human influenza A viruses", "ORGANISM", 96, 121], ["type II alveolar cells", "CELL", 195, 217], ["alveolar macrophages", "CELL", 245, 265], ["alveolar type I cells", "CELL", 286, 307], ["human lung organ cultures", "CELL_LINE", 32, 57], ["infected type II alveolar cells", "CELL_TYPE", 186, 217], ["alveolar macrophages", "CELL_TYPE", 245, 265], ["alveolar type I cells", "CELL_TYPE", 286, 307], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 32, 37], ["human influenza A viruses", "SPECIES", 96, 121], ["a recent study", "TEST", 11, 25], ["human lung organ cultures", "TEST", 32, 57], ["human influenza A viruses", "PROBLEM", 96, 121], ["all preferentially infected type II alveolar cells", "PROBLEM", 167, 217], ["minimal infection of alveolar macrophages", "PROBLEM", 224, 265], ["infection of alveolar type I cells", "PROBLEM", 273, 307], ["lung", "ANATOMY", 38, 42], ["human influenza", "OBSERVATION", 96, 111], ["viruses", "OBSERVATION", 114, 121], ["preferentially", "OBSERVATION_MODIFIER", 171, 185], ["infected", "OBSERVATION", 186, 194], ["alveolar cells", "OBSERVATION", 203, 217], ["minimal", "OBSERVATION_MODIFIER", 224, 231], ["infection", "OBSERVATION", 232, 241], ["alveolar macrophages", "OBSERVATION", 245, 265], ["no", "UNCERTAINTY", 270, 272], ["infection", "OBSERVATION", 273, 282], ["alveolar", "ANATOMY_MODIFIER", 286, 294]]], ["Their study also highlighted that the different pathogenic potential of influenza A viruses was not attributed to differences in cellular tropism, as they all infected the same cells, but rather to the capacity of the viruses to productively replicate in type II alveolar cells.", [["cellular", "ANATOMY", 129, 137], ["cells", "ANATOMY", 177, 182], ["type II alveolar cells", "ANATOMY", 255, 277], ["influenza A viruses", "DISEASE", 72, 91], ["influenza A viruses", "ORGANISM", 72, 91], ["cellular", "CELL", 129, 137], ["cells", "CELL", 177, 182], ["type II alveolar cells", "CELL", 255, 277], ["type II alveolar cells", "CELL_TYPE", 255, 277], ["influenza A viruses", "SPECIES", 72, 91], ["Their study", "TEST", 0, 11], ["influenza A viruses", "PROBLEM", 72, 91], ["cellular tropism", "PROBLEM", 129, 145], ["the viruses", "PROBLEM", 214, 225], ["type II alveolar cells", "PROBLEM", 255, 277], ["influenza", "OBSERVATION", 72, 81], ["viruses", "OBSERVATION", 84, 91], ["cellular tropism", "OBSERVATION", 129, 145], ["viruses", "OBSERVATION", 218, 225], ["type II", "OBSERVATION_MODIFIER", 255, 262], ["alveolar cells", "OBSERVATION", 263, 277]]], ["Overall, these studies emphasize the importance of ATII cells in the pathogenesis of viral induced lower respiratory tract disease.", [["ATII cells", "ANATOMY", 51, 61], ["lower respiratory tract", "ANATOMY", 99, 122], ["lower respiratory tract disease", "DISEASE", 99, 130], ["ATII cells", "CELL", 51, 61], ["lower", "ORGANISM_SUBDIVISION", 99, 104], ["respiratory tract", "ORGANISM_SUBDIVISION", 105, 122], ["ATII cells", "CELL_TYPE", 51, 61], ["these studies", "TEST", 9, 22], ["ATII cells", "PROBLEM", 51, 61], ["viral induced lower respiratory tract disease", "PROBLEM", 85, 130], ["ATII cells", "OBSERVATION", 51, 61], ["viral", "OBSERVATION", 85, 90], ["lower", "ANATOMY_MODIFIER", 99, 104], ["respiratory tract", "ANATOMY", 105, 122], ["disease", "OBSERVATION", 123, 130]]], ["In contrast to these viruses, human coronavirus 229E, an alphacoronavirus, can readily infect human alveolar macrophages, but not type I-like or type II alveolar cells [17].", [["alveolar macrophages", "ANATOMY", 100, 120], ["type II alveolar cells", "ANATOMY", 145, 167], ["human coronavirus 229E", "ORGANISM", 30, 52], ["alphacoronavirus", "GENE_OR_GENE_PRODUCT", 57, 73], ["human", "ORGANISM", 94, 99], ["alveolar macrophages", "CELL", 100, 120], ["human alveolar macrophages", "CELL_TYPE", 94, 120], ["type I-like or type II alveolar cells", "CELL_TYPE", 130, 167], ["human", "SPECIES", 30, 35], ["coronavirus", "SPECIES", 36, 47], ["human", "SPECIES", 94, 99], ["human coronavirus 229E", "SPECIES", 30, 52], ["human", "SPECIES", 94, 99], ["human coronavirus 229E", "PROBLEM", 30, 52], ["an alphacoronavirus", "PROBLEM", 54, 73], ["human alveolar macrophages", "PROBLEM", 94, 120], ["type I", "PROBLEM", 130, 136], ["type II alveolar cells", "PROBLEM", 145, 167], ["viruses", "OBSERVATION", 21, 28], ["alveolar macrophages", "OBSERVATION", 100, 120], ["alveolar cells", "OBSERVATION", 153, 167]]], ["Interestingly, in contrast to SARS-CoV, HCoV-229E is a common cause of upper respiratory tract infection and rarely causes severe lower respiratory tract disease [26], [27].", [["upper respiratory tract", "ANATOMY", 71, 94], ["lower respiratory tract", "ANATOMY", 130, 153], ["SARS", "DISEASE", 30, 34], ["HCoV-229E", "CHEMICAL", 40, 49], ["respiratory tract infection", "DISEASE", 77, 104], ["lower respiratory tract disease", "DISEASE", 130, 161], ["SARS-CoV", "ORGANISM", 30, 38], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 40, 49], ["upper", "ORGANISM_SUBDIVISION", 71, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["tract", "ORGANISM_SUBDIVISION", 148, 153], ["SARS-CoV", "SPECIES", 30, 38], ["HCoV-229E", "SPECIES", 40, 49], ["SARS", "TEST", 30, 34], ["HCoV", "TEST", 40, 44], ["upper respiratory tract infection", "PROBLEM", 71, 104], ["severe lower respiratory tract disease", "PROBLEM", 123, 161], ["upper", "ANATOMY_MODIFIER", 71, 76], ["respiratory tract", "ANATOMY", 77, 94], ["infection", "OBSERVATION", 95, 104], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["lower", "ANATOMY_MODIFIER", 130, 135], ["respiratory tract", "ANATOMY", 136, 153]]], ["The differences in clinical presentation between these coronavirus may be partially explained by whether that can infect type II alveolar cells.DiscussionSeveral observations regarding infection of the type II cells with HCoV-HKU1 are worth noting.", [["type II alveolar cells", "ANATOMY", 121, 143], ["type II cells", "ANATOMY", 202, 215], ["coronavirus", "DISEASE", 55, 66], ["infection", "DISEASE", 185, 194], ["coronavirus", "ORGANISM", 55, 66], ["alveolar cells", "CELL", 129, 143], ["type II cells", "CELL", 202, 215], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 221, 230], ["type II alveolar cells", "CELL_TYPE", 121, 143], ["type II cells", "CELL_TYPE", 202, 215], ["HCoV", "PROTEIN", 221, 225], ["HKU1", "DNA", 226, 230], ["these coronavirus", "PROBLEM", 49, 66], ["type II alveolar cells", "PROBLEM", 121, 143], ["infection", "PROBLEM", 185, 194], ["HCoV", "TEST", 221, 225], ["alveolar cells", "OBSERVATION", 129, 143]]], ["Growing and infecting the cultures at an air-liquid interface, as opposed to keeping them submerged, greatly increased the susceptibility of type II cells to HCoV-HKU1.", [["cultures", "ANATOMY", 26, 34], ["type II cells", "ANATOMY", 141, 154], ["type II cells", "CELL", 141, 154], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 158, 167], ["type II cells", "CELL_TYPE", 141, 154], ["HCoV", "PROTEIN", 158, 162], ["HKU1", "PROTEIN", 163, 167], ["the cultures", "TEST", 22, 34], ["HCoV", "TEST", 158, 162], ["infecting", "OBSERVATION_MODIFIER", 12, 21], ["increased", "OBSERVATION_MODIFIER", 109, 118]]], ["These results are identical to what we previously described for SARS-CoV [25].", [["SARS", "DISEASE", 64, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["SARS-CoV", "SPECIES", 64, 72], ["SARS", "PROBLEM", 64, 68]]], ["Interestingly, there is very little fluid at the apical surface of the alveolar epithelium [28], [29], except in diseased states, and therefore the AL/I conditions more accurately approximate in vivo conditions for type II cells.", [["apical surface", "ANATOMY", 49, 63], ["alveolar epithelium", "ANATOMY", 71, 90], ["type II cells", "ANATOMY", 215, 228], ["apical surface", "CELLULAR_COMPONENT", 49, 63], ["alveolar epithelium", "TISSUE", 71, 90], ["type II cells", "CELL", 215, 228], ["type II cells", "CELL_TYPE", 215, 228], ["very little fluid", "PROBLEM", 24, 41], ["the AL/I conditions", "PROBLEM", 144, 163], ["type II cells", "PROBLEM", 215, 228], ["very", "OBSERVATION_MODIFIER", 24, 28], ["little", "OBSERVATION_MODIFIER", 29, 35], ["fluid", "OBSERVATION", 36, 41], ["apical", "ANATOMY_MODIFIER", 49, 55], ["surface", "ANATOMY_MODIFIER", 56, 63], ["alveolar", "ANATOMY_MODIFIER", 71, 79], ["epithelium", "ANATOMY_MODIFIER", 80, 90], ["diseased", "OBSERVATION", 113, 121]]], ["Over the course of our experiments we infected cells from 20 different donors.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["donors", "ORGANISM", 71, 77], ["infected cells", "CELL_TYPE", 38, 52], ["infected cells", "PROBLEM", 38, 52], ["infected cells", "OBSERVATION", 38, 52]]], ["Type II cells from 17 of these donors were susceptible to HCoV-HKU1 infection, although there was significant variability in the degree of susceptibility between donors.", [["Type II cells", "ANATOMY", 0, 13], ["infection", "DISEASE", 68, 77], ["Type II cells", "CELL", 0, 13], ["donors", "ORGANISM", 31, 37], ["HCoV", "GENE_OR_GENE_PRODUCT", 58, 62], ["HKU1", "GENE_OR_GENE_PRODUCT", 63, 67], ["donors", "ORGANISM", 162, 168], ["Type II cells", "CELL_TYPE", 0, 13], ["HCoV", "SPECIES", 58, 62], ["Type II cells", "PROBLEM", 0, 13], ["these donors", "TREATMENT", 25, 37], ["HCoV", "PROBLEM", 58, 62], ["HKU1 infection", "PROBLEM", 63, 77], ["significant variability", "PROBLEM", 98, 121], ["susceptibility between donors", "PROBLEM", 139, 168], ["infection", "OBSERVATION", 68, 77], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["variability", "OBSERVATION_MODIFIER", 110, 121], ["degree", "OBSERVATION_MODIFIER", 129, 135], ["susceptibility", "OBSERVATION", 139, 153]]], ["One possible explanation for these differences might be differential levels of receptor expression.", [["receptor expression", "PROBLEM", 79, 98], ["possible explanation for", "UNCERTAINTY", 4, 28]]], ["As the receptor for HCoV-HKU1 is currently unknown we were not able to explore this hypothesis.", [["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 20, 29], ["HCoV", "PROTEIN", 20, 24], ["HKU1", "PROTEIN", 25, 29], ["HCoV", "TEST", 20, 24]]], ["Elucidating the mechanism(s) for the increased susceptibility in the AL/I conditions and the variability exhibited between donors might unravel important cellular determinants of infection.DiscussionInduction of syncytia formation by HCoV-HKU1 most likely indicates direct cell to cell spread of virus and undoubtedly plays an important role in the pathogenesis of HCoV-HKU1 in lung disease and escape from immune surveillance.", [["cellular", "ANATOMY", 154, 162], ["syncytia", "ANATOMY", 212, 220], ["cell", "ANATOMY", 273, 277], ["cell", "ANATOMY", 281, 285], ["lung", "ANATOMY", 378, 382], ["infection", "DISEASE", 179, 188], ["lung disease", "DISEASE", 378, 390], ["donors", "ORGANISM", 123, 129], ["cellular", "CELL", 154, 162], ["syncytia", "CELL", 212, 220], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 234, 243], ["cell", "CELL", 273, 277], ["cell", "CELL", 281, 285], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 365, 374], ["lung", "ORGAN", 378, 382], ["HCoV", "PROTEIN", 234, 238], ["HKU1", "PROTEIN", 239, 243], ["HCoV", "SPECIES", 365, 369], ["the increased susceptibility in the AL/I conditions", "PROBLEM", 33, 84], ["donors", "TREATMENT", 123, 129], ["infection", "PROBLEM", 179, 188], ["syncytia formation", "PROBLEM", 212, 230], ["direct cell to cell spread of virus", "PROBLEM", 266, 301], ["HCoV", "PROBLEM", 365, 369], ["HKU1", "PROBLEM", 370, 374], ["lung disease", "PROBLEM", 378, 390], ["immune surveillance", "TEST", 407, 426], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["susceptibility", "OBSERVATION", 47, 61], ["infection", "OBSERVATION", 179, 188], ["syncytia formation", "OBSERVATION", 212, 230], ["most likely indicates", "UNCERTAINTY", 244, 265], ["direct cell", "OBSERVATION", 266, 277], ["lung", "ANATOMY", 378, 382], ["disease", "OBSERVATION", 383, 390]]], ["Many infections with enveloped viruses can directly move from cell to cell by fusion of adjacent plasma membranes resulting in large, multinucleated giant cells.", [["cell", "ANATOMY", 62, 66], ["cell", "ANATOMY", 70, 74], ["plasma membranes", "ANATOMY", 97, 113], ["multinucleated giant cells", "ANATOMY", 134, 160], ["infections", "DISEASE", 5, 15], ["cell", "CELL", 62, 66], ["cell", "CELL", 70, 74], ["plasma membranes", "CELLULAR_COMPONENT", 97, 113], ["multinucleated giant cells", "CELL", 134, 160], ["large, multinucleated giant cells", "CELL_TYPE", 127, 160], ["Many infections", "PROBLEM", 0, 15], ["enveloped viruses", "PROBLEM", 21, 38], ["adjacent plasma membranes", "PROBLEM", 88, 113], ["large, multinucleated giant cells", "PROBLEM", 127, 160], ["infections", "OBSERVATION", 5, 15], ["enveloped", "OBSERVATION_MODIFIER", 21, 30], ["viruses", "OBSERVATION", 31, 38], ["cell to cell", "OBSERVATION", 62, 74], ["plasma membranes", "ANATOMY", 97, 113], ["large", "OBSERVATION_MODIFIER", 127, 132], ["multinucleated", "OBSERVATION_MODIFIER", 134, 148], ["giant cells", "OBSERVATION", 149, 160]]], ["This ability confers multiple potential pathogenic advantages over cell free spread.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["multiple", "OBSERVATION_MODIFIER", 21, 29], ["potential", "OBSERVATION_MODIFIER", 30, 39], ["pathogenic", "OBSERVATION_MODIFIER", 40, 50]]], ["Direct cell to cell spread is more efficient by eliminating the intrinsic barriers of fluid-phase diffusion required by cell free spread to encounter another target cells and engage the appropriate receptors.", [["cell", "ANATOMY", 7, 11], ["cell", "ANATOMY", 15, 19], ["cell", "ANATOMY", 120, 124], ["cells", "ANATOMY", 165, 170], ["cell", "CELL", 7, 11], ["cell", "CELL", 15, 19], ["cell", "CELL", 120, 124], ["cells", "CELL", 165, 170], ["target cells", "CELL_TYPE", 158, 170], ["Direct cell to cell spread", "PROBLEM", 0, 26], ["fluid-phase diffusion", "TEST", 86, 107], ["cell spread", "OBSERVATION", 15, 26]]], ["Movement of infection between cells also allows the virus to evade innate humoral and cellular defenses [30], [31].", [["cells", "ANATOMY", 30, 35], ["cellular", "ANATOMY", 86, 94], ["infection", "DISEASE", 12, 21], ["cells", "CELL", 30, 35], ["cellular", "CELL", 86, 94], ["infection between cells", "PROBLEM", 12, 35], ["the virus", "PROBLEM", 48, 57], ["infection", "OBSERVATION", 12, 21]]], ["Viral fusion with cell membranes of their target cells (virus-cell fusion) is an essential first step in infection for all coronaviruses.", [["cell membranes", "ANATOMY", 18, 32], ["cells", "ANATOMY", 49, 54], ["cell", "ANATOMY", 62, 66], ["infection", "DISEASE", 105, 114], ["cell membranes", "CELLULAR_COMPONENT", 18, 32], ["cells", "CELL", 49, 54], ["virus-cell", "CELL", 56, 66], ["coronaviruses", "ORGANISM", 123, 136], ["target cells", "CELL_TYPE", 42, 54], ["Viral fusion", "PROBLEM", 0, 12], ["cell membranes", "TREATMENT", 18, 32], ["virus-cell fusion", "TREATMENT", 56, 73], ["an essential first step in infection", "PROBLEM", 78, 114], ["all coronaviruses", "PROBLEM", 119, 136], ["fusion", "OBSERVATION", 6, 12], ["cell membranes", "OBSERVATION", 18, 32], ["target cells", "OBSERVATION", 42, 54], ["cell fusion", "OBSERVATION", 62, 73], ["infection", "OBSERVATION", 105, 114]]], ["Syncytia formation is also commonly seen in other coronaviruses and plays an important step in viral pathogenesis [32], [33], [34].", [["Syncytia", "ANATOMY", 0, 8], ["Syncytia", "DISEASE", 0, 8], ["Syncytia", "PATHOLOGICAL_FORMATION", 0, 8], ["Syncytia formation", "PROBLEM", 0, 18]]], ["Syncytia formation of dendritic cells resulting in cell death was recently shown to be important in an in vitro infection model of another human respiratory coronavirus, 229E [35].", [["Syncytia", "ANATOMY", 0, 8], ["dendritic cells", "ANATOMY", 22, 37], ["cell", "ANATOMY", 51, 55], ["respiratory", "ANATOMY", 145, 156], ["Syncytia", "DISEASE", 0, 8], ["death", "DISEASE", 56, 61], ["infection", "DISEASE", 112, 121], ["respiratory coronavirus", "DISEASE", 145, 168], ["Syncytia", "CELL", 0, 8], ["dendritic cells", "CELL", 22, 37], ["cell", "CELL", 51, 55], ["human", "ORGANISM", 139, 144], ["respiratory coronavirus", "ORGANISM", 145, 168], ["dendritic cells", "CELL_TYPE", 22, 37], ["human", "SPECIES", 139, 144], ["human respiratory coronavirus", "SPECIES", 139, 168], ["Syncytia formation", "PROBLEM", 0, 18], ["dendritic cells", "PROBLEM", 22, 37], ["cell death", "PROBLEM", 51, 61], ["another human respiratory coronavirus", "PROBLEM", 131, 168], ["dendritic cells", "OBSERVATION", 22, 37], ["cell death", "OBSERVATION", 51, 61]]], ["Syncytia forming activity has been shown to greatly enhance the infectivity of avian coronavirus infectious bronchitis [36].", [["coronavirus infectious bronchitis", "DISEASE", 85, 118], ["avian coronavirus", "ORGANISM", 79, 96], ["avian coronavirus infectious bronchitis", "SPECIES", 79, 118], ["avian coronavirus", "SPECIES", 79, 96], ["Syncytia forming activity", "PROBLEM", 0, 25], ["avian coronavirus infectious bronchitis", "PROBLEM", 79, 118], ["infectivity", "OBSERVATION_MODIFIER", 64, 75], ["coronavirus", "OBSERVATION_MODIFIER", 85, 96], ["infectious", "OBSERVATION_MODIFIER", 97, 107]]], ["Modulation of syncytial formation helps to establish viral persistence in in vitro culture models of infection with the murine coronavirus, mouse hepatitis virus (MHV) [37].", [["syncytial", "ANATOMY", 14, 23], ["infection", "DISEASE", 101, 110], ["mouse hepatitis virus", "DISEASE", 140, 161], ["syncytial", "ORGANISM", 14, 23], ["murine coronavirus", "ORGANISM", 120, 138], ["mouse hepatitis virus", "ORGANISM", 140, 161], ["murine", "SPECIES", 120, 126], ["coronavirus", "SPECIES", 127, 138], ["mouse", "SPECIES", 140, 145], ["hepatitis virus", "SPECIES", 146, 161], ["murine coronavirus", "SPECIES", 120, 138], ["mouse hepatitis virus", "SPECIES", 140, 161], ["MHV", "SPECIES", 163, 166], ["syncytial formation", "PROBLEM", 14, 33], ["viral persistence", "PROBLEM", 53, 70], ["infection", "PROBLEM", 101, 110], ["the murine coronavirus", "PROBLEM", 116, 138], ["mouse hepatitis virus", "PROBLEM", 140, 161], ["syncytial formation", "OBSERVATION", 14, 33], ["infection", "OBSERVATION", 101, 110]]], ["Both virus-cell entry and syncytia formation are mediated by the coronavirus spike protein, a class 1 viral fusion protein that is a major determinant of cell and host specificity.", [["cell", "ANATOMY", 11, 15], ["syncytia", "ANATOMY", 26, 34], ["cell", "ANATOMY", 154, 158], ["cell", "CELL", 11, 15], ["syncytia", "CELL", 26, 34], ["coronavirus spike protein", "GENE_OR_GENE_PRODUCT", 65, 90], ["cell", "CELL", 154, 158], ["coronavirus spike protein", "PROTEIN", 65, 90], ["class 1 viral fusion protein", "PROTEIN", 94, 122], ["syncytia formation", "PROBLEM", 26, 44], ["the coronavirus spike protein", "PROBLEM", 61, 90], ["a class 1 viral fusion protein", "PROBLEM", 92, 122], ["virus", "OBSERVATION", 5, 10], ["cell entry", "OBSERVATION", 11, 21], ["syncytia formation", "OBSERVATION", 26, 44], ["coronavirus spike", "OBSERVATION", 65, 82], ["viral fusion protein", "OBSERVATION", 102, 122]]], ["These two important processes in the pathogenesis of HCoV-HKU1, however, may occur through different mechanisms as has been shown for SARS-CoV and MHV [38], [39], [40], [41].DiscussionThe innate immune system serves as the first line of defense in protection of the host against viral infections and helps to shape the resultant adaptive immune response.", [["viral infections", "DISEASE", 279, 295], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 53, 62], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 134, 142], ["[39], [40]", "SIMPLE_CHEMICAL", 157, 167], ["HCoV", "PROTEIN", 53, 57], ["HKU1", "PROTEIN", 58, 62], ["HCoV", "SPECIES", 53, 57], ["SARS-CoV", "SPECIES", 134, 142], ["HCoV", "TEST", 53, 57], ["SARS", "PROBLEM", 134, 138], ["viral infections", "PROBLEM", 279, 295], ["adaptive immune response", "OBSERVATION", 329, 353]]], ["Expression of pro-inflammatory cytokines in response to viral infection argues that type II alveolar cells are not only target cells for infection but are also immune-competent and may directly influence the immune response to viral infection.", [["type II alveolar cells", "ANATOMY", 84, 106], ["cells", "ANATOMY", 127, 132], ["viral infection", "DISEASE", 56, 71], ["infection", "DISEASE", 137, 146], ["viral infection", "DISEASE", 227, 242], ["type II alveolar cells", "CELL", 84, 106], ["cells", "CELL", 127, 132], ["pro-inflammatory cytokines", "PROTEIN", 14, 40], ["type II alveolar cells", "CELL_TYPE", 84, 106], ["pro-inflammatory cytokines", "PROBLEM", 14, 40], ["viral infection", "PROBLEM", 56, 71], ["type II alveolar cells", "PROBLEM", 84, 106], ["infection", "PROBLEM", 137, 146], ["viral infection", "PROBLEM", 227, 242], ["pro-inflammatory cytokines", "OBSERVATION", 14, 40], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71], ["alveolar cells", "OBSERVATION", 92, 106], ["infection", "OBSERVATION", 137, 146], ["viral infection", "OBSERVATION", 227, 242]]], ["Many of the cytokine responses of the human type II alveolar cells at the AL/I to HCoV-HKU1 (induction of CXCL-10, IL29, and CCL5) were similar to those we previously described for influenza and SARS-CoV [20][25].", [["type II alveolar cells", "ANATOMY", 44, 66], ["influenza", "DISEASE", 181, 190], ["SARS", "DISEASE", 195, 199], ["human", "ORGANISM", 38, 43], ["type II alveolar cells", "CELL", 44, 66], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 82, 91], ["CXCL-10", "GENE_OR_GENE_PRODUCT", 106, 113], ["IL29", "GENE_OR_GENE_PRODUCT", 115, 119], ["CCL5", "GENE_OR_GENE_PRODUCT", 125, 129], ["SARS-CoV", "ORGANISM", 195, 203], ["cytokine", "PROTEIN", 12, 20], ["human type II alveolar cells", "CELL_TYPE", 38, 66], ["HCoV", "PROTEIN", 82, 86], ["HKU1", "PROTEIN", 87, 91], ["CXCL", "PROTEIN", 106, 110], ["IL29", "PROTEIN", 115, 119], ["CCL5", "PROTEIN", 125, 129], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["SARS-CoV", "SPECIES", 195, 203], ["the human type II alveolar cells", "PROBLEM", 34, 66], ["HCoV", "TEST", 82, 86], ["HKU1", "TEST", 87, 91], ["CXCL", "TEST", 106, 110], ["IL29", "TEST", 115, 119], ["CCL5", "TEST", 125, 129], ["influenza", "PROBLEM", 181, 190], ["SARS", "PROBLEM", 195, 199], ["alveolar cells", "OBSERVATION", 52, 66]]], ["One significant difference was a lack of expression of the type I interferon, IFN\u03b2, which may reflect that our current assays were conducted at a later time point during the course of infection.", [["infection", "DISEASE", 184, 193], ["type I interferon", "GENE_OR_GENE_PRODUCT", 59, 76], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 78, 82], ["type I interferon", "PROTEIN", 59, 76], ["IFN\u03b2", "PROTEIN", 78, 82], ["the type I interferon", "PROBLEM", 55, 76], ["our current assays", "TEST", 107, 125], ["infection", "PROBLEM", 184, 193], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["difference", "OBSERVATION", 16, 26], ["infection", "OBSERVATION", 184, 193]]], ["Alternatively, it could be due to the presence of unique viral proteins which can suppress the IFN response.", [["IFN", "GENE_OR_GENE_PRODUCT", 95, 98], ["viral proteins", "PROTEIN", 57, 71], ["IFN", "PROTEIN", 95, 98], ["unique viral proteins", "PROBLEM", 50, 71], ["could be due to", "UNCERTAINTY", 18, 33], ["viral proteins", "OBSERVATION", 57, 71]]], ["Another difference was that the degree of induction of these cytokines was overall approximately 10 fold less for HCoV-HKU1 compared with influenza and SARS-CoV.", [["SARS", "DISEASE", 152, 156], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 114, 123], ["SARS-CoV", "ORGANISM", 152, 160], ["cytokines", "PROTEIN", 61, 70], ["HCoV", "PROTEIN", 114, 118], ["HCoV", "SPECIES", 114, 118], ["SARS-CoV", "SPECIES", 152, 160], ["these cytokines", "TEST", 55, 70], ["HCoV", "TEST", 114, 118], ["HKU1", "PROBLEM", 119, 123], ["influenza", "PROBLEM", 138, 147], ["SARS", "PROBLEM", 152, 156]]], ["This may have important implications as recently it was shown that the level of cytokine responses in type II alveolar cells induced by different strains of influenza A viruses were correlated with degree of pathogenicity [21].", [["type II alveolar cells", "ANATOMY", 102, 124], ["type II alveolar cells", "CELL", 102, 124], ["influenza A viruses", "ORGANISM", 157, 176], ["cytokine", "PROTEIN", 80, 88], ["type II alveolar cells", "CELL_TYPE", 102, 124], ["influenza A viruses", "SPECIES", 157, 176], ["cytokine responses", "PROBLEM", 80, 98], ["type II alveolar cells", "PROBLEM", 102, 124], ["influenza A viruses", "PROBLEM", 157, 176], ["pathogenicity", "PROBLEM", 208, 221], ["alveolar cells", "OBSERVATION", 110, 124]]], ["Similarly, the differences in cytokine responses exhibited by different human donors might partially explain the variability in clinical outcomes to HCoV-HKU1 infections.DiscussionIn summary, HCoV-HKU1 can infect, be serially propagated, and induce an anti-viral response in human alveolar type II cells maintained at an air-liquid interface.", [["alveolar type II cells", "ANATOMY", 281, 303], ["infections", "DISEASE", 159, 169], ["human", "ORGANISM", 72, 77], ["donors", "ORGANISM", 78, 84], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 149, 158], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 192, 201], ["human", "ORGANISM", 275, 280], ["alveolar type II cells", "CELL", 281, 303], ["air-liquid", "MULTI-TISSUE_STRUCTURE", 321, 331], ["cytokine", "PROTEIN", 30, 38], ["HCoV", "PROTEIN", 192, 196], ["HKU1", "PROTEIN", 197, 201], ["human alveolar type II cells", "CELL_TYPE", 275, 303], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 275, 280], ["human", "SPECIES", 72, 77], ["HCoV", "SPECIES", 149, 153], ["human", "SPECIES", 275, 280], ["different human donors", "TREATMENT", 62, 84], ["HKU1 infections", "PROBLEM", 154, 169], ["an anti-viral response in human alveolar type II cells", "TREATMENT", 249, 303], ["infections", "OBSERVATION", 159, 169], ["anti-viral response", "OBSERVATION", 252, 271], ["alveolar", "ANATOMY", 281, 289], ["air-liquid", "OBSERVATION", 321, 331]]], ["Type II cells infected with HCoV-HKU1 demonstrated syncytia formation indicating cell to cell spread may be a major factor for virus spreading in vivo, suggesting a potential mechanism for evasion of host immune surveillance.", [["Type II cells", "ANATOMY", 0, 13], ["syncytia", "ANATOMY", 51, 59], ["cell", "ANATOMY", 81, 85], ["cell", "ANATOMY", 89, 93], ["Type II cells", "CELL", 0, 13], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 28, 37], ["syncytia", "CELL", 51, 59], ["cell", "CELL", 81, 85], ["cell", "CELL", 89, 93], ["Type II cells", "CELL_TYPE", 0, 13], ["HCoV", "PROTEIN", 28, 32], ["HKU1", "PROTEIN", 33, 37], ["HCoV", "SPECIES", 28, 32], ["Type II cells", "PROBLEM", 0, 13], ["HCoV", "TEST", 28, 32], ["HKU1", "PROBLEM", 33, 37], ["syncytia formation", "PROBLEM", 51, 69], ["cell to cell spread", "PROBLEM", 81, 100], ["virus", "PROBLEM", 127, 132], ["host immune surveillance", "TEST", 200, 224], ["syncytia", "OBSERVATION", 51, 59], ["cell to cell spread", "OBSERVATION", 81, 100]]], ["These experiments demonstrate that HCoV-HKU1 has strong tropism for type II alveolar cells and demonstrate the ability to use human alveolar cells to isolate and study novel human respiratory viruses that cause lower respiratory tract disease which display a stringent degree of cell, tissue, and host specificity.", [["type II alveolar cells", "ANATOMY", 68, 90], ["alveolar cells", "ANATOMY", 132, 146], ["lower respiratory tract", "ANATOMY", 211, 234], ["cell", "ANATOMY", 279, 283], ["tissue", "ANATOMY", 285, 291], ["respiratory viruses", "DISEASE", 180, 199], ["respiratory tract disease", "DISEASE", 217, 242], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 35, 44], ["type II alveolar cells", "CELL", 68, 90], ["human", "ORGANISM", 126, 131], ["alveolar cells", "CELL", 132, 146], ["human", "ORGANISM", 174, 179], ["lower", "ORGANISM_SUBDIVISION", 211, 216], ["respiratory tract", "ORGANISM_SUBDIVISION", 217, 234], ["cell", "CELL", 279, 283], ["tissue", "TISSUE", 285, 291], ["HCoV", "PROTEIN", 35, 39], ["HKU1", "PROTEIN", 40, 44], ["type II alveolar cells", "CELL_TYPE", 68, 90], ["human alveolar cells", "CELL_TYPE", 126, 146], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 126, 131], ["human respiratory viruses", "SPECIES", 174, 199], ["HCoV", "TEST", 35, 39], ["type II alveolar cells", "PROBLEM", 68, 90], ["human alveolar cells", "TREATMENT", 126, 146], ["novel human respiratory viruses", "PROBLEM", 168, 199], ["lower respiratory tract disease", "PROBLEM", 211, 242], ["alveolar cells", "OBSERVATION", 76, 90], ["respiratory viruses", "OBSERVATION", 180, 199], ["lower", "ANATOMY_MODIFIER", 211, 216], ["respiratory tract", "ANATOMY", 217, 234], ["stringent degree", "OBSERVATION_MODIFIER", 259, 275], ["cell", "OBSERVATION", 279, 283]]]], "PMC7478877": [["IntroductionThe COVID-19 pandemic, a disease caused by the novel human coronavirus (SARS-CoV-2),has affected people in all continents, with 6,912,751 cases confirmed up to June8th, 2020, along with 400,469 deaths(1).", [["human coronavirus", "DISEASE", 65, 82], ["deaths", "DISEASE", 206, 212], ["human", "ORGANISM", 65, 70], ["coronavirus", "ORGANISM", 71, 82], ["SARS-CoV-2", "ORGANISM", 84, 94], ["people", "ORGANISM", 109, 115], ["human", "SPECIES", 65, 70], ["coronavirus", "SPECIES", 71, 82], ["people", "SPECIES", 109, 115], ["human coronavirus", "SPECIES", 65, 82], ["a disease", "PROBLEM", 35, 44], ["the novel human coronavirus", "PROBLEM", 55, 82]]], ["Brazil ranks third in the world in the number ofdeaths; more than 680,456 cases and 36,151 deaths were confirmed up to the same datein the country(1-2).IntroductionSymptoms among those infected with SARS-CoV-2 range from no symptoms up to severecases of pulmonary disease.", [["pulmonary", "ANATOMY", 254, 263], ["deaths", "DISEASE", 91, 97], ["SARS", "DISEASE", 199, 203], ["pulmonary disease", "DISEASE", 254, 271], ["SARS-CoV-2", "ORGANISM", 199, 209], ["pulmonary", "ORGAN", 254, 263], ["CoV-", "SPECIES", 204, 208], ["SARS-CoV", "SPECIES", 199, 207], ["IntroductionSymptoms", "PROBLEM", 152, 172], ["SARS", "TEST", 199, 203], ["CoV", "TEST", 204, 207], ["symptoms", "PROBLEM", 224, 232], ["pulmonary disease", "PROBLEM", 254, 271], ["infected", "OBSERVATION", 185, 193], ["pulmonary", "ANATOMY", 254, 263], ["disease", "OBSERVATION", 264, 271]]], ["The incubation period that involves the onset of thefirst symptoms may range from two to 14 days after the infection, though some peopledo not present any symptoms(3).IntroductionNote that, even if asymptomatic, individuals infected with SARS-CoV-2 have thepotential to transmit the virus(3-4).", [["infection", "DISEASE", 107, 116], ["SARS", "DISEASE", 238, 242], ["SARS-CoV-2", "ORGANISM", 238, 248], ["SARS-CoV", "SPECIES", 238, 246], ["thefirst symptoms", "PROBLEM", 49, 66], ["the infection", "PROBLEM", 103, 116], ["any symptoms", "PROBLEM", 151, 163], ["asymptomatic", "PROBLEM", 198, 210], ["SARS", "PROBLEM", 238, 242], ["CoV", "TEST", 243, 246], ["infection", "OBSERVATION", 107, 116]]], ["Transmission mainly occurs fromperson to person through respiratory droplets, when an individual coughs, sneezes orspeaks near other people, while contaminated surfaces or objects may also be sourcesof transmission(5).IntroductionTherefore, the general population is advised to wear face masks as a mechanicalbarrier to prevent the dispersion of droplets, in addition to frequent handsanitization using soap and water or alcohol-based solutions(3).", [["respiratory droplets", "ANATOMY", 56, 76], ["alcohol", "CHEMICAL", 421, 428], ["alcohol", "CHEMICAL", 421, 428], ["water", "SIMPLE_CHEMICAL", 412, 417], ["alcohol", "SIMPLE_CHEMICAL", 421, 428], ["person", "SPECIES", 41, 47], ["people", "SPECIES", 133, 139], ["an individual coughs", "PROBLEM", 83, 103], ["face masks", "TREATMENT", 283, 293], ["a mechanicalbarrier", "TREATMENT", 297, 316], ["the dispersion of droplets", "TREATMENT", 328, 354]]], ["Hence, to self-protect againstdiseases and also prevent the transmission of pathogens between healthy and sickindividuals, masks have been used as a popular public health intervention(6).IntroductionIn Brazil, given a shortage of personal protective equipment (PPE), especiallysurgical masks, the Ministry of Health advised the population, through aninformative note published on April 2nd, 2020, to make and wear theirhomemade masks.", [["againstdiseases", "DISEASE", 23, 38], ["againstdiseases", "TREATMENT", 23, 38], ["masks", "TREATMENT", 123, 128], ["a popular public health intervention", "TREATMENT", 147, 183], ["personal protective equipment", "TREATMENT", 230, 259], ["theirhomemade masks", "TREATMENT", 414, 433]]], ["It also advises that masks made of vacuum bags, cotton, orantimicrobial pillowcases ensure an effective physical barrier, provided they areproperly designed and sanitized(7).IntroductionNote that to ensure masks are effective for what they are proposed, that is, toimpede the dissemination of expelled droplets, masks need to completely cover mouthand nose and adjust well to the face, without side clearances.", [["nose", "ORGANISM_SUBDIVISION", 352, 356], ["vacuum bags", "TREATMENT", 35, 46], ["cotton", "TREATMENT", 48, 54], ["orantimicrobial pillowcases", "TREATMENT", 56, 83], ["expelled droplets", "PROBLEM", 293, 310], ["mouthand nose", "PROBLEM", 343, 356], ["side clearances", "PROBLEM", 394, 409], ["vacuum bags", "OBSERVATION", 35, 46], ["face", "ANATOMY", 380, 384]]], ["Surgical masks are disposable and should not be sanitizedbecause they lose their filtering capacity.", [["Surgical masks", "TREATMENT", 0, 14]]], ["Similarly, N95 respirators should not bewashed and the number of times it may be reused is informed bymanufacturers(8).IntroductionHow frequently the population wears masks increases with the onset of localepidemics.", [["localepidemics", "DISEASE", 201, 215], ["N95 respirators", "TREATMENT", 11, 26], ["localepidemics", "TREATMENT", 201, 215]]], ["It is, however, necessary to better investigate factors such as theduration of protection and how this piece of PPE is used and reused, consideringthat inappropriate use, especially of disposable masks, may compromise itsprotective effect and even raise the risk of infection(9).IntroductionIn this sense, considering that the use of masks is not a common practice in thepopulation in general, in times of pandemic, this measure has been stronglyencouraged and represents a new reality experienced by the Brazilian people.Therefore, identify how people have used and reused this protective piece ofequipment is extremely important to discuss the potential effects of not wearing thedifferent types of masks or wearing them inappropriately in the face of the COVID-19pandemic.", [["infection", "DISEASE", 266, 275], ["people", "ORGANISM", 515, 521], ["people", "ORGANISM", 546, 552], ["people", "SPECIES", 515, 521], ["people", "SPECIES", 546, 552], ["protection", "TREATMENT", 79, 89], ["PPE", "TREATMENT", 112, 115], ["disposable masks", "TREATMENT", 185, 201], ["infection", "PROBLEM", 266, 275], ["masks", "TREATMENT", 334, 339], ["pandemic", "PROBLEM", 406, 414], ["this protective piece ofequipment", "TREATMENT", 574, 607], ["masks", "TREATMENT", 701, 706], ["infection", "OBSERVATION", 266, 275], ["new", "OBSERVATION_MODIFIER", 474, 477]]], ["Hence, this study\u2019s objective was to identify the factors associated withthe use and reuse of masks among Brazilian individuals during the COVID-19pandemic.MethodThis cross-sectional study was conducted between April 16th and27th in the North, Northeast, Southeast, Midwest, and South ofBrazil.", [["this study", "TEST", 7, 17], ["the COVID", "TEST", 135, 144], ["This cross-sectional study", "TEST", 162, 188]]], ["This study is part of a multinational project addressing the practice ofreusing masks in the population in general during the COVID-19 pandemic in Braziland is part of an international study \u201cPractice of face mask use among generalpublic during the outbreak of COVID-19: a multi-country cross-sectional study\u201d, inpartnership with Squina International Centre for Infection Control, Hong KongPolytechnic University.MethodAccording to data made available by the Brazilian Institute of Geography andStatistics (Instituto Brasileiro de Geografia e Estat\u00edstica - IBGE)concerning the 4th trimester of 2019, the population of Brazilianindividuals aged over 18 years old is approximately 159,095,000.", [["Infection", "DISEASE", 362, 371], ["This study", "TEST", 0, 10], ["the practice ofreusing masks", "TREATMENT", 57, 85], ["the COVID", "TEST", 122, 131], ["an international study", "TEST", 168, 190], ["Practice of face mask", "TREATMENT", 192, 213], ["Infection Control", "TREATMENT", 362, 379], ["Infection", "OBSERVATION", 362, 371]]], ["A representativesample of this population group was used.", [["this population group", "TREATMENT", 26, 47]]], ["A finite population sample was calculatedwith a confidence interval of 98%, sampling error of 2%, prevalence of 50%, and testpower of 80% and a minimum sample of 3,393 individuals was found.", [["A finite population sample", "TEST", 0, 26], ["sampling error", "TEST", 76, 90], ["prevalence", "TEST", 98, 108], ["testpower", "TEST", 121, 130], ["a minimum sample", "TEST", 142, 158]]], ["The inclusioncriterion was being 18 years old or older, while the exclusion criterion was being aforeigner living in Brazil or a health worker.MethodData were collected through social media such as Facebook, Twitter, Instagram,Whatsapp, and e-mail.", [["MethodData", "TREATMENT", 143, 153]]], ["A form composed of two parts was applied: 1- Generalinformation (sex, age, state of residence, educational level, marital status, andcontact with individuals with respiratory symptoms); 2- Information concerning theuse of masks: type of mask used (paper mask, fabric mask, surgical mask, activecarbon mask, N95, or others), frequency of reuse (number of times a mask is reused).Considering that it is a multinational study, the questions were translated fromEnglish to Portuguese by two independent translators and were content validated by apanel composed of five experts in the subject.", [["respiratory", "ANATOMY", 163, 174], ["respiratory symptoms", "DISEASE", 163, 183], ["respiratory symptoms", "PROBLEM", 163, 183], ["type of mask", "TREATMENT", 229, 241], ["paper mask", "TREATMENT", 248, 258], ["fabric mask", "TREATMENT", 260, 271], ["surgical mask", "TREATMENT", 273, 286], ["activecarbon mask", "TREATMENT", 288, 305], ["N95", "TREATMENT", 307, 310], ["a mask", "TREATMENT", 360, 366], ["a multinational study", "TEST", 401, 422]]], ["A pilottest was conducted prior to the data collection with 20 individuals convenientlyselected from five different Brazilian regions to verify the instrument\u2019ssensitiveness and applicability.", [["A pilottest", "TREATMENT", 0, 11], ["the data collection", "TEST", 35, 54]]], ["The instrument was convertedto the online format using Google Forms.MethodInvitation to participate in the study was sent through messages disseminated insocial media, containing a link to the survey.", [["MethodInvitation", "TREATMENT", 68, 84], ["the study", "TEST", 103, 112]]], ["Afree and informed consent form was presented on the initial page and participantsonly accessed the instrument of data collection after providing their consent.MethodThe outcome (dependent) variables were mask use and surgical mask reuse.", [["surgical mask reuse", "TREATMENT", 218, 237]]], ["Theindependent variables for both were: sex, age group, educational level, maritalstatus, and contact with people presenting respiratory symptoms.MethodData were exported from Google Forms directly to a spreadsheet in Microsoft OfficeExcel\u00ae and later to IBM\u00ae SPSS, version 20.0.", [["respiratory", "ANATOMY", 125, 136], ["respiratory symptoms", "DISEASE", 125, 145], ["people", "ORGANISM", 107, 113], ["MethodData", "SIMPLE_CHEMICAL", 146, 156], ["people", "SPECIES", 107, 113], ["respiratory symptoms", "PROBLEM", 125, 145]]], ["Descriptivestatistical analysis included absolute and relative frequencies, to characterize theparticipants and data concerning the use and reuse of masks, in addition to centraltendency (mean, median, maximum and minimum) and dispersion measures (standarddeviation) for age.MethodPrevalence concerning the use and reuse of masks was estimated considering aconfidence interval of 95% (CI 95%).", [["Descriptivestatistical analysis", "TEST", 0, 31], ["masks", "TREATMENT", 149, 154], ["centraltendency (mean, median, maximum and minimum) and dispersion measures", "TREATMENT", 171, 246], ["MethodPrevalence", "TREATMENT", 275, 291], ["masks", "TREATMENT", 324, 329], ["CI", "TEST", 385, 387]]], ["The Chi-square test was adopted to analyze theassociation between the outcome and independent variables.", [["The Chi-square test", "TEST", 0, 19]]], ["Associations withp<0.20 were verified using binary logistic regression considering the dependentvariables were dichotomous, the probabilities concerning the use of face masks andreuse of surgical masks in the population were verified using Odds Ratio (OR) andits respective confidence intervals of 95%.", [["binary logistic regression", "TREATMENT", 44, 70], ["face masks", "TREATMENT", 164, 174], ["surgical masks", "TREATMENT", 187, 201], ["surgical masks", "OBSERVATION", 187, 201]]], ["All ethical aspects were complied with inBrazil according to Resolutions 466/2012 and 510/2016 of the National HealthCouncil.", [["inBrazil", "TREATMENT", 39, 47], ["the National HealthCouncil", "TREATMENT", 98, 124]]], ["Financial support: Conselho Nacional de Desenvolvimento Cient\u00edficoe Tecnol\u00f3gico (CNPq), Brazil, grant #401371/2020-4.ResultsIn total, 3,981 (100%) individuals participated in the study.", [["individuals", "ORGANISM", 147, 158], ["the study", "TEST", 175, 184]]], ["Regardingsociodemographic characteristics, the regions with the largest number ofparticipants were the Southeast with 1,874 (47.1%) and Northeast with 1,348 (33.9%),followed by the Midwest with 320 (8.0%), North with 265 (6.7%), and South with 174(4.4%).", [["South", "TEST", 233, 238], ["regions", "ANATOMY_MODIFIER", 47, 54], ["largest", "OBSERVATION_MODIFIER", 64, 71]]], ["Most, 2,893 (72.7%) were women, 2,057 (51.7%) were married, aged 40 yearsold on average (SD=13.9); minimum 18 and maximum 86 years old.", [["women", "ORGANISM", 25, 30], ["women", "SPECIES", 25, 30]]], ["Concerning theeducational level, most participants, 3,280 (82.4%), reported holding a collegeeducation degree.", [["participants", "SPECIES", 38, 50]]], ["Most, 2,622 (65.9%), reported no close contact with individualswith respiratory symptoms; 1,359 (34.1%) mentioned at least one contact, 224 (5.6%)of whom had daily and continuous contact with people presenting respiratory symptoms(Table 1).Results", [["respiratory", "ANATOMY", 68, 79], ["respiratory", "ANATOMY", 210, 221], ["respiratory symptoms", "DISEASE", 68, 88], ["respiratory symptoms", "DISEASE", 210, 230], ["people", "ORGANISM", 192, 198], ["people", "SPECIES", 192, 198], ["respiratory symptoms", "PROBLEM", 68, 88], ["respiratory symptoms", "PROBLEM", 210, 230]]]]}